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This report provides reference information for blood or urine concentrations of 27 
biochemical indicators of diet and nutrition measured by the Centers for Disease 
Control and Prevention (CDC), Division of Laboratory Sciences at the National 
Center for Environmental Health (NCEH/DLS). The indicators were measured in 
specimens from a representative sample of the noninstitutionalized civilian U.S. 
population during all or part of the four-year period from 1999 through 2002. These 
specimens were collected by CDC’s National Health and Nutrition Examination 
Survey (NHANES), which is conducted by CDC’s National Center for Health Statistics 
(NCHS). NHANES is a series of surveys designed to collect data on the health and 
nutritional status of the U.S. population. This report covers one important facet in the 
assessment of nutritional status of the U.S. population: biochemical measurements. 
Other aspects, such as anthropometric body measurements, hematologic 
measurements, clinical signs of nutritional deficiency or excess, and dietary intake, 
are not covered. 
For this report, a biochemical indicator means a vitamin, iron-status indicator, trace 
element, or other dietary indicator with potential health relevance. Although most 
biochemical indicators presented in this report enter the human body from foods 
or supplements, the body itself produces some indicators in response to dietary 
intake. Blood and urine concentrations reflect the amount of nutrients and dietary 
compounds actually in the body from all of these sources. 
The biochemical indicators covered in this report are: 
•	 Water-soluble vitamins and related biochemical compounds. 
•	 Fat-soluble vitamins and micronutrients. 
•	 Iron-status indicators. 
•	 Trace elements. 
•	 Isoflavones and lignans (so-called phytoestrogens). 
Some indicators covered in this report have no nutritional value (e.g., homocysteine, 

methylmalonic acid, iron-status indicators, phytoestrogens). Yet, they are important 

because 1) they reflect micronutrient or metabolic status or 2) because they are a 

naturally occurring ingredient in the human diet (i.e., they are consumed as food 





On the other hand, some important micronutrients, such as vitamin C, vitamin 

B6, or certain minerals (e.g., sodium, potassium, calcium, phosphorus, chloride, 

magnesium) are omitted from this report. Data were either unavailable for the report 

years covered or were not representative of micronutrient status. Future reports may, 






This report is CDC’s first product that presents data—in a single source—concerning 
NCEH/DLS measurements of a wide range of biochemical indicators of diet and 
nutrition from the most recent continuous NHANES survey, starting in 1999. 
NCHS has historically released or commissioned a variety of products presenting 
NHANES results. Among these are Data Briefs, Data Tables, Advance Data, Series 
Reports, and Reports through the Life Sciences Research Office (LSRO). See the 
following for further information: http://www.cdc.gov/nchs/about/major/nhanes/ 
survey_results_and_products.htm. 
NHANES Series Reports (mainly Series 11) and LSRO Reports have always been of 
particular value to the nutrition community (see Appendix A). The two latest reports on 
nutritional biochemistry reference data were prepared for NHANES III (1988–1994). 
One covered hematologic and iron-related analytes, and the other covered blood 
folate and vitamin B12. 
Public Health Uses 
The primary purpose of this report is to improve our understanding of the 
concentrations of biochemical indicators of diet and nutrition in the general U.S. 
population and in selected subpopulations. These data will help assess inadequate or 
excess intake and will inform analyses on the relation between biochemical indicators 
and health outcomes. Other potential public health uses of the information include 
the following: 
•	 Establishing and improving upon existing population reference levels 
that physicians, clinicians, scientists, and public health officials can use to 
determine whether a person or a group of people has an unusually high or 
low level of a biochemical indicator of diet and nutrition. 
•	 Determining whether the nutritional status of special population groups, such 
as minorities, children, women of childbearing age, or the elderly is different 
from that of other groups, or whether it needs improvement. 
•	 Tracking, over time, trends in biochemical indicator levels in the population. 
•	 Assessing the effectiveness of public health efforts to improve the diet and 
nutritional status of U.S. residents. 
•	 Stimulating research to perform more in-depth analyses of the NHANES data 
and to generate hypotheses for future nutrition and human health studies. 
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Data Presented for Each Biochemical Indicator 
This publication contains tables of descriptive statistics on the distribution 
of blood and urine concentrations for each biochemical indicator of diet and 
nutrition. Statistics include unadjusted geometric means and selected percentiles 
with confidence intervals. 
The data are grouped by age, sex, and race/ethnicity. A geometric mean provides 
a better estimate of central tendency for data distributions with a long tail at the 
upper end of the distribution. When measuring biochemical indicators, this type of 
distribution is common. The geometric mean is influenced less by high values than is 
the arithmetic mean. Scientists can use the presented percentile levels (5th or 10th, 
50th, and 90th or 95th) to determine which serum, blood, or urine concentrations of 
indicators are common to people in the U.S. population and which concentrations 
are unusual. We used the unweighted sample size as a criterion for indicating reliable 
results (U.S. Centers for Disease for Control and Prevention 1996, Appendix B, Table 1). We assumed 
an average design effect of 1.4 and used a sample size of at least 112 persons to 
define estimates for the 10th and 90th percentiles as reliable and a sample size of 
at least 224 persons to define estimates for the 5th and 95th percentiles as reliable. 
We present 10th and 90th percentile levels for a biochemical indicator when the 
sample size was too small for 5th and 95th percentile levels in several subgroups. This 
is the case after stratifying by age, sex, and race/ethnicity with data from only two 
years (carotenoids, 25-hydroxyvitamin D, some iron-status indicators) or with data 
from only a subset of the population (iodine, selenium, phytoestrogens). For urine 
measurements, data are shown for both the concentration and for the concentration 
corrected for the urinary creatinine level. 
General information is provided for each indicator that also aids in interpreting 
levels. 
To address sources of these nutrients, biochemical pathways in the body, and known 
health effects, the text contains a brief overview about each indicator. 
Selected observations and highlights—mainly derived from the data tables 
provided in this publication—are presented in each chapter. 
The observations describe categorical differences between demographic subgroups, 




Chemists prepare serum material for quality 
assurance. 
Adequate serum or blood concentrations of biochemical indicators do not 
necessarily indicate that NHANES participants consume healthful and balanced diets. 
Some foods are fortified with micronutrients (e.g., iron, thiamin, riboflavin, niacin, 
folate, vitamin A, vitamin D), and some people take dietary supplements that contain 
vitamins, minerals, or both. 
Although certain dietary deficiencies are well documented and have characteristic 
signs and symptoms, suboptimal concentrations have been associated with the risk 
for adverse health effects such as cardiovascular disease, stroke, impaired cognitive 
function, cancer, eye diseases, poor bone health, and other conditions. Adverse 
health effects, including toxicity, are also possible from consuming excess amounts 
of certain nutrients. Research studies, separate from this report, are required to 
determine those concentrations of a biochemical indicator that may indicate 
risk for disease and those concentrations that are of negligible health concern. 
In collaboration with other agencies and institutions, CDC encourages, and itself 
conducts, measurements for this type of research. 
This report contains unadjusted geometric means and selected percentiles of 
biochemical indicators of diet and nutrition for the civilian, noninstitutionalized U.S. 
population. A limited interpretation of relative differences 
between population groups is possible by identifying groups 
with non-overlapping confidence intervals. These observed 
differences, however, should not be interpreted as causal. 
The intent is to describe the characteristics of the population 
and of selected subgroups, and not to explain why the 
groups look the way they do or why they differ from each 
other. For example, for biochemical indicators correlated with 
age, age may account for some of the effects. Furthermore, 
differences in biochemical indicator concentrations of 
selected subgroups do not necessarily imply health 
problems. More in-depth statistical analyses, such as 
adjusting for demographic variables or covariates, and taking 
interactions or predictive variables into consideration, are 
beyond the scope of this publication. We hope nonetheless 
that scientists will be stimulated to examine the data further 
by analyzing the raw data available at this Web site: http:// 
www.cdc.gov/nchs/nhanes.htm. 
Laboratories may use different methods for measuring the 
indicators reported here. Different methods may result in 
different method-specific reference ranges. Consequently, 
to apply these results, health science professionals should 
check with their particular laboratory to be sure their 
methods compare closely with those used in this report (see 
Appendix B). 
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Useful Sources of Information about Using 
Nutrition Monitoring to Interpret Data 
Information about dietary intake is critical to research examining the reasons for 
nutritional inadequacies and for programs to improve diet and nutritional status. 
Selected NCHS Advance Data Reports provide useful overviews (see Appendix A). Also 
of value are the U.S. Department of Agriculture’s (USDA) databases on food surveys 
and food composition: 
What We Eat in America (WWEIA) is the dietary intake interview section of NHANES 
(http://www.ars.usda.gov/foodsurvey). 
The Food and Nutrient Database for Dietary Studies (FNDDS) (http://www.ars.usda.gov/ 
Services/docs.htm?docid=12089) is a database of foods, their nutrient values, and weights 
for typical food portions. This database helps to analyze data from the WWEIA survey 
by using the nutrient values from the National Nutrient Database for Standard 
Reference (http://www.ars.usda.gov/Services/docs.htm?docid=8964). 
The Directory of Federal and State Nutrition Monitoring and Related Research Activities 
(Interagency Board for Nutrition Monitoring and Related Research 2000) is the fourth update in a 
series that provides information on the complex system of nutrition monitoring in the 
United States. It is a guide to those federal and state survey, surveillance, and research 
activities that are part of the National Nutrition Monitoring and Related Research 
Program (http://www.cdc.gov/nchs/about/otheract/nutrishn/nutrishn.htm). 
The Third Report on Nutrition Monitoring in the United States (Interagency Board for 
Nutrition Monitoring and Related Research 1995) provides the latest update on the dietary, 
nutritional, and nutrition-related health status of United States residents, the relation 
between diet and health, and the factors that influence dietary and nutritional status. 
The National Health and Nutrition Examination 
Survey (NHANES) 
CDC laboratory scientists used biological specimens obtained from participants in 
NHANES to measure biochemical indicators of diet and nutrition for this publication. 
NHANES is a series of NCHS-conducted surveys designed to collect data on the 
health and nutritional status of the U.S. population. This is the only national survey 
that collects biological samples. The NHANES surveys began in 1960 with the fielding 
of the first Health Examination Survey (HES 1). The nutritional component was 
added in the early 1970s in NHANES I. In 1999 NHANES became a continuous survey, 
sampling the U.S. population annually and releasing the data in two-year cycles. 
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NHANES collects information on a wide range of health-related behaviors, conducts 
physical examinations, and collects samples for laboratory tests. Because of physical 
examination and biological measures, NHANES is unique in its ability to examine 
public health issues, such as risk factors for cardiovascular disease, in the U.S. 
population. To select a representative sample of the civilian, noninstitutionalized 
population in the United States, the survey sampling plan follows a complex, 
stratified, multistage, probability-cluster design. The civilian, noninstitutionalized 
population consists of persons who are neither in the military nor institutionalized 
(e.g., residents of nursing homes, college dormitories, or prisons). 
The NHANES protocol includes a home interview followed by a standardized 
physical examination at a mobile examination center. As part of the examination, 
for participants aged 1 year and older, blood is obtained by venipuncture. Urine 
specimens are collected from participants aged 6 years and older. By design, 
approximately half of the participants are evaluated after an overnight fast. 
Furthermore, close to 90 percent of all participants have fasted for more than 3 hours 
before providing a biological sample. Because the mobile examination centers can be 
adversely affected by weather, data are collected in northern latitudes in summer and 
in southern latitudes in winter. This seasonal-latitude structure might indirectly affect 
biochemical indicators. 
Additional detailed information about the design and conduct of the NHANES survey 
is available at: http://www.cdc.gov/nchs/nhanes.htm. Information about how biological 
specimens are collected is available at the following Web site: http://www.cdc.gov/nchs/ 
data/nhanes/blood.pdf and in the Laboratory Procedures Manual, which can be found at: 
http://www.cdc.gov/nchs/data/nhanes/lab1-6.pdf or at http://www.cdc.gov/nchs/data/nhanes/ 
lab7-11.pdf. 
Data Analysis 
NCHS has developed a comprehensive Web-based tutorial (http://www.cdc.gov/nchs/ 
tutorials/Nhanes/index.htm) to help users better understand the complex survey design 
and to help them analyze continuous NHANES data. 
Because the NHANES sample design is complex, sample weights adjust for the 
unequal probability of selection into the survey. Sample weights also adjust for 
possible bias resulting from nonresponse and are post-stratified to U.S. Census 
Bureau estimates of the U.S. population. Data were analyzed using the statistical 
software package Statistical Analysis System (SAS) (SAS Institute Inc., 2002) and the 
statistical software package SUDAAN (SUDAAN Release 8.0, 2001). SUDAAN uses 
sample weights and calculates variance estimates that account for the complex 
survey design. Guidelines for the analysis of NHANES data are provided by NCHS at: 
http://www.cdc.gov/nchs/about/major/nhanes/nhanes2003-2004/analytical_guidelines.htm. Variance 
estimates were calculated using the Taylor series (linearization) method within 
SUDAAN. The Korn and Graubard method was used to compute Clopper-Pearson 95 
percent confidence intervals (see Appendix C). 
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The tables show selected percentiles and unadjusted geometric means of analyte 
concentrations. Geometric means were calculated by taking the log of each 
concentration, calculating the mean of those log values, then taking the antilog 
of that mean (the calculation can be done using any log base, such as 10 or e). 
Percentile estimates were calculated using SAS Proc Univariate with weighted data. 
Results are shown for the total population and also by age group, sex, and race/ 
ethnicity as defined in NHANES. For these analyses, sex is coded as male or female, 
and race/ethnicity is categorized as Mexican American, non-Hispanic black, and non-
Hispanic white. Other racial or ethnic groups are sampled, but the proportion of the 
total population represented by these other groups is not large enough to produce 
valid estimates. Other racial/ethnic groups are included in estimates based on the 
entire population sample. Data for each racial/ethnic group are presented in three 
separate tables. 
For calculation of geometric means, concentrations less than the limit of detection 
(LOD) were assigned a value equal to the LOD divided by the square root of 2. The 
LOD is the level at which the measurement has a 95 percent probability of being 
greater than zero (Taylor 1987). By comparison, assigning a value of the LOD divided 
by 2 made little difference in geometric mean estimates. Percentile estimates less 
than the LOD for the nutritional indicators are reported as "< LOD." If the proportion 
of results below the LOD was greater than 40 percent, geometric means were not 
calculated. Appendix D contains a table of LOD values for each biochemical indicator. 
As a result of changes to analytical methods, even for the same indicator, LOD values 
may change over the time period of the report. This was the case only for urinary 
phytoestrogens. We used the higher of the two LOD values for the analysis of the 
combined four-year data. 
For biochemical indicators measured in urine, we present separate tables for the 
concentration of the indicator expressed as “per volume of urine” (uncorrected 
table) and the concentration of the indicator expressed as “per gram of creatinine” 
(creatinine-corrected table). Comparison of an individual participant’s result to 
population data in the tables requires correction for urinary dilution: thus, an 
individual creatinine-corrected result is best compared to the creatinine-corrected 
data tables. Study populations of sufficient size can be compared to the tables 
having either of the corresponding units. We used the uncorrected tables to 
compare urine concentrations across groups. Because instrument responses are 
measured in units of weight per volume, LOD calculations were performed using 
the concentration of the indicator expressed as per volume of urine. For this reason, 
LOD results for urine measurements in Appendix D are in weight per volume of 
urine. In the creatinine-corrected tables, a result for a geometric mean or percentile 
was reported as less than the LOD (< LOD) if the corresponding geometric mean 
or percentile was < LOD in the uncorrected table. Thus, for example, if the 5th 
percentile for males was < LOD in the uncorrected table, it would also be < LOD in 
the creatinine-corrected table. 
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Water-Soluble Vitamins & 
Related Biochemical Compounds 
•	 Folate (serum and red blood cell) 
•	 Vitamin B12 
•	 Homocysteine 
•	 Methylmalonic acid 
11 
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Water-Soluble Vitamins & 
Related Biochemical 
Compounds 
Folate and vitamin B12 belong to the group of water-soluble B vitamins 
that occur naturally in food. Leafy green vegetables (such as spinach and 
turnip greens), fruits (such as citrus fruits and juices), and dried beans 
and peas are all natural sources of folate. Folic acid is the synthetic form 
of folate found in supplements and added to fortified foods. Because of 
wide consumption of fortified foods in the United States, these products 
have become an important contributor of folic acid to the U.S. diet. Folate 
functions as a coenzyme in single-carbon transfers in the metabolism 
of nucleic and amino acids and is therefore especially important during 
periods of rapid cell division and growth, such as occurs during infancy 
and pregnancy. 
Vitamin B12 (cobalamin) is found naturally in animal foods including fish, 
meat, poultry, eggs, milk, and milk products. For vegetarians, fortified 
breakfast cereals are a particularly valuable source of vitamin B12. Vitamin 
B12 functions as a coenzyme for a critical methyl transfer reaction that 
converts homocysteine to methionine and for a separate reaction that 
converts L-methylmalonyl-coenzyme A to succinyl-coenzyme A. 
Homocysteine (Hcy) is an amino acid naturally found in the blood. Plasma 
Hcy concentrations are strongly influenced by diet as well as by genetic 
factors. Elevated concentrations are found in people whose folate, vitamin 
B12, or vitamin B6 status is suboptimal (Selhub 1993), and in people with 
impaired renal function (Wollensen 1999). 
Methylmalonic acid (MMA) is a dicarboxylic acid naturally found in the 
blood. Plasma MMA concentrations are elevated when serum vitamin 
B12 concentrations are low or intermediate and are therefore a useful 
diagnostic test for confirming vitamin B12 deficiency (Baik 1999). 
A chronic dietary deficiency of either folate or vitamin B12 causes 
macrocytic anemia, although strict dietary deficiencies are rare. Certain 
drugs (e.g., alcohol, methotrexate, anticonvulsants, sulfa drugs) may 
interfere with the absorption or utilization of folate, and disorders of the 
small bowel that limit absorption (e.g., Crohn’s disease, jejunal bypass 
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surgery) can cause folate deficiency (Halsted 1990). Most people who develop a vitamin 
B12 deficiency have an underlying stomach or intestinal disorder that limits the 
absorption of vitamin B12. Subtly reduced cognitive function resulting from early 
vitamin B12 deficiency is sometimes the only symptom of these intestinal disorders. 
Severe vitamin B12 deficiency can cause permanent nerve damage and dementia. 
Hematologic signs, however, are not always present in vitamin B12 deficiency and 
hematologic signs and neurologic abnormalities can be inversely correlated (Baik 
1999). 
Clinical trials have shown that folic acid supplementation effectively reduces the 
number of neural tube birth defects (NTDs) (Czeizel 1992; MRC Vitamin Study Research Group 
1991). Thus, CDC and the U.S. Public Health Service have recommended that every 
woman who could become pregnant consume at least 400 micrograms (µg) of folic 
acid each day (U.S. Centers for Disease Control and Prevention 1992). Since 1998, the U.S. Food 
and Drug Administration (FDA) has required the addition of folic acid to enriched 
breads, cereals, flours, corn meals, pastas, rice, and other grain products (U.S. Food 
and Drug Administration 1996a). Recent observational studies have suggested potential 
benefits of the U.S. folic acid fortification, such as reduced NTD rates (Williams 2005), 
decreased prevalence of inadequate serum and RBC folate concentrations (Pfeiffer 
2005), and declines in the incidence of stroke (Yang 2006) and neuroblastoma (French 
2003). Potential roles are currently being studied for 1) folate in altering the risks 
for heart disease and cancer, 2) vitamin B12 in modulating the risks for cognitive 
impairment, and 3) Hcy as a risk factor for or a marker of cardiovascular disease. 
The recommended dietary allowance (RDA) for both men and women is 400 µg per 
day of dietary folate equivalents (DFEs). DFEs adjust for the nearly 50 percent lower 
bioavailability of dietary folate compared with the bioavailability of folic acid: 1 µg 
of dietary folate equivalent equals 0.6 µg of folic acid from fortified food or from a 
supplement taken on an empty stomach (Institute of Medicine 1998). The RDA for vitamin 
B12 for adults is 2.4 µg per day. Because as many as 10 to 30 percent of older people 
may be unable to absorb naturally occurring vitamin B12, it is advisable for people 
older than 50 years to meet their RDA mainly by consuming foods fortified with 
vitamin B12 or by taking a supplement containing vitamin B12. People with vitamin 
B12 deficiency caused by a lack of intrinsic factor or intestinal malabsorption require 
parenteral B12 treatment (Institute of Medicine 1998). 
Excess folic acid may mask and potentially delay diagnosis of anemia among people 
with vitamin B12 deficiency resulting in increased risk for neurological damage. 
Consequently, the Institute of Medicine (1998) recommends that folic acid intake for 
adults (aged 19 years and older) not exceed 1000 µg per day. Because no data were 
available for children, the Institute of Medicine used the level for adults adjusted by 
weight: 300–800 µg per day, depending on the age group. Folate intake from food is 
not associated with any health risk. 
Clinical laboratories typically use conventional units for measuring concentrations of 
folate (nanograms per milliliter [ng/mL]) and vitamin B12 (picograms [pg]/mL) but 
use international system (SI) units for Hcy and MMA (micromole per liter [µmol/L]). 
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Conversion factors to SI units are as follows: 1 ng/mL = 2.266 nanomol (nmol)/L for 
folate and 1 pg/mL = 0.738 picomol (pmol)/L for vitamin B12. 
Several methods measure concentrations in blood of these B vitamins and related 
biochemical compounds. Because of significant differences in measuring folate 
concentrations, caution should be used when comparing other data sets with the 
tables in this report. Method-specific cut-off values and reference ranges should be 
used in medical diagnostics (Life Sciences Research Office 1994). Folate data presented 
in this report were generated using 
the BioRad Quantaphase II radioassay. 
This assay measures approximately 35 
percent lower than the microbiologic 
gold-standard assay (Life Sciences Research 
Office 1994). As a result, for this report, 
the conventional cut-off values of less 
than 3 ng/mL for low serum folate 
concentrations and less than 140 ng/ 
mL for low red blood cell (RBC) folate 
concentrations (Life Sciences Research 
Office 1984) should be adjusted to less 
than 2 ng/mL and less than 95 ng/mL, 
respectively. Common methods for 
measuring serum vitamin B12, plasma 
Hcy, and MMA generally produce 
comparable results. A widely used cut­
off value for low serum vitamin B12 
concentrations is 200 pg/mL (Gibson 1990). 
Generally used cut-off values for elevated concentrations of plasma Hcy and MMA 
are 13 µmol/L (Jacques 1999) and 0.37 µmol/L (Hølleland 1999), respectively. 
For more information on B vitamins and related biochemical indicators, see the 
Institute of Medicine’s Dietary Reference Intake reports (Institute of Medicine 1998), fact 
sheets from the National Institutes of Health (NIH), Office of Dietary Supplements 
(http://ods.od.nih.gov/Health_Information/Information_About_Individual_Dietary_Supplements.aspx), 
as well as information from the American Society for Nutrition (http://jn.nutrition.org/ 
nutinfo/). 
One national health objective for Healthy People 2010 is to increase the proportion 
of pregnancies for which RBC folate concentration is optimum by increasing the 
median RBC folate concentration to 220 ng/mL among women aged 15–44 years 
(objective 16.16b; U.S. Department of Health and Human Services 2000). 
Monitoring the folate status of the U.S. population over time has been a priority since 
serum and RBC folate results from NHANES II (1976–1980) (Senti 1985) and NHANES III 
(1988–1994) (Wright 1998) suggested that the folate status of some population groups 
might be of public health concern. Vitamin B12 status of the U.S. population has 
been monitored since the second phase of NHANES III (1991–1994) (Wright 1998). In 
Chemist reviews data for methylmalonic acid. 
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a recent (2007) study, Pfeiffer et al. showed that, in women of childbearing age, the 
introduction of folic acid fortification has dramatically lowered the prevalence of low 
serum (< 3 ng/mL) and RBC folate concentrations (< 140 ng/mL) from 21 percent and 
38 percent, respectively, to less than 1 percent and 5 percent, respectively. Serum 
vitamin B12 concentrations, however, did not change appreciably. Circulating Hcy 
concentrations from prefortification to postfortification decreased by approximately 
10 percent in a national sample of the U.S. population (Pfeiffer 2008). 
Selected Observations and Highlights 
The following representative observations are taken from the tables of 1999–2002 
data contained in this report. Statements about categorical differences between 
demographic groups noted below are based on non-overlapping confidence limits 
from univariate analysis without adjusting for demographic variables (e.g., age, 
sex, race/ethnicity) or other blood concentration determinants (e.g., dietary intake, 
supplement usage, smoking, BMI). A multivariate analysis may alter the size and 
statistical significance of these categorical differences. Furthermore, additional 
significant differences of smaller magnitude may be present despite their lack of 
mention here (e.g., if confidence limits slightly overlap or if differences are not 
statistically significant before covariate adjustment has occurred). For a selection of 
citations of descriptive NHANES papers related to these biochemical indicators of diet 
and nutrition, see Appendix E. 
General Observations 
•	 Serum and RBC folate concentrations show a U-shaped age pattern with 
higher concentrations in children and older people (≥ 60 years) than in young 
or middle-aged adults. 
•	 Serum vitamin B12 concentrations first decline from childhood to middle-age, 
then stabilize. Plasma MMA concentrations are similar across all age groups, 
except that older people have higher concentrations. 
•	 Plasma Hcy concentrations increase with age. 
•	 Women have higher serum and RBC folate concentrations than do men, and 
men have higher plasma Hcy and MMA concentrations. 
•	 For serum and RBC folate, non-Hispanic whites have higher concentrations 
than do Mexican Americans, who themselves have higher concentrations than 
do non-Hispanic blacks. 
•	 Serum vitamin B12 concentrations are higher in non-Hispanic blacks than 
in the other two racial/ethnic groups, and plasma MMA concentrations are 
higher in non-Hispanic whites than in either Mexican Americans or in non-
Hispanic blacks. 
•	 Plasma Hcy concentrations are higher in non-Hispanic whites than in the 
other two racial/ethnic groups. 
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•	 Less than 5 percent of adolescent and adult women have low serum (< 2 ng/ 
mL) and RBC folate concentrations (< 95 ng/mL)–cut-off values indicative of 
inadequate folate status (based on 5th percentile). 
•	 Approximately 5 percent of older people have moderately low concentrations 
of serum vitamin B12 (< 200 pg/mL) (based on 5th percentile), and over 5 
percent of older people have elevated concentrations of plasma Hcy (> 13 
µmol/L) and of MMA (> 0.37 µmol/L) (based on 95th percentile). 
Highlights 
Since 1998, when fortification of enriched grains and cereal products with folic acid 
became mandatory, serum folate concentrations have more than doubled, and 
RBC folate concentrations have increased by about 50 percent in all population 
subgroups (Fig. 1.a). This greater than expected increase in blood concentrations 
was shown previously (Pfeiffer 2007). Underreporting of foods consumed, increased 
consumer selection of folate-rich foods as a result of health claims, and increasing 
availability of the number and types of nonstandardized folate-fortified foods 
(e.g., breakfast cereals) could be some of the reasons for the greater than expected 
increase in blood concentrations  (U.S. Food and Drug Administration 1996b). 
Figure 1.a. 
Geometric mean concentrations (95 percent confidence intervals) of serum folate in the U.S. 
population, aged 3 years and older, and in population subgroups, National Health and Nutrition 
Examination Survey, 1988–2002. Data shown for NHANES 1988–1994 are not part of the tables 
displayed in this report but were analyzed separately to generate this figure. 
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The Healthy People 2010 objective to increase the median RBC folate concentration 
in women to 220 ng/mL was achieved for Mexican-American and non-Hispanic white 
women aged 20–39 years: their median RBC folate concentrations were 250 ng/ 
mL and 278 ng/mL, respectively (Fig. 1.b). This objective was, however, not achieved 
for non-Hispanic black women (210 ng/mL) (Fig. 1.b). Interestingly, offspring of non-
Hispanic black women have the lowest incidence of NTDs, whereas offspring of 
Mexican-American women have the highest NTD incidence (Williams 2005). These 
findings show that RBC folate concentrations alone do not account for differences in 
NTD rates among race/ethnic groups in the U.S. population. 
Figure 1.b 
Median concentrations (95 percent confidence intervals) of red blood cell (RBC) folate among 
20–39 year-old women by race/ethnicity, National Health and Nutrition Examination Survey, 
1999–2002. 
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Although the majority (> 95 percent) of females have an adequate folate status, it 
is interesting to note that adolescents (aged 12–19 years) and adult women (aged 
20–59 years), age groups for which good folate status is most critical, have lower 
serum folate concentrations than do females in other age groups (Fig. 1.c). Adolescent 
females aged 12–19 years also have lower RBC folate concentrations than do females 
in other age groups (Fig. 1.c). 
Figure 1.c 
Cross-sectional age pattern showing geometric mean concentrations (95 percent confidence 
intervals) of serum and red blood cell (RBC) folate in females, National Health and Nutrition 
Examination Survey, 1999–2002. 
Table 1.1.a. Serum folate: Total population 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 13.5 (13.1-13.8) 5.70 (5.50-6.00) 13.6 (13.2-13.9) 30.8 (29.9-32.0) 15912
 3–5 years 18.5 (17.7-19.3) 9.90 (8.80-10.8) 18.3 (17.7-18.8) 34.8 (32.0-41.0) 799
 6–11 years 18.1 (17.6-18.7) 9.90 (9.40-10.6) 18.0 (17.6-18.5) 33.2 (31.6-35.0) 1908
 12–19 years 12.6 (12.2-13.1) 6.00 (5.60-6.30) 12.8 (12.4-13.4) 24.7 (23.0-26.6) 4332
 20–39 years 11.4 (11.0-11.9) 5.10 (4.80-5.40) 11.2 (10.8-11.8) 25.1 (23.4-26.9) 3184
 40–59 years 12.8 (12.3-13.2) 5.50 (5.20-5.90) 12.9 (12.4-13.3) 28.7 (27.1-30.1) 2674
 60 years and older 16.8 (16.3-17.3) 6.80 (6.40-7.20) 17.0 (16.4-17.6) 40.3 (37.4-43.0) 3015 
Males 
Total, 3 years and older 12.8 (12.4-13.2) 5.50 (5.20-5.90) 13.0 (12.5-13.4) 28.3 (27.4-29.4) 7747
 3–5 years 18.2 (17.1-19.4) 9.40 (8.60-10.7) 17.7 (16.4-18.6) 41.0 (31.2-44.8) 417
 6–11 years 17.8 (17.0-18.6) 9.70 (8.90-10.7) 17.7 (16.8-18.4) 32.3 (29.6-35.9) 973
 12–19 years 12.5 (12.0-13.0) 6.00 (5.50-6.30) 12.9 (12.3-13.3) 24.6 (22.8-26.6) 2169
 20–39 years 10.7 (10.3-11.2) 5.00 (4.40-5.60) 10.8 (10.2-11.3) 21.9 (19.8-23.2) 1355
 40–59 years 12.3 (11.9-12.7) 5.40 (4.70-5.90) 12.4 (12.1-12.9) 26.7 (25.1-28.1) 1337
 60 years and older 15.2 (14.7-15.8) 6.10 (5.70-6.70) 15.3 (14.7-16.1) 35.4 (34.1-37.6) 1496 
Females 
Total, 3 years and older 14.1 (13.7-14.5) 5.80 (5.60-6.20) 14.3 (13.8-14.7) 32.9 (31.2-34.5) 8165
 3–5 years 18.8 (18.0-19.7) 10.3 (8.30-11.6) 18.7 (17.5-19.1) 33.5 (31.0-36.6) 382
 6–11 years 18.5 (18.0-19.1) 10.0 (9.30-10.7) 18.6 (17.8-19.0) 33.4 (30.0-37.4) 935
 12–19 years 12.7 (12.2-13.3) 6.20 (5.70-6.60) 12.8 (12.3-13.5) 24.8 (22.2-28.1) 2163
 20–39 years 12.1 (11.6-12.6) 5.40 (5.10-5.60) 12.0 (11.4-12.8) 28.7 (26.2-30.8) 1829
 40–59 years 13.2 (12.7-13.8) 5.50 (5.10-6.20) 13.4 (12.7-14.0) 30.2 (27.5-34.1) 1337
 60 years and older 18.1 (17.3-18.8) 7.40 (6.80-7.80) 18.2 (17.3-18.9) 43.0 (39.8-45.6) 1519 
Table 1.1.b. Serum folate: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 12.4 (11.9-12.9) 5.70 (5.30-6.20) 12.5 (12.0-12.9) 26.3 (24.8-28.1) 4695
 3–5 years 18.1 (17.1-19.2) 10.9 (9.90-11.5) 17.7 (16.7-18.7) 33.6 (28.6-36.8) 266
 6–11 years 17.7 (17.1-18.4) 10.4 (9.60-11.0) 17.3 (16.7-17.9) 31.0 (28.8-34.8) 652
 12–19 years 12.4 (12.0-12.8) 6.60 (6.10-6.90) 12.6 (12.0-13.2) 22.4 (21.7-24.0) 1637
 20–39 years 10.5 (9.96-11.0) 5.00 (4.20-5.60) 10.3 (9.80-11.0) 20.1 (19.4-21.9) 866
 40–59 years 11.8 (11.1-12.5) 5.90 (5.10-6.50) 11.9 (11.2-12.4) 23.8 (20.6-28.0) 634
 60 years and older 14.4 (13.6-15.2) 6.00 (5.00-6.90) 14.8 (13.5-15.8) 34.1 (30.2-38.7) 640 
Males 
Total, 3 years and older 12.0 (11.4-12.5) 5.50 (4.80-6.20) 12.1 (11.4-12.6) 25.3 (23.5-27.4) 2293
 3–5 years 17.7 (16.6-18.9) 10.5† (9.70-11.6) 17.4 (16.1-18.5) 34.0† (27.1-44.8) 139
 6–11 years 17.6 (16.7-18.5) 10.1 (9.00-11.0) 17.5 (16.4-18.4) 32.1 (26.2-42.0) 338
 12–19 years 12.5 (12.0-13.1) 6.40 (5.80-7.00) 12.6 (12.0-13.3) 24.1 (22.1-26.3) 811
 20–39 years 9.85 (9.24-10.5) 4.50 (3.80-5.60) 9.80 (9.20-10.6) 19.3 (17.2-20.0) 383
 40–59 years 11.6 (10.8-12.5) 5.80 (5.10-6.60) 11.7 (10.7-12.6) 22.0 (18.4-28.7) 301
 60 years and older 13.5 (12.5-14.5) 6.20 (5.00-7.10) 13.2 (12.2-14.8) 29.8 (24.0-48.3) 321 
Females 
Total, 3 years and older 12.9 (12.4-13.4) 5.90 (5.70-6.40) 13.0 (12.6-13.7) 27.2 (25.6-28.8) 2402
 3–5 years 18.5 (17.1-20.0) 11.0† (9.60-12.0) 18.3 (16.9-19.0) 31.6† (27.4-36.6) 127
 6–11 years 17.9 (17.2-18.6) 10.5 (9.60-11.7) 17.3 (16.6-18.2) 30.8 (28.8-32.1) 314
 12–19 years 12.2 (11.8-12.7) 6.60 (6.10-7.00) 12.5 (11.8-13.3) 21.6 (19.8-22.4) 826
 20–39 years 11.2 (10.7-11.8) 5.20 (4.90-5.90) 11.0 (10.3-11.7) 22.3 (20.0-27.6) 483
 40–59 years 11.9 (11.1-12.8) 5.90 (4.60-6.50) 12.0 (11.1-12.5) 25.4 (21.4-26.6) 333
 60 years and older 15.2 (14.3-16.2) 6.10 (5.00-7.20) 15.8 (14.4-16.7) 36.0 (31.5-39.6) 319 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 1.1.c. Serum folate: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 11.3 (10.9-11.8) 5.10 (4.60-5.30) 11.1 (10.6-11.6) 25.5 (23.9-27.1) 3716
 3–5 years 16.9 (16.0-17.8) 9.80 (8.70-10.5) 16.2 (15.1-17.8) 34.8 (28.2-39.3) 235
 6–11 years 16.9 (16.2-17.6) 9.60 (8.80-10.6) 16.4 (15.8-17.4) 31.8 (28.0-39.5) 604
 12–19 years 10.9 (10.5-11.4) 5.30 (5.00-5.70) 11.0 (10.5-11.4) 19.8 (19.0-21.0) 1256
 20–39 years 9.73 (9.18-10.3) 5.10 (4.50-5.40) 9.60 (9.10-10.4) 19.8 (18.7-21.4) 593
 40–59 years 10.3 (9.86-10.8) 4.40 (4.10-5.10) 10.1 (9.60-10.8) 22.7 (19.4-26.0) 541
 60 years and older 12.7 (11.6-13.8) 4.80 (4.20-5.40) 12.2 (11.0-14.0) 38.1 (31.1-43.3) 487 
Males 
Total, 3 years and older 10.9 (10.5-11.3) 4.80 (4.40-5.10) 10.8 (10.5-11.3) 22.7 (21.2-25.0) 1822
 3–5 years 16.6 (15.3-17.9) 9.00† (7.50-10.6) 15.6 (14.4-17.2) 36.5† (26.1-55.9) 122
 6–11 years 17.0 (16.3-17.8) 9.60 (8.80-10.8) 16.6 (15.9-17.6) 31.6 (26.8-39.5) 305
 12–19 years 11.0 (10.5-11.5) 5.10 (4.60-5.80) 11.2 (10.5-11.7) 20.1 (19.2-22.2) 640
 20–39 years 9.17 (8.63-9.74) 4.50 (3.50-5.10) 9.50 (8.40-10.2) 17.4 (16.3-19.5) 249
 40–59 years 9.69 (9.20-10.2) 4.20 (3.00-4.70) 9.80 (9.20-10.2) 19.2 (17.8-20.6) 274
 60 years and older 11.3 (10.3-12.4) 4.60 (3.90-5.20) 11.3 (9.90-12.6) 33.8 (20.0-40.4) 232 
Females 
Total, 3 years and older 11.7 (11.1-12.3) 5.40 (4.80-5.70) 11.2 (10.7-11.9) 27.4 (25.1-30.4) 1894
 3–5 years 17.2 (15.8-18.8) 10.2† (7.80-10.9) 17.2 (15.2-18.8) 30.9† (27.1-36.3) 113
 6–11 years 16.7 (16.0-17.5) 9.60 (7.90-10.5) 16.3 (15.5-17.3) 32.5 (27.1-38.4) 299
 12–19 years 10.8 (10.3-11.4) 5.40 (5.00-5.80) 10.8 (10.3-11.3) 19.4 (18.3-21.0) 616
 20–39 years 10.2 (9.49-10.9) 5.40 (4.50-5.70) 9.70 (9.20-10.7) 21.4 (19.2-24.0) 344
 40–59 years 10.9 (10.2-11.7) 4.70 (3.50-5.90) 10.6 (9.50-12.1) 24.8 (19.6-29.2) 267
 60 years and older 13.6 (12.2-15.2) 5.10 (3.80-6.60) 12.7 (11.6-14.9) 39.5 (30.5-48.0) 255 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 1.1.d. Serum folate: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 14.1 (13.6-14.6) 6.00 (5.70-6.30) 14.2 (13.7-14.8) 32.0 (30.9-33.3) 6147
 3–5 years 19.6 (18.3-21.1) 10.1† (8.30-12.3) 18.9 (17.8-20.2) 38.0† (31.5-48.9) 219
 6–11 years 18.7 (17.9-19.5) 9.70 (8.90-10.8) 18.8 (17.9-19.5) 34.2 (31.6-37.8) 494
 12–19 years 13.3 (12.8-13.9) 6.20 (5.70-6.70) 13.6 (13.1-14.3) 26.5 (24.0-27.6) 1073
 20–39 years 11.9 (11.4-12.6) 5.50 (4.80-5.90) 12.2 (11.2-12.9) 26.3 (24.0-29.1) 1381
 40–59 years 13.3 (12.7-13.8) 5.60 (5.20-6.10) 13.3 (12.9-14.0) 29.8 (27.4-31.0) 1276
 60 years and older 17.4 (16.8-18.0) 7.20 (6.60-7.60) 17.8 (16.9-18.4) 41.0 (37.4-43.5) 1704 
Males 
Total, 3 years and older 13.3 (12.9-13.9) 6.00 (5.60-6.30) 13.6 (13.0-14.1) 29.4 (28.1-30.6) 3013
 3–5 years 19.2 (17.2-21.4) 9.00† (7.80-11.1) 18.7 (16.3-19.9) 42.0† (29.9-57.6) 116
 6–11 years 18.2 (17.0-19.5) 8.90 (7.60-11.0) 18.0 (16.8-19.2) 34.7 (29.7-38.0) 260
 12–19 years 13.0 (12.4-13.7) 6.20 (5.60-6.80) 13.4 (12.8-13.9) 26.0 (22.8-27.3) 536
 20–39 years 11.3 (10.6-12.0) 5.40 (4.40-6.10) 11.3 (10.4-12.4) 23.0 (20.2-24.5) 577
 40–59 years 12.7 (12.2-13.3) 5.70 (5.20-6.40) 13.0 (12.3-13.5) 27.3 (25.4-28.8) 666
 60 years and older 15.8 (15.1-16.5) 6.30 (6.10-7.30) 16.0 (15.2-17.0) 35.9 (33.6-37.6) 858 
Females 
Total, 3 years and older 14.9 (14.3-15.4) 6.10 (5.80-6.50) 15.1 (14.5-15.7) 34.2 (32.4-35.8) 3134
 3–5 years 20.1 (18.8-21.5) 11.6† (8.30-14.1) 19.1 (18.4-21.6) 33.5† (28.9-39.0) 103
 6–11 years 19.2 (18.3-20.1) 10.2 (8.90-11.1) 19.4 (18.8-20.2) 33.6 (29.4-40.3) 234
 12–19 years 13.7 (12.9-14.5) 6.40 (5.20-7.10) 13.9 (13.2-14.7) 26.6 (23.0-31.6) 537
 20–39 years 12.6 (12.0-13.4) 5.60 (5.10-5.90) 13.0 (11.8-13.7) 30.4 (26.3-32.4) 804
 40–59 years 13.8 (13.1-14.6) 5.70 (5.10-6.30) 13.9 (12.9-15.1) 31.0 (28.7-35.0) 610
 60 years and older 18.8 (18.0-19.7) 7.70 (7.20-8.60) 18.9 (18.0-19.8) 43.6 (40.0-46.1) 846 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 1.2.a. Red blood cell (RBC) folate: Total population 
Geometric mean and selected percentiles of RBC concentrations (in ng/mL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 280 (273-287) 154 (149-159) 276 (270-282) 526 (510-541) 16102
 3–5 years 288 (281-296) 192 (184-203) 286 (278-293) 464 (403-512) 840
 6–11 years 280 (273-287) 186 (178-192) 277 (269-284) 431 (413-482) 1938
 12–19 years 244 (237-251) 150 (145-155) 240 (234-246) 411 (393-436) 4362
 20–39 years 255 (248-262) 142 (135-149) 252 (241-261) 452 (437-474) 3195
 40–59 years 291 (283-299) 159 (151-167) 289 (282-297) 538 (500-576) 2709
 60 years and older 338 (330-345) 169 (160-178) 341 (331-351) 667 (634-688) 3058 
Males 
Total, 3 years and older 272 (265-279) 153 (148-159) 268 (260-275) 494 (480-515) 7827
 3–5 years 291 (278-304) 192 (180-206) 287 (277-300) 477 (394-559) 438
 6–11 years 287 (279-295) 201 (189-209) 280 (272-288) 448 (423-504) 989
 12–19 years 240 (232-249) 150 (142-159) 238 (232-245) 398 (372-436) 2179
 20–39 years 246 (238-254) 146 (139-151) 245 (235-256) 418 (395-440) 1358
 40–59 years 282 (274-291) 157 (148-168) 280 (271-291) 516 (481-545) 1349
 60 years and older 325 (314-337) 159 (147-170) 324 (310-339) 644 (593-702) 1514 
Females 
Total, 3 years and older 288 (281-295) 155 (149-161) 285 (278-292) 552 (531-573) 8275
 3–5 years 286 (277-295) 190 (177-201) 287 (276-293) 441 (386-519) 402
 6–11 years 272 (264-280) 178 (171-185) 271 (261-281) 402 (385-469) 949
 12–19 years 247 (239-255) 148 (145-155) 244 (235-251) 422 (386-476) 2183
 20–39 years 264 (256-274) 140 (132-152) 261 (251-273) 492 (455-540) 1837
 40–59 years 300 (288-312) 164 (151-174) 297 (285-309) 565 (505-595) 1360
 60 years and older 347 (340-355) 176 (163-185) 353 (339-364) 673 (634-698) 1544 
Table 1.2.b. Red blood cell (RBC) folate: Mexican Americans 
Geometric mean and selected percentiles of RBC concentrations (in ng/mL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 258 (251-265) 155 (146-161) 254 (248-261) 456 (435-473) 4726
 3–5 years 289 (280-298) 201 (194-210) 278 (270-289) 458 (403-524) 273
 6–11 years 282 (276-288) 197 (180-211) 276 (270-282) 444 (402-492) 658
 12–19 years 245 (239-252) 156 (145-164) 241 (237-248) 408 (381-428) 1642
 20–39 years 239 (231-248) 140 (126-149) 235 (229-243) 423 (392-443) 870
 40–59 years 273 (263-283) 167 (160-172) 267 (255-275) 496 (454-552) 634
 60 years and older 301 (285-317) 161 (141-180) 291 (275-314) 590 (534-711) 649 
Males 
Total, 3 years and older 250 (242-258) 145 (133-155) 251 (241-257) 430 (401-457) 2306
 3–5 years 297 (284-311) 210† (196-220) 283 (270-299) 514† (401-599) 144
 6–11 years 287 (280-295) 201 (185-214) 283 (274-292) 443 (383-511) 339
 12–19 years 241 (234-248) 155 (141-166) 238 (233-246) 376 (356-406) 813
 20–39 years 227 (215-239) 129 (114-147) 225 (211-237) 392 (351-435) 385
 40–59 years 263 (252-275) 165 (152-171) 265 (251-278) 432 (392-498) 302
 60 years and older 293 (269-318) 152 (133-190) 285 (266-299) 567 (525-702) 323 
Females 
Total, 3 years and older 268 (260-275) 159 (155-168) 260 (251-266) 488 (457-517) 2420
 3–5 years 279 (267-292) 188† (182-203) 272 (259-289) 418† (371-458) 129
 6–11 years 276 (268-285) 194 (173-212) 268 (263-275) 434 (384-492) 319
 12–19 years 250 (242-258) 157 (145-167) 243 (237-250) 434 (393-486) 829
 20–39 years 255 (246-265) 152 (141-159) 250 (233-260) 436 (421-512) 485
 40–59 years 284 (269-299) 171 (163-181) 269 (248-291) 538 (464-624) 332
 60 years and older 308 (295-321) 168 (154-184) 305 (280-318) 600 (532-785) 326 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 1.2.c. Red blood cell (RBC) folate: Non-Hispanic blacks 
Geometric mean and selected percentiles of RBC concentrations (in ng/mL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 221 (216-226) 123 (120-129) 220 (214-224) 383 (370-399) 3783
 3–5 years 247 (240-254) 166 (159-180) 244 (235-251) 364 (326-411) 248
 6–11 years 238 (232-243) 161 (151-172) 240 (233-247) 336 (322-350) 623
 12–19 years 200 (196-205) 123 (117-129) 203 (197-209) 310 (295-320) 1265
 20–39 years 209 (202-216) 117 (113-124) 209 (201-215) 361 (340-385) 598
 40–59 years 222 (215-230) 120 (111-130) 222 (213-231) 396 (367-427) 553
 60 years and older 254 (243-267) 125 (110-136) 255 (240-267) 535 (476-590) 496 
Males 
Total, 3 years and older 216 (210-222) 122 (116-132) 219 (212-226) 360 (341-372) 1856
 3–5 years 246 (235-257) 168† (145-188) 244 (234-254) 364† (314-508) 130
 6–11 years 243 (237-250) 161 (153-178) 248 (238-255) 334 (313-361) 316
 12–19 years 203 (198-209) 124 (116-131) 208 (202-214) 310 (292-327) 645
 20–39 years 203 (194-211) 118 (101-135) 207 (197-214) 322 (302-350) 249
 40–59 years 211 (202-221) 121 (104-132) 211 (194-226) 364 (348-396) 277
 60 years and older 244 (229-260) 117 (103-134) 248 (227-266) 460 (403-592) 239 
Females 
Total, 3 years and older 225 (219-231) 124 (117-130) 221 (216-226) 411 (378-453) 1927
 3–5 years 248 (238-258) 165† (159-181) 244 (233-258) 379† (319-453) 118
 6–11 years 232 (224-240) 158 (132-177) 230 (221-242) 336 (319-369) 307
 12–19 years 197 (192-202) 124 (111-131) 197 (189-201) 303 (291-320) 620
 20–39 years 214 (205-223) 119 (113-127) 210 (200-220) 379 (352-445) 349
 40–59 years 233 (222-244) 122 (109-141) 233 (220-247) 409 (370-512) 276
 60 years and older 262 (246-279) 127 (104-151) 262 (241-277) 553 (496-599) 257 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 1.2.d. Red blood cell (RBC) folate: Non-Hispanic whites 
Geometric mean and selected percentiles of RBC concentrations (in ng/mL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 297 (289-304) 166 (160-172) 292 (284-299) 551 (536-570) 6210
 3–5 years 303 (289-318) 204 (180-231) 300 (290-309) 474 (390-546) 231
 6–11 years 292 (283-301) 189 (183-207) 290 (282-296) 464 (422-519) 498
 12–19 years 257 (249-265) 160 (152-164) 253 (246-261) 436 (400-458) 1083
 20–39 years 268 (257-279) 150 (135-165) 265 (252-278) 475 (449-524) 1383
 40–59 years 305 (296-313) 173 (166-180) 302 (293-309) 545 (506-597) 1291
 60 years and older 352 (342-361) 182 (170-193) 355 (344-365) 674 (639-702) 1724 
Males 
Total, 3 years and older 287 (279-296) 165 (158-173) 281 (272-291) 523 (501-544) 3037
 3–5 years 308 (286-332) 204† (165-231) 310 (290-324) 512† (403-634) 120
 6–11 years 300 (289-311) 211 (189-225) 290 (276-299) 473 (422-533) 263
 12–19 years 251 (241-261) 158 (145-164) 246 (238-256) 410 (372-454) 538
 20–39 years 258 (247-269) 157 (147-165) 256 (241-270) 432 (402-463) 578
 40–59 years 295 (286-304) 171 (157-180) 292 (280-303) 527 (491-601) 672
 60 years and older 339 (325-355) 170 (158-190) 342 (322-359) 660 (601-717) 866 
Females 
Total, 3 years and older 306 (297-315) 167 (159-174) 302 (293-310) 580 (551-604) 3173
 3–5 years 298 (285-311) 201† (189-236) 294 (279-307) 436† (382-546) 111
 6–11 years 283 (273-294) 182 (173-192) 290 (277-298) 453 (381-508) 235
 12–19 years 264 (253-275) 160 (149-167) 262 (250-270) 451 (395-539) 545
 20–39 years 278 (265-293) 143 (130-167) 278 (261-293) 548 (490-591) 805
 40–59 years 315 (300-330) 176 (165-190) 308 (295-327) 570 (503-611) 619
 60 years and older 361 (354-369) 191 (182-201) 364 (351-372) 680 (639-711) 858 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 1.3.a. Serum vitamin B12: Total population 
Geometric mean and selected percentiles of serum concentrations (in pg/mL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 488 (483-494) 237 (234-242) 485 (477-492) 1000 (977-1030) 15914
 3–5 years 783 (745-822) 446 (425-475) 788 (741-823) 1380 (1300-1520) 800
 6–11 years 692 (672-712) 369 (344-410) 700 (682-718) 1260 (1190-1310) 1907
 12–19 years 505 (496-515) 267 (254-279) 510 (499-523) 941 (912-979) 4331
 20–39 years 446 (439-453) 233 (222-238) 446 (438-455) 812 (787-843) 3185
 40–59 years 461 (453-469) 233 (224-241) 452 (442-460) 919 (883-973) 2676
 60 years and older 478 (466-489) 225 (212-233) 474 (467-485) 1010 (976-1060) 3015 
Males 
Total, 3 years and older 488 (480-497) 248 (240-258) 485 (477-494) 961 (922-993) 7741
 3–5 years 763 (715-814) 432 (373-468) 756 (699-824) 1450 (1250-1650) 417
 6–11 years 690 (667-715) 368 (344-393) 697 (673-718) 1270 (1200-1330) 972
 12–19 years 507 (493-522) 278 (254-297) 512 (494-528) 920 (892-952) 2165
 20–39 years 458 (446-470) 243 (231-263) 460 (445-475) 795 (766-826) 1355
 40–59 years 458 (447-469) 241 (226-256) 452 (438-460) 847 (792-898) 1337
 60 years and older 451 (439-464) 224 (204-236) 456 (439-469) 907 (859-1000) 1495 
Females 
Total, 3 years and older 488 (482-494) 232 (226-237) 483 (475-492) 1040 (1010-1080) 8173
 3–5 years 806 (762-852) 475 (446-514) 804 (755-859) 1340 (1270-1440) 383
 6–11 years 694 (668-720) 382 (338-425) 700 (676-731) 1250 (1110-1310) 935
 12–19 years 504 (494-514) 256 (241-267) 509 (495-525) 966 (936-1000) 2166
 20–39 years 435 (427-443) 222 (210-232) 433 (418-447) 839 (784-913) 1830
 40–59 years 463 (448-479) 223 (201-238) 453 (435-473) 1000 (920-1120) 1339
 60 years and older 499 (482-515) 227 (209-237) 494 (479-510) 1060 (994-1140) 1520 
Table 1.3.b. Serum vitamin B12: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in pg/mL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 532 (513-553) 260 (249-273) 514 (493-531) 1120 (1060-1200) 4695
 3–5 years 821 (784-860) 447 (402-526) 809 (764-870) 1470 (1330-1530) 266
 6–11 years 701 (672-731) 415 (390-447) 705 (676-731) 1190 (1090-1270) 652
 12–19 years 507 (491-523) 268 (249-288) 504 (494-519) 883 (847-920) 1637
 20–39 years 477 (452-504) 242 (213-260) 453 (437-469) 1010 (875-1180) 866
 40–59 years 518 (491-546) 264 (258-295) 475 (452-514) 1100 (947-1500) 634
 60 years and older 497 (464-532) 215 (203-237) 482 (454-514) 1090 (969-1460) 640 
Males 
Total, 3 years and older 507 (486-529) 263 (245-278) 494 (473-516) 999 (936-1100) 2293
 3–5 years 798 (744-855) 428† (351-553) 779 (704-833) 1490† (1250-2310) 139
 6–11 years 690 (646-738) 411 (379-455) 694 (659-729) 1190 (1040-1370) 338
 12–19 years 489 (472-507) 264 (242-292) 488 (479-501) 849 (808-896) 811
 20–39 years 454 (423-489) 249 (200-279) 452 (423-468) 771 (731-858) 383
 40–59 years 486 (465-507) 292 (264-308) 469 (429-514) 891 (792-1390) 301
 60 years and older 451 (414-491) 206 (162-238) 444 (410-473) 1070 (911-1250) 321 
Females 
Total, 3 years and older 562 (536-589) 257 (241-269) 533 (514-552) 1200 (1120-1360) 2402
 3–5 years 848 (799-901) 451† (408-548) 853 (775-933) 1390† (1200-1520) 127
 6–11 years 713 (681-747) 424 (382-475) 711 (689-746) 1160 (1080-1280) 314
 12–19 years 527 (505-549) 277 (254-296) 525 (504-534) 915 (870-939) 826
 20–39 years 506 (463-553) 232 (202-257) 461 (444-482) 1190 (1040-1720) 483
 40–59 years 553 (507-603) 258 (214-277) 491 (461-528) 1310 (1000-4570) 333
 60 years and older 540 (494-592) 235 (196-271) 525 (484-581) 1180 (965-2170) 319 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 1.3.c. Serum vitamin B12: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in pg/mL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 568 (558-579) 273 (263-289) 569 (556-583) 1180 (1150-1220) 3712
 3–5 years 867 (829-906) 486 (403-567) 859 (815-929) 1540 (1330-1700) 234
 6–11 years 803 (775-832) 413 (375-452) 812 (786-845) 1460 (1320-1630) 603
 12–19 years 585 (569-602) 298 (274-313) 588 (566-609) 1150 (1070-1230) 1254
 20–39 years 508 (491-525) 261 (233-289) 511 (492-530) 939 (864-977) 593
 40–59 years 525 (506-545) 263 (251-277) 522 (502-553) 1110 (1020-1190) 541
 60 years and older 542 (511-576) 246 (224-280) 560 (506-605) 1190 (1030-1410) 487 
Males 
Total, 3 years and older 558 (543-574) 270 (254-291) 563 (545-575) 1150 (1090-1230) 1818
 3–5 years 861 (799-928) 479† (361-558) 859 (791-931) 1650† (1320-1880) 121
 6–11 years 780 (744-818) 413 (368-478) 775 (752-822) 1390 (1250-1520) 304
 12–19 years 561 (540-583) 295 (256-324) 567 (535-602) 1000 (952-1080) 638
 20–39 years 511 (483-541) 253 (228-296) 518 (492-549) 939 (838-1170) 249
 40–59 years 507 (485-531) 261 (245-294) 507 (477-551) 1020 (888-1140) 274
 60 years and older 493 (458-531) 239 (215-269) 481 (458-542) 1030 (910-1320) 232 
Females 
Total, 3 years and older 577 (566-589) 277 (264-291) 576 (560-590) 1200 (1160-1260) 1894
 3–5 years 873 (815-934) 564† (419-611) 857 (804-953) 1430† (1250-1560) 113
 6–11 years 827 (791-865) 409 (373-452) 854 (803-891) 1490 (1320-1930) 299
 12–19 years 611 (592-630) 302 (270-315) 607 (584-634) 1280 (1160-1460) 616
 20–39 years 505 (485-526) 271 (238-301) 505 (476-530) 911 (814-975) 344
 40–59 years 542 (516-568) 263 (228-287) 538 (507-575) 1160 (1100-1250) 267
 60 years and older 577 (539-617) 249 (219-300) 607 (554-647) 1260 (1080-1630) 255 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 1.3.d. Serum vitamin B12: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in pg/mL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 472 (465-479) 235 (230-238) 471 (461-479) 938 (904-976) 6150
 3–5 years 728 (679-781) 440† (389-471) 730 (659-795) 1300† (1110-1510) 219
 6–11 years 662 (639-686) 350 (336-385) 680 (660-699) 1170 (1060-1280) 494
 12–19 years 493 (478-508) 265 (244-276) 503 (483-523) 918 (883-963) 1072
 20–39 years 431 (422-441) 228 (216-236) 434 (422-450) 763 (741-800) 1382
 40–59 years 449 (440-457) 228 (218-238) 440 (428-456) 882 (831-934) 1279
 60 years and older 473 (460-486) 226 (209-236) 471 (462-480) 1000 (954-1060) 1704 
Males 
Total, 3 years and older 477 (466-487) 244 (236-256) 474 (463-486) 897 (868-944) 3011
 3–5 years 701 (635-773) 424† (303-471) 682 (612-778) 1200† (1070-1590) 116
 6–11 years 666 (634-699) 344 (310-369) 679 (647-713) 1250 (1080-1430) 260
 12–19 years 500 (479-522) 279 (253-299) 509 (482-532) 903 (846-935) 534
 20–39 years 451 (436-468) 245 (233-271) 454 (436-475) 762 (721-811) 577
 40–59 years 452 (439-465) 236 (220-251) 445 (429-461) 817 (772-883) 667
 60 years and older 452 (438-467) 226 (204-244) 457 (439-471) 893 (836-986) 857 
Females 
Total, 3 years and older 467 (459-475) 226 (215-234) 467 (453-478) 976 (930-1010) 3139
 3–5 years 760 (703-820) 471† (424-517) 754 (690-820) 1310† (1100-1510) 103
 6–11 years 657 (627-689) 378 (336-425) 679 (632-701) 1090 (976-1250) 234
 12–19 years 486 (470-502) 248 (236-267) 497 (470-523) 940 (870-1000) 538
 20–39 years 413 (403-423) 216 (206-227) 412 (398-424) 758 (736-859) 805
 40–59 years 445 (428-463) 218 (192-236) 434 (413-459) 920 (853-1060) 612
 60 years and older 490 (472-508) 227 (199-238) 482 (470-502) 1060 (983-1170) 847 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 1.4.a. Plasma homocysteine: Total population 
Geometric mean and selected percentiles of plasma concentrations (in µmol/L) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 7.36 (7.26-7.46) 3.92 (3.83-4.02) 7.36 (7.25-7.47) 13.6 (13.3-14.1) 16071
 3–5 years 4.26 (4.15-4.37) 2.84 (2.70-3.04) 4.24 (4.17-4.38) 6.16 (5.81-6.40) 830
 6–11 years 4.53 (4.44-4.63) 3.06 (2.93-3.23) 4.51 (4.42-4.60) 6.74 (6.53-6.97) 1933
 12–19 years 5.98 (5.87-6.10) 3.82 (3.65-3.95) 5.90 (5.79-6.03) 9.57 (9.34-9.91) 4357
 20–39 years 7.25 (7.15-7.36) 4.37 (4.21-4.53) 7.21 (7.12-7.31) 12.0 (11.6-12.4) 3194
 40–59 years 8.28 (8.17-8.38) 5.25 (5.17-5.35) 8.13 (8.02-8.23) 13.4 (12.8-14.1) 2703
 60 years and older 10.0 (9.80-10.3) 6.20 (6.12-6.32) 9.67 (9.40-9.93) 18.4 (17.6-19.0) 3054 
Males 
Total, 3 years and older 7.92 (7.81-8.03) 4.14 (4.02-4.23) 8.06 (7.92-8.17) 14.3 (13.8-14.7) 7811
 3–5 years 4.35 (4.23-4.48) 3.05 (2.69-3.31) 4.31 (4.20-4.48) 6.16 (5.82-6.32) 432
 6–11 years 4.60 (4.48-4.71) 3.08 (2.91-3.26) 4.57 (4.48-4.70) 6.90 (6.47-7.23) 988
 12–19 years 6.35 (6.21-6.49) 3.96 (3.74-4.23) 6.24 (6.14-6.40) 9.96 (9.54-10.9) 2177
 20–39 years 8.21 (8.06-8.36) 5.58 (5.37-5.74) 8.07 (7.87-8.20) 12.8 (12.1-13.8) 1358
 40–59 years 9.10 (8.94-9.26) 6.20 (5.99-6.50) 8.90 (8.70-9.13) 14.0 (13.0-14.7) 1345
 60 years and older 10.7 (10.5-10.9) 6.85 (6.53-7.09) 10.4 (10.1-10.7) 18.5 (17.6-19.0) 1511 
Females 
Total, 3 years and older 6.87 (6.76-6.98) 3.76 (3.65-3.87) 6.79 (6.67-6.88) 12.9 (12.5-13.3) 8260
 3–5 years 4.16 (4.01-4.32) 2.74 (2.60-3.01) 4.22 (4.03-4.37) 6.16 (5.76-6.53) 398
 6–11 years 4.47 (4.36-4.58) 3.04 (2.91-3.23) 4.45 (4.27-4.59) 6.58 (6.18-7.02) 945
 12–19 years 5.62 (5.48-5.77) 3.65 (3.46-3.90) 5.58 (5.42-5.73) 8.84 (8.28-9.57) 2180
 20–39 years 6.43 (6.30-6.57) 3.85 (3.64-4.08) 6.42 (6.25-6.55) 10.4 (9.81-11.4) 1836
 40–59 years 7.56 (7.43-7.69) 4.94 (4.75-5.05) 7.36 (7.20-7.52) 12.9 (12.3-13.4) 1358
 60 years and older 9.58 (9.29-9.87) 6.07 (5.93-6.18) 9.12 (8.90-9.37) 18.2 (16.9-19.4) 1543 
Table 1.4.b. Plasma homocysteine: Mexican Americans 
Geometric mean and selected percentiles of plasma concentrations (in µmol/L) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 6.35 (6.18-6.52) 3.54 (3.45-3.62) 6.35 (6.14-6.51) 11.6 (11.2-12.0) 4725
 3–5 years 4.10 (3.92-4.29) 2.84 (2.66-3.11) 4.09 (3.84-4.33) 5.80 (5.37-6.41) 271
 6–11 years 4.45 (4.34-4.56) 3.04 (2.82-3.25) 4.43 (4.30-4.61) 6.47 (6.18-6.60) 656
 12–19 years 5.73 (5.58-5.90) 3.74 (3.59-3.92) 5.65 (5.47-5.85) 9.06 (8.59-9.54) 1643
 20–39 years 6.77 (6.62-6.93) 4.08 (3.88-4.24) 6.80 (6.60-6.93) 11.8 (10.9-12.5) 870
 40–59 years 7.66 (7.38-7.94) 4.79 (4.47-5.08) 7.48 (7.18-7.89) 11.7 (11.3-12.4) 634
 60 years and older 9.57 (9.03-10.1) 5.63 (5.35-6.21) 9.34 (8.61-10.1) 17.7 (16.1-19.4) 651 
Males 
Total, 3 years and older 6.98 (6.81-7.17) 3.76 (3.60-3.87) 7.02 (6.87-7.20) 12.4 (11.9-12.8) 2305
 3–5 years 4.13 (3.97-4.29) 2.69† (2.60-3.20) 4.11 (3.84-4.48) 5.68† (5.26-6.40) 142
 6–11 years 4.59 (4.47-4.71) 3.04 (2.80-3.37) 4.62 (4.42-4.77) 6.56 (6.42-7.11) 339
 12–19 years 6.23 (6.07-6.40) 4.10 (3.92-4.22) 6.23 (6.01-6.42) 9.84 (9.07-10.7) 814
 20–39 years 7.77 (7.54-8.02) 5.01 (4.66-5.32) 7.43 (7.18-7.76) 12.8 (11.9-14.8) 386
 40–59 years 8.52 (8.17-8.89) 5.63 (5.27-6.22) 8.41 (8.04-8.91) 12.0 (11.4-14.5) 301
 60 years and older 10.1 (9.53-10.7) 6.34 (5.58-6.73) 10.1 (9.19-10.6) 18.7 (16.5-20.3) 323 
Females 
Total, 3 years and older 5.72 (5.53-5.92) 3.43 (3.30-3.56) 5.65 (5.47-5.80) 10.0 (9.26-11.2) 2420
 3–5 years 4.07 (3.78-4.39) 3.06† (2.72-3.23) 4.01 (3.69-4.31) 5.83† (4.89-8.23) 129
 6–11 years 4.31 (4.18-4.44) 3.04 (2.82-3.23) 4.28 (4.12-4.46) 5.91 (5.77-6.38) 317
 12–19 years 5.24 (5.07-5.40) 3.48 (3.31-3.69) 5.19 (5.01-5.41) 8.05 (7.65-8.31) 829
 20–39 years 5.75 (5.60-5.90) 3.66 (3.51-3.90) 5.79 (5.52-5.93) 8.56 (8.15-9.20) 484
 40–59 years 6.86 (6.54-7.19) 4.40 (3.92-4.82) 6.68 (6.35-7.08) 11.2 (9.70-13.7) 333
 60 years and older 9.16 (8.46-9.92) 5.44 (5.14-5.88) 8.84 (8.01-9.97) 17.2 (15.0-21.6) 328 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 1.4.c. Plasma homocysteine: Non-Hispanic blacks 
Geometric mean and selected percentiles of plasma concentrations (in µmol/L) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 7.14 (6.95-7.33) 3.72 (3.58-3.84) 7.07 (6.84-7.29) 14.3 (13.3-14.9) 3777
 3–5 years 4.16 (4.01-4.32) 2.82 (2.67-3.08) 4.08 (3.91-4.34) 6.18 (5.81-6.43) 246
 6–11 years 4.43 (4.29-4.57) 2.99 (2.84-3.21) 4.42 (4.29-4.57) 6.43 (6.23-6.75) 621
 12–19 years 5.96 (5.83-6.10) 3.73 (3.57-3.92) 5.92 (5.78-6.05) 9.66 (9.34-10.1) 1265
 20–39 years 7.22 (7.03-7.42) 4.33 (4.12-4.43) 7.22 (7.00-7.46) 11.9 (11.3-12.8) 597
 40–59 years 8.71 (8.33-9.09) 5.27 (4.87-5.66) 8.43 (8.08-8.83) 15.3 (13.7-18.8) 552
 60 years and older 10.9 (10.5-11.3) 6.39 (6.12-6.67) 10.2 (9.86-10.8) 21.3 (18.9-25.9) 496 
Males 
Total, 3 years and older 7.68 (7.43-7.92) 3.83 (3.72-4.00) 7.77 (7.52-8.04) 15.2 (14.6-15.9) 1853
 3–5 years 4.38 (4.17-4.60) 3.05† (2.68-3.34) 4.27 (4.06-4.61) 6.38† (5.79-6.57) 127
 6–11 years 4.53 (4.38-4.69) 2.99 (2.81-3.39) 4.53 (4.38-4.64) 6.51 (6.23-6.80) 314
 12–19 years 6.37 (6.22-6.52) 3.87 (3.69-4.08) 6.32 (6.16-6.44) 10.4 (9.70-11.0) 646
 20–39 years 8.46 (8.18-8.74) 5.54 (5.34-5.91) 8.22 (7.96-8.59) 14.3 (11.9-15.5) 249
 40–59 years 9.49 (9.03-9.97) 6.04 (5.32-6.45) 9.20 (8.62-9.54) 18.1 (14.7-20.2) 278
 60 years and older 11.5 (11.0-12.0) 6.83 (6.13-7.33) 11.0 (10.2-11.9) 21.3 (18.4-25.9) 239 
Females 
Total, 3 years and older 6.71 (6.50-6.94) 3.60 (3.50-3.76) 6.59 (6.38-6.78) 12.8 (12.2-13.7) 1924
 3–5 years 3.93 (3.72-4.16) 2.72† (2.54-2.97) 3.85 (3.58-4.29) 5.85† (5.13-6.39) 119
 6–11 years 4.33 (4.18-4.47) 2.94 (2.71-3.21) 4.33 (4.18-4.47) 6.39 (5.90-6.81) 307
 12–19 years 5.58 (5.41-5.75) 3.65 (3.46-3.82) 5.62 (5.45-5.77) 8.51 (7.92-9.32) 619
 20–39 years 6.41 (6.18-6.64) 4.07 (3.70-4.33) 6.42 (6.18-6.75) 9.75 (9.08-10.0) 348
 40–59 years 8.07 (7.67-8.50) 4.91 (4.63-5.33) 7.72 (7.38-8.48) 13.3 (11.7-19.2) 274
 60 years and older 10.6 (10.1-11.1) 6.20 (5.89-6.62) 9.92 (9.55-10.5) 22.5 (17.5-27.7) 257 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 1.4.d. Plasma homocysteine: Non-Hispanic whites 
Geometric mean and selected percentiles of plasma concentrations (in µmol/L) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 7.59 (7.47-7.71) 4.07 (3.97-4.19) 7.60 (7.48-7.74) 14.0 (13.4-14.4) 6192
 3–5 years 4.30 (4.14-4.45) 2.74 (2.64-3.19) 4.28 (4.19-4.49) 6.19 (5.74-6.90) 229
 6–11 years 4.56 (4.44-4.69) 3.14 (2.94-3.26) 4.51 (4.40-4.68) 6.94 (6.60-7.13) 497
 12–19 years 5.99 (5.86-6.12) 3.83 (3.59-4.03) 5.89 (5.76-6.07) 9.54 (9.23-10.2) 1078
 20–39 years 7.36 (7.24-7.49) 4.66 (4.37-4.83) 7.33 (7.16-7.49) 12.0 (11.5-12.4) 1383
 40–59 years 8.31 (8.19-8.42) 5.30 (5.18-5.44) 8.17 (8.03-8.28) 13.4 (12.5-14.1) 1286
 60 years and older 10.0 (9.74-10.3) 6.22 (6.12-6.44) 9.63 (9.33-9.92) 18.2 (17.4-19.0) 1719 
Males 
Total, 3 years and older 8.12 (7.99-8.25) 4.25 (4.15-4.38) 8.23 (8.11-8.38) 14.3 (13.9-14.8) 3026
 3–5 years 4.39 (4.18-4.61) 3.10† (2.44-3.48) 4.28 (4.20-4.56) 6.14† (5.65-7.22) 120
 6–11 years 4.62 (4.49-4.75) 3.15 (2.94-3.31) 4.55 (4.41-4.76) 6.91 (6.47-7.23) 264
 12–19 years 6.28 (6.11-6.46) 3.95 (3.64-4.25) 6.19 (6.00-6.36) 9.72 (9.38-11.4) 534
 20–39 years 8.21 (8.03-8.41) 5.62 (5.37-5.81) 8.10 (7.84-8.28) 12.4 (11.7-12.9) 577
 40–59 years 9.10 (8.92-9.28) 6.31 (5.99-6.56) 8.91 (8.68-9.18) 13.8 (12.7-14.4) 668
 60 years and older 10.7 (10.4-11.0) 6.88 (6.53-7.25) 10.3 (10.0-10.7) 18.2 (17.3-19.0) 863 
Females 
Total, 3 years and older 7.11 (6.97-7.25) 3.89 (3.69-4.07) 7.01 (6.89-7.14) 13.4 (12.8-14.2) 3166
 3–5 years 4.20 (3.97-4.44) 2.71† (2.06-3.19) 4.25 (4.04-4.59) 6.17† (5.58-6.90) 109
 6–11 years 4.50 (4.33-4.68) 3.11 (2.91-3.30) 4.47 (4.19-4.73) 6.94 (6.16-7.35) 233
 12–19 years 5.70 (5.52-5.88) 3.68 (3.43-3.97) 5.63 (5.40-5.84) 9.09 (8.36-10.2) 544
 20–39 years 6.61 (6.45-6.78) 3.90 (3.63-4.32) 6.52 (6.37-6.72) 11.2 (9.87-12.0) 806
 40–59 years 7.57 (7.40-7.75) 4.97 (4.67-5.13) 7.36 (7.18-7.57) 12.9 (11.7-14.0) 618
 60 years and older 9.53 (9.19-9.89) 6.04 (5.82-6.19) 9.09 (8.78-9.31) 18.2 (16.6-19.8) 856 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 1.5.a. Plasma methylmalonic acid: Total population 
Geometric mean and selected percentiles of plasma concentrations (in µmol/L) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older .131 (.129-.134) .070 (.060-.070) .120 (.120-.130) .290 (.280-.300) 16048
 3–5 years .120 (.116-.124) .060 (.060-.070) .120 (.110-.120) .230 (.200-.250) 829
 6–11 years .121 (.117-.125) .070 (.060-.070) .120 (.110-.120) .210 (.190-.220) 1929
 12–19 years .116 (.113-.120) .050 (.050-.060) .110 (.100-.110) .230 (.210-.240) 4352
 20–39 years .122 (.119-.125) .060 (.060-.070) .110 (.110-.120) .260 (.240-.270) 3189
 40–59 years .132 (.129-.134) .060 (.060-.070) .120 (.120-.130) .250 (.240-.270) 2701
 60 years and older .171 (.166-.176) .080 (.070-.080) .160 (.150-.160) .450 (.410-.530) 3048 
Males 
Total, 3 years and older .135 (.132-.138) .070 (.060-.070) .130 (.120-.130) .280 (.270-.300) 7799
 3–5 years .123 (.118-.129) .060 (.060-.070) .110 (.110-.120) .230 (.200-.280) 432
 6–11 years .125 (.120-.130) .060 (.060-.070) .110 (.110-.120) .200 (.180-.220) 986
 12–19 years .122 (.118-.126) .070 (.060-.070) .120 (.110-.120) .230 (.220-.270) 2175
 20–39 years .128 (.123-.132) .060 (.060-.070) .130 (.120-.130) .250 (.230-.290) 1355
 40–59 years .136 (.132-.140) .080 (.070-.080) .130 (.120-.130) .270 (.240-.300) 1343
 60 years and older .173 (.168-.178) .070 (.070-.080) .160 (.150-.160) .450 (.420-.500) 1508 
Females 
Total, 3 years and older .128 (.126-.131) .070 (.060-.070) .110 (.110-.120) .280 (.260-.280) 8249
 3–5 years .116 (.111-.122) .060 (.060-.070) .110 (.110-.120) .200 (.180-.250) 397
 6–11 years .117 (.112-.123) .070 (.060-.070) .110 (.110-.120) .190 (.180-.200) 943
 12–19 years .111 (.107-.116) .050 (.050-.060) .100 (.100-.110) .220 (.200-.260) 2177
 20–39 years .117 (.114-.120) .050 (.050-.060) .100 (.100-.110) .260 (.230-.270) 1834
 40–59 years .127 (.124-.131) .060 (.060-.070) .110 (.110-.120) .250 (.230-.300) 1358
 60 years and older .170 (.164-.177) .070 (.070-.080) .150 (.140-.150) .460 (.380-.570) 1540 
Table 1.5.b. Plasma methylmalonic acid: Mexican Americans 
Geometric mean and selected percentiles of plasma concentrations (in µmol/L) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older .111 (.108-.113) .050 (.050-.060) .110 (.100-.110) .220 (.220-.240) 4726
 3–5 years .108 (.103-.112) .070 (.060-.070) .110 (.100-.110) .180 (.170-.210) 271
 6–11 years .104 (.100-.109) .060 (<LOD-.060) .100 (.090-.100) .180 (.160-.190) 656
 12–19 years .104 (.102-.107) .060 (.050-.060) .100 (.090-.100) .190 (.180-.220) 1644
 20–39 years .108 (.103-.113) .050 (<LOD-.060) .100 (.090-.100) .230 (.210-.270) 870
 40–59 years .116 (.112-.120) .060 (.050-.060) .110 (.100-.110) .230 (.220-.270) 634
 60 years and older .150 (.145-.155) .060 (.060-.080) .130 (.120-.130) .440 (.400-.530) 651 
Males 
Total, 3 years and older .117 (.114-.121) .060 (<LOD-.060) .100 (.100-.110) .250 (.230-.280) 2305
 3–5 years .108 (.102-.115) .060† (.050-.080) .100 (.100-.110) .180† (.160-.210) 142
 6–11 years .104 (.099-.109) .050 (<LOD-.070) .110 (.100-.110) .170 (.150-.200) 339
 12–19 years .111 (.107-.115) .050 (<LOD-.060) .110 (.100-.110) .210 (.190-.230) 814
 20–39 years .118 (.112-.125) .060 (<LOD-.060) .110 (.100-.110) .280 (.230-.390) 385
 40–59 years .125 (.119-.132) .070 (.060-.070) .110 (.110-.120) .260 (.220-.350) 301
 60 years and older .151 (.141-.162) .070 (.060-.080) .140 (.130-.150) .500 (.330-.630) 324 
Females 
Total, 3 years and older .104 (.102-.106) .050 (.050-.060) .095 (.090-.100) .210 (.190-.220) 2421
 3–5 years .107 (.100-.114) .060† (<LOD-.070) .110 (.100-.120) .170† (.160-.210) 129
 6–11 years .105 (.100-.111) .070 (.060-.070) .100 (.090-.100) .170 (.150-.200) 317
 12–19 years .097 (.095-.100) .060 (.050-.060) .100 (.090-.100) .170 (.170-.200) 830
 20–39 years .097 (.093-.103) < LOD .100 (.090-.100) .170 (.160-.210) 485
 40–59 years .107 (.102-.112) .060 (.050-.060) .090 (.090-.100) .190 (.180-.220) 333
 60 years and older .148 (.140-.157) .070 (<LOD-.080) .120 (.120-.130) .430 (.380-.560) 327 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 1.5.c. Plasma methylmalonic acid: Non-Hispanic blacks 
Geometric mean and selected percentiles of plasma concentrations (in µmol/L) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older .110 (.107-.114) .050 (.050-.060) .100 (.100-.110) .220 (.210-.240) 3768
 3–5 years .102 (.097-.107) .060 (<LOD-.060) .090 (.090-.100) .170 (.160-.200) 245
 6–11 years .103 (.099-.107) .070 (.060-.070) .100 (.090-.100) .170 (.150-.190) 619
 12–19 years .101 (.097-.105) .050 (.050-.060) .100 (.090-.100) .180 (.180-.200) 1264
 20–39 years .101 (.097-.106) .060 (.050-.060) .100 (.090-.100) .180 (.160-.220) 596
 40–59 years .115 (.109-.122) .060 (<LOD-.060) .110 (.100-.110) .230 (.190-.270) 551
 60 years and older .156 (.148-.165) .070 (.070-.080) .140 (.130-.140) .400 (.310-.500) 493 
Males 
Total, 3 years and older .115 (.111-.119) .050 (.050-.060) .100 (.100-.110) .230 (.220-.260) 1846
 3–5 years .103 (.096-.110) .060† (<LOD-.060) .090 (.090-.110) .180† (.150-.230) 127
 6–11 years .104 (.100-.109) .060 (<LOD-.060) .100 (.090-.100) .160 (.150-.190) 312
 12–19 years .107 (.102-.112) .060 (<LOD-.060) .100 (.090-.100) .190 (.180-.240) 645
 20–39 years .110 (.103-.119) .060 (<LOD-.070) .100 (.100-.110) .220 (.170-.260) 248
 40–59 years .119 (.111-.128) < LOD .120 (.110-.120) .250 (.200-.290) 277
 60 years and older .155 (.143-.167) .070 (.050-.070) .140 (.120-.150) .450 (.310-.560) 237 
Females 
Total, 3 years and older .107 (.104-.110) .050 (.050-.060) .090 (.090-.100) .220 (.200-.230) 1922
 3–5 years .101 (.094-.109) .050† (<LOD-.070) .100 (.090-.100) .150† (.130-.190) 118
 6–11 years .102 (.097-.107) .060 (.060-.070) .100 (.090-.100) .170 (.150-.200) 307
 12–19 years .095 (.090-.100) < LOD .080 (.080-.090) .170 (.160-.180) 619
 20–39 years .095 (.092-.099) .060 (.050-.060) .080 (.080-.090) .160 (.140-.180) 348
 40–59 years .112 (.104-.121) .050 (<LOD-.070) .110 (.100-.110) .210 (.170-.230) 274
 60 years and older .157 (.147-.168) .080 (.070-.080) .140 (.120-.140) .390 (.270-.620) 256 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 1.5.d. Plasma methylmalonic acid: Non-Hispanic whites 
Geometric mean and selected percentiles of plasma concentrations (in µmol/L) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older .139 (.136-.142) .080 (.070-.080) .130 (.120-.130) .290 (.280-.300) 6178
 3–5 years .129 (.123-.136) .080 (.070-.080) .120 (.110-.120) .240 (.210-.270) 229
 6–11 years .130 (.124-.137) .070 (.070-.080) .130 (.110-.130) .230 (.200-.270) 495
 12–19 years .124 (.120-.128) .070 (.060-.070) .110 (.110-.120) .230 (.220-.280) 1073
 20–39 years .130 (.126-.133) .070 (.060-.070) .120 (.120-.130) .250 (.230-.270) 1380
 40–59 years .136 (.132-.139) .070 (.070-.080) .130 (.120-.130) .250 (.240-.280) 1285
 60 years and older .174 (.168-.179) .090 (.080-.090) .160 (.150-.160) .450 (.380-.530) 1716 
Males 
Total, 3 years and older .141 (.138-.145) .080 (.070-.080) .140 (.130-.140) .280 (.270-.300) 3021
 3–5 years .136 (.127-.146) .080† (.050-.080) .130 (.120-.140) .250† (.210-.340) 120
 6–11 years .134 (.126-.143) .080 (.060-.080) .120 (.110-.130) .240 (.200-.310) 264
 12–19 years .129 (.124-.134) .060 (.060-.070) .110 (.110-.120) .240 (.220-.280) 533
 20–39 years .132 (.127-.138) .060 (.060-.070) .130 (.120-.130) .250 (.230-.290) 576
 40–59 years .139 (.134-.144) .070 (.070-.080) .120 (.120-.130) .270 (.240-.300) 667
 60 years and older .174 (.168-.180) .090 (.080-.100) .170 (.160-.170) .440 (.380-.490) 861 
Females 
Total, 3 years and older .137 (.134-.140) .080 (.070-.080) .120 (.120-.130) .290 (.280-.310) 3157
 3–5 years .122 (.113-.132) .070† (.070-.090) .120 (.110-.120) .200† (.160-.250) 109
 6–11 years .125 (.117-.134) .070 (.060-.080) .110 (.110-.130) .210 (.180-.270) 231
 12–19 years .119 (.114-.125) .070 (.060-.070) .100 (.100-.110) .230 (.200-.300) 540
 20–39 years .127 (.123-.131) .060 (.060-.070) .110 (.110-.120) .260 (.250-.280) 804
 40–59 years .132 (.128-.137) .080 (.070-.080) .130 (.120-.130) .250 (.220-.300) 618
 60 years and older .173 (.166-.181) .090 (.080-.090) .160 (.150-.160) .450 (.370-.570) 855 
† Estimate is subject to greater uncertainty due to small cell size. 
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Vitamins A and E and Carotenoids 
•	 Vitamin A 
•	 Vitamin E 
•	 gamma-Tocopherol 
•	 alpha-Carotene 
•	 trans-beta -Carotene 




•	 25-Hydroxyvitamin D 
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Fat-Soluble Vitamins & Micronutrients: 
Vitamins A and E and 
Carotenoids 
Vitamins A (retinol) and E (tocopherol) and the carotenoids are fat-soluble 
micronutrients that are found in many foods, including some vegetables, 
fruits, meats, and animal products. Fish-liver oils, liver, egg yolks, butter, 
and cream are known for their higher content of vitamin A. Nuts and 
seeds are particularly rich sources of vitamin E (Thomas 2006). At least 700 
carotenoids—fat-soluble red and yellow pigments—are found in nature 
(Britton 2004). Americans consume 40–50 of these carotenoids, primarily 
in fruits and vegetables (Khachik 1992), and smaller amounts in poultry 
products, including egg yolks, and in seafoods (Boylston 2007). Six major 
carotenoids are found in human serum: alpha-carotene, beta-carotene, 
beta-cryptoxanthin, lutein, trans-lycopene, and zeaxanthin. Major 
carotene sources are orange-colored fruits and vegetables such as carrots, 
pumpkins, and mangos. Lutein and zeaxanthin are also found in dark 
green leafy vegetables, where any orange coloring is overshadowed by 
chlorophyll. Trans-Lycopene is obtained primarily from tomato and tomato 
products. For information on the carotenoid content of U.S. foods, see the 
1998 carotenoid database created by the U.S. Department of Agriculture 
and the Nutrition Coordinating Center at the University of Minnesota 
(http://www.nal.usda.gov/fnic/foodcomp/Data/car98/car98.html). 
Vitamin A, found in foods that come from animal sources, is called 
preformed vitamin A. Some carotenoids found in colorful fruits and 
vegetables are called provitamin A; they are metabolized in the body to 
vitamin A. Among the carotenoids, beta-carotene, a retinol dimer, has 
the most significant provitamin A activity. Because of limitations in the 
body’s ability to absorb and metabolize vitamin A, approximately 12 
micrograms (µg) of dietary beta-carotene are needed to equal 1 µg of 
retinol. Other provitamin A carotenoids, such as alpha-carotene and beta-
cryptoxanthin, are half as active as beta-carotene (Institute of Medicine 2000). 
The bioconversion of carotenoids to vitamin A is highly variable from 
person to person (Krinsky 2005). Vitamin E activity is derived from at least 
eight naturally occurring tocopherols, the most potent of which is alpha-
tocopherol. Other less active forms of vitamin E are plentiful in the U.S. 
diet, with gamma-tocopherol being the predominant form. 
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The absorption of fat-soluble micronutrients from the gastrointestinal tract 
depends on processes responsible for fat absorption or metabolism. Thus, people 
with conditions resulting in fat malabsorption (e.g., celiac disease, Crohn’s disease, 
pancreatic disorders) can develop vitamin A deficiency over time. Vitamin A also 
has interactions with other nutrients. Iron and zinc deficiency can affect vitamin A 
metabolism and transport of vitamin A stores from the liver to body tissues (Institute 
of Medicine 2001). The absorption of carotenoids from foods is highly dependent on 
cooking techniques that break down plant cell walls and release carotenoids and 
also on the availability of dietary fat to enhance carotenoid uptake (Krinsky 2005). 
The liver regulates the concentration of vitamin A in the circulation by releasing 
stored retinyl esters as needed; only when liver reserves are nearly exhausted does 
serum vitamin A fall into the deficient range (Napoli 2006). The variation in serum 
carotenoid concentrations among people in the United States is relatively large, 
primarily reflecting wide-ranging differences in dietary intake (Lacher 2005). Plasma 
concentrations of tocopherols vary widely among healthy individuals and are highly 
correlated with plasma lipid concentrations (Ford 1999; Ford 2006). 
Inadequate or excessive intake of vitamins A or E can lead to various disorders. For 
example, vitamin A deficiency is considered to be the main cause of childhood 
blindness (Roodhooft 2002), a rare condition in the United States. Prominent signs of 
vitamin A deficiency include night blindness, corneal thinning, and conjunctival 
metaplasia. Vitamin A is also essential for proper immune function, epithelial 
growth and repair, bone growth, reproduction, and normal embryonic and fetal 
development (West 2006). Acute toxicity, resulting from single or short-term large 
doses of preformed vitamin A, is characterized by nausea, vomiting, headache, 
vertigo, blurred vision, increased cerebrospinal fluid pressure, and lack of muscular 
coordination. Central nervous system effects, liver abnormalities, bone and skin 
changes, and other nonspecific adverse effects can be indicative of chronic 
hypervitaminosis A. Consuming excess amounts of vitamin A during early pregnancy 
may lead to serious birth defects (Institute of Medicine 2001). The U.S. Food and Drug 
Administration (FDA) currently recommends that pregnant women obtain vitamin A 
from foods containing beta-carotene (U.S. Food and Drug Administration 1995). 
Carotenoids are considered among the best biological markers for fruit 
and vegetable intake. The strongest dietary predictors of serum carotenoid 
concentrations are fruits (for sources of beta-cryptoxanthin), carrots and root 
vegetables (for sources of carotenes), and tomato products (for sources of trans-
lycopene) (Al-Delaimy 2005). Research studies have shown inconsistencies in the relation 
between carotenoid intake and protection from cancer. Carotenoids in foods, even 
when consumed over long periods and in large amounts, are not known to produce 
adverse health effects. However, results of intervention studies of smokers who used 
20-30 milligrams (mg) of beta-carotene per day showed that this group had more 
lung cancers than placebo-treated groups (Redlich 1998; Albanes 1996). 
Vitamin E deficiency occurs only rarely in people, and overt deficiency symptoms in 
people consuming low-vitamin E diets have never been described (Institute of Medicine 
2000). The main manifestation of vitamin E deficiency is peripheral neuropathy 
characterized by the degeneration of the large-caliber axons of sensory neurons 
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(Institute of Medicine 2000). The upper limit (UL) for vitamin E intake (1000 mg/day) was 
based on hemorrhagic effects; however, a causal association between excess alpha-
tocopherol intake in apparently healthy individuals and adverse health outcomes 
has not consistently been shown (Institute of Medicine 2000). Studies evaluating 
tocopherols to reduce the risk for cardiovascular disease demonstrated inconsistent 
findings (Agency for Healthcare Research and Quality 2003). The American Heart Association 
currently advises that antioxidant supplements (such as vitamins E and C and beta-
carotene) should not be used for primary or secondary prevention of cardiovascular 
disease (Lichtenstein 2006). Nevertheless, the American Heart Association recommends 
consuming food sources of antioxidant nutrients, principally from a variety of plant-
derived foods such as fruits, vegetables, whole grains, and vegetable oils. 
The National Academy of Sciences has established dietary-requirement intake values 
for vitamins A and E by determining the adequate intake (AI) for infants and the 
recommended dietary allowance (RDA) for older age groups (Institute of Medicine 2000 
and 2001). The  RDA for vitamin A for adults is 900 µg/day of retinol equivalents; for 
children, the RDA ranges from 300–700 µg/day. For infants (aged 0–12 months), the 
AI is set at 400–500 µg/day of retinol equivalents. For adults, the RDA for vitamin E 
is 15 mg/day of alpha-tocopherol; for children (1–18 years), the RDA ranges from 
6 mg to 15 mg/day. There is no RDA for other forms of vitamin E such as gamma-
tocopherol. Although no quantitative recommendations are available for the intake 
of carotenoids, existing recommendations support increased consumption of 
carotenoid-rich fruits and vegetables. Current public health guidelines advise that 
people consume 5 to 13 servings of fruits and vegetables a day, depending on caloric 
need, to ensure adequate nutrient intake (U.S. Department of Health and Human Services and 
U.S. Department of Agriculture 2005). 
Clinical laboratories typically use 
conventional units for serum 
concentrations of these fat-soluble 
micronutrients (µg per deciliter 
[dL]). Conversion factors to 
international system (SI) units are 1 
µg/dL = 0.0349 micromole per liter 
(µmol/L) for vitamin A and 1 µg/ 
dL = 0.02322 µmol/L for vitamin 
E. Depending on its molecular 
weight, each carotenoid has a 
specific conversion factor. 
The diagnosis of vitamin A or 
E deficiency is supported by 
measuring these concentrations in 
the body. Vitamin A deficiency can 
be diagnosed in a number of ways. 
People with serum concentrations of retinol of less than 20 µg/dL are considered 
vitamin A deficient, and those with serum concentrations of less than 10 µg/dL are 
considered severely deficient (West 2006). Carotenoid deficiency has no defined serum 
Chemists perform extraction of fat-soluble vitamins from serum. 
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concentrations. The laboratory diagnosis of vitamin E deficiency is based on serum 
concentrations of alpha-tocopherol (less than 500 µg/dL or less than 0.8 mg of alpha-
tocopherol per gram of total lipids) (Beers 2006). Such concentrations are associated 
with in vitro hydrogen peroxide-induced red blood cell lysis, not with clinical 
deficiency symptoms (Institute of Medicine 2000). Among most laboratories participating 
in an external quality assurance program, standardized high performance liquid 
chromatography (HPLC) methods for measuring fat-soluble micronutrients show 
consistent agreement of values (Duewer 2000). 
For more information on these fat-soluble micronutrients, see the Institute of 
Medicine’s Dietary Reference Intake reports (Institute of Medicine 2000 and 2001), 
the vitamin fact sheets from the National Institutes of Health, Office of Dietary 
Supplements (http://ods.od.nih.gov/Health_Information/Vitamin_and_Mineral 
_Supplement_Fact_Sheets.aspx), as well as information from the American Society for 
Nutrition (http://jn.nutrition.org/nutinfo/). 
Since 1971, various fat-soluble micronutrients have been measured in the serum 
of NHANES participants. In NHANES III (1988–1994), clinically low concentrations of 
serum retinol were uncommon in U.S. residents aged 4 years and older, although 
racial/ethnic and socioeconomic differences existed (Ballew 2001). Variations in serum 
carotenoid concentrations by ethnicity and sex were found for adults, children, and 
adolescents (Ford 2000; Ford 2002). Ford et al. also found sociodemographic variations 
in serum concentrations of alpha-tocopherol among U.S. adults in NHANES III (1999) 
and alpha- and gamma-tocopherol in NHANES 1999–2000 (2006). Application of the 
most common cut-off value for serum alpha-tocopherol concentrations in NHANES 
1999–2000 (500 µg/dL), resulted in a low prevalence of vitamin E deficiency, despite 
the fact that the U.S. Department of Agriculture (USDA) estimated dietary intakes of 
vitamin E were low and that most of the U.S. population (> 90 percent) did not meet 
dietary recommendations either in 1999–2000 (Ahuja 2004) or in 2001–2002 (Moshfegh 
2005). However, the USDA report is based on intakes from food only and does not 
include dietary supplements. Furthermore, in NHANES only alpha-tocopherol is 
estimated for assessing dietary vitamin E intake. In NHANES 2001–2002, 44 percent 
of survey participants had an estimated dietary intake (from food only) of vitamin 
A (including carotenoids) that was less than the vitamin A estimated average 
requirement (EAR) (Moshfegh 2005). Low dietary intakes of certain micronutrients 
without widespread manifestation of deficiency suggest the need for further 
evaluations to determine whether improved estimates are necessary, either in the 
nutrient tables or in dietary intake. 
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Selected Observations and Highlights 
The following sample observations are taken from the tables of 1999–2002 (for 
vitamins A and E) or 2001–2002 data (for all carotenoids) contained in this report.	 
Statements about categorical differences between demographic groups noted 
below are based on non-overlapping confidence limits from univariate analysis 
without adjusting for demographic variables (e.g., age, sex, race/ethnicity) or other 
determinants of these blood concentrations (e.g., dietary intake, supplement usage, 
smoking, BMI). A multivariate analysis may alter the size and statistical significance 
of these categorical differences. Furthermore, additional significant differences 
of smaller magnitude may be present despite their lack of mention here (e.g., if 
confidence limits slightly overlap or if differences are unobservable before covariate 
adjustment has occurred). For a selection of citations of descriptive NHANES papers 
related to these biochemical indicators of diet and nutrition, see Appendix E. 
General Observations 
•	 Serum vitamin A and E concentrations are lower in children and adolescents 
than in adults. 
•	 Serum beta-carotene concentrations are higher in older people (≥ 60 years), 
whereas serum alpha-carotene and lutein/zeaxanthin concentrations are 
higher in middle-aged and older people compared with people in younger 
age groups. 
•	 Serum beta-cryptoxanthin concentrations are higher in children than in 
adolescents or adults. 
•	 Serum trans-lycopene and gamma-tocopherol concentrations are lower in 
young children and older people than in people in other age groups. 
•	 Serum alpha-carotene and lutein/zeaxanthin concentrations are lower in 
adolescents, whereas serum beta-carotene concentrations are lower in 
adolescents and in adults 20–39 years old than in people in other age groups. 
•	 Females have lower concentrations of serum vitamin A and trans-lycopene 
than do males. Females have higher concentrations of serum vitamin E and 
beta-carotene than do males. 
•	 Non-Hispanic blacks and Mexican Americans have lower serum 

concentrations of vitamin A than do non-Hispanic whites.
 
•	 Non-Hispanic blacks have lower serum concentrations of vitamin E than do 
Mexican Americans, who have lower serum concentrations of vitamin E than 
do non-Hispanic whites. 
•	 Non-Hispanic blacks have higher serum concentrations of gamma-tocopherol 
than do Mexican Americans and non-Hispanic whites. 
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•	 Non-Hispanic blacks have lower serum concentrations of alpha-carotene than 
do non-Hispanic whites or Mexican Americans. 
•	 Non-Hispanic whites have lower serum concentrations of beta-cryptoxanthin 
than do non-Hispanic blacks, who have lower serum concentrations of beta-
cryptoxanthin than do Mexican Americans. 
•	 Non-Hispanic blacks have higher serum concentrations of trans-lycopene than 
do Mexican Americans. 
Highlights 
The majority of the U.S. population (> 95 percent) has adequate serum concentrations of 
vitamin A (≥ 20 µg/dL) and vitamin E (≥ 500 µg/dL). 
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Table 2.1.a. Serum vitamin A: Total population 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 53.5 (52.7-54.3) 30.9 (30.3-31.7) 54.5 (53.6-55.4) 87.0 (85.8-88.4) 15819
 3–5 years 33.1 (32.6-33.7) 22.7 (21.4-24.4) 33.7 (33.0-34.4) 46.5 (44.1-47.8) 782
 6–11 years 36.3 (35.7-37.0) 26.0 (24.8-26.3) 36.4 (35.7-37.1) 51.2 (49.4-52.6) 1880
 12–19 years 47.0 (46.3-47.6) 30.8 (30.1-31.4) 47.4 (46.6-48.0) 70.6 (68.9-72.1) 4317
 20–39 years 53.6 (52.6-54.6) 33.6 (32.5-34.6) 54.6 (53.5-55.6) 82.3 (80.3-83.8) 3177
 40–59 years 59.7 (58.8-60.6) 37.1 (35.0-38.7) 60.6 (59.4-61.4) 92.6 (88.9-95.2) 2665
 60 years and older 63.8 (62.9-64.7) 40.2 (38.1-41.4) 64.5 (63.2-65.3) 98.8 (95.6-102) 2998 
Males 
Total, 3 years and older 56.3 (55.3-57.3) 31.7 (30.8-32.9) 58.1 (56.9-59.3) 88.7 (86.5-91.2) 7701
 3–5 years 32.9 (32.1-33.7) 21.9 (17.1-25.0) 33.9 (33.0-35.0) 45.4 (43.2-47.5) 410
 6–11 years 36.1 (35.2-37.1) 26.0 (24.5-26.5) 36.1 (35.3-37.1) 51.3 (49.4-52.6) 956
 12–19 years 49.1 (48.2-50.1) 32.1 (30.9-33.8) 49.8 (48.8-50.9) 71.3 (69.3-72.9) 2164
 20–39 years 58.4 (57.5-59.4) 40.3 (39.0-41.6) 59.0 (58.0-60.1) 83.5 (80.9-85.5) 1349
 40–59 years 64.6 (63.3-65.9) 42.4 (40.4-44.3) 66.0 (65.0-67.7) 95.3 (92.8-98.4) 1332
 60 years and older 65.4 (63.9-66.9) 41.2 (38.7-42.7) 66.1 (64.6-68.2) 101 (96.4-106) 1490 
Females 
Total, 3 years and older 50.9 (50.1-51.7) 30.3 (29.4-31.1) 50.9 (50.1-51.8) 85.2 (83.3-87.2) 8118
 3–5 years 33.4 (32.7-34.1) 24.1 (22.2-25.3) 33.1 (32.5-34.5) 47.1 (44.7-49.7) 372
 6–11 years 36.5 (35.8-37.2) 26.2 (24.7-26.9) 36.7 (36.1-37.5) 50.4 (49.0-52.2) 924
 12–19 years 44.8 (43.9-45.6) 29.7 (29.0-30.9) 44.7 (43.5-45.9) 68.8 (66.0-71.9) 2153
 20–39 years 49.2 (48.1-50.4) 30.7 (29.7-31.8) 49.1 (47.3-50.7) 80.8 (78.0-82.4) 1828
 40–59 years 55.3 (54.3-56.3) 34.4 (32.4-35.4) 55.5 (54.2-56.4) 87.3 (84.8-91.3) 1333
 60 years and older 62.6 (61.6-63.6) 39.4 (36.2-41.4) 63.0 (62.0-64.4) 96.8 (92.0-101) 1508 
Table 2.1.b. Serum vitamin A: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 46.8 (46.0-47.7) 28.1 (27.2-28.9) 47.1 (46.0-48.1) 75.6 (73.7-77.8) 4662
 3–5 years 31.6 (30.7-32.6) 22.6 (21.7-23.8) 31.9 (30.2-33.7) 43.2 (40.4-45.6) 261
 6–11 years 35.4 (34.8-36.0) 24.6 (23.8-26.2) 35.6 (34.9-36.2) 48.9 (47.2-50.8) 644
 12–19 years 44.8 (44.2-45.5) 30.7 (28.7-31.9) 45.0 (44.1-45.8) 64.6 (63.6-65.9) 1626
 20–39 years 50.6 (49.6-51.6) 31.9 (29.8-33.5) 50.9 (49.0-52.8) 75.2 (73.8-77.8) 866
 40–59 years 52.8 (51.4-54.3) 32.5 (30.4-35.0) 53.9 (52.4-55.3) 83.7 (78.8-87.4) 628
 60 years and older 55.9 (52.9-59.2) 34.0 (31.2-36.5) 55.3 (52.2-59.9) 91.0 (82.4-107) 637 
Males 
Total, 3 years and older 50.6 (49.7-51.6) 29.8 (28.8-30.5) 51.7 (50.5-53.2) 79.1 (77.0-82.4) 2277
 3–5 years 32.5 (30.6-34.5) 22.4† (20.1-25.0) 32.9 (30.7-34.5) 45.2† (41.1-51.2) 136
 6–11 years 35.4 (34.6-36.2) 24.6 (23.2-27.1) 35.4 (34.5-36.2) 49.2 (45.9-51.3) 333
 12–19 years 48.1 (47.1-49.1) 33.7 (32.1-34.9) 48.3 (47.0-49.7) 67.8 (65.6-69.7) 807
 20–39 years 56.6 (55.3-57.9) 39.3 (37.4-41.9) 57.5 (55.8-59.1) 78.3 (75.2-86.5) 382
 40–59 years 57.9 (55.9-59.9) 36.3 (32.4-40.4) 57.9 (56.1-60.2) 87.4 (83.0-95.3) 298
 60 years and older 57.0 (54.3-60.0) 35.3 (33.1-37.1) 55.5 (52.9-61.3) 93.4 (79.8-118) 321 
Females 
Total, 3 years and older 43.0 (42.1-43.9) 27.0 (26.1-27.8) 42.6 (41.5-43.6) 69.8 (65.7-73.1) 2385
 3–5 years 30.8 (29.4-32.2) 22.6† (20.3-24.7) 30.4 (27.9-33.3) 40.0† (38.9-43.7) 125
 6–11 years 35.3 (34.4-36.3) 23.8 (23.1-26.5) 35.9 (34.7-36.7) 48.6 (47.2-51.2) 311
 12–19 years 41.5 (40.8-42.3) 28.4 (26.9-30.8) 41.1 (40.5-41.5) 60.3 (57.6-62.2) 819
 20–39 years 44.3 (43.1-45.5) 28.7 (26.4-30.7) 44.6 (42.8-46.3) 69.1 (63.4-72.8) 484
 40–59 years 48.1 (46.4-49.9) 30.6 (25.7-34.1) 48.1 (46.4-50.1) 74.7 (68.3-77.1) 330
 60 years and older 55.0 (51.2-59.0) 31.8 (27.8-39.3) 54.8 (51.3-59.9) 90.0 (82.9-99.0) 316 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.1.c. Serum vitamin A: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 46.0 (45.1-47.0) 27.3 (26.3-27.9) 45.7 (44.4-47.1) 79.3 (75.9-81.6) 3680
 3–5 years 31.8 (30.6-33.1) 21.6 (19.3-23.9) 32.1 (30.8-33.3) 44.6 (41.6-47.9) 226
 6–11 years 35.0 (34.1-35.9) 23.7 (21.9-25.6) 35.1 (34.0-36.5) 50.5 (48.2-52.2) 591
 12–19 years 41.4 (40.6-42.2) 27.9 (26.7-28.6) 41.7 (40.6-42.6) 61.9 (60.2-64.1) 1252
 20–39 years 46.1 (44.8-47.5) 28.4 (27.6-30.7) 46.8 (45.2-48.5) 72.0 (67.7-74.6) 590
 40–59 years 52.2 (50.4-54.1) 30.6 (27.3-34.0) 52.1 (50.6-54.0) 87.3 (80.6-95.6) 540
 60 years and older 58.6 (56.6-60.6) 33.5 (31.2-36.7) 59.0 (56.8-60.4) 102 (93.4-117) 481 
Males 
Total, 3 years and older 48.5 (47.6-49.5) 27.9 (26.9-28.7) 49.6 (48.5-50.7) 80.7 (77.6-84.3) 1806
 3–5 years 32.7 (31.2-34.2) 22.6† (19.3-24.9) 32.7 (31.0-34.6) 45.4† (41.9-53.6) 119
 6–11 years 34.5 (33.5-35.5) 24.2 (20.8-25.5) 34.4 (33.2-35.6) 50.7 (47.2-54.3) 297
 12–19 years 43.7 (42.7-44.6) 28.7 (28.0-30.0) 43.5 (42.4-44.6) 64.8 (62.6-67.5) 640
 20–39 years 51.7 (50.1-53.4) 34.3 (28.8-37.8) 53.2 (51.2-55.2) 74.8 (70.3-79.6) 246
 40–59 years 56.3 (53.8-58.9) 34.4 (30.2-38.1) 56.3 (53.1-59.3) 92.9 (80.8-107) 274
 60 years and older 59.3 (56.1-62.7) 34.9 (30.0-39.9) 58.5 (53.5-62.8) 106 (87.7-144) 230 
Females 
Total, 3 years and older 44.0 (42.7-45.3) 26.7 (25.5-27.9) 42.9 (41.9-43.9) 75.6 (72.6-80.4) 1874
 3–5 years 30.9 (29.3-32.6) 19.5† (16.1-23.6) 31.7 (29.9-33.1) 42.7† (38.6-45.7) 107
 6–11 years 35.5 (34.3-36.7) 23.6 (21.5-26.7) 36.0 (34.3-37.6) 50.4 (48.0-52.2) 294
 12–19 years 39.2 (38.3-40.1) 26.0 (24.5-27.5) 39.5 (38.5-40.7) 56.8 (54.5-59.0) 612
 20–39 years 42.3 (40.4-44.2) 27.6 (24.7-29.1) 41.7 (39.8-43.8) 66.3 (62.0-72.4) 344
 40–59 years 48.9 (46.5-51.4) 29.3 (25.2-31.5) 47.7 (44.5-51.1) 82.0 (74.4-92.0) 266
 60 years and older 58.1 (55.3-61.1) 32.9 (30.2-36.8) 59.4 (56.8-61.2) 97.8 (86.7-115) 251 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 2.1.d. Serum vitamin A: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 56.3 (55.3-57.4) 33.1 (32.1-34.2) 57.3 (56.2-58.8) 88.9 (87.4-90.9) 6128
 3–5 years 34.0 (33.1-34.8) 24.0† (21.4-25.8) 34.2 (33.0-35.7) 47.2† (44.1-49.7) 217
 6–11 years 36.8 (35.9-37.7) 26.5 (25.4-28.3) 36.7 (35.8-37.9) 51.3 (49.0-52.7) 489
 12–19 years 49.0 (47.9-50.0) 32.6 (31.3-34.2) 49.0 (48.0-50.0) 72.9 (70.9-75.0) 1073
 20–39 years 56.1 (54.8-57.4) 36.1 (34.6-37.6) 57.0 (55.0-58.7) 83.9 (81.9-86.8) 1377
 40–59 years 62.0 (60.9-63.1) 40.1 (38.1-42.0) 63.1 (61.5-64.3) 93.5 (90.3-96.2) 1276
 60 years and older 65.2 (64.3-66.2) 41.6 (40.1-43.1) 65.5 (64.4-67.5) 99.1 (96.1-102) 1696 
Males 
Total, 3 years and older 58.9 (57.6-60.2) 33.6 (32.0-35.1) 60.8 (59.3-62.9) 91.4 (88.7-93.5) 3001
 3–5 years 33.4 (32.3-34.4) 21.4† (17.1-25.8) 34.4 (32.7-36.6) 45.6† (41.4-47.8) 115
 6–11 years 36.6 (35.2-38.0) 26.2 (24.3-28.6) 36.4 (35.1-38.4) 52.2 (48.6-53.0) 257
 12–19 years 50.6 (49.3-51.9) 32.4 (30.5-36.0) 51.0 (49.8-52.3) 72.9 (70.0-74.9) 535
 20–39 years 60.4 (59.1-61.7) 41.7 (40.5-43.1) 60.4 (59.2-63.0) 84.8 (81.6-87.5) 575
 40–59 years 66.6 (65.1-68.1) 44.5 (42.5-47.8) 68.2 (66.3-69.8) 96.2 (92.9-99.9) 665
 60 years and older 66.8 (65.2-68.4) 42.0 (40.4-44.6) 67.9 (65.3-70.1) 101 (96.6-105) 854 
Females 
Total, 3 years and older 54.0 (52.9-55.2) 32.6 (31.6-34.1) 54.5 (52.8-55.8) 87.5 (85.9-89.4) 3127
 3–5 years 34.7 (33.3-36.1) 26.2† (24.0-27.8) 34.0 (32.5-36.3) 49.1† (45.9-51.8) 102
 6–11 years 37.0 (36.0-38.0) 26.2 (24.7-28.4) 36.8 (36.0-38.0) 50.2 (48.1-54.0) 232
 12–19 years 47.3 (46.0-48.6) 33.2 (31.2-34.3) 46.9 (45.3-47.9) 72.1 (68.3-76.8) 538
 20–39 years 52.2 (50.5-54.0) 34.1 (30.9-35.9) 51.7 (49.9-54.8) 83.1 (80.5-87.3) 802
 40–59 years 57.7 (56.5-58.8) 36.0 (34.6-39.2) 57.2 (56.0-58.4) 88.8 (86.1-94.8) 611
 60 years and older 64.1 (62.9-65.2) 41.4 (39.0-43.5) 64.5 (62.5-65.6) 97.4 (92.0-102) 842 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.2.a. Serum vitamin E: Total population 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 1090 (1070-1110) 615 (604-626) 1030 (1010-1050) 2380 (2300-2480) 15766
 3–5 years 800 (777-824) 567 (547-593) 782 (758-813) 1160 (1110-1310) 777
 6–11 years 794 (779-810) 556 (546-570) 790 (772-812) 1130 (1090-1180) 1873
 12–19 years 762 (750-774) 532 (518-548) 753 (741-766) 1140 (1100-1200) 4314
 20–39 years 991 (977-1010) 629 (618-645) 963 (943-980) 1740 (1650-1800) 3168
 40–59 years 1300 (1280-1330) 774 (743-792) 1250 (1220-1280) 2620 (2470-2760) 2655
 60 years and older 1530 (1500-1560) 808 (771-850) 1480 (1440-1520) 3220 (3010-3330) 2979 
Males 
Total, 3 years and older 1070 (1040-1090) 605 (593-617) 1010 (984-1030) 2280 (2170-2380) 7673
 3–5 years 796 (768-825) 569 (556-594) 791 (759-823) 1110 (1030-1300) 406
 6–11 years 789 (770-809) 554 (543-576) 785 (760-815) 1130 (1040-1210) 951
 12–19 years 749 (731-767) 521 (503-544) 739 (724-757) 1120 (1060-1200) 2163
 20–39 years 993 (972-1020) 625 (611-646) 969 (940-985) 1750 (1660-1880) 1344
 40–59 years 1310 (1270-1350) 752 (724-776) 1250 (1220-1280) 2570 (2390-2830) 1328
 60 years and older 1420 (1380-1450) 769 (727-803) 1370 (1330-1400) 2850 (2740-3010) 1481 
Females 
Total, 3 years and older 1120 (1100-1140) 626 (612-640) 1050 (1030-1070) 2480 (2350-2620) 8093
 3–5 years 804 (772-838) 560 (513-602) 774 (750-812) 1270 (1120-1460) 371
 6–11 years 801 (779-822) 560 (542-587) 799 (775-820) 1140 (1090-1190) 922
 12–19 years 776 (763-788) 548 (539-556) 769 (756-784) 1160 (1110-1210) 2151
 20–39 years 990 (974-1010) 630 (615-654) 955 (933-978) 1700 (1620-1830) 1824
 40–59 years 1300 (1260-1340) 797 (744-820) 1240 (1200-1280) 2670 (2360-2970) 1327
 60 years and older 1620 (1580-1660) 860 (819-889) 1590 (1530-1650) 3370 (3170-3550) 1498 
Table 2.2.b. Serum vitamin E: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 967 (944-990) 587 (572-602) 919 (904-938) 1800 (1720-1950) 4662
 3–5 years 768 (748-788) 569 (514-593) 762 (737-787) 1050 (980-1110) 261
 6–11 years 770 (758-782) 555 (538-573) 765 (746-780) 1090 (1050-1110) 640
 12–19 years 754 (744-764) 516 (503-531) 744 (729-758) 1150 (1110-1200) 1628
 20–39 years 987 (954-1020) 642 (605-667) 959 (931-983) 1680 (1550-1780) 867
 40–59 years 1260 (1210-1310) 757 (720-804) 1230 (1160-1280) 2250 (2070-2620) 629
 60 years and older 1380 (1320-1440) 762 (696-810) 1310 (1260-1390) 2810 (2610-3350) 637 
Males 
Total, 3 years and older 968 (943-995) 580 (564-590) 922 (902-943) 1810 (1690-2010) 2277
 3–5 years 766 (736-797) 567† (530-608) 749 (719-784) 1070† (971-1230) 135
 6–11 years 768 (748-789) 544 (532-577) 758 (736-785) 1070 (1030-1160) 331
 12–19 years 741 (723-759) 503 (490-516) 733 (718-753) 1110 (1080-1150) 808
 20–39 years 999 (954-1050) 617 (587-662) 964 (923-1020) 1650 (1530-1920) 383
 40–59 years 1300 (1210-1400) 790 (707-860) 1250 (1160-1340) 2370 (2060-3340) 299
 60 years and older 1280 (1220-1350) 729 (651-799) 1230 (1200-1300) 2610 (2080-3530) 321 
Females 
Total, 3 years and older 965 (939-992) 593 (574-616) 915 (898-939) 1780 (1690-1980) 2385
 3–5 years 770 (740-800) 577† (495-594) 780 (735-819) 992† (953-1110) 126
 6–11 years 772 (756-789) 558 (526-586) 768 (744-790) 1090 (1040-1170) 309
 12–19 years 769 (761-777) 539 (529-551) 757 (732-778) 1220 (1130-1260) 820
 20–39 years 972 (945-1000) 651 (592-675) 947 (921-981) 1670 (1480-1750) 484
 40–59 years 1220 (1170-1260) 739 (715-795) 1190 (1130-1260) 2100 (1810-2400) 330
 60 years and older 1470 (1380-1570) 780 (587-929) 1400 (1330-1470) 2850 (2670-3490) 316 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.2.c. Serum vitamin E: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 917 (897-936) 579 (564-595) 884 (865-903) 1700 (1620-1820) 3670
 3–5 years 761 (736-787) 560† (511-586) 748 (728-768) 1120† (1080-1170) 222
 6–11 years 769 (752-786) 548 (521-583) 765 (745-789) 1070 (1010-1120) 592
 12–19 years 728 (714-741) 530 (512-542) 721 (707-740) 1030 (1010-1060) 1249
 20–39 years 879 (860-899) 607 (567-627) 867 (840-895) 1390 (1300-1470) 589
 40–59 years 1090 (1050-1120) 686 (636-712) 1040 (1010-1070) 2250 (1840-2390) 539
 60 years and older 1200 (1140-1250) 692 (655-736) 1150 (1090-1190) 2280 (2070-2780) 479 
Males 
Total, 3 years and older 888 (866-912) 573 (554-589) 864 (842-883) 1620 (1450-1770) 1802
 3–5 years 761 (725-798) 550† (497-614) 749 (702-782) 1100† (989-1130) 117
 6–11 years 780 (763-797) 565 (531-580) 772 (757-811) 1080 (1010-1160) 297
 12–19 years 722 (706-738) 528 (506-539) 716 (701-732) 1020 (975-1050) 639
 20–39 years 870 (834-908) 614 (567-643) 863 (809-900) 1340 (1200-1560) 246
 40–59 years 1040 (995-1080) 636 (579-707) 1010 (971-1070) 1850 (1620-2250) 274
 60 years and older 1110 (1060-1170) 655 (582-721) 1070 (1020-1140) 2180 (1910-2390) 229 
Females 
Total, 3 years and older 942 (916-968) 588 (560-609) 907 (884-923) 1800 (1640-2080) 1868
 3–5 years 761 (731-792) 545† (491-586) 748 (713-800) 1150† (1010-1240) 105
 6–11 years 757 (732-783) 536 (505-588) 757 (726-788) 1010 (982-1120) 295
 12–19 years 734 (719-748) 534 (503-560) 733 (706-758) 1050 (1000-1100) 610
 20–39 years 886 (863-909) 605 (519-626) 877 (839-907) 1450 (1300-1510) 343
 40–59 years 1130 (1090-1180) 712 (679-780) 1050 (1020-1090) 2410 (2020-2700) 265
 60 years and older 1250 (1180-1330) 727 (686-815) 1180 (1140-1270) 2690 (1930-3650) 250 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 2.2.d. Serum vitamin E: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 1150 (1130-1180) 638 (620-652) 1090 (1050-1120) 2530 (2440-2630) 6085
 3–5 years 822 (782-865) 567† (547-622) 803 (757-853) 1240† (1110-1460) 216
 6–11 years 804 (782-826) 556 (545-577) 800 (772-825) 1150 (1090-1230) 485
 12–19 years 774 (757-791) 543 (526-556) 763 (744-777) 1180 (1100-1250) 1071
 20–39 years 1010 (991-1030) 646 (619-665) 978 (957-994) 1780 (1660-1930) 1368
 40–59 years 1340 (1310-1370) 796 (770-820) 1280 (1250-1310) 2670 (2500-2980) 1266
 60 years and older 1580 (1540-1610) 831 (795-868) 1530 (1500-1580) 3300 (3070-3460) 1679 
Males 
Total, 3 years and older 1120 (1090-1150) 619 (598-643) 1060 (1020-1100) 2420 (2300-2540) 2977
 3–5 years 819 (773-867) 576† (556-622) 818 (751-860) 1100† (1010-1470) 114
 6–11 years 788 (759-818) 550 (502-575) 779 (746-825) 1130 (1030-1220) 254
 12–19 years 758 (731-785) 532 (509-556) 742 (724-771) 1150 (1040-1300) 534
 20–39 years 1010 (974-1040) 637 (607-669) 976 (939-1000) 1850 (1620-2060) 569
 40–59 years 1350 (1310-1400) 774 (728-810) 1280 (1250-1330) 2630 (2470-3150) 660
 60 years and older 1450 (1410-1500) 779 (734-815) 1400 (1370-1440) 2880 (2750-3240) 846 
Females 
Total, 3 years and older 1180 (1150-1210) 654 (639-670) 1120 (1090-1160) 2640 (2490-2770) 3108
 3–5 years 826 (770-886) 564† (430-662) 776 (742-874) 1440† (1150-1520) 102
 6–11 years 822 (793-852) 557 (530-603) 811 (781-851) 1150 (1100-1400) 231
 12–19 years 791 (773-810) 554 (537-568) 781 (761-811) 1180 (1110-1250) 537
 20–39 years 1020 (996-1030) 647 (623-682) 982 (951-1010) 1760 (1620-1930) 799
 40–59 years 1330 (1290-1380) 818 (783-852) 1280 (1230-1320) 2690 (2360-3090) 606
 60 years and older 1680 (1630-1730) 884 (853-924) 1660 (1600-1740) 3460 (3230-3760) 833 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.3.a. Serum gamma-tocopherol: Total population 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 198 (190-206) 65.7 (61.0-71.0) 212 (204-221) 462 (438-482) 14738
 3–5 years 176 (162-192) 63.0 (52.0-83.5) 186 (170-199) 364 (340-407) 730
 6–11 years 207 (198-217) 97.8 (92.0-105) 217 (206-225) 389 (363-428) 1730
 12–19 years 197 (190-204) 100 (93.0-108) 201 (192-208) 372 (359-386) 4009
 20–39 years 206 (198-215) 83.0 (71.7-89.2) 219 (208-227) 442 (427-468) 3005
 40–59 years 205 (194-218) 60.0 (55.0-68.0) 225 (213-238) 530 (478-568) 2491
 60 years and older 174 (165-184) 47.8 (46.0-51.0) 190 (177-203) 496 (462-531) 2773 
Males 
Total, 3 years and older 199 (191-208) 65.1 (59.0-72.0) 212 (204-221) 466 (442-481) 7169
 3–5 years 167 (151-184) 58.6 (42.8-89.0) 178 (165-193) 340 (298-400) 380
 6–11 years 201 (190-213) 92.0 (81.0-104) 213 (195-225) 366 (361-408) 870
 12–19 years 193 (186-200) 98.1 (91.0-108) 193 (187-201) 371 (341-390) 2005
 20–39 years 208 (200-217) 75.5 (66.0-88.5) 223 (210-233) 473 (436-481) 1279
 40–59 years 214 (200-228) 61.0 (57.0-72.0) 230 (216-248) 548 (499-608) 1253
 60 years and older 169 (160-180) 43.9 (40.0-47.8) 191 (176-200) 463 (427-510) 1382 
Females 
Total, 3 years and older 197 (189-205) 65.8 (62.0-71.0) 213 (202-221) 457 (433-484) 7569
 3–5 years 188 (172-205) 72.0 (56.0-95.9) 195 (176-215) 385 (328-446) 350
 6–11 years 214 (203-226) 106 (95.0-117) 221 (206-238) 408 (361-473) 860
 12–19 years 202 (194-211) 102 (89.0-111) 208 (198-219) 373 (357-391) 2004
 20–39 years 203 (193-214) 85.0 (75.0-91.4) 216 (202-226) 424 (410-440) 1726
 40–59 years 198 (186-210) 57.2 (51.0-67.0) 221 (206-233) 505 (453-559) 1238
 60 years and older 178 (167-189) 51.3 (47.1-55.2) 189 (175-207) 508 (482-542) 1391 
Table 2.3.b. Serum gamma-tocopherol: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 206 (199-214) 92.0 (87.9-99.0) 211 (203-218) 437 (404-466) 3983
 3–5 years 180 (168-192) 93.0 (82.2-109) 185 (175-200) 318 (287-370) 224
 6–11 years 219 (210-229) 112 (99.9-122) 226 (217-239) 419 (372-456) 546
 12–19 years 203 (197-209) 108 (103-117) 206 (197-214) 370 (349-394) 1399
 20–39 years 196 (185-208) 91.0 (84.0-99.6) 199 (187-213) 397 (363-456) 771
 40–59 years 232 (220-244) 88.9 (74.0-104) 235 (220-251) 544 (469-631) 535
 60 years and older 209 (194-225) 67.0 (56.0-80.7) 231 (205-254) 496 (449-527) 508 
Males 
Total, 3 years and older 206 (198-215) 93.0 (84.0-101) 211 (203-217) 448 (402-473) 1937
 3–5 years 180 (167-194) 93.5† (82.2-112) 183 (173-195) 312† (283-340) 115
 6–11 years 222 (210-234) 116 (105-124) 221 (212-242) 440 (364-483) 272
 12–19 years 198 (190-207) 106 (98.0-116) 201 (192-212) 367 (332-398) 691
 20–39 years 197 (183-211) 91.5 (72.0-102) 199 (183-214) 408 (371-469) 346
 40–59 years 234 (214-256) 78.0 (58.0-103) 246 (219-267) 544 (456-659) 258
 60 years and older 212 (189-237) 66.0 (47.0-85.0) 237 (211-274) 443 (371-527) 255 
Females 
Total, 3 years and older 206 (198-215) 92.0 (86.0-101) 212 (201-224) 428 (399-460) 2046
 3–5 years 180 (161-201) 88.3† (45.0-116) 196 (160-209) 355† (252-392) 109
 6–11 years 217 (204-231) 105 (83.5-123) 228 (216-243) 401 (361-452) 274
 12–19 years 209 (200-218) 113 (105-123) 210 (194-226) 372 (338-418) 708
 20–39 years 195 (183-209) 90.0 (76.0-102) 200 (186-216) 349 (336-418) 425
 40–59 years 229 (216-243) 89.3 (74.0-105) 230 (216-250) 494 (460-640) 277
 60 years and older 206 (189-225) 70.0 (52.9-80.0) 226 (183-252) 515 (462-683) 253 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.3.c. Serum gamma-tocopherol: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 223 (215-232) 97.9 (86.0-106) 235 (223-245) 444 (427-458) 3578
 3–5 years 188 (174-203) 90.0† (75.0-109) 196 (182-209) 336† (309-367) 220
 6–11 years 218 (207-230) 116 (104-124) 221 (206-237) 393 (365-441) 569
 12–19 years 208 (202-215) 109 (101-121) 212 (204-218) 356 (334-384) 1217
 20–39 years 222 (209-236) 98.5 (86.0-115) 234 (213-253) 426 (394-452) 571
 40–59 years 234 (223-247) 84.4 (65.0-111) 257 (241-271) 470 (440-508) 529
 60 years and older 238 (223-254) 69.0 (54.0-90.0) 270 (256-282) 515 (492-575) 472 
Males 
Total, 3 years and older 214 (205-224) 97.1 (80.4-109) 222 (212-233) 417 (402-442) 1756
 3–5 years 189 (171-207) 83.5† (63.0-119) 194 (180-211) 331† (287-364) 116
 6–11 years 213 (201-224) 107 (93.0-120) 213 (201-229) 386 (365-427) 288
 12–19 years 202 (194-209) 104 (95.0-118) 206 (195-215) 351 (321-386) 620
 20–39 years 215 (199-231) 98.5 (80.3-115) 226 (202-248) 404 (370-450) 237
 40–59 years 224 (206-243) 84.0 (44.7-130) 249 (219-268) 418 (393-553) 267
 60 years and older 223 (206-242) 69.0 (54.0-103) 248 (214-265) 511 (449-583) 228 
Females 
Total, 3 years and older 231 (221-242) 97.9 (84.4-109) 244 (230-257) 460 (437-480) 1822
 3–5 years 188 (167-210) 78.0† (74.0-111) 195 (167-220) 356† (314-380) 104
 6–11 years 224 (209-240) 124 (114-138) 224 (210-247) 393 (351-455) 281
 12–19 years 216 (207-225) 122 (104-132) 215 (206-226) 369 (338-428) 597
 20–39 years 229 (212-247) 98.0 (79.0-124) 245 (212-270) 435 (390-469) 334
 40–59 years 244 (226-264) 84.4 (70.6-109) 271 (244-293) 478 (440-559) 262
 60 years and older 249 (229-270) 61.8 (45.2-91.0) 282 (265-304) 524 (492-583) 244 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 2.3.d. Serum gamma-tocopherol: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 3 years and older 194 (184-205) 60.0 (55.0-65.0) 211 (200-221) 473 (444-499) 5877
 3–5 years 176 (155-199) 56.0† (42.8-83.0) 188 (162-215) 366† (329-441) 211
 6–11 years 204 (192-218) 90.9 (82.2-102) 215 (199-231) 408 (359-484) 469
 12–19 years 195 (185-204) 94.9 (88.0-103) 199 (188-210) 375 (357-393) 1036
 20–39 years 207 (196-219) 77.4 (65.6-88.9) 221 (208-232) 453 (430-477) 1326
 40–59 years 199 (185-215) 57.0 (51.0-64.8) 221 (203-235) 532 (481-573) 1217
 60 years and older 170 (160-180) 46.7 (44.9-50.7) 186 (170-198) 498 (460-537) 1618 
Males 
Total, 3 years and older 196 (186-208) 59.0 (51.0-67.0) 212 (202-224) 473 (446-502) 2885
 3–5 years 164 (142-189) 47.1† (22.5-89.0) 186 (153-199) 355† (298-489) 112
 6–11 years 195 (180-211) 82.2 (78.0-97.7) 212 (174-230) 365 (327-408) 246
 12–19 years 191 (181-201) 94.3 (86.0-108) 189 (183-200) 378 (340-399) 519
 20–39 years 211 (198-224) 71.0 (51.2-89.2) 230 (214-242) 473 (441-484) 554
 40–59 years 209 (192-227) 59.0 (53.0-69.6) 226 (211-249) 548 (471-617) 635
 60 years and older 165 (154-177) 42.8 (39.8-46.7) 186 (170-197) 463 (426-520) 819 
Females 
Total, 3 years and older 192 (182-203) 61.9 (56.9-65.6) 209 (196-221) 478 (439-506) 2992
 3–5 years 190 (164-220) 58.0† (52.0-96.0) 204 (164-241) 388† (313-482) 99
 6–11 years 216 (199-234) 99.0† (87.0-112) 221 (197-248) 418† (361-555) 223
 12–19 years 199 (186-212) 95.1 (82.0-108) 207 (188-224) 367 (345-402) 517
 20–39 years 204 (190-218) 84.0 (65.0-97.0) 217 (199-227) 428 (406-478) 772
 40–59 years 190 (174-207) 51.0 (43.8-60.2) 213 (187-230) 511 (452-572) 582
 60 years and older 173 (161-186) 51.3 (47.0-55.9) 185 (167-203) 525 (479-546) 799 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.4.a. Serum alpha-carotene: Total population 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 2.48 (2.23-2.76) .700 (<LOD-.800) 2.36 (2.10-2.70) 8.50 (7.40-9.30) 8359
 3–5 years 2.41 (2.13-2.74) .800 (<LOD-1.00) 2.20 (1.90-2.50) 8.50 (7.00-10.3) 430
 6–11 years 2.24 (2.00-2.51) .800 (.800-.900) 2.00 (1.80-2.30) 6.10 (5.20-7.70) 1014
 12–19 years 1.68 (1.52-1.86) < LOD 1.40 (1.30-1.60) 5.10 (4.40-6.20) 2206
 20–39 years 2.22 (1.93-2.56) < LOD 2.20 (1.90-2.50) 7.80 (6.70-8.80) 1716
 40–59 years 2.98 (2.60-3.42) .800 (.700-1.00) 2.80 (2.50-3.30) 10.7 (8.60-13.0) 1470
 60 years and older 3.08 (2.74-3.46) .800 (<LOD-1.00) 3.10 (2.70-3.60) 9.10 (8.60-9.80) 1523 
Males 
Total, 3 years and older 2.22 (1.98-2.49) < LOD 2.10 (1.90-2.30) 7.20 (6.30-8.60) 4052
 3–5 years 2.29 (1.91-2.74) .700 (<LOD-.800) 2.00 (1.70-2.40) 7.20 (5.00-11.1) 217
 6–11 years 2.28 (1.96-2.65) .800 (.800-1.00) 2.00 (1.80-2.40) 6.60 (5.00-8.50) 507
 12–19 years 1.55 (1.38-1.75) < LOD 1.40 (1.20-1.60) 4.40 (3.80-6.00) 1092
 20–39 years 1.99 (1.72-2.31) < LOD 1.80 (1.50-2.10) 6.90 (5.60-8.60) 724
 40–59 years 2.53 (2.17-2.95) .800 (<LOD-.900) 2.40 (2.00-2.90) 8.60 (6.30-11.3) 763
 60 years and older 2.81 (2.48-3.18) .800 (<LOD-.900) 2.90 (2.50-3.50) 8.40 (7.40-9.30) 749 
Females 
Total, 3 years and older 2.75 (2.47-3.07) .700 (<LOD-.900) 2.70 (2.30-3.00) 9.20 (8.20-10.5) 4307
 3–5 years 2.55 (1.99-3.26) .700 (<LOD-1.50) 2.30 (1.80-3.10) 9.70 (7.10-12.4) 213
 6–11 years 2.20 (1.97-2.45) .800 (.800-.900) 2.10 (1.80-2.30) 5.80 (4.90-6.50) 507
 12–19 years 1.83 (1.63-2.04) < LOD 1.70 (1.50-2.00) 5.40 (4.60-6.90) 1114
 20–39 years 2.45 (2.10-2.86) < LOD 2.30 (1.90-2.70) 8.10 (6.80-9.20) 992
 40–59 years 3.55 (3.10-4.06) 1.10 (.900-1.30) 3.40 (2.90-3.70) 12.4 (10.5-15.8) 707
 60 years and older 3.30 (2.87-3.79) 1.00 (.800-1.20) 3.20 (2.80-3.90) 9.70 (8.70-10.4) 774 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
Table 2.4.b. Serum alpha-carotene: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 2.72 (2.39-3.10) 1.00 (.900-1.10) 2.50 (2.30-2.80) 7.40 (6.30-8.90) 2116
 3–5 years 2.56 (2.12-3.08) 1.00 (.800-1.50) 2.20 (2.10-2.50) 6.40 (4.50-9.00) 126
 6–11 years 2.43 (2.12-2.79) .900 (.800-1.10) 2.20 (2.00-2.70) 5.40 (4.70-6.70) 290
 12–19 years 1.90 (1.71-2.11) .700 (<LOD-.800) 1.70 (1.50-2.10) 5.30 (3.90-6.40) 696
 20–39 years 2.92 (2.48-3.43) 1.00 (.800-1.30) 2.80 (2.50-3.40) 8.00 (6.60-9.10) 460
 40–59 years 3.39 (2.71-4.24) 1.10 (.900-1.40) 3.30 (2.60-4.10) 8.70 (7.20-14.3) 289
 60 years and older 3.04 (2.35-3.94) .900 (<LOD-1.30) 2.90 (2.30-4.00) 8.90 (6.20-13.7) 255 
Males 
Total, 3 years and older 2.46 (2.13-2.83) .800 (.700-1.00) 2.44 (2.20-2.70) 6.60 (5.30-8.00) 1019
 3–5 years 2.37 (1.70-3.32) .800† (<LOD-1.50) 2.20 (1.70-2.80) 5.90† (2.90-12.1) 62
 6–11 years 2.39 (1.89-3.03) .800 (.700-1.00) 2.20 (1.70-2.90) 5.50 (3.90-8.40) 140
 12–19 years 1.69 (1.48-1.92) .700 (<LOD-.800) 1.50 (1.30-1.90) 4.20 (3.30-6.20) 330
 20–39 years 2.51 (2.06-3.06) .800 (<LOD-1.10) 2.60 (2.10-3.10) 6.70 (5.20-7.90) 213
 40–59 years 3.33 (2.61-4.23) 1.20 (.800-1.70) 3.20 (2.50-4.10) 8.10 (5.90-13.2) 149
 60 years and older 2.49 (1.83-3.38) .700 (<LOD-1.10) 2.60 (1.90-3.00) 7.00 (5.50-9.10) 125 
Females 
Total, 3 years and older 3.04 (2.66-3.48) 1.00 (.900-1.20) 2.80 (2.50-3.30) 8.50 (7.10-10.8) 1097
 3–5 years 2.75 (2.28-3.32) 1.20† (<LOD-1.60) 2.40 (2.00-3.10) 6.00† (4.20-9.00) 64
 6–11 years 2.48 (2.16-2.85) 1.20 (.900-1.50) 2.30 (1.90-3.00) 5.00 (4.00-6.00) 150
 12–19 years 2.16 (1.92-2.43) .800 (.700-.900) 2.00 (1.60-2.50) 5.80 (4.40-7.30) 366
 20–39 years 3.45 (2.87-4.15) 1.20 (.900-1.40) 3.20 (2.60-4.30) 9.10 (8.00-12.7) 247
 40–59 years 3.46 (2.66-4.49) .900 (.700-1.40) 3.30 (2.40-4.80) 10.8 (8.00-14.8) 140
 60 years and older 3.58 (2.63-4.86) 1.30 (.900-1.80) 3.60 (2.40-4.80) 11.5 (6.00-15.2) 130 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.4.c. Serum alpha-carotene: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 1.77 (1.51-2.08) < LOD 1.60 (1.30-1.90) 6.10 (4.80-8.20) 1992
 3–5 years 1.75 (1.40-2.17) < LOD 1.40 (1.10-1.80) 5.00 (3.20-13.9) 128
 6–11 years 1.92 (1.69-2.19) .900 (.800-1.00) 1.70 (1.40-1.90) 4.30 (3.50-5.60) 340
 12–19 years 1.38 (1.20-1.59) < LOD 1.20 (1.10-1.50) 3.90 (2.80-5.30) 671
 20–39 years 1.71 (1.27-2.29) < LOD 1.50 (1.10-2.10) 5.80 (3.90-11.4) 319
 40–59 years 1.88 (1.65-2.13) < LOD 1.80 (1.50-2.00) 7.20 (6.10-9.70) 291
 60 years and older 2.22 (1.70-2.90) < LOD 2.00 (1.40-2.70) 9.30 (4.90-15.1) 243 
Males 
Total, 3 years and older 1.65 (1.38-1.96) < LOD 1.40 (1.20-1.80) 5.80 (4.20-7.40) 984
 3–5 years 1.54 (1.18-2.02) < LOD† 1.30 (1.00-1.90) 3.90† (2.20-13.9) 64
 6–11 years 2.08 (1.82-2.36) .900 (.800-1.20) 1.90 (1.70-2.20) 4.60 (3.50-6.60) 175
 12–19 years 1.32 (1.11-1.57) < LOD 1.10 (1.00-1.34) 3.30 (2.70-5.50) 340
 20–39 years 1.55 (1.07-2.24) < LOD 1.40 (.900-2.30) 6.10 (3.40-9.60) 132
 40–59 years 1.71 (1.44-2.03) < LOD 1.80 (1.20-2.10) 6.60 (4.50-8.40) 154
 60 years and older 1.94 (1.56-2.43) < LOD 1.50 (1.30-2.40) 6.70 (4.20-12.5) 119 
Females 
Total, 3 years and older 1.88 (1.58-2.23) < LOD 1.70 (1.40-1.90) 6.50 (4.90-9.40) 1008
 3–5 years 1.98 (1.52-2.60) < LOD† 1.70 (1.30-2.20) 6.00† (3.20-33.8) 64
 6–11 years 1.76 (1.40-2.22) .700 (<LOD-.900) 1.60 (1.30-1.90) 3.70 (2.60-8.30) 165
 12–19 years 1.45 (1.27-1.65) < LOD 1.30 (1.10-1.60) 4.00 (2.90-5.50) 331
 20–39 years 1.83 (1.33-2.50) < LOD 1.80 (1.10-2.20) 5.30 (3.90-11.5) 187
 40–59 years 2.04 (1.69-2.46) < LOD 1.70 (1.50-2.10) 7.90 (5.90-13.8) 137
 60 years and older 2.44 (1.71-3.47) < LOD 2.10 (1.40-3.20) 9.40 (5.90-17.6) 124 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 2.4.d. Serum alpha-carotene: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 2.57 (2.25-2.94) .800 (<LOD-.900) 2.40 (2.10-2.90) 8.80 (7.70-10.2) 3583
 3–5 years 2.46 (1.95-3.11) .800 (<LOD-1.40) 2.10 (1.70-3.00) 8.50 (5.60-11.1) 133
 6–11 years 2.29 (1.98-2.65) .700 (<LOD-.900) 2.20 (1.80-2.50) 6.50 (4.90-10.2) 301
 12–19 years 1.69 (1.48-1.93) < LOD 1.40 (1.20-1.70) 5.30 (4.40-6.50) 656
 20–39 years 2.17 (1.86-2.55) < LOD 2.00 (1.60-2.30) 8.10 (6.30-9.20) 772
 40–59 years 3.12 (2.66-3.67) .900 (.800-1.20) 2.90 (2.50-3.40) 11.3 (8.60-14.2) 777
 60 years and older 3.16 (2.78-3.58) .900 (<LOD-1.00) 3.30 (2.80-3.80) 9.20 (8.50-9.90) 944 
Males 
Total, 3 years and older 2.28 (1.99-2.62) < LOD 2.10 (1.90-2.60) 7.80 (6.30-9.20) 1739
 3–5 years 2.44 (1.99-2.98) 1.00† (<LOD-1.30) 2.20 (1.70-2.50) 8.50† (4.40-11.3) 72
 6–11 years 2.35 (1.87-2.96) .900 (<LOD-1.10) 2.00 (1.60-2.70) 8.10 (4.40-13.4) 157
 12–19 years 1.53 (1.31-1.79) < LOD 1.30 (1.10-1.70) 4.40 (3.80-6.20) 323
 20–39 years 1.95 (1.66-2.28) < LOD 1.90 (1.50-2.10) 7.30 (5.20-8.90) 312
 40–59 years 2.59 (2.16-3.11) .800 (<LOD-.900) 2.50 (2.00-3.00) 8.80 (5.70-12.0) 407
 60 years and older 2.86 (2.47-3.32) .800 (<LOD-.900) 3.00 (2.30-3.70) 8.40 (7.40-9.80) 468 
Females 
Total, 3 years and older 2.89 (2.49-3.35) .700 (<LOD-.900) 2.90 (2.40-3.20) 9.70 (8.30-11.5) 1844
 3–5 years 2.49 (1.49-4.17) < LOD† 2.20 (1.50-4.70) 8.50† (5.40-14.7) 61
 6–11 years 2.22 (1.97-2.50) .700 (<LOD-.900) 2.20 (1.80-2.60) 6.00 (4.40-8.40) 144
 12–19 years 1.86 (1.58-2.19) < LOD 1.70 (1.50-2.20) 5.90 (4.80-7.50) 333
 20–39 years 2.40 (2.00-2.89) < LOD 2.30 (1.80-2.80) 8.30 (7.20-10.5) 460
 40–59 years 3.83 (3.26-4.51) 1.20 (.900-1.40) 3.60 (3.10-4.50) 12.7 (10.4-17.0) 370
 60 years and older 3.40 (2.92-3.96) 1.10 (.800-1.30) 3.37 (2.90-4.10) 9.50 (8.60-10.5) 476 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.5.a. Serum trans-beta-carotene: Total population 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 12.2 (11.5-13.0) 4.30 (4.10-4.70) 11.9 (11.3-12.5) 34.3 (31.7-37.4) 8358
 3–5 years 13.6 (12.6-14.6) 5.80 (4.90-7.10) 13.5 (12.1-15.3) 31.1 (27.5-35.9) 429
 6–11 years 13.3 (12.7-13.9) 6.50 (6.10-6.90) 13.2 (12.6-13.9) 27.0 (23.3-29.8) 1012
 12–19 years 9.69 (9.20-10.2) 4.20 (3.90-4.70) 9.60 (9.00-10.4) 21.6 (20.1-23.7) 2206
 20–39 years 10.3 (9.38-11.2) 3.70 (3.30-4.20) 9.90 (9.10-10.9) 29.0 (25.7-32.8) 1716
 40–59 years 13.3 (12.1-14.7) 4.20 (3.70-4.90) 12.9 (12.0-14.2) 42.8 (35.3-49.8) 1471
 60 years and older 16.5 (14.9-18.3) 5.50 (4.40-6.10) 17.6 (15.3-19.6) 46.0 (41.5-50.9) 1524 
Males 
Total, 3 years and older 10.9 (10.2-11.7) 3.90 (3.60-4.30) 11.0 (10.3-11.7) 30.2 (26.8-33.0) 4053
 3–5 years 13.3 (11.7-15.2) 5.60 (5.00-6.80) 14.2 (11.9-16.1) 30.1 (23.8-44.8) 216
 6–11 years 13.5 (12.4-14.7) 6.50 (6.10-7.10) 13.4 (11.9-14.7) 26.4 (23.0-31.3) 507
 12–19 years 9.27 (8.57-10.0) 4.10 (3.80-4.40) 9.10 (8.30-10.2) 20.1 (18.8-22.0) 1092
 20–39 years 9.07 (8.24-10.0) 3.40 (2.90-4.10) 8.80 (7.90-9.80) 24.6 (21.3-29.6) 724
 40–59 years 11.3 (10.2-12.7) 3.70 (3.30-4.10) 11.6 (10.2-12.6) 33.0 (27.0-43.9) 764
 60 years and older 14.5 (13.0-16.2) 4.30 (3.60-5.20) 15.5 (13.6-17.3) 42.2 (35.0-47.0) 750 
Females 
Total, 3 years and older 13.6 (12.7-14.6) 5.10 (4.70-5.50) 13.0 (12.2-14.2) 38.2 (35.3-41.4) 4305
 3–5 years 13.8 (12.1-15.7) 5.80 (4.30-7.90) 12.6 (10.9-15.7) 32.6 (24.6-55.1) 213
 6–11 years 13.0 (12.3-13.7) 6.30 (5.70-7.10) 12.6 (12.0-13.5) 28.0 (22.3-31.3) 505
 12–19 years 10.1 (9.53-10.8) 4.50 (3.90-5.30) 10.3 (9.60-11.0) 23.3 (20.3-26.4) 1114
 20–39 years 11.4 (10.3-12.6) 4.20 (3.50-4.80) 10.8 (9.50-12.3) 32.1 (28.9-37.0) 992
 40–59 years 15.8 (14.1-17.8) 5.50 (4.70-5.90) 15.1 (13.4-17.1) 49.9 (39.1-63.2) 707
 60 years and older 18.1 (16.0-20.6) 6.00 (5.00-7.60) 19.0 (16.9-21.8) 48.1 (42.6-55.8) 774 
Table 2.5.b. Serum trans-beta-carotene: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 12.5 (11.7-13.4) 4.70 (4.20-5.50) 12.8 (11.7-13.9) 31.0 (28.4-33.6) 2116
 3–5 years 13.9 (11.7-16.5) 7.10 (4.80-9.70) 13.0 (10.9-16.1) 24.3 (22.0-29.0) 126
 6–11 years 13.4 (12.4-14.4) 6.60 (5.70-7.60) 13.6 (12.1-14.9) 28.2 (24.2-30.8) 289
 12–19 years 10.0 (9.53-10.5) 4.50 (4.10-4.80) 10.2 (9.60-10.6) 21.8 (19.3-25.4) 696
 20–39 years 12.4 (11.2-13.7) 4.30 (3.70-5.70) 13.0 (10.8-14.5) 30.6 (27.0-34.1) 460
 40–59 years 13.8 (11.7-16.4) 4.30 (3.70-5.70) 13.9 (11.1-17.4) 37.7 (33.1-45.6) 289
 60 years and older 14.6 (12.7-16.7) 4.10 (3.20-5.00) 15.8 (13.2-17.6) 39.1 (35.5-52.1) 256 
Males 
Total, 3 years and older 11.3 (10.4-12.3) 4.20 (3.80-5.10) 11.4 (9.90-13.2) 28.0 (25.2-29.4) 1020
 3–5 years 13.8 (10.4-18.4) 7.20† (4.80-10.6) 12.6 (9.70-17.3) 24.1† (17.4-41.5) 62
 6–11 years 13.0 (11.4-14.9) 5.80 (4.70-7.70) 13.4 (10.0-16.4) 24.6 (22.0-31.4) 140
 12–19 years 8.98 (8.36-9.65) 4.20 (3.80-4.70) 9.10 (7.90-10.0) 18.9 (17.0-20.9) 330
 20–39 years 10.6 (9.13-12.3) 3.90 (3.00-5.20) 11.1 (9.00-13.5) 25.8 (22.4-29.4) 213
 40–59 years 13.3 (11.4-15.6) 4.30 (3.60-6.50) 13.0 (10.2-17.1) 33.9 (28.6-45.6) 149
 60 years and older 11.8 (9.61-14.5) 3.60 (1.90-5.50) 12.6 (9.20-16.5) 37.3 (27.6-58.4) 126 
Females 
Total, 3 years and older 14.1 (13.0-15.2) 5.60 (5.00-6.10) 14.2 (13.3-15.0) 33.9 (29.2-40.8) 1096
 3–5 years 14.0 (12.0-16.4) 6.70† (4.60-9.70) 13.0 (10.2-20.1) 25.1† (21.9-32.6) 64
 6–11 years 13.7 (12.5-15.1) 7.00 (5.70-8.40) 13.7 (12.0-14.7) 26.5 (22.1-33.5) 149
 12–19 years 11.3 (10.3-12.3) 4.70 (4.10-5.90) 11.4 (10.1-12.7) 25.4 (21.6-29.7) 366
 20–39 years 14.8 (12.7-17.1) 5.70 (3.70-7.60) 14.8 (13.0-17.4) 36.7 (27.4-48.1) 247
 40–59 years 14.4 (11.3-18.4) 4.30 (3.10-5.70) 14.4 (10.9-20.4) 39.3 (29.3-64.9) 140
 60 years and older 17.3 (14.0-21.3) 4.20 (3.30-8.30) 18.4 (13.9-21.6) 40.1 (36.1-52.1) 130 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.5.c. Serum trans-beta-carotene: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 10.8 (9.96-11.8) 4.00 (3.40-4.50) 10.8 (10.0-11.5) 28.7 (25.8-33.0) 1992
 3–5 years 11.5 (10.3-12.9) 5.10 (4.00-6.00) 11.3 (10.0-13.4) 24.6 (18.9-31.4) 128
 6–11 years 12.9 (12.1-13.6) 6.50 (5.90-7.40) 12.4 (11.5-12.9) 27.7 (22.7-31.8) 340
 12–19 years 9.64 (8.86-10.5) 4.40 (4.00-5.00) 9.70 (8.70-10.7) 20.5 (18.4-23.4) 671
 20–39 years 9.62 (7.80-11.9) 3.50 (2.90-4.50) 9.50 (7.50-12.3) 25.6 (17.6-37.0) 319
 40–59 years 10.3 (9.20-11.6) 3.00 (2.50-4.20) 10.4 (9.10-11.4) 30.5 (24.5-39.4) 291
 60 years and older 16.6 (13.8-19.9) 5.00 (4.10-6.80) 17.0 (14.4-20.9) 46.6 (36.0-65.7) 243 
Males 
Total, 3 years and older 10.1 (9.24-11.0) 4.10 (3.20-4.50) 10.3 (9.60-11.2) 25.6 (22.4-28.7) 984
 3–5 years 11.3 (9.60-13.2) 5.10† (4.60-7.00) 12.0 (8.30-14.3) 22.7† (16.0-30.1) 64
 6–11 years 14.4 (13.0-16.0) 7.40 (6.30-8.40) 13.5 (12.7-15.5) 28.7 (22.7-35.1) 175
 12–19 years 9.20 (8.22-10.3) 4.20 (3.30-5.20) 9.40 (8.30-10.8) 20.1 (17.6-22.5) 340
 20–39 years 8.88 (6.97-11.3) 3.40 (2.90-4.40) 9.10 (6.60-11.7) 23.6 (14.8-34.0) 132
 40–59 years 9.09 (7.95-10.4) 2.90 (1.90-4.10) 9.60 (8.00-10.9) 25.8 (18.6-37.1) 154
 60 years and older 13.0 (10.6-15.9) 3.80 (3.20-5.00) 14.1 (10.8-17.0) 42.1 (26.8-51.3) 119 
Females 
Total, 3 years and older 11.5 (10.4-12.7) 4.00 (3.50-4.80) 11.2 (10.3-12.7) 32.5 (27.1-38.2) 1008
 3–5 years 11.8 (9.69-14.3) 4.60† (3.60-6.50) 11.4 (9.20-14.4) 31.1† (16.5-57.7) 64
 6–11 years 11.3 (9.51-13.5) 5.80 (5.10-6.60) 10.5 (9.30-12.5) 21.7 (17.0-35.5) 165
 12–19 years 10.1 (9.10-11.2) 4.70 (4.30-5.40) 10.0 (8.50-11.3) 20.9 (18.3-26.2) 331
 20–39 years 10.2 (7.98-12.9) 3.50 (2.80-4.90) 10.0 (7.50-13.6) 27.3 (17.6-42.6) 187
 40–59 years 11.6 (9.90-13.7) 3.00 (2.10-5.60) 12.2 (9.50-15.3) 37.1 (26.1-45.6) 137
 60 years and older 19.6 (15.1-25.3) 6.80 (3.00-11.9) 19.7 (15.2-25.2) 51.7 (36.9-93.4) 124 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 2.5.d. Serum trans-beta-carotene: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 12.6 (11.6-13.7) 4.50 (4.10-5.00) 12.1 (11.4-13.1) 36.4 (32.8-40.6) 3582
 3–5 years 14.0 (12.2-16.0) 6.10 (4.20-7.90) 14.7 (11.7-16.7) 30.9 (26.1-36.4) 132
 6–11 years 13.6 (12.5-14.8) 6.80 (5.70-8.20) 13.4 (12.0-14.9) 27.9 (22.7-31.1) 300
 12–19 years 9.69 (8.94-10.5) 4.20 (3.60-4.90) 9.30 (8.60-10.5) 22.0 (19.6-24.9) 656
 20–39 years 10.1 (8.99-11.3) 3.90 (3.20-4.60) 9.50 (8.60-10.7) 29.0 (23.7-36.2) 772
 40–59 years 13.9 (12.5-15.5) 4.70 (4.00-5.30) 13.5 (12.2-14.7) 44.4 (35.2-55.1) 778
 60 years and older 16.5 (14.7-18.5) 5.50 (4.30-6.40) 17.6 (15.1-19.9) 45.8 (40.8-51.5) 944 
Males 
Total, 3 years and older 11.2 (10.3-12.3) 3.90 (3.50-4.30) 11.3 (10.2-12.1) 32.1 (27.9-36.2) 1739
 3–5 years 14.1 (12.2-16.2) 5.60† (3.80-6.80) 15.0 (11.9-16.6) 31.4† (23.8-46.0) 71
 6–11 years 13.8 (12.2-15.7) 6.70 (5.60-8.40) 13.8 (11.9-15.9) 25.8 (22.1-33.0) 157
 12–19 years 9.28 (8.36-10.3) 4.00 (3.50-4.60) 9.00 (8.00-10.3) 20.3 (18.4-24.0) 323
 20–39 years 9.02 (8.00-10.2) 3.80 (3.10-4.60) 8.60 (7.70-9.50) 26.4 (19.3-33.6) 312
 40–59 years 11.7 (10.5-13.2) 3.80 (3.40-4.30) 11.9 (10.2-12.9) 35.0 (28.4-44.4) 408
 60 years and older 14.7 (13.0-16.7) 4.50 (3.40-5.70) 15.6 (13.7-17.9) 43.0 (35.2-50.9) 468 
Females 
Total, 3 years and older 14.0 (12.7-15.5) 5.10 (4.70-5.70) 13.5 (12.1-15.1) 40.1 (36.0-45.1) 1843
 3–5 years 13.8 (10.4-18.4) 7.60† (3.20-9.50) 12.8 (9.60-17.3) 30.6† (17.1-73.7) 61
 6–11 years 13.3 (12.1-14.7) 6.70 (5.30-8.00) 12.8 (11.8-15.1) 28.6 (21.5-31.3) 143
 12–19 years 10.1 (9.16-11.2) 4.50 (3.50-5.70) 10.0 (8.60-11.5) 24.2 (19.4-30.0) 333
 20–39 years 11.1 (9.78-12.6) 4.30 (3.40-5.00) 10.4 (9.10-12.1) 32.8 (27.4-39.8) 460
 40–59 years 16.8 (14.5-19.4) 5.70 (5.30-6.60) 15.7 (13.8-18.4) 54.7 (40.2-76.2) 370
 60 years and older 18.0 (15.7-20.7) 5.70 (4.80-7.60) 19.0 (16.8-23.0) 48.1 (41.1-56.3) 476 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.6.a. Serum beta-cryptoxanthin: Total population 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 7.51 (7.12-7.93) 3.20 (3.00-3.50) 7.50 (7.00-7.90) 17.8 (16.5-19.2) 8317
 3–5 years 9.43 (8.40-10.6) 4.10 (3.30-5.50) 9.00 (7.80-10.5) 22.8 (18.3-27.8) 427
 6–11 years 9.40 (8.71-10.2) 4.60 (4.10-5.10) 9.10 (8.20-10.1) 20.0 (17.0-22.9) 1006
 12–19 years 7.63 (7.20-8.09) 3.70 (3.40-4.00) 7.50 (7.00-8.00) 15.8 (14.4-17.6) 2199
 20–39 years 7.11 (6.57-7.69) 3.10 (2.80-3.50) 6.80 (6.30-7.50) 17.1 (15.2-19.3) 1707
 40–59 years 7.28 (6.75-7.86) 3.00 (2.70-3.40) 7.10 (6.70-7.80) 17.4 (15.3-19.7) 1459
 60 years and older 7.44 (6.84-8.09) 2.80 (2.50-3.20) 7.70 (7.00-8.30) 18.6 (17.5-19.6) 1519 
Males 
Total, 3 years and older 7.35 (6.96-7.77) 3.14 (2.80-3.40) 7.50 (6.90-7.90) 17.1 (16.0-18.5) 4032
 3–5 years 9.80 (8.43-11.4) 4.20 (3.20-5.60) 9.60 (7.90-11.8) 22.8 (15.6-31.9) 217
 6–11 years 9.63 (8.84-10.5) 5.00 (4.10-5.50) 9.30 (8.40-10.2) 21.2 (16.5-25.9) 503
 12–19 years 7.64 (7.14-8.19) 3.70 (3.30-4.20) 7.50 (7.00-8.10) 15.5 (14.2-17.7) 1085
 20–39 years 7.15 (6.49-7.88) 3.20 (2.80-3.50) 7.10 (6.10-8.00) 16.8 (15.2-19.8) 723
 40–59 years 6.98 (6.57-7.42) 2.90 (2.50-3.30) 7.00 (6.50-7.60) 16.1 (14.6-18.5) 756
 60 years and older 6.64 (6.02-7.31) 2.40 (1.90-2.90) 7.00 (6.00-7.60) 16.7 (15.8-17.7) 748 
Females 
Total, 3 years and older 7.67 (7.23-8.12) 3.40 (3.10-3.50) 7.50 (7.00-7.90) 18.2 (16.7-19.7) 4285
 3–5 years 9.07 (7.79-10.6) 3.90 (3.00-5.30) 8.20 (6.40-10.4) 23.3 (17.3-32.1) 210
 6–11 years 9.15 (8.21-10.2) 4.30 (4.00-4.80) 8.70 (7.80-10.7) 18.4 (16.1-21.6) 503
 12–19 years 7.61 (7.10-8.16) 3.70 (3.40-4.00) 7.50 (7.00-8.00) 16.0 (14.3-17.5) 1114
 20–39 years 7.07 (6.50-7.70) 3.10 (2.60-3.50) 6.70 (6.10-7.50) 17.5 (14.6-19.6) 984
 40–59 years 7.61 (6.88-8.43) 3.10 (2.80-3.50) 7.30 (6.70-8.10) 18.5 (15.4-21.9) 703
 60 years and older 8.10 (7.41-8.86) 3.10 (2.70-3.50) 8.20 (7.40-8.80) 20.1 (18.1-22.7) 771 
Table 2.6.b. Serum beta-cryptoxanthin: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 12.1 (11.1-13.1) 5.10 (4.80-5.70) 12.1 (10.8-13.5) 27.1 (25.0-29.8) 2114
 3–5 years 11.0 (9.50-12.8) 5.20 (4.20-6.70) 10.3 (9.10-12.3) 23.6 (18.8-42.0) 126
 6–11 years 11.9 (10.6-13.3) 6.20 (5.30-7.10) 11.1 (10.0-13.4) 24.1 (19.9-28.7) 290
 12–19 years 9.72 (9.07-10.4) 4.80 (4.20-5.40) 9.70 (9.00-10.5) 19.8 (17.2-21.4) 696
 20–39 years 13.4 (11.9-15.1) 5.60 (4.90-6.80) 14.0 (11.6-15.9) 30.0 (26.9-33.7) 460
 40–59 years 12.2 (10.4-14.3) 4.70 (3.80-5.80) 12.7 (10.4-15.2) 27.3 (23.2-36.9) 287
 60 years and older 11.0 (9.19-13.2) 3.70 (3.20-4.50) 11.1 (9.20-13.4) 28.5 (21.2-37.1) 255 
Males 
Total, 3 years and older 11.8 (10.7-13.1) 5.20 (4.70-5.70) 11.7 (10.4-13.4) 26.6 (23.8-29.9) 1018
 3–5 years 11.1 (8.25-14.8) 5.50† (3.60-6.90) 10.3 (6.80-15.9) 22.8† (14.1-43.1) 62
 6–11 years 11.6 (10.2-13.0) 5.60 (4.90-7.20) 10.9 (9.70-12.6) 24.1 (19.9-28.7) 140
 12–19 years 9.32 (8.39-10.4) 4.70 (3.50-5.50) 9.34 (8.10-10.8) 18.5 (15.2-22.2) 330
 20–39 years 12.9 (11.3-14.8) 5.30 (4.80-7.00) 13.4 (10.6-15.4) 29.8 (24.1-35.1) 213
 40–59 years 12.9 (10.7-15.6) 5.10 (3.20-7.50) 13.1 (9.70-18.4) 28.7 (24.1-38.3) 147
 60 years and older 9.87 (8.17-11.9) 3.50 (2.40-4.40) 10.8 (8.40-13.2) 23.9 (16.7-37.1) 126 
Females 
Total, 3 years and older 12.3 (11.4-13.3) 5.30 (4.90-6.00) 12.2 (10.9-13.9) 27.7 (25.3-32.1) 1096
 3–5 years 11.0 (9.59-12.6) 4.70† (3.20-7.50) 9.90 (7.70-12.7) 25.7† (17.7-44.1) 64
 6–11 years 12.2 (10.7-14.0) 6.80 (5.30-7.30) 11.4 (9.50-14.3) 25.4 (19.1-28.8) 150
 12–19 years 10.2 (9.61-10.8) 5.10 (4.50-5.80) 10.0 (9.40-10.7) 20.8 (18.8-22.5) 366
 20–39 years 13.9 (12.1-16.1) 6.00 (4.80-7.10) 14.6 (11.3-17.6) 32.2 (26.1-37.6) 247
 40–59 years 11.5 (9.71-13.7) 4.50 (3.80-5.80) 11.9 (10.1-13.8) 26.5 (18.8-42.9) 140
 60 years and older 12.0 (9.47-15.3) 4.30 (3.20-6.10) 11.7 (8.50-17.3) 29.7 (21.2-43.4) 129 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.6.c. Serum beta-cryptoxanthin: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 8.13 (7.50-8.81) 3.90 (3.40-4.20) 7.90 (7.40-8.50) 18.0 (15.7-20.7) 1987
 3–5 years 10.9 (9.72-12.2) 5.80 (5.30-6.30) 10.2 (8.30-12.7) 20.9 (16.7-23.5) 128
 6–11 years 12.0 (10.7-13.4) 6.50 (5.50-7.90) 11.8 (9.90-13.9) 23.0 (20.4-26.3) 338
 12–19 years 8.94 (8.44-9.47) 4.70 (4.40-5.10) 8.80 (8.30-9.30) 16.6 (14.9-17.6) 670
 20–39 years 7.60 (6.69-8.63) 4.00 (3.60-4.30) 7.00 (6.20-8.20) 15.4 (12.7-21.9) 318
 40–59 years 6.79 (6.35-7.26) 3.10 (2.90-3.50) 6.60 (6.10-7.50) 15.5 (13.2-18.8) 290
 60 years and older 7.89 (6.22-10.0) 3.00 (2.30-3.40) 7.80 (5.70-10.2) 20.5 (15.7-29.6) 243 
Males 
Total, 3 years and older 8.26 (7.59-8.99) 4.00 (3.50-4.30) 8.10 (7.30-9.10) 17.8 (15.7-20.4) 982
 3–5 years 10.7 (9.29-12.3) 5.90† (5.30-6.40) 10.2 (8.70-12.6) 20.1† (16.1-22.7) 64
 6–11 years 12.7 (11.2-14.4) 6.70 (5.60-8.30) 12.8 (10.9-14.2) 23.1 (18.6-30.9) 174
 12–19 years 8.91 (8.29-9.58) 5.00 (4.50-5.40) 8.90 (8.20-9.30) 16.3 (14.4-18.8) 339
 20–39 years 8.00 (6.63-9.67) 4.00 (2.80-5.00) 7.80 (5.70-10.2) 15.9 (13.9-21.9) 132
 40–59 years 6.69 (6.09-7.34) 3.30 (2.90-3.70) 6.50 (5.80-7.30) 14.8 (12.1-19.1) 154
 60 years and older 7.02 (5.69-8.66) 3.10 (2.20-3.50) 6.80 (5.70-8.20) 15.7 (9.30-27.1) 119 
Females 
Total, 3 years and older 8.02 (7.38-8.73) 3.70 (3.30-4.10) 7.80 (7.20-8.30) 18.0 (15.3-21.6) 1005
 3–5 years 11.1 (9.30-13.2) 5.60† (5.00-6.40) 10.6 (7.70-14.9) 20.9† (15.4-53.1) 64
 6–11 years 11.3 (9.47-13.4) 6.30 (4.40-7.70) 11.0 (8.50-13.8) 21.6 (14.7-28.4) 164
 12–19 years 8.97 (8.48-9.49) 4.60 (4.00-5.00) 8.90 (8.60-9.80) 17.0 (15.2-17.7) 331
 20–39 years 7.33 (6.38-8.42) 3.80 (3.40-4.30) 6.30 (6.10-7.30) 15.3 (10.8-24.6) 186
 40–59 years 6.89 (6.31-7.52) 3.20 (2.50-3.70) 6.70 (5.90-7.80) 16.1 (12.9-19.1) 136
 60 years and older 8.55 (6.37-11.5) 2.70 (2.30-4.10) 8.80 (5.10-13.9) 23.0 (16.5-34.7) 124 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 2.6.d. Serum beta-cryptoxanthin: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 6.84 (6.47-7.24) 3.00 (2.70-3.30) 6.80 (6.30-7.20) 15.6 (14.6-16.9) 3552
 3–5 years 8.53 (7.14-10.2) 3.90 (2.80-5.50) 7.90 (6.40-10.4) 19.8 (14.4-31.9) 130
 6–11 years 8.49 (7.67-9.38) 4.20 (3.80-4.90) 8.30 (7.40-9.10) 16.6 (14.6-21.8) 296
 12–19 years 6.87 (6.41-7.36) 3.30 (2.80-3.80) 6.60 (6.10-7.00) 14.3 (12.5-16.6) 651
 20–39 years 6.16 (5.63-6.73) 2.90 (2.60-3.40) 5.90 (5.40-6.50) 13.3 (11.1-16.4) 765
 40–59 years 6.87 (6.39-7.38) 2.90 (2.70-3.30) 6.80 (6.20-7.40) 15.6 (13.9-18.0) 770
 60 years and older 7.14 (6.56-7.76) 2.70 (2.30-3.20) 7.50 (6.70-8.10) 17.6 (16.4-19.1) 940 
Males 
Total, 3 years and older 6.64 (6.31-6.99) 2.90 (2.60-3.30) 6.50 (6.20-7.00) 14.7 (13.8-16.1) 1724
 3–5 years 9.29 (7.45-11.6) 3.80† (2.20-6.10) 8.90 (6.50-11.3) 23.9† (12.1-56.4) 72
 6–11 years 8.68 (7.70-9.77) 4.10 (3.70-5.10) 8.30 (7.40-9.20) 18.4 (13.8-26.3) 155
 12–19 years 6.80 (6.30-7.33) 3.20 (2.80-3.60) 6.60 (6.10-7.40) 14.0 (11.8-16.6) 318
 20–39 years 6.23 (5.54-7.01) 3.10 (2.70-3.50) 6.00 (5.40-6.70) 13.3 (10.8-16.5) 311
 40–59 years 6.50 (6.17-6.84) 2.80 (2.35-3.30) 6.50 (5.90-7.10) 14.3 (12.5-16.0) 402
 60 years and older 6.34 (5.77-6.96) 2.10 (1.90-2.60) 6.80 (5.70-7.60) 16.2 (15.2-17.2) 466 
Females 
Total, 3 years and older 7.04 (6.57-7.55) 3.10 (2.90-3.40) 6.80 (6.30-7.40) 16.4 (14.8-18.4) 1828
 3–5 years 7.73 (5.91-10.1) 3.90† (2.00-5.70) 7.10 (5.30-11.3) 15.0† (11.7-33.0) 58
 6–11 years 8.27 (6.92-9.87) 4.10 (3.50-4.90) 8.20 (6.40-10.9) 15.4 (13.5-18.7) 141
 12–19 years 6.93 (6.33-7.59) 3.50 (3.00-4.00) 6.60 (6.00-7.10) 14.5 (12.7-16.9) 333
 20–39 years 6.09 (5.54-6.70) 2.80 (2.40-3.40) 6.00 (5.40-6.60) 13.5 (10.8-17.8) 454
 40–59 years 7.29 (6.52-8.16) 3.10 (2.90-3.70) 7.00 (6.10-7.90) 17.5 (13.5-22.2) 368
 60 years and older 7.82 (7.06-8.66) 3.20 (2.70-3.60) 8.00 (7.30-8.60) 19.5 (16.9-21.6) 474 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.7.a. Serum lutein/zeaxanthin: Total population 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 13.0 (12.5-13.6) 7.00 (6.60-7.30) 12.8 (12.2-13.5) 25.0 (24.0-25.8) 8353
 3–5 years 12.5 (11.8-13.2) 7.30 (7.00-7.90) 12.5 (12.0-13.4) 20.7 (18.5-22.7) 430
 6–11 years 12.5 (11.9-13.2) 7.60 (7.00-8.20) 12.4 (11.6-13.2) 20.3 (19.1-21.8) 1014
 12–19 years 10.4 (9.91-11.0) 6.10 (5.70-6.60) 10.4 (9.80-11.1) 17.8 (16.5-19.1) 2205
 20–39 years 12.1 (11.5-12.9) 6.30 (6.00-6.80) 12.0 (11.2-12.8) 23.0 (21.7-24.4) 1714
 40–59 years 14.4 (13.6-15.2) 7.70 (7.40-8.30) 14.2 (13.5-15.0) 27.3 (25.5-29.6) 1468
 60 years and older 15.2 (14.3-16.2) 7.60 (7.00-8.30) 15.3 (14.3-16.5) 30.0 (27.3-32.5) 1522 
Males 
Total, 3 years and older 13.0 (12.5-13.5) 7.00 (6.70-7.30) 13.0 (12.4-13.6) 24.9 (23.5-26.0) 4049
 3–5 years 12.2 (11.0-13.5) 7.30 (6.40-8.00) 12.1 (10.8-13.8) 19.5 (18.2-21.8) 217
 6–11 years 12.6 (11.7-13.4) 7.70 (6.40-8.60) 12.5 (11.5-13.5) 21.3 (19.4-24.6) 507
 12–19 years 10.3 (9.71-10.9) 5.90 (5.30-6.30) 10.2 (9.60-10.9) 17.7 (16.5-18.9) 1091
 20–39 years 12.4 (11.7-13.1) 6.70 (6.20-7.10) 12.4 (11.2-13.2) 22.8 (21.6-24.5) 724
 40–59 years 14.5 (13.8-15.3) 7.90 (7.30-8.50) 14.5 (13.7-15.5) 27.6 (25.5-30.4) 761
 60 years and older 14.5 (13.4-15.8) 7.30 (6.30-8.50) 14.7 (13.3-16.4) 28.5 (24.9-32.0) 749 
Females 
Total, 3 years and older 13.1 (12.5-13.7) 6.80 (6.50-7.10) 12.7 (12.2-13.5) 25.0 (24.1-25.9) 4304
 3–5 years 12.8 (11.6-14.1) 7.50 (6.40-8.10) 12.6 (11.8-13.8) 21.4 (17.6-26.5) 213
 6–11 years 12.5 (11.9-13.2) 7.90 (7.00-8.90) 12.2 (11.5-13.3) 19.4 (18.0-20.7) 507
 12–19 years 10.6 (9.95-11.3) 6.50 (5.60-7.00) 10.4 (9.90-11.3) 17.9 (16.5-20.2) 1114
 20–39 years 11.9 (11.1-12.8) 6.20 (5.80-6.90) 11.6 (10.7-12.5) 23.0 (20.8-25.1) 990
 40–59 years 14.2 (13.2-15.2) 7.60 (7.10-8.40) 13.9 (13.0-14.7) 26.8 (24.8-30.2) 707
 60 years and older 15.8 (14.9-16.7) 8.00 (7.10-8.70) 15.7 (14.6-17.5) 32.0 (27.6-33.7) 773 
Table 2.7.b. Serum lutein/zeaxanthin: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 13.7 (13.3-14.1) 7.70 (7.30-8.10) 13.5 (13.1-14.0) 24.1 (23.0-25.1) 2114
 3–5 years 12.5 (11.3-13.9) 7.20 (5.80-9.70) 12.5 (11.8-13.8) 19.1 (16.9-22.5) 126
 6–11 years 12.4 (11.5-13.2) 8.00 (6.40-9.20) 12.2 (11.6-12.8) 19.2 (17.2-21.2) 290
 12–19 years 10.8 (10.4-11.1) 6.70 (6.00-6.80) 10.6 (10.2-11.0) 18.0 (16.7-18.9) 696
 20–39 years 14.4 (13.5-15.4) 8.10 (7.10-8.60) 14.9 (13.8-15.9) 24.4 (23.0-25.7) 460
 40–59 years 15.7 (14.3-17.1) 8.90 (8.20-9.50) 15.5 (13.9-16.7) 28.4 (23.9-32.9) 287
 60 years and older 15.8 (15.0-16.7) 8.00 (6.00-9.70) 16.0 (14.4-17.4) 32.5 (27.3-34.3) 255 
Males 
Total, 3 years and older 14.1 (13.6-14.6) 8.10 (7.40-8.40) 14.2 (13.7-14.6) 24.1 (22.6-26.1) 1018
 3–5 years 12.8 (10.6-15.4) 6.70† (5.30-10.8) 13.1 (11.3-15.4) 19.1† (15.9-25.7) 62
 6–11 years 12.2 (11.2-13.2) 8.20 (6.30-9.30) 12.3 (11.4-12.9) 19.1 (15.7-22.5) 140
 12–19 years 10.7 (10.1-11.3) 6.60 (5.70-7.00) 10.4 (9.60-11.4) 18.2 (15.6-20.1) 330
 20–39 years 15.0 (14.0-15.9) 8.60 (7.30-9.90) 15.8 (14.4-16.5) 23.9 (22.1-26.2) 213
 40–59 years 17.4 (15.7-19.3) 9.50 (8.90-11.4) 17.3 (14.8-19.9) 31.6 (26.6-36.4) 147
 60 years and older 15.3 (14.0-16.6) 7.70 (5.70-9.80) 14.9 (13.4-17.4) 29.5 (25.8-37.9) 126 
Females 
Total, 3 years and older 13.2 (12.8-13.6) 7.40 (6.90-7.70) 13.0 (12.5-13.5) 23.9 (21.9-25.1) 1096
 3–5 years 12.3 (10.8-14.0) 6.70† (5.00-10.0) 12.4 (9.90-14.9) 18.5† (16.0-22.5) 64
 6–11 years 12.6 (11.7-13.6) 8.30 (6.40-9.30) 12.4 (11.6-13.5) 19.2 (16.6-24.2) 150
 12–19 years 10.9 (10.4-11.4) 6.80 (6.10-7.40) 10.9 (10.2-11.3) 17.5 (16.2-19.7) 366
 20–39 years 13.8 (12.7-15.0) 7.30 (6.60-8.20) 13.8 (12.2-15.8) 24.9 (23.8-26.5) 247
 40–59 years 14.0 (12.5-15.6) 8.20 (6.80-9.10) 13.9 (12.3-15.9) 22.7 (18.7-30.8) 140
 60 years and older 16.3 (15.2-17.6) 8.60 (6.00-11.3) 16.0 (13.8-19.0) 32.5 (26.4-34.3) 129 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.7.c. Serum lutein/zeaxanthin: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 14.3 (13.2-15.5) 8.10 (7.30-8.80) 14.2 (12.8-15.5) 26.1 (24.1-28.5) 1992
 3–5 years 15.4 (14.0-17.1) 9.80 (8.50-11.2) 15.3 (13.0-18.2) 24.5 (19.6-32.5) 128
 6–11 years 15.3 (14.4-16.3) 9.50 (8.50-10.3) 15.7 (14.7-16.6) 24.7 (22.4-25.3) 340
 12–19 years 12.5 (11.6-13.5) 7.80 (7.20-8.50) 12.5 (11.4-13.7) 19.6 (17.9-22.2) 671
 20–39 years 13.3 (11.9-14.8) 7.50 (6.70-8.10) 12.8 (11.4-14.4) 25.3 (21.8-28.6) 319
 40–59 years 14.9 (13.6-16.4) 8.60 (7.00-9.40) 15.5 (13.2-17.2) 28.2 (24.7-31.2) 291
 60 years and older 17.6 (15.1-20.5) 9.10 (7.30-11.2) 17.7 (14.7-21.5) 33.7 (29.7-36.5) 243 
Males 
Total, 3 years and older 14.5 (13.4-15.7) 8.00 (7.40-9.00) 14.6 (13.4-15.8) 26.2 (24.1-28.5) 984
 3–5 years 15.4 (13.4-17.7) 10.6† (8.50-12.7) 14.5 (13.0-18.4) 21.8† (18.5-34.3) 64
 6–11 years 16.4 (15.2-17.7) 10.1 (8.90-11.4) 16.4 (15.6-17.2) 25.1 (23.9-27.0) 175
 12–19 years 12.3 (11.5-13.0) 7.80 (7.50-8.30) 12.0 (11.4-13.3) 19.6 (18.2-20.8) 340
 20–39 years 13.8 (12.0-15.8) 7.50 (6.80-8.40) 13.5 (11.0-15.6) 25.9 (21.9-29.8) 132
 40–59 years 15.1 (13.5-17.0) 8.60 (7.10-9.70) 15.5 (13.5-17.5) 28.7 (24.2-31.2) 154
 60 years and older 16.1 (14.2-18.1) 7.50 (5.80-10.4) 16.0 (14.7-18.4) 29.6 (22.7-38.9) 119 
Females 
Total, 3 years and older 14.1 (12.9-15.5) 8.10 (7.10-8.80) 13.9 (12.2-15.4) 26.0 (23.3-29.5) 1008
 3–5 years 15.5 (12.9-18.5) 9.40† (7.90-11.8) 15.6 (12.3-18.2) 25.7† (19.3-37.1) 64
 6–11 years 14.2 (12.8-15.9) 8.90 (7.40-10.1) 14.8 (12.3-16.1) 21.8 (19.2-25.3) 165
 12–19 years 12.8 (11.5-14.2) 8.10 (6.80-9.40) 12.8 (11.3-14.4) 20.4 (17.6-24.2) 331
 20–39 years 12.9 (11.4-14.6) 7.10 (6.30-8.10) 12.7 (11.3-14.3) 23.3 (19.5-28.9) 187
 40–59 years 14.7 (13.2-16.3) 8.70 (6.20-9.60) 14.2 (12.5-17.1) 27.4 (22.1-33.3) 137
 60 years and older 18.8 (15.5-22.7) 9.40 (8.00-12.2) 19.3 (14.4-25.4) 35.0 (31.0-36.7) 124 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 2.7.d. Serum lutein/zeaxanthin: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 12.6 (11.9-13.2) 6.80 (6.40-7.10) 12.4 (11.6-13.1) 24.1 (22.5-25.7) 3580
 3–5 years 11.5 (10.8-12.3) 7.20 (6.40-7.60) 11.8 (10.4-12.8) 17.7 (16.9-21.4) 133
 6–11 years 11.7 (10.9-12.6) 7.20 (6.70-7.90) 11.4 (10.8-12.4) 18.7 (17.0-21.8) 301
 12–19 years 9.87 (9.21-10.6) 5.90 (5.20-6.40) 9.80 (9.10-10.5) 16.8 (15.2-19.3) 656
 20–39 years 11.3 (10.6-12.1) 6.00 (5.70-6.50) 11.3 (10.3-12.4) 21.2 (19.3-22.9) 770
 40–59 years 13.8 (13.0-14.8) 7.50 (7.10-7.80) 13.7 (13.1-14.4) 26.3 (24.1-28.5) 777
 60 years and older 14.7 (13.8-15.7) 7.40 (6.80-8.10) 14.9 (13.5-16.4) 28.0 (25.6-31.7) 943 
Males 
Total, 3 years and older 12.5 (11.9-13.1) 6.80 (6.30-7.10) 12.5 (11.7-13.2) 23.9 (22.0-26.0) 1738
 3–5 years 11.2 (9.93-12.6) 7.10† (6.20-7.70) 10.7 (9.00-13.5) 17.1† (15.2-21.7) 72
 6–11 years 11.7 (10.6-13.0) 7.10 (5.70-8.30) 11.3 (10.2-13.0) 19.6 (17.2-25.5) 157
 12–19 years 9.65 (9.05-10.3) 5.50 (4.90-6.20) 9.60 (9.10-10.2) 16.7 (15.5-18.7) 323
 20–39 years 11.6 (10.7-12.6) 6.20 (5.70-6.90) 11.7 (10.6-13.0) 20.7 (17.7-23.7) 312
 40–59 years 13.9 (13.2-14.8) 7.70 (7.10-8.50) 13.9 (13.3-14.9) 26.8 (24.9-28.3) 407
 60 years and older 13.9 (12.8-15.2) 7.30 (6.20-8.10) 14.1 (12.6-16.0) 26.1 (24.2-28.9) 467 
Females 
Total, 3 years and older 12.6 (11.9-13.4) 6.60 (6.20-7.00) 12.2 (11.6-13.0) 24.4 (22.8-25.8) 1842
 3–5 years 11.9 (10.6-13.5) 7.30† (4.30-8.30) 12.6 (10.8-13.8) 18.4† (15.2-23.2) 61
 6–11 years 11.7 (11.0-12.5) 7.50 (6.60-8.10) 11.5 (10.9-12.3) 17.9 (15.5-20.2) 144
 12–19 years 10.1 (9.25-11.0) 6.10 (5.00-6.70) 10.1 (9.10-10.7) 16.8 (14.8-20.8) 333
 20–39 years 11.1 (10.2-12.0) 5.90 (5.60-6.60) 10.6 (9.50-12.0) 21.4 (18.4-23.3) 458
 40–59 years 13.7 (12.6-15.0) 7.40 (6.50-8.00) 13.5 (12.3-14.3) 26.4 (23.4-31.6) 370
 60 years and older 15.4 (14.4-16.4) 7.70 (6.70-8.70) 15.5 (14.0-17.4) 30.4 (25.8-34.3) 476 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.8.a. Serum trans-lycopene: Total population 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 20.5 (19.8-21.1) 10.5 (10.0-11.0) 22.0 (21.2-22.8) 37.5 (36.1-38.6) 8348
 3–5 years 16.1 (15.2-17.1) 7.90 (7.30-8.90) 17.4 (16.2-18.1) 30.7 (28.5-32.8) 427
 6–11 years 21.6 (20.7-22.5) 11.4 (10.4-12.7) 22.7 (21.4-23.7) 36.0 (35.0-37.2) 1012
 12–19 years 21.6 (21.1-22.1) 12.8 (11.9-13.6) 22.3 (21.8-22.8) 36.1 (35.1-37.5) 2205
 20–39 years 22.7 (21.5-23.9) 12.5 (11.7-13.8) 23.7 (22.5-24.8) 39.1 (37.6-41.0) 1714
 40–59 years 21.1 (20.1-22.1) 10.7 (9.80-11.7) 22.6 (21.3-24.1) 38.1 (36.6-39.8) 1468
 60 years and older 15.4 (14.6-16.3) 6.70 (5.70-7.30) 17.1 (15.9-17.9) 33.4 (31.5-34.5) 1522 
Males 
Total, 3 years and older 21.2 (20.5-22.0) 10.8 (10.3-11.3) 23.1 (22.2-24.0) 39.0 (37.4-40.6) 4048
 3–5 years 16.0 (14.9-17.2) 7.80 (7.10-9.00) 17.7 (16.0-19.1) 28.4 (27.1-30.9) 216
 6–11 years 21.7 (20.4-23.1) 11.5 (9.40-13.3) 23.0 (21.2-25.0) 36.4 (34.1-40.1) 507
 12–19 years 22.5 (21.8-23.2) 13.4 (12.4-14.0) 23.5 (22.5-24.5) 37.5 (35.3-39.8) 1091
 20–39 years 24.2 (22.6-25.9) 13.8 (11.7-15.0) 25.0 (23.6-26.3) 42.1 (39.1-45.2) 724
 40–59 years 21.7 (20.4-23.2) 11.1 (9.20-11.9) 23.7 (21.9-25.5) 39.8 (37.5-41.7) 761
 60 years and older 15.2 (14.1-16.4) 6.30 (5.60-7.50) 16.8 (15.5-17.9) 33.2 (30.5-36.0) 749 
Females 
Total, 3 years and older 19.7 (19.1-20.4) 10.3 (9.70-10.9) 21.1 (20.1-21.9) 35.6 (34.3-36.7) 4300
 3–5 years 16.2 (14.6-18.1) 8.00 (6.20-10.3) 16.6 (14.9-18.6) 32.5 (29.1-34.3) 211
 6–11 years 21.5 (20.6-22.4) 10.7 (9.70-13.0) 22.2 (20.6-23.3) 35.5 (34.1-37.3) 505
 12–19 years 20.6 (20.0-21.3) 12.3 (11.5-13.1) 21.4 (20.0-22.2) 34.8 (32.1-36.3) 1114
 20–39 years 21.3 (20.2-22.5) 12.2 (10.5-13.6) 22.3 (21.2-23.6) 36.7 (33.8-39.3) 990
 40–59 years 20.4 (19.4-21.4) 10.7 (9.30-12.1) 21.8 (20.9-22.8) 36.5 (34.4-37.8) 707
 60 years and older 15.6 (14.5-16.9) 6.70 (5.60-7.50) 17.3 (15.7-18.6) 33.3 (30.6-34.5) 773 
Table 2.8.b. Serum trans-lycopene: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 19.7 (18.9-20.5) 10.6 (9.90-11.6) 20.6 (19.8-21.5) 34.6 (33.0-36.0) 2111
 3–5 years 15.0 (12.9-17.4) 7.30 (5.80-9.20) 15.7 (12.5-19.4) 30.4 (23.0-39.8) 124
 6–11 years 19.7 (18.3-21.3) 10.5 (9.20-13.1) 20.5 (18.7-22.5) 33.7 (29.6-36.1) 289
 12–19 years 20.4 (19.4-21.4) 12.3 (11.2-13.4) 20.7 (19.6-22.0) 32.9 (30.4-36.2) 696
 20–39 years 21.4 (20.1-22.8) 12.1 (11.2-13.6) 21.7 (20.6-22.5) 36.0 (33.1-39.9) 460
 40–59 years 19.1 (17.5-20.9) 10.2 (8.70-11.3) 20.0 (17.9-22.3) 34.4 (29.9-39.1) 287
 60 years and older 13.9 (11.7-16.6) 6.20 (2.20-9.60) 15.3 (13.1-17.7) 30.1 (26.6-31.6) 255 
Males 
Total, 3 years and older 20.4 (19.6-21.2) 11.4 (10.2-12.0) 21.3 (20.6-21.9) 35.9 (32.7-39.4) 1018
 3–5 years 15.2 (13.3-17.2) 8.60† (1.80-11.3) 15.7 (12.4-18.1) 28.5† (23.8-33.3) 62
 6–11 years 20.8 (18.5-23.4) 12.6 (8.70-14.7) 20.6 (19.2-24.1) 33.4 (28.4-45.7) 140
 12–19 years 21.1 (20.2-22.0) 12.9 (11.6-13.9) 21.5 (20.4-22.6) 34.6 (30.3-39.4) 330
 20–39 years 22.0 (20.7-23.5) 12.4 (11.2-14.1) 22.2 (20.7-23.6) 39.1 (33.0-43.7) 213
 40–59 years 20.0 (17.9-22.3) 10.2 (8.90-11.8) 20.9 (16.8-24.5) 35.5 (30.2-43.3) 147
 60 years and older 13.0 (10.4-16.3) 5.20 (.800-7.50) 14.2 (10.6-17.7) 27.8 (24.0-31.4) 126 
Females 
Total, 3 years and older 19.0 (18.0-20.0) 10.2 (9.10-11.3) 20.0 (18.6-21.4) 33.7 (31.6-34.9) 1093
 3–5 years 14.8 (11.0-19.8) 6.70† (4.30-9.50) 15.0 (9.50-22.8) 32.7† (20.3-37.9) 62
 6–11 years 18.7 (16.8-20.7) 9.90 (9.10-11.0) 20.0 (16.9-22.9) 33.2 (28.6-35.4) 149
 12–19 years 19.6 (18.4-20.9) 11.7 (10.2-13.6) 19.8 (18.3-21.2) 31.7 (29.7-35.9) 366
 20–39 years 20.6 (18.9-22.5) 11.6 (10.3-13.2) 21.3 (19.0-22.7) 34.8 (30.1-37.6) 247
 40–59 years 18.2 (16.4-20.2) 9.10 (5.30-13.2) 19.3 (17.9-20.8) 30.5 (28.2-36.9) 140
 60 years and older 14.7 (12.1-18.0) 6.80 (1.90-10.3) 15.8 (13.7-20.7) 30.5 (24.4-36.1) 129 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 2.8.c. Serum trans-lycopene: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 21.6 (21.0-22.3) 10.9 (10.1-11.7) 23.4 (22.1-24.2) 40.1 (37.9-42.2) 1992
 3–5 years 20.8 (18.3-23.6) 10.9 (8.90-13.4) 20.8 (18.6-24.9) 40.9 (28.5-54.9) 128
 6–11 years 25.9 (24.1-27.9) 15.0 (13.1-16.8) 27.1 (24.1-29.6) 42.1 (36.7-47.1) 340
 12–19 years 24.7 (23.6-25.8) 13.9 (12.4-16.0) 25.4 (24.0-27.0) 41.0 (38.4-43.0) 671
 20–39 years 24.3 (23.3-25.4) 13.1 (12.4-14.6) 25.2 (23.5-26.8) 41.6 (39.0-46.9) 319
 40–59 years 19.0 (17.7-20.5) 8.70 (6.20-11.3) 20.6 (19.6-22.0) 35.9 (34.4-41.3) 291
 60 years and older 14.1 (12.9-15.4) 5.40 (4.50-7.10) 14.5 (13.3-16.7) 31.4 (28.8-34.1) 243 
Males 
Total, 3 years and older 22.3 (21.4-23.2) 10.7 (9.90-12.4) 23.8 (22.8-24.6) 41.2 (37.4-44.1) 984
 3–5 years 21.6 (18.2-25.5) 9.90† (5.10-15.1) 23.8 (19.3-27.0) 41.7† (30.5-57.7) 64
 6–11 years 27.1 (24.3-30.1) 15.9 (13.0-18.5) 28.0 (23.9-32.2) 44.0 (36.4-49.1) 175
 12–19 years 25.1 (23.9-26.4) 15.2 (13.4-16.7) 25.9 (24.4-27.6) 40.1 (36.8-44.6) 340
 20–39 years 25.6 (24.4-26.9) 14.2 (12.5-16.2) 26.5 (23.8-28.1) 45.3 (37.4-56.2) 132
 40–59 years 19.4 (17.8-21.0) 9.20 (6.20-11.2) 21.3 (19.3-22.7) 35.7 (32.4-41.2) 154
 60 years and older 13.5 (11.8-15.4) 5.40 (4.30-7.10) 14.0 (11.4-16.4) 30.9 (26.2-34.9) 119 
Females 
Total, 3 years and older 21.1 (20.2-22.0) 11.0 (10.1-11.6) 22.6 (20.9-24.2) 39.7 (37.1-41.3) 1008
 3–5 years 20.0 (17.2-23.2) 11.1† (7.60-14.4) 19.6 (15.7-25.5) 40.9† (26.3-44.6) 64
 6–11 years 24.7 (22.7-26.9) 13.8 (11.7-16.8) 25.9 (23.6-28.2) 39.2 (35.2-44.8) 165
 12–19 years 24.3 (22.7-26.0) 12.5 (11.3-15.8) 25.2 (22.7-27.6) 41.0 (38.8-44.4) 331
 20–39 years 23.5 (22.1-25.0) 13.0 (11.8-14.6) 24.4 (22.1-26.6) 39.7 (37.1-46.5) 187
 40–59 years 18.7 (16.9-20.7) 7.90 (5.40-11.9) 19.9 (17.7-22.0) 36.2 (30.9-43.9) 137
 60 years and older 14.5 (12.8-16.5) 5.60 (4.50-8.20) 14.8 (12.5-18.6) 31.4 (28.0-34.1) 124 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 2.8.d. Serum trans-lycopene: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 3 years and older 20.7 (19.9-21.4) 10.8 (10.2-11.4) 22.1 (21.0-23.2) 37.6 (36.3-38.7) 3578
 3–5 years 15.4 (14.0-17.0) 7.90 (6.20-9.30) 16.6 (14.8-17.9) 27.5 (25.3-31.2) 132
 6–11 years 21.5 (20.2-22.9) 11.4 (9.70-13.2) 22.2 (20.6-23.6) 35.8 (33.3-37.8) 300
 12–19 years 21.1 (20.5-21.8) 12.8 (11.5-13.8) 21.9 (20.8-22.6) 35.3 (34.0-36.8) 656
 20–39 years 22.9 (21.3-24.6) 13.1 (11.7-14.2) 24.2 (22.8-25.7) 39.6 (37.7-42.1) 770
 40–59 years 21.9 (20.7-23.1) 11.8 (10.3-13.4) 23.2 (21.3-24.9) 38.5 (36.8-40.0) 777
 60 years and older 16.1 (15.2-17.0) 7.00 (6.20-7.70) 17.8 (16.4-18.6) 33.9 (31.7-35.9) 943 
Males 
Total, 3 years and older 21.4 (20.5-22.4) 11.0 (9.90-11.6) 23.5 (22.3-24.5) 39.5 (37.9-40.9) 1737
 3–5 years 14.4 (12.6-16.5) 7.80† (4.40-9.50) 16.4 (14.3-19.1) 27.4† (24.7-30.9) 71
 6–11 years 21.7 (19.9-23.6) 12.2 (9.40-14.1) 22.2 (20.3-25.2) 36.0 (32.0-40.1) 157
 12–19 years 22.1 (21.2-23.1) 12.9 (11.5-14.0) 23.2 (21.4-24.6) 37.0 (34.3-40.2) 323
 20–39 years 24.8 (22.4-27.3) 13.9 (11.1-16.6) 25.8 (23.9-28.9) 42.4 (38.8-45.6) 312
 40–59 years 22.6 (21.0-24.2) 11.4 (9.20-13.5) 24.5 (22.4-26.9) 40.0 (37.9-42.9) 407
 60 years and older 15.7 (14.6-17.0) 6.90 (5.80-7.70) 17.5 (15.7-18.6) 33.8 (30.6-37.6) 467 
Females 
Total, 3 years and older 19.9 (19.2-20.7) 10.6 (9.90-11.4) 21.1 (20.1-22.1) 35.4 (33.9-36.7) 1841
 3–5 years 16.6 (14.7-18.8) 8.70† (6.20-13.1) 16.6 (14.7-18.9) 26.8† (22.8-31.8) 61
 6–11 years 21.3 (19.8-22.9) 11.0 (9.40-13.8) 21.7 (20.0-23.7) 34.2 (32.5-38.0) 143
 12–19 years 20.2 (19.4-21.0) 12.6 (11.0-13.9) 21.3 (19.4-22.2) 32.4 (28.9-35.8) 333
 20–39 years 21.3 (19.8-23.0) 12.3 (9.40-14.3) 22.4 (20.9-24.1) 36.5 (33.1-39.6) 458
 40–59 years 21.2 (20.2-22.3) 12.6 (10.7-13.7) 22.0 (20.7-23.5) 36.6 (34.0-37.8) 370
 60 years and older 16.4 (15.1-17.7) 6.90 (5.70-8.40) 17.9 (15.9-19.0) 33.8 (31.4-36.1) 476 
† Estimate is subject to greater uncertainty due to small cell size. 
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Fat-Soluble Vitamins & Micronutrients: 
Vitamin D 
Vitamin D (calciferol) comprises a group of fat soluble seco-sterols found 
naturally only in a few foods, such as fish-liver oils, fatty fish, mushrooms, 
egg yolks, and liver. The two major physiologically relevant forms of 
vitamin D are D2 (ergocalciferol) and D3 (cholecalciferol). Vitamin D3 
is photosynthesized in the skin of vertebrates by the action of solar 
ultraviolet (UV) B radiation on 7-dehydrocholesterol (Fieser 1959). Vitamin D2 
is produced by UV irradiation of ergosterol, which occurs in molds, yeast, 
and higher-order plants. Under conditions of regular sun exposure, dietary 
vitamin D intake is of minor importance. However, latitude, season, aging, 
sunscreen use, and skin pigmentation influence the production of vitamin 
D3 by the skin (Institute of Medicine 1997). Most of the dietary intake of vitamin 
D comes from fortified milk products and other fortified foods such as 
breakfast cereals and orange juice (Institute of Medicine 1997). Both vitamin D2 
and D3 are used in nonprescription vitamin D supplements, but vitamin D2 
is the form available by prescription in the United States (Holick 2007). 
Vitamin D without a subscript represents either D2 or D3 or both and is 
biologically inert. Vitamin D from the skin or diet is only short-lived in 
circulation (with a half-life of 1–2 days), as it is either stored in fat cells or 
metabolized in the liver (Mawer 1972). In circulation, vitamin D is bound 
to vitamin D-binding protein and transported to the liver, where it is 
converted to 25-hydroxyvitamin D [25(OH)D] (DeLuca 1984). This major 
circulating form of vitamin D is a good reflection of cumulative effects of 
exposure to sunlight and dietary intake of vitamin D (Haddad 1973; Holick 
1995) and is therefore used by clinicians to determine vitamin D status. To 
be biologically activated at physiologic concentrations, 25(OH)D must be 
converted in the kidneys to 1,25-dihydroxyvitamin D [1,25(OH)2D], which 
is thought to be responsible for most, if not all, of the biologic functions of 
vitamin D (DeLuca 1988; Reichel 1989). The production of 25(OH)D in the liver 
and of 1,25(OH)2D in the kidney is tightly regulated. In the liver, vitamin 
D-25-hydroxylase is down-regulated by vitamin D and its metabolites, 
thereby limiting any increase in the circulating concentration of 
25(OH)D following intakes or following production of vitamin D after 
exposure to sunlight. In the kidney, in response to serum calcium and 
phosphorus concentrations, the production of 1,25(OH)2D is regulated 
through the action of parathyroid hormone (PTH) (DeLuca 1988; Reichel 1989). 
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Active vitamin D functions as a hormone, and its main biologic function in people is 
to maintain serum calcium and phosphorus concentrations within the normal range 
by enhancing the efficiency of the small intestine to absorb these minerals from the 
diet (DeLuca 1988; Reichel 1989). When dietary calcium intake is inadequate to satisfy the 
body’s calcium requirement, 1,25(OH)2D, along with PTH, mobilizes calcium stores 
from the bone. In the kidney, 1,25(OH)2D increases calcium reabsorption by the distal 
renal tubules. Apart from these traditional calcium-related actions, 1,25(OH)2D and 
its synthetic analogs are increasingly recognized for their potent antiproliferative, 
prodifferentiative, and immunomodulatory activities (Nagpal 2005). 
Vitamin D deficiency is characterized by inadequate mineralization or by 
demineralization of the skeleton. Among children, vitamin D deficiency is a common 
cause of bone deformities known as rickets. Vitamin D deficiency in adults leads to a 
mineralization defect in the skeleton, causing osteomalacia, and induces secondary 
hyperparathyroidism with consequent bone loss and osteoporosis. Potential roles for 
vitamin D beyond bone health, such as effects on muscle strength, the risk for cancer 
and for type 2 diabetes, are currently being studied. The Agency for Healthcare 
Research and Quality recently reviewed the effectiveness and safety of vitamin D on 
outcomes related to bone health (Cranney 2007). The report suggests that vitamin D 
supplementation has positive effects on bone health in postmenopausal women and 
older men. 
Still, what constitutes the optimal intake of vitamin D remains a matter of some 
disagreement. Current recommendations from the Institute of Medicine (1997) call 
for 200 international units (IU) [5.0 micrograms (µg)] of vitamin D daily from birth 
through age 50, 400 IU (10 µg) for those aged 51–70 years, and 600 IU (15 µg) for 
those older than 70 years. According to the Dietary Guidelines for Americans (U.S. 
Department of Health and Human Services and U.S. Department of Agriculture 2005) older adults, 
people with dark skin, and people exposed to insufficient UV B radiation should 
consume extra vitamin D from vitamin D-fortified foods or supplements. The 
American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer 
Prevention echo this recommendation (Kushi 2006). Some experts say that optimal 
amounts for all adults are closer to 800–1000 IU (20–25 µg) daily (Vieth 2007; Bischoff-
Ferrari 2006; Dawson-Hughes 2005). The tolerable upper intake level for vitamin D is 2000 IU 
(50 µg) per day in North America and in Europe; however, some scientists are calling 
for an upward revision (Hathcock 2007; Vieth 2006). 
Some clinical laboratories use conventional units for 25(OH)D (nanogram per milliliter 
[ng/mL]) whereas other laboratories use international system (SI) units (nanomole 
per liter [nmol/L]). The conversion factor to SI units is: 1 ng/mL = 2.496 nmol/L. 
No common definition exists for adequate vitamin D status measured as 25(OH)D 
serum concentrations (Dawson-Hughes 2005). The Institute of Medicine (1997) defined 
vitamin D deficiency as serum 25(OH)D concentrations of less than 11 ng/mL (27.5 
nmol/L) for neonates, infants, and young children. Because the lower limit of the 
normal range can be as low as 8 ng/mL (20 nmol/L) and as high as 15 ng/mL (37.5 
nmol/L), depending on the geographic location, vitamin D deficiency has been 
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defined as a concentration of less than 12 ng/mL (mid-range between 8 and 15 ng/ 
mL) for adults (Institute of Medicine 1997). More recently, some scientists have suggested 
that the criteria used to define adequate status should be revised upwards; serum 
25(OH)D concentrations between 20 ng/mL (50 nmol/L) and 32 ng/mL (80 nmol/L) 
have been defined as sufficient (Hollis 2005; Dawson-Hughes 2005; Bischoff-Ferrari 2006; Norman 
2007). A common definition for high serum vitamin D concentrations is also lacking. 
The Institute of Medicine (1997) used serum calcium concentrations greater than 11 
milligrams per deciliter (mg/dL) for assessing the potential for increased risk of harm 
associated with high vitamin D intakes. To date, however, no evidence has surfaced 
of adverse effects with serum 25(OH)D concentrations as high as 56 ng/mL (140 
nmol/L) in healthy individuals (Vieth 1999). 
Different assays measure serum 
25(OH)D, and at times large variations 
occur among methods and even 
between laboratories using the same 
method (Singh 2008; Binkley 2004; Carter 
2004). Standard reference materials 
(SRMs) for serum 25(OH)D are currently 
under development by the U.S. National 
Institute of Standards and Technology 
(U.S. NIST) (http://www.cstl.nist.gov/projects/ 
fy06/food0683904.pdf ). Improvement in the 
agreement between laboratories and 
methods is expected as laboratories 
begin to use the SRMs. 
For more information about vitamin D, 

see the Institute of Medicine’s Dietary 

Reference Intake reports (Institute of 









Since 1988, NHANES has monitored the vitamin D status of the U.S. population. 

By design, this survey collects information and biological samples in the summer 

from people living at higher latitudes and in the winter from people living at 

lower latitudes. Because the different racial and ethnic groups are not evenly 

distributed across all geographic regions in the United States, the season-latitude 

structure of the survey can affect comparisons by race or ethnicity. In two seasonal 

subpopulations from NHANES III (1988–1994), Looker et al. (2002) showed that in 

the winter and lower latitude subpopulation, 1–5 percent and 25–57 percent had 

25(OH)D concentrations less than 10 ng/mL (25 nmol/L) and less than 25 ng/mL (62.5 

nmol/L), respectively. In the summer and higher latitude subpopulation, 1–3 percent 

and 21–49 percent had 25(OH)D concentrations below these cutoffs. Mean 

Medical technologist checks samples for vitamin D analysis. 
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25(OH)D concentrations were highest in non-Hispanic whites, intermediate in 
Mexican Americans, and lowest in non-Hispanic blacks. Nesby-O’Dell et al. (2002) 
restricted the analysis of NHANES III data to African-American and white women of 
reproductive age and found the prevalence of hypovitaminosis 
[25(OH)D concentrations < 15 ng/mL (37.5 nmol/L)] to be 42.2 percent among African 
Americans and 4.2 percent among whites. 
Selected Observations and Highlights 
The following sample observations and figures are taken from the tables of 
2001–2002 data contained in this report. Statements about categorical differences 
between demographic groups noted below are based on non-overlapping 
confidence limits from univariate analysis without adjusting for demographic 
variables (e.g., age, sex, race/ethnicity) or other determinants of these blood 
concentrations (e.g., dietary intake, supplement usage, smoking, BMI). A multivariate 
analysis may alter the size and statistical significance of these categorical differences. 
Furthermore, additional significant differences of smaller magnitude may be 
present despite their lack of mention here (e.g., if confidence limits slightly overlap 
or if differences are unobservable before covariate adjustment has occurred). For 
a selection of citations of descriptive NHANES papers related to these biochemical 
indicators of diet and nutrition, see Appendix E. 
General Observations 
•	 Serum 25(OH)D concentrations are similar throughout all age groups, except 
that children 6–11 years of age have higher concentrations than do people in 
other age groups. 
•	 Non-Hispanic whites have higher concentrations of 25(OH)D than do Mexican 
Americans, who themselves have higher concentrations than do non-Hispanic 
blacks. 
•	 Approximately 10 percent of the population has concentrations of 25(OH)D 
that are less than 11 ng/mL. The values at the 10th percentile vary greatly by 
racial-ethnic group, with non-Hispanic blacks having the highest prevalence 
of low 25(OH)D concentrations. 
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Highlights 
Because of the current disagreement regarding appropriate criteria by which to 
define adequate status on the basis of serum 25(OH)D concentrations, the figure 
below presents prevalence estimates for older people (≥ 60 years) for three cut-off 
values: 11 ng/mL, 20 ng/mL, and 30 ng/mL. Regardless of the cut-off value, non-
Hispanic blacks have the highest prevalence of low serum 25(OH)D concentrations 
(Fig. 2.a). 
Figure 2.a 
Prevalence estimates (95 percent confidence intervals) of serum 25-hydroxyvitamin D among U.S. 
persons 60 years and older by race/ethnicity, National Health and Nutrition Examination Survey, 
2001–2002. Prevalence estimates shown here are not part of the tables displayed in this report; 
rather, the data were analyzed separately to generate this figure. 
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Table 2.9.a. Serum 25-hydroxyvitamin D: Total population 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for the total U.S. population aged 
6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 21.9 (21.0-22.7) 11.0 (11.0-12.0) 22.0 (22.0-23.0) 35.0 (33.0-36.0) 7807 
6–11 years 25.5 (24.2-26.9) 17.0 (16.0-19.0) 26.0 (24.0-27.0) 35.0 (32.0-39.0) 991 
12–19 years 22.0 (21.0-23.1) 13.0 (11.0-14.0) 23.0 (22.0-24.0) 35.0 (33.0-35.0) 2167 
20–39 years 21.6 (20.7-22.6) 11.0 (11.0-12.0) 22.0 (22.0-24.0) 35.0 (33.0-38.0) 1691 
40–59 years 21.6 (20.6-22.6) 11.0 (11.0-13.0) 22.0 (22.0-23.0) 34.0 (32.0-36.0) 1449 
60 years and older 21.0 (20.0-22.1) 12.0 (10.0-12.0) 22.0 (21.0-24.0) 33.0 (32.0-34.0) 1509 
Males 
Total, 6 years and older 22.6 (21.8-23.4) 13.0 (13.0-14.0) 24.0 (23.0-24.0) 34.0 (33.0-36.0) 3782 
6–11 years 26.1 (24.5-27.9) 18.0 (17.0-20.0) 26.0 (24.0-27.0) 38.0 (33.0-44.0) 497 
12–19 years 23.1 (21.9-24.3) 13.0 (11.0-16.0) 24.0 (22.0-25.0) 35.0 (34.0-37.0) 1068 
20–39 years 22.2 (21.4-23.1) 13.0 (11.0-14.0) 23.0 (21.0-24.0) 34.0 (32.0-37.0) 709 
40–59 years 22.3 (21.2-23.5) 12.0 (11.0-14.0) 22.0 (22.0-23.0) 33.0 (32.0-37.0) 762 
60 years and older 21.5 (20.7-22.5) 13.0 (11.0-14.0) 22.0 (21.0-24.0) 32.0 (31.0-33.0) 746 
Females 
Total, 6 years and older 21.2 (20.2-22.2) 10.0 (9.00-12.0) 23.0 (22.0-23.0) 34.0 (33.0-36.0) 4025 
6–11 years 24.9 (23.6-26.3) 17.0 (15.0-19.0) 26.0 (24.0-27.0) 35.0 (32.0-37.0) 494 
12–19 years 21.0 (20.0-22.0) 11.0 (9.00-13.0) 22.0 (20.0-22.0) 33.0 (32.0-35.0) 1099 
20–39 years 21.1 (19.9-22.4) 10.0 (9.00-12.0) 22.0 (21.0-24.0) 37.0 (32.0-40.0) 982 
40–59 years 20.8 (19.6-22.1) 10.0 (9.00-12.0) 23.0 (21.0-24.0) 34.0 (32.0-35.0) 687 
60 years and older 20.6 (19.3-22.0) 11.0 (10.0-12.0) 22.0 (20.0-23.0) 34.0 (33.0-36.0) 763 
Table 2.9.b. Serum 25-hydroxyvitamin D: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for Mexican Americans in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 19.6 (18.5-20.7) 11.0 (10.0-12.0) 20.0 (19.0-22.0) 29.0 (28.0-32.0) 1961 
6–11 years 22.6 (21.7-23.6) 17.0 (15.0-17.0) 22.0 (22.0-24.0) 30.0 (28.0-32.0) 283 
12–19 years 19.7 (18.5-21.0) 12.0 (11.0-14.0) 20.0 (18.0-21.0) 29.0 (27.0-32.0) 687 
20–39 years 19.5 (18.2-20.9) 12.0 (10.0-13.0) 20.0 (18.0-21.0) 31.0 (27.0-33.0) 452 
40–59 years 18.1 (16.5-19.8) 10.0 (8.00-11.0) 20.0 (18.0-21.0) 28.0 (24.0-33.0) 286 
60 years and older 18.3 (15.9-21.1) 10.0 (8.00-11.0) 18.0 (16.0-21.0) 29.0 (24.0-36.0) 253 
Males 
Total, 6 years and older 20.6 (19.4-21.8) 13.0 (11.0-13.0) 21.0 (19.0-22.0) 30.0 (27.0-32.0) 942 
6–11 years 22.8 (21.8-23.9) 17.0 (15.0-18.0) 22.0 (22.0-24.0) 28.0 (26.0-31.0) 138 
12–19 years 21.1 (19.7-22.7) 13.0 (11.0-15.0) 21.0 (19.0-24.0) 29.0 (27.0-33.0) 323 
20–39 years 20.1 (18.7-21.7) 12.0 (10.0-13.0) 20.0 (19.0-22.0) 31.0 (26.0-34.0) 208 
40–59 years 19.9 (18.3-21.7) 12.0 (9.00-14.0) 21.0 (19.0-22.0) 28.0 (25.0-33.0) 148 
60 years and older 19.5 (16.6-22.9) 9.00 (6.00-11.0) 21.0 (16.0-25.0) 31.0 (25.0-39.0) 125 
Females 
Total, 6 years and older 18.6 (17.5-19.7) 10.0 (10.0-11.0) 18.0 (17.0-20.0) 29.0 (27.0-31.0) 1019 
6–11 years 22.4 (21.4-23.5) 17.0 (15.0-18.0) 22.0 (20.0-23.0) 30.0 (28.0-33.0) 145 
12–19 years 18.3 (17.0-19.6) 11.0 (9.00-14.0) 18.0 (17.0-20.0) 26.0 (25.0-28.0) 364 
20–39 years 18.8 (17.3-20.4) 10.0 (9.00-12.0) 18.0 (17.0-21.0) 31.0 (27.0-33.0) 244 
40–59 years 16.3 (14.5-18.3) 8.00 (7.00-10.0) 18.0 (14.0-20.0) 25.0 (22.0-33.0) 138 
60 years and older 17.4 (14.7-20.7) 10.0 (7.00-12.0) 18.0 (16.0-21.0) 27.0 (22.0-30.0) 128 
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Table 2.9.c. Serum 25-hydroxyvitamin D: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for non-Hispanic blacks in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 13.0 (12.5-13.6) 7.00 (6.00-7.00) 13.0 (13.0-14.0) 22.0 (22.0-23.0) 1821 
6–11 years 18.7 (17.7-19.8) 11.0 (10.0-14.0) 19.0 (18.0-19.0) 25.0 (24.0-27.0) 334 
12–19 years 13.2 (12.4-14.0) 7.00 (7.00-8.00) 14.0 (13.0-14.0) 22.0 (20.0-23.0) 653 
20–39 years 11.6 (11.0-12.2) 7.00 (6.00-7.00) 12.0 (11.0-12.0) 20.0 (17.0-22.0) 312 
40–59 years 12.2 (11.4-13.0) 5.00 (5.00-6.00) 12.0 (11.0-14.0) 23.0 (21.0-24.0) 285 
60 years and older 14.6 (13.4-15.9) 6.00 (6.00-7.00) 14.0 (13.0-17.0) 28.0 (24.0-29.0) 237 
Males 
Total, 6 years and older 14.2 (13.4-15.0) 7.00 (7.00-8.00) 14.0 (13.0-15.0) 23.0 (22.0-25.0) 898 
6–11 years 19.8 (18.5-21.2) 12.0 (10.0-15.0) 20.0 (18.0-21.0) 27.0 (26.0-29.0) 172 
12–19 years 14.6 (13.5-15.7) 7.00 (6.00-9.00) 14.0 (13.0-16.0) 22.0 (22.0-25.0) 328 
20–39 years 12.7 (11.6-13.8) 7.00 (7.00-8.00) 13.0 (11.0-15.0) 20.0 (19.0-23.0) 127 
40–59 years 13.2 (12.1-14.5) 5.00 (5.00-6.00) 13.0 (11.0-15.0) 23.0 (21.0-24.0) 154 
60 years and older 14.6 (13.7-15.6) 7.00 (6.00-9.00) 15.0 (13.0-17.0) 26.0 (22.0-29.0) 117 
Females 
Total, 6 years and older 12.2 (11.5-12.8) 7.00 (6.00-7.00) 12.0 (12.0-13.0) 22.0 (22.0-24.0) 923 
6–11 years 17.5 (16.1-19.1) 11.0 (9.00-14.0) 18.0 (16.0-19.0) 25.0 (23.0-26.0) 162 
12–19 years 11.9 (11.1-12.8) 7.00 (5.00-7.00) 11.0 (11.0-12.0) 21.0 (18.0-24.0) 325 
20–39 years 11.0 (10.2-11.7) 6.00 (3.00-7.00) 11.0 (10.0-11.0) 19.0 (16.0-23.0) 185 
40–59 years 11.3 (10.2-12.5) 5.00 (5.00-6.00) 10.0 (9.00-12.0) 21.0 (17.0-26.0) 131 
60 years and older 14.6 (12.5-17.0) 6.00 (3.00-7.00) 14.0 (12.0-17.0) 26.0 (21.0-31.0) 120 
Table 2.9.d. Serum 25-hydroxyvitamin D: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for non-Hispanic whites in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 24.3 (23.5-25.2) 15.0 (14.0-16.0) 25.0 (24.0-25.0) 37.0 (34.0-38.0) 3416 
6–11 years 28.5 (26.6-30.5) 21.0 (19.0-22.0) 28.0 (26.0-29.0) 39.0 (33.0-45.0) 294 
12–19 years 25.8 (25.0-26.6) 17.0 (16.0-18.0) 25.0 (25.0-26.0) 36.0 (35.0-38.0) 648 
20–39 years 25.2 (24.4-26.1) 17.0 (15.0-18.0) 26.0 (25.0-26.0) 38.0 (36.0-42.0) 766 
40–59 years 23.7 (22.6-24.9) 13.0 (12.0-15.0) 25.0 (23.0-26.0) 36.0 (33.0-38.0) 768 
60 years and older 22.0 (20.9-23.3) 13.0 (11.0-14.0) 23.0 (21.0-24.0) 34.0 (32.0-34.0) 940 
Males 
Total, 6 years and older 24.8 (23.8-25.8) 15.0 (14.0-17.0) 26.0 (24.0-26.0) 37.0 (34.0-39.0) 1655 
6–11 years 29.1 (26.9-31.4) 22.0 (19.0-24.0) 28.0 (26.0-31.0) 39.0 (35.0-46.0) 152 
12–19 years 26.7 (25.4-28.1) 20.0 (17.0-20.0) 27.0 (25.0-28.0) 38.0 (35.0-41.0) 320 
20–39 years 25.0 (24.0-26.0) 16.0 (14.0-18.0) 25.0 (23.0-26.0) 36.0 (33.0-39.0) 309 
40–59 years 24.2 (22.9-25.7) 14.0 (14.0-16.0) 25.0 (22.0-26.0) 37.0 (33.0-38.0) 406 
60 years and older 22.6 (21.6-23.7) 13.0 (12.0-15.0) 23.0 (23.0-25.0) 33.0 (31.0-34.0) 468 
Females 
Total, 6 years and older 23.9 (23.0-24.9) 13.0 (13.0-15.0) 25.0 (24.0-25.0) 37.0 (34.0-39.0) 1761 
6–11 years 27.8 (25.8-30.0) 21.0 (19.0-22.0) 27.0 (26.0-29.0) 38.0 (33.0-44.0) 142 
12–19 years 25.0 (24.3-25.7) 16.0 (14.0-18.0) 26.0 (24.0-27.0) 36.0 (34.0-38.0) 328 
20–39 years 25.5 (24.1-26.9) 15.0 (14.0-18.0) 25.0 (24.0-27.0) 39.0 (35.0-44.0) 457 
40–59 years 23.1 (22.0-24.2) 12.0 (10.0-13.0) 25.0 (23.0-26.0) 34.0 (33.0-37.0) 362 
60 years and older 21.6 (20.1-23.1) 11.0 (10.0-13.0) 23.0 (21.0-24.0) 35.0 (33.0-36.0) 472 
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•	 Total iron-binding capacity 
•	 Transferrin saturation 
•	 Protoporphyrin 
National Report on Biochemical Indicators of Diet and Nutrition in the U.S. Population 1999-2002 72 
National Report on Biochemical Indicators of Diet and Nutrition in the U.S. Population 1999-2002
Iron-Status Indicators
 
Iron functions as a component of proteins and enzymes.  Almost two-
thirds of the iron in the body (approximately 2.5 grams of iron) is found 
in hemoglobin, the protein in red blood cells that carries oxygen to 
tissues, and about 15 percent is in the myoglobin of muscle tissue. The 
average American diet provides 10–15 milligrams (mg) of iron daily 
in the form of heme and nonheme iron. Heme iron is found in animal 
foods that originally contained hemoglobin and myoglobin, such as red 
meat, fish, and poultry. Nonheme iron is found in plant foods, such as 
lentils and beans, and also is provided in iron-enriched and iron-fortified 
foods. Although heme iron is absorbed better than nonheme iron, most 
dietary iron is nonheme iron (Miret 2003). Each day the body absorbs 
approximately 1–2 mg of iron to compensate for the 1–2 mg of iron that 
the (nonmenstruating) body loses (Institute of Medicine 2001). 
Transporting iron from one organ to another is accomplished by the 
reversible binding of iron to the transport protein, transferrin, which 
will then form a complex with a highly specific transferrin receptor (TfR) 
located on the plasma membrane surfaces of cells. Intracellular iron 
availability is regulated through the increased expression of cellular TfR 
concentration by iron-deficient cells. Ferritin is the major iron-storage 
compound: its production increases in cells as iron supplies increase. 
Although all cells are capable of storing iron, the liver, spleen, and bone 
marrow cells are primary iron-storage sites in people (Institute of Medicine 
2001). 
Iron deficiency and iron overload are the two major disorders of iron 
metabolism. Iron-deficiency anemia is the most severe form of iron 
deficiency. It is linked to many adverse consequences of iron deficiency, 
such as reduced physical capacity (Haas 2001) and poor pregnancy 
outcomes (Schorr 1994). Iron deficiency without anemia, however, has 
been linked to negative effects on cognitive development among infants 
and adolescents (Grantham-McGregor 2001; Beard 1999). Iron overload is the 
accumulation of excess iron in body tissues, and it usually occurs as a 
result of a genetic predisposition to absorb iron in excess of normal but 
can also be caused by excessive ingestion of iron supplements or multiple 
blood transfusions (Pietrangelo 2004). In advanced stages of iron overload 
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Medical technologist places samples for ferritin measurement into a clinical 
analyzer. 
disease (hemochromatosis), the iron accumulates in the parenchymal cells of several 
organs, but particularly the liver, followed by the heart and pancreas; this condition 
can lead to organ dysfunction and even death (Pietrangelo 2004). 
The Recommended Dietary Allowance (RDA) for all age groups of men and 
postmenopausal women is 8 mg per day; the RDA for premenopausal women is 18 
mg per day. The Tolerable Upper Uptake Level for adults is 45 mg per day of iron, a 
level based on gastrointestinal distress as an adverse effect (Institute of Medicine 2001). 
Clinical laboratories typically use conventional units for iron-status indicators: 
iron, total iron-binding capacity (TIBC), and erythrocyte protoporphyrin (EPP) are 
calculated in micrograms per deciliter (µg/dL), ferritin in nanograms per milliliter (ng/ 
mL). Conversion factors to international 
system (SI) units are as follows: 1 µg/dL 
= 0.179 micromole per liter (µmol/L) for 
iron and TIBC, 1 µg/dL = 0.01777 µmol/L 
for EPP, and 1 ng/mL = 2.247 picomole 
(pmol)/L for ferritin. 
Several methods are used to measure 
iron and related analytes. Serum iron 
concentration measures the amount 
of ferric iron (Fe3+) bound mainly 
to serum transferrin but does not 
include the divalent iron contained 
in serum as hemoglobin. Serum iron 
concentration is decreased in many 
people with iron-deficiency anemia and 
in people with chronic inflammatory 
disorders. Elevated concentrations 
of serum iron occur in iron-loading 
disorders such as hemochromatosis. 
Serum iron is not, however, a good indicator of iron stores and is not a sensitive 
measure of iron deficiency, partly because of daily fluctuations. For enhanced 
utility, serum iron measurements are used in conjunction with TIBC measurements. 
Normally, because only about one third of the iron-binding sites of transferrin are 
occupied by Fe3+, serum transferrin has considerable reserve iron-binding capacity. 
TIBC is a measurement of serum transferrin after saturation of all available binding 
sites with reagent iron. Concentrations of serum TIBC vary with the type of iron-
metabolism disorder. For example, in iron deficiency TIBC is often increased, and 
in chronic inflammatory disorders, malignancies, and hemochromatosis, it is often 
decreased. The ratio of serum iron to TIBC is called transferrin saturation. Low iron 
values in conjunction with elevated TIBC values (or specifically measured transferrin 
concentrations), yielding less than 16 percent transferrin saturation, generally 
indicate iron-deficiency anemia (World Health Organization 2001). Transferrin saturation 
values in excess of 60 percent may be indicative of hemochromatosis or iron overload 
(World Health Organization 2001). 
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Ferritin is present in the blood in very low concentrations. Plasma ferritin is 
in equilibrium with body stores, and its concentration declines early in the 
development of iron deficiency. Low serum ferritin concentrations thus are sensitive 
indicators of iron deficiency. Ferritin is also an acute-phase protein; acute and 
chronic diseases can result in increased ferritin concentration, potentially masking 
an iron-deficiency diagnosis. The generally accepted cut-off level for serum ferritin 
below which iron stores are considered to be depleted is 15 ng/mL for people aged 
5 years and older and 12 ng/mL for people younger than 5 years of age (World Health 
Organization 2001). 
Finally, when iron delivery to the bone marrow is not sufficient for maintaining the 
incorporation of iron into newly synthesized globin and porphyrin protein, EPP 
concentrations increase. Yet EPP is not useful to distinguish iron deficiency from 
infection and also elevates in response to lead poisoning (Roels 1975). As a result, 
the measurement of EPP is most useful in settings where iron deficiency levels are 
common and where infections, lead poisoning, and other forms of anemia are rare. 
The generally accepted cut-off level for EPP is 80 µg/dL red blood cells for people 
aged 5 years and older and 70 µg/dL red blood cells for children younger than 5 
years of age (World Health Organization 2001). 
For more information about iron, see the Institute of Medicine’s Dietary Reference 
Intake reports (Institute of Medicine 2001), fact sheets from the National Institutes of 
Health, Office of Dietary Supplements (http://ods.od.nih.gov/Health_Information/Information_ 
About_Individual_Dietary_Supplements.aspx), and information from the American Society 
for Nutrition (http://jn.nutrition.org/nutinfo/). 
Three national health objectives for Healthy People 2010 relate to iron deficiency 
reduction: Objective 19–12 (reduce iron deficiency among young children and 
females of childbearing age), Objective 19–13 (reduce anemia among low-income 
pregnant females in their third trimester), and Objective 19–14 (reduce iron 
deficiency among pregnant females) (U.S. Department of Health and Human Services 2000). 
To address the changing epidemiology of iron deficiency in the United States, CDC 
staff, in consultation with outside experts, developed recommendations in 1998 for 
use by primary health-care providers to prevent, detect, and treat iron deficiency 
(U.S. Centers for Disease Control and Prevention 1998). Since the inception of NHANES in 1971, 
monitoring the iron status of the U.S. population has been an important component. 
To provide the best possible assessment of this element, each NHANES has included 
a battery of hematologic and biochemical indicators of iron status (Looker 1995). 
Since NHANES II (1976–1980), models that employ multiple biochemical iron-status 
indicators have been used to define iron deficiency in the population (Pilch 1984). The 
three-indicator model, using serum ferritin, transferrin saturation, and erythrocyte 
protoporphyrin, was developed in 1980 and applied to NHANES III (1988–1994) as 
well as to the other most recent surveys that became continuous beginning in 1999. 
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Reference data for hematologic and iron-related analytes were published for 
NHANES II (Fulwood 1982) and NHANES III (Hollowell, 2005). Prevalence estimates of iron 
deficiency using the three-indicator model were similar in NHANES III (Looker 1997) and 
in NHANES 1999–2000 (Looker 2002). In NHANES 1999–2000, the estimated prevalence 
of iron deficiency was greatest among toddlers aged 1–2 years (7 percent) and 
adolescent and adult females aged 12–49 years (9 percent to 16 percent). The 
prevalence of iron deficiency was approximately two times higher among non-
Hispanic black and Mexican-American females (19 percent to 22 percent) than 
among non-Hispanic white females (10 percent). Across all age and sex groups in 
the United States, iron-deficiency anemia has an estimated prevalence of less than 5 
percent. 
Selected Observations and Highlights 
The following example observations and figures are taken from the tables of 
1999–2002 data (for ferritin) and 1999–2000 data (for all other iron-status indicators) 
contained in this report. Statements about categorical differences between 
demographic groups noted below are based on non-overlapping confidence limits 
from univariate analysis without adjusting for demographic variables (e.g., age, sex, 
race/ethnicity) or other determinants of these blood concentrations (e.g., dietary 
intake, supplement usage, smoking, BMI). A multivariate analysis may alter the size 
and statistical significance of these categorical differences. Furthermore, additional 
significant differences of smaller magnitude may be present despite their lack of 
mention here (e.g., if confidence limits slightly overlap or if differences are not 
statistically significant before covariate adjustment has occurred). For a selection of 
citations of descriptive NHANES papers related to these biochemical indicators of diet 
and nutrition, see Appendix E. 
General Observations 
•	 Among all age groups, 1–5 year-old children have the lowest ferritin 
concentrations. Children up to age 11 have lower transferrin saturation levels 
than do adolescents or adults. 
•	 Women 12 years and older are more likely to be defined as iron deficient than 
are men. These women have lower concentrations of serum ferritin, lower 
transferrin saturation, and higher EPP concentrations. 
•	 Mexican Americans have lower serum ferritin and higher EPP concentrations 
than do either non-Hispanic whites or non-Hispanic blacks. 
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•	 Non-Hispanic blacks have lower serum transferrin saturation levels than do 
non-Hispanic whites. 
•	 Mexican-American and non-Hispanic white children (aged 1–5 years) have 
lower serum ferritin concentrations than do non-Hispanic black children. 
•	 Mexican-American children (aged 1–5 years) have higher EPP concentrations 
than do non-Hispanic black or non-Hispanic white children. 
•	 Mexican-American women of childbearing age (aged 20–39 years) have 
lower serum ferritin concentrations than do non-Hispanic white women. 
Concentrations for non-Hispanic black women of childbearing age fall 
between those of Mexican-American and non-Hispanic white women. 
•	 Non-Hispanic black women of childbearing age (aged 20–39 years) have 
lower serum transferrin saturation levels than do non-Hispanic white 
women. Serum transferrin saturation levels for Mexican-American women 
of childbearing age fall between levels for non-Hispanic white and Mexican-
American women of childbearing age. 
Highlights 
Because children and women have lower serum ferritin and transferrin saturation 
levels than do men and older people (≥ 60 years), children and women are at greater 
risk for iron deficiency. 
Two minority groups, non-Hispanic blacks and Mexican Americans, typically are at 
greater risk for iron deficiency than are non-Hispanic whites. 
At least 5 percent of persons in each age group, except for older people (≥ 60 years), 
have low serum ferritin concentrations (< 12 ng/mL for children younger than 5 years 
and < 15 ng/mL for people aged 5 years and older) that are consistent with depleted 
iron storage. 
At least 10 percent of persons in each age group have low transferrin saturation 
levels (< 16 percent), which are indicative of iron deficiency. 
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Table 3.1.a. Serum ferritin: Total population 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for the total U.S. population aged 
1 year and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 1 year and older 60.2 (58.3-62.1) 9.00 (9.00-10.0) 62.0 (59.0-64.0) 343 (329-359) 16656
 1–5 years 21.5 (20.3-22.9) 6.00 (3.00-8.00) 21.0 (20.0-23.0) 62.0 (53.0-77.0) 1523
 6–11 years 29.8 (28.1-31.5) 11.0 (11.0-13.0) 30.0 (28.0-31.0) 74.0 (67.0-83.0) 1909
 12–19 years 32.8 (31.4-34.3) 8.00 (6.00-9.00) 34.0 (32.0-35.0) 115 (103-125) 4340
 20–39 years 62.2 (58.9-65.6) 8.00 (7.00-10.0) 71.0 (66.0-76.0) 301 (272-321) 3186
 40–59 years 80.8 (76.7-85.0) 9.00 (7.00-11.0) 93.0 (88.0-96.0) 404 (379-433) 2680
 60 years and older 101 (95.5-107) 19.0 (16.0-22.0) 105 (97.0-112) 481 (434-518) 3018 
Males 
Total, 1 year and older 93.0 (89.3-96.8) 16.0 (15.0-17.0) 101 (97.0-107) 416 (391-439) 8142
 1–5 years 20.2 (18.7-21.7) 3.00 (3.00-6.00) 20.0 (19.0-22.0) 62.0 (50.0-79.0) 805
 6–11 years 29.7 (27.3-32.3) 11.0 (9.00-12.0) 31.0 (29.0-32.0) 73.0 (64.0-83.0) 972
 12–19 years 44.3 (41.6-47.1) 15.0 (13.0-17.0) 42.0 (40.0-45.0) 142 (125-154) 2172
 20–39 years 129 (122-137) 41.0 (34.0-46.0) 134 (125-142) 382 (344-406) 1356
 40–59 years 145 (135-157) 32.0 (24.0-42.0) 150 (138-168) 500 (434-574) 1340
 60 years and older 127 (118-136) 21.0 (18.0-24.0) 134 (125-147) 552 (493-623) 1497 
Females 
Total, 1 year and older 39.7 (38.1-41.4) 6.00 (6.00-8.00) 39.0 (37.0-41.0) 213 (198-228) 8514
 1–5 years 23.2 (21.8-24.8) 7.00 (5.00-9.00) 23.0 (22.0-25.0) 69.0 (52.0-88.0) 718
 6–11 years 29.9 (28.2-31.7) 12.0 (10.0-14.0) 30.0 (27.0-31.0) 76.0 (67.0-83.0) 937
 12–19 years 24.0 (22.7-25.3) 5.00 (3.00-7.00) 26.0 (24.0-27.0) 76.0 (70.0-85.0) 2168
 20–39 years 30.4 (28.6-32.4) < LOD 32.0 (30.0-35.0) 126 (110-146) 1830
 40–59 years 45.6 (42.8-48.6) 4.00 (3.00-6.00) 53.0 (46.0-57.0) 228 (201-243) 1340
 60 years and older 84.9 (79.7-90.4) 15.0 (14.0-21.0) 86.0 (80.0-93.0) 391 (349-445) 1521 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
Table 3.1.b. Serum ferritin: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for Mexican Americans in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 1 year and older 46.6 (43.4-50.1) 7.00 (6.00-8.00) 44.0 (40.0-47.0) 298 (265-334) 4946
 1–5 years 19.0 (18.2-19.9) 5.00 (3.00-7.00) 19.0 (18.0-20.0) 48.0 (45.0-54.0) 515
 6–11 years 27.7 (26.1-29.5) 12.0 (10.0-13.0) 27.0 (25.0-28.0) 70.0 (59.0-81.0) 651
 12–19 years 29.9 (28.1-31.8) 6.00 (3.00-7.00) 32.0 (29.0-34.0) 114 (101-122) 1639
 20–39 years 56.8 (51.9-62.2) 6.00 (3.00-8.00) 67.0 (60.0-74.0) 300 (256-336) 867
 40–59 years 76.0 (67.5-85.6) < LOD 97.0 (81.0-111) 463 (409-589) 634
 60 years and older 100 (91.8-110) 18.0 (12.0-24.0) 102 (90.0-120) 433 (342-568) 640 
Males 
Total, 1 year and older 77.1 (72.9-81.6) 14.0 (13.0-16.0) 85.0 (77.0-91.0) 373 (317-408) 2422
 1–5 years 19.0 (18.0-20.0) 5.00 (3.00-7.00) 19.0 (18.0-21.0) 48.0 (42.0-59.0) 268
 6–11 years 28.4 (26.3-30.7) 12.0 (11.0-14.0) 27.0 (25.0-29.0) 70.0 (56.0-88.0) 337
 12–19 years 43.2 (40.5-46.2) 14.0 (10.0-16.0) 42.0 (40.0-46.0) 131 (121-143) 812
 20–39 years 121 (112-131) 39.0 (31.0-51.0) 122 (111-134) 349 (298-395) 383
 40–59 years 160 (142-180) 44.0 (33.0-53.0) 159 (142-177) 646 (457-959) 301
 60 years and older 122 (105-143) 19.0 (13.0-28.0) 136 (102-162) 569 (364-831) 321 
Females 
Total, 1 year and older 26.9 (24.2-30.0) < LOD 27.0 (24.0-29.0) 161 (123-201) 2524
 1–5 years 19.1 (17.6-20.8) 5.00 (3.00-8.00) 20.0 (17.0-20.0) 47.0 (44.0-56.0) 247
 6–11 years 27.0 (24.7-29.6) 12.0 (8.00-14.0) 27.0 (24.0-29.0) 68.0 (59.0-84.0) 314
 12–19 years 20.0 (18.3-21.9) < LOD 22.0 (19.0-24.0) 69.0 (59.0-77.0) 827
 20–39 years 23.3 (20.6-26.3) < LOD 24.0 (22.0-26.0) 98.0 (78.0-144) 484
 40–59 years 35.2 (29.2-42.4) < LOD 38.0 (32.0-44.0) 293 (195-385) 333
 60 years and older 84.6 (76.6-93.4) 17.0 (11.0-24.0) 87.0 (76.0-100) 324 (237-375) 319 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
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Table 3.1.c. Serum ferritin: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for non-Hispanic blacks in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 1 year and older 59.2 (55.6-62.9) 8.00 (6.00-10.0) 58.0 (54.0-62.0) 381 (342-423) 3898
 1–5 years 25.9 (23.9-28.1) 8.00 (5.00-10.0) 25.0 (24.0-28.0) 73.0 (62.0-98.0) 415
 6–11 years 36.8 (34.7-39.0) 15.0 (13.0-17.0) 36.0 (34.0-38.0) 86.0 (78.0-91.0) 604
 12–19 years 32.9 (31.3-34.6) 7.00 (6.00-10.0) 33.0 (31.0-36.0) 122 (110-132) 1258
 20–39 years 54.4 (48.0-61.6) < LOD 63.0 (56.0-73.0) 313 (266-368) 592
 40–59 years 96.9 (86.7-108) 7.00 (6.00-12.0) 111 (100-129) 482 (425-642) 543
 60 years and older 133 (118-150) 22.0 (18.0-31.0) 141 (125-162) 613 (509-724) 486 
Males 
Total, 1 year and older 92.8 (87.2-98.8) 17.0 (16.0-19.0) 98.0 (90.0-108) 452 (420-494) 1917
 1–5 years 24.6 (21.8-27.7) 7.00† (3.00-10.0) 24.0 (21.0-27.0) 69.0† (57.0-122) 215
 6–11 years 36.1 (33.6-38.7) 16.0 (13.0-18.0) 34.0 (31.0-38.0) 79.0 (75.0-90.0) 304
 12–19 years 44.1 (42.1-46.1) 14.0 (12.0-16.0) 43.0 (40.0-46.0) 146 (128-171) 642
 20–39 years 137 (126-150) 35.0 (24.0-52.0) 150 (137-161) 381 (325-450) 249
 40–59 years 176 (156-199) 42.0 (30.0-53.0) 178 (157-206) 642 (494-984) 275
 60 years and older 159 (135-186) 26.0 (18.0-34.0) 173 (132-204) 710 (521-851) 232 
Females 
Total, 1 year and older 40.1 (36.5-44.2) 6.00 (3.00-7.00) 40.0 (37.0-42.0) 267 (246-297) 1981
 1–5 years 27.5 (25.0-30.2) 10.0† (7.00-12.0) 26.0 (24.0-30.0) 73.0† (56.0-96.0) 200
 6–11 years 37.6 (34.8-40.6) 16.0 (12.0-17.0) 37.0 (33.0-41.0) 88.0 (73.0-107) 300
 12–19 years 24.5 (22.3-26.8) 3.00 (3.00-6.00) 24.0 (22.0-29.0) 91.0 (78.0-104) 616
 20–39 years 26.6 (22.0-32.2) < LOD 31.0 (24.0-34.0) 142 (102-232) 343
 40–59 years 57.4 (50.1-65.8) 6.00 (3.00-6.00) 61.0 (52.0-75.0) 343 (255-481) 268
 60 years and older 118 (101-138) 21.0 (8.00-30.0) 131 (107-151) 534 (396-613) 254 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 3.1.d. Serum ferritin: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for non-Hispanic whites in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size5th 50th 95th 
Males and Females 
Total, 1 year and older 63.0 (60.4-65.6) 11.0 (10.0-11.0) 65.0 (63.0-69.0) 343 (327-357) 6360
 1–5 years 21.3 (19.2-23.6) 5.00 (3.00-8.00) 21.0 (19.0-23.0) 61.0 (46.0-80.0) 420
 6–11 years 28.4 (26.0-31.1) 10.0 (9.00-12.0) 30.0 (27.0-32.0) 69.0 (59.0-83.0) 496
 12–19 years 32.9 (31.0-34.8) 8.00 (7.00-11.0) 34.0 (31.0-36.0) 107 (95.0-122) 1075
 20–39 years 64.3 (59.6-69.5) 9.00 (7.00-12.0) 74.0 (66.0-81.0) 293 (261-328) 1382
 40–59 years 79.8 (75.7-84.1) 10.0 (9.00-12.0) 91.0 (85.0-96.0) 386 (349-406) 1280
 60 years and older 97.9 (92.2-104) 17.0 (15.0-21.0) 102 (94.0-110) 448 (393-503) 1707 
Males 
Total, 1 year and older 96.0 (91.4-101) 16.0 (14.0-18.0) 107 (99.0-115) 414 (391-435) 3127
 1–5 years 19.4 (17.3-21.8) < LOD 19.0 (17.0-21.0) 61.0 (42.0-79.0) 226
 6–11 years 28.4 (24.8-32.6) 11.0 (9.00-14.0) 29.0 (27.0-33.0) 68.0 (50.0-97.0) 261
 12–19 years 42.9 (39.7-46.4) 14.0 (10.0-17.0) 43.0 (39.0-46.0) 127 (111-143) 536
 20–39 years 131 (121-141) 43.0 (32.0-49.0) 135 (124-144) 382 (331-416) 577
 40–59 years 139 (127-153) 31.0 (18.0-39.0) 144 (132-168) 453 (409-517) 668
 60 years and older 125 (116-135) 20.0 (18.0-25.0) 135 (122-148) 531 (471-601) 859 
Females 
Total, 1 year and older 41.7 (39.5-44.0) 8.00 (6.00-9.00) 41.0 (39.0-44.0) 205 (193-227) 3233
 1–5 years 23.6 (20.9-26.8) 8.00† (5.00-11.0) 24.0 (20.0-26.0) 59.0† (42.0-98.0) 194
 6–11 years 28.4 (25.9-31.2) 10.0 (9.00-14.0) 28.0 (25.0-31.0) 73.0 (56.0-83.0) 235
 12–19 years 24.8 (23.0-26.6) 7.00 (3.00-8.00) 26.0 (25.0-28.0) 71.0 (61.0-85.0) 539
 20–39 years 32.0 (29.1-35.2) 5.00 (3.00-8.00) 34.0 (29.0-40.0) 127 (108-149) 805
 40–59 years 45.2 (41.8-48.8) 6.00 (3.00-8.00) 51.0 (45.0-57.0) 206 (181-235) 612
 60 years and older 80.7 (75.7-86.1) 16.0 (13.0-22.0) 83.0 (77.0-89.0) 353 (296-391) 848 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 3.2.a. Serum iron: Total population 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for the total U.S. population aged 
1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 81.2 (79.5-83.0) 45.0 (42.0-46.0) 85.0 (84.0-87.0) 137 (134-139) 7877
 1–5 years 65.2 (62.0-68.4) 31.0 (27.0-35.0) 70.0 (64.0-79.0) 115 (110-124) 704
 6–11 years 71.5 (68.2-75.0) 39.0 (34.0-41.0) 76.0 (69.0-82.0) 126 (117-131) 887
 12–19 years 82.1 (79.7-84.7) 45.0 (42.0-47.0) 87.0 (83.0-89.0) 141 (133-145) 2127
 20–39 years 84.5 (81.3-87.8) 45.0 (41.0-48.0) 88.0 (86.0-93.0) 146 (139-154) 1470
 40–59 years 83.3 (80.3-86.4) 50.0 (46.0-52.0) 87.0 (83.0-92.0) 135 (131-139) 1199
 60 years and older 82.0 (78.5-85.8) 49.0 (44.0-54.0) 83.0 (80.0-86.0) 132 (126-139) 1490 
Males 
Total, 1 year and older 88.1 (86.1-90.0) 51.0 (49.0-54.0) 92.0 (89.0-94.0) 144 (141-147) 3879
 1–5 years 64.9 (61.3-68.7) 33.0 (26.0-38.0) 67.0 (65.0-73.0) 116 (103-125) 388
 6–11 years 69.6 (65.9-73.5) 38.0 (31.0-41.0) 75.0 (67.0-81.0) 115 (105-129) 463
 12–19 years 92.0 (86.3-98.0) 52.0 (43.0-59.0) 96.0 (91.0-100) 150 (139-161) 1080
 20–39 years 93.8 (91.4-96.3) 60.0 (56.0-63.0) 94.0 (92.0-98.0) 154 (141-163) 632
 40–59 years 93.7 (89.1-98.6) 56.0 (52.0-63.0) 97.0 (92.0-103) 141 (137-148) 570
 60 years and older 86.6 (83.2-90.0) 52.0 (44.0-56.0) 88.0 (85.0-91.0) 145 (137-154) 746 
Females 
Total, 1 year and older 75.1 (73.3-76.9) 39.0 (37.0-43.0) 79.0 (77.0-81.0) 130 (124-135) 3998
 1–5 years 65.5 (58.8-72.9) 30.0 (24.0-37.0) 76.0 (60.0-85.0) 114 (108-128) 316
 6–11 years 73.8 (66.9-81.4) 37.0 (27.0-46.0) 76.0 (67.0-87.0) 133 (111-148) 424
 12–19 years 72.9 (69.0-77.0) 40.0 (36.0-42.0) 77.0 (71.0-81.0) 128 (116-135) 1047
 20–39 years 76.2 (72.0-80.6) 36.0 (33.0-41.0) 82.0 (74.0-87.0) 137 (128-151) 838
 40–59 years 74.7 (71.6-77.9) 44.0 (38.0-48.0) 78.0 (71.0-83.0) 125 (115-134) 629
 60 years and older 78.5 (73.9-83.5) 49.0 (40.0-54.0) 80.0 (76.0-85.0) 125 (114-133) 744 
Table 3.2.b. Serum iron: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for Mexican Americans in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 80.1 (77.7-82.6) 40.0 (38.0-44.0) 84.0 (81.0-87.0) 139 (136-147) 2710
 1–5 years 62.3 (56.6-68.6) 28.0 (21.0-35.0) 70.0 (60.0-79.0) 120 (111-135) 277
 6–11 years 71.2 (65.8-77.1) 41.0 (34.0-45.0) 75.0 (68.0-83.0) 117 (110-133) 361
 12–19 years 83.3 (79.3-87.4) 44.0 (38.0-48.0) 89.0 (83.0-93.0) 143 (138-148) 938
 20–39 years 85.1 (80.1-90.4) 43.0 (37.0-51.0) 88.0 (80.0-97.0) 149 (138-162) 407
 40–59 years 85.1 (81.7-88.6) 47.0 (41.0-52.0) 89.0 (83.0-96.0) 147 (131-162) 344
 60 years and older 82.1 (76.7-87.7) 48.0 (42.0-52.0) 85.0 (77.0-95.0) 134 (130-139) 383 
Males 
Total, 1 year and older 90.0 (86.1-94.1) 49.0 (45.0-55.0) 96.0 (90.0-99.0) 153 (143-162) 1348
 1–5 years 61.6 (54.7-69.4) 28.0 (21.0-35.0) 65.0 (57.0-75.0) 120 (97.0-148) 152
 6–11 years 71.4 (63.3-80.6) 42.0 (32.0-49.0) 74.0 (66.0-84.0) 115 (100-134) 198
 12–19 years 94.1 (90.8-97.6) 53.0 (49.0-58.0) 97.0 (92.0-103) 156 (150-162) 481
 20–39 years 102 (96.5-109) 62.0 (56.0-69.0) 107 (101-111) 162 (150-176) 170
 40–59 years 101 (93.9-108) 62.0 (50.0-76.0) 102 (93.0-112) 151 (133-178) 152
 60 years and older 87.3 (81.9-93.0) 44.0 (30.0-60.0) 95.0 (82.0-102) 141 (130-155) 195 
Females 
Total, 1 year and older 70.8 (67.7-74.1) 36.0 (33.0-38.0) 76.0 (71.0-79.0) 127 (117-132) 1362
 1–5 years 63.3 (56.3-71.1) 26.0 (16.0-37.0) 74.0 (58.0-86.0) 117 (105-138) 125
 6–11 years 71.1 (64.4-78.4) 38.0 (22.0-51.0) 79.0 (70.0-84.0) 118 (110-129) 163
 12–19 years 74.2 (66.6-82.7) 36.0 (30.0-46.0) 79.0 (71.0-87.0) 127 (96.0-144) 457
 20–39 years 69.2 (61.3-78.1) 35.0 (30.0-41.0) 75.0 (66.0-84.0) 124 (111-129) 237
 40–59 years 72.6 (68.4-77.0) 36.0 (27.0-47.0) 73.0 (66.0-83.0) 130 (116-154) 192
 60 years and older 77.4 (70.5-85.1) 48.0 (37.0-57.0) 78.0 (72.0-86.0) 123 (109-137) 188 
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Table 3.2.c. Serum iron: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic blacks in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 71.7 (69.0-74.6) 38.0 (35.0-39.0) 75.0 (71.0-80.0) 122 (119-130) 1784
 1–5 years 67.2 (60.0-75.3) 37.0 (30.0-50.0) 69.0 (62.0-80.0) 109 (96.0-125) 172
 6–11 years 71.5 (67.2-76.1) 40.0 (34.0-48.0) 77.0 (73.0-80.0) 117 (103-124) 261
 12–19 years 73.5 (68.0-79.4) 39.0 (33.0-42.0) 79.0 (71.0-84.0) 127 (118-138) 584
 20–39 years 74.1 (70.0-78.5) 35.0 (31.0-41.0) 81.0 (74.0-83.0) 133 (122-147) 274
 40–59 years 71.5 (66.6-76.8) 39.0 (34.0-45.0) 71.0 (66.0-80.0) 126 (112-139) 251
 60 years and older 65.4 (61.5-69.5) 33.0 (30.0-40.0) 67.0 (65.0-72.0) 109 (99.0-119) 242 
Males 
Total, 1 year and older 80.4 (76.3-84.7) 47.0 (39.0-52.0) 82.0 (78.0-85.0) 132 (121-141) 875
 1–5 years 68.4 (60.4-77.6) 37.0† (33.0-40.0) 69.0 (58.0-80.0) 110† (88.0-149) 93
 6–11 years 71.4 (65.7-77.6) 37.0 (28.0-50.0) 79.0 (73.0-84.0) 117 (103-122) 129
 12–19 years 82.2 (77.7-86.9) 46.0 (41.0-54.0) 89.0 (82.0-94.0) 132 (121-138) 301
 20–39 years 88.4 (82.2-95.0) 57.0 (44.0-67.0) 91.0 (82.0-98.0) 137 (120-153) 117
 40–59 years 80.4 (71.8-90.1) 50.0 (31.0-55.0) 80.0 (70.0-94.0) 136 (119-157) 122
 60 years and older 73.0 (66.1-80.5) 35.0 (32.0-54.0) 72.0 (64.0-81.0) 119 (101-141) 113 
Females 
Total, 1 year and older 64.7 (62.1-67.4) 33.0 (30.0-36.0) 67.0 (65.0-70.0) 118 (110-122) 909
 1–5 years 65.8 (56.5-76.7) 33.0† (21.0-54.0) 71.0 (60.0-82.0) 103† (97.0-123) 79
 6–11 years 71.6 (66.3-77.3) 40.0 (27.0-49.0) 76.0 (69.0-80.0) 119 (101-128) 132
 12–19 years 65.3 (57.6-74.1) 34.0 (22.0-40.0) 69.0 (60.0-81.0) 123 (108-135) 283
 20–39 years 63.9 (59.3-68.9) 30.0 (20.0-33.0) 67.0 (61.0-77.0) 123 (112-159) 157
 40–59 years 64.7 (58.2-71.9) 36.0 (31.0-45.0) 67.0 (60.0-71.0) 106 (91.0-115) 129
 60 years and older 60.3 (57.3-63.3) 35.0 (29.0-40.0) 65.0 (58.0-68.0) 103 (86.0-116) 129 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 3.2.d. Serum iron: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in µg/dL) for non-Hispanic whites in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 84.0 (81.8-86.2) 47.0 (45.0-51.0) 88.0 (86.0-89.0) 139 (135-141) 2645
 1–5 years 68.5 (63.2-74.3) 35.0 (25.0-44.0) 76.0 (66.0-85.0) 117 (109-132) 170
 6–11 years 72.6 (67.2-78.5) 37.0 (30.0-41.0) 80.0 (66.0-90.0) 131 (113-146) 191
 12–19 years 85.2 (81.2-89.4) 45.0 (40.0-51.0) 89.0 (85.0-91.0) 145 (137-153) 419
 20–39 years 87.3 (81.7-93.3) 46.0 (41.0-56.0) 90.0 (85.0-96.0) 148 (139-158) 609
 40–59 years 85.9 (82.0-90.0) 51.0 (48.0-54.0) 90.0 (85.0-96.0) 135 (129-140) 496
 60 years and older 84.0 (80.4-87.8) 51.0 (47.0-56.0) 86.0 (84.0-90.0) 132 (127-139) 760 
Males 
Total, 1 year and older 89.9 (86.9-92.9) 53.0 (50.0-56.0) 93.0 (90.0-96.0) 146 (141-151) 1315
 1–5 years 67.7 (59.9-76.4) 33.0† (21.0-45.0) 72.0 (64.0-85.0) 118† (100-149) 91
 6–11 years 70.0 (63.9-76.7) 32.0† (29.0-41.0) 79.0 (66.0-87.0) 115† (101-141) 101
 12–19 years 94.4 (85.3-104) 52.0 (42.0-64.0) 97.0 (89.0-108) 161 (145-173) 214
 20–39 years 94.8 (91.7-98.0) 60.0 (52.0-64.0) 95.0 (92.0-101) 154 (141-169) 265
 40–59 years 95.3 (88.6-103) 59.0 (53.0-65.0) 98.0 (92.0-106) 140 (132-147) 254
 60 years and older 87.6 (83.9-91.6) 53.0 (47.0-58.0) 88.0 (85.0-92.0) 146 (136-155) 390 
Females 
Total, 1 year and older 78.5 (76.2-80.9) 43.0 (40.0-46.0) 84.0 (80.0-87.0) 132 (124-141) 1330
 1–5 years 69.5 (62.4-77.5) 35.0† (25.0-40.0) 82.0 (58.0-88.0) 116† (108-132) 79
 6–11 years 75.8 (64.4-89.1) 38.0† (24.0-50.0) 80.0 (60.0-99.0) 136† (118-155) 90
 12–19 years 75.8 (68.3-84.1) 42.0 (36.0-46.0) 80.0 (69.0-87.0) 127 (115-144) 205
 20–39 years 80.4 (72.7-89.0) 41.0 (29.0-47.0) 88.0 (74.0-96.0) 144 (130-161) 344
 40–59 years 77.6 (74.6-80.6) 46.0 (39.0-51.0) 80.0 (72.0-85.0) 126 (113-135) 242
 60 years and older 81.1 (76.2-86.3) 51.0 (43.0-58.0) 83.0 (79.0-87.0) 125 (113-135) 370 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 3.3.a. Serum total iron-binding capacity: Total population 
Geometric mean and selected percentiles of serum concentrations (in μg/dL) for the total U.S. population, 
aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 366 (360-371) 297 (292-304) 367 (359-374) 447 (441-453) 7847
 1–5 years 371 (359-383) 309 (286-322) 374 (361-384) 446 (434-454) 699
 6–11 years 369 (361-378) 312 (295-320) 372 (361-380) 438 (423-444) 883
 12–19 years 383 (374-391) 312 (301-328) 385 (377-392) 461 (451-471) 2124
 20–39 years 365 (359-371) 299 (289-306) 363 (357-371) 450 (446-459) 1468
 40–59 years 364 (359-370) 298 (291-305) 364 (354-373) 441 (433-453) 1195
 60 years and older 353 (347-358) 284 (276-290) 355 (347-361) 437 (424-450) 1478 
Males 
Total, 1 year and older 356 (349-364) 294 (287-300) 358 (351-365) 431 (421-438) 3860
 1–5 years 375 (363-387) 306 (276-327) 379 (363-390) 449 (429-477) 385
 6–11 years 364 (351-377) 304 (281-323) 366 (357-381) 426 (408-442) 460
 12–19 years 374 (366-383) 313 (297-329) 379 (367-386) 448 (436-461) 1076
 20–39 years 349 (341-357) 293 (282-298) 350 (342-358) 416 (402-432) 631
 40–59 years 357 (350-364) 294 (289-302) 357 (351-365) 425 (409-436) 567
 60 years and older 345 (337-353) 283 (269-288) 348 (338-357) 431 (409-446) 741 
Females 
Total, 1 year and older 375 (370-381) 305 (298-309) 377 (369-383) 460 (454-465) 3987
 1–5 years 366 (352-381) 307 (271-321) 369 (351-386) 439 (424-447) 314
 6–11 years 375 (367-383) 312 (305-320) 374 (370-387) 441 (427-453) 423
 12–19 years 391 (382-402) 312 (302-335) 393 (383-401) 475 (456-491) 1048
 20–39 years 382 (375-390) 308 (303-316) 383 (374-397) 477 (463-485) 837
 40–59 years 371 (365-378) 300 (290-310) 373 (360-384) 450 (442-466) 628
 60 years and older 359 (354-364) 289 (282-296) 361 (354-371) 439 (424-457) 737 
Table 3.3.b. Serum total iron-binding capacity: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in μg/dL) for Mexican Americans in the U.S. 
population, aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 373 (363-384) 303 (288-314) 375 (366-385) 455 (438-478) 2707
 1–5 years 378 (370-387) 316 (303-323) 377 (368-390) 453 (444-476) 274
 6–11 years 379 (371-388) 320 (308-327) 385 (372-395) 441 (433-451) 361
 12–19 years 396 (380-413) 328 (316-336) 395 (386-408) 486 (447-551) 938
 20–39 years 370 (357-384) 299 (277-319) 375 (354-387) 457 (426-485) 407
 40–59 years 365 (359-370) 291 (275-308) 367 (358-372) 439 (431-476) 344
 60 years and older 345 (334-357) 277 (263-290) 350 (338-363) 415 (405-434) 383 
Males 
Total, 1 year and older 365 (356-375) 301 (282-314) 370 (357-380) 437 (427-449) 1345
 1–5 years 382 (370-394) 318 (299-329) 387 (368-396) 456 (436-492) 150
 6–11 years 382 (371-393) 324 (313-337) 386 (366-403) 441 (425-452) 198
 12–19 years 383 (374-392) 319 (304-330) 388 (381-395) 460 (448-469) 480
 20–39 years 359 (344-374) 300 (275-319) 361 (348-380) 428 (411-442) 170
 40–59 years 353 (345-361) 281 (270-305) 357 (347-367) 417 (403-437) 152
 60 years and older 339 (327-352) 276 (250-288) 345 (324-362) 409 (383-434) 195 
Females 
Total, 1 year and older 382 (370-395) 308 (293-318) 384 (373-393) 476 (449-504) 1362
 1–5 years 374 (360-389) 316 (301-334) 368 (355-392) 449 (422-473) 124
 6–11 years 376 (368-384) 315 (305-325) 383 (370-391) 449 (430-456) 163
 12–19 years 409 (383-437) 337 (325-345) 405 (384-428) 529 (436-579) 458
 20–39 years 384 (366-402) 301 (275-325) 383 (371-404) 485 (452-526) 237
 40–59 years 376 (365-388) 299 (284-311) 374 (361-390) 475 (438-496) 192
 60 years and older 351 (337-366) 276 (245-304) 354 (343-365) 421 (408-451) 188 
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Table 3.3.c. Serum total iron-binding capacity: Non-Hispanic blacks 
[Geometric mean and selected percentiles of serum concentrations (in μg/dL) for non-Hispanic blacks in the U.S. 
population, aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 354 (349-359) 287 (282-293) 354 (346-360) 435 (427-443) 1774
 1–5 years 370 (363-377) 315 (306-334) 365 (360-375) 435 (415-455) 172
 6–11 years 366 (362-371) 316 (303-327) 367 (360-375) 427 (418-434) 257
 12–19 years 374 (368-379) 312 (301-321) 375 (370-380) 447 (432-460) 582
 20–39 years 356 (346-366) 288 (273-301) 346 (341-360) 444 (428-475) 273
 40–59 years 342 (332-353) 276 (262-286) 346 (331-359) 426 (409-443) 249
 60 years and older 323 (315-331) 259 (242-271) 322 (315-330) 401 (380-435) 241 
Males 
Total, 1 year and older 342 (337-348) 283 (266-291) 344 (340-349) 414 (407-421) 868
 1–5 years 368 (358-378) 320† (295-340) 367 (359-381) 416† (401-435) 93
 6–11 years 365 (358-372) 318 (306-328) 364 (355-374) 423 (409-431) 126
 12–19 years 365 (360-371) 307 (293-317) 369 (360-376) 432 (416-450) 299
 20–39 years 331 (320-342) 265 (253-288) 331 (314-344) 401 (367-428) 117
 40–59 years 333 (319-347) 266 (222-296) 333 (313-362) 405 (384-423) 120
 60 years and older 324 (317-331) 259 (232-282) 325 (313-338) 397 (375-421) 113 
Females 
Total, 1 year and older 364 (359-370) 290 (283-298) 364 (354-375) 447 (441-457) 906
 1–5 years 372 (360-384) 315† (286-334) 362 (351-382) 475† (415-481) 79
 6–11 years 368 (359-376) 311 (295-329) 371 (353-384) 432 (417-443) 131
 12–19 years 382 (374-391) 321 (304-328) 382 (372-390) 456 (433-487) 283
 20–39 years 379 (370-387) 309 (293-319) 379 (362-398) 478 (436-496) 156
 40–59 years 351 (337-365) 275 (262-296) 352 (338-368) 442 (414-448) 129
 60 years and older 323 (310-336) 254 (235-276) 321 (306-333) 406 (375-450) 128 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 3.3.d. Serum total iron-binding capacity: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in μg/dL) for non-Hispanic whites in the U.S. 
population, aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 367 (361-373) 300 (294-307) 367 (359-375) 448 (441-454) 2630
 1–5 years 368 (349-387) 305 (265-331) 377 (351-394) 442 (424-451) 168
 6–11 years 372 (363-382) 313 (304-321) 372 (359-388) 442 (413-467) 191
 12–19 years 379 (368-391) 311 (293-328) 384 (374-395) 461 (448-474) 418
 20–39 years 367 (362-371) 299 (291-307) 365 (359-374) 450 (442-463) 608
 40–59 years 369 (362-376) 302 (294-314) 367 (354-379) 444 (433-458) 494
 60 years and older 357 (351-362) 288 (284-293) 358 (349-368) 438 (427-454) 751 
Males 
Total, 1 year and older 358 (350-366) 295 (286-302) 357 (350-366) 433 (419-442) 1306
 1–5 years 370 (355-386) 301† (253-331) 379 (348-398) 446† (411-473) 90
 6–11 years 364 (345-384) 304† (269-326) 367 (352-388) 426† (397-475) 101
 12–19 years 372 (362-384) 310 (285-332) 377 (361-385) 447 (436-464) 213
 20–39 years 351 (342-360) 296 (282-304) 352 (345-362) 418 (401-442) 264
 40–59 years 364 (355-372) 301 (290-319) 362 (352-370) 426 (419-442) 253
 60 years and older 347 (339-356) 284 (271-289) 348 (338-358) 434 (414-447) 385 
Females 
Total, 1 year and older 376 (370-382) 306 (300-311) 378 (370-386) 461 (453-471) 1324
 1–5 years 365 (338-395) 304† (201-336) 372 (334-401) 436† (398-457) 78
 6–11 years 382 (374-391) 317† (313-338) 374 (370-393) 444† (427-467) 90
 12–19 years 387 (375-400) 311 (295-335) 391 (378-403) 471 (450-479) 205
 20–39 years 383 (375-391) 307 (303-316) 383 (367-401) 478 (454-495) 344
 40–59 years 374 (365-384) 302 (289-317) 376 (355-389) 454 (440-479) 241
 60 years and older 365 (360-370) 293 (287-307) 369 (359-376) 450 (424-471) 366 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 3.4.a. Serum transferrin saturation: Total population 
Geometric mean and selected percentiles of serum concentrations (in %) for the total U.S. population aged 
1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 22.2 (21.6-22.9) 12.0 (11.4-12.5) 23.5 (22.8-24.1) 38.8 (37.8-40.4) 7845
 1–5 years 17.6 (16.7-18.6) 8.20 (7.30-9.20) 19.4 (16.8-20.8) 32.9 (29.7-35.3) 697
 6–11 years 19.4 (18.4-20.5) 10.4 (9.40-11.2) 21.1 (18.9-22.4) 34.4 (32.0-35.8) 883
 12–19 years 21.5 (20.6-22.4) 11.3 (10.2-12.3) 22.5 (21.5-23.4) 38.7 (36.0-41.4) 2124
 20–39 years 23.1 (22.2-24.2) 12.3 (11.2-12.7) 24.5 (23.4-25.5) 42.0 (40.0-44.2) 1468
 40–59 years 22.9 (22.0-23.9) 13.1 (12.3-14.1) 23.8 (22.7-25.3) 38.6 (36.4-40.5) 1195
 60 years and older 23.2 (22.2-24.3) 13.3 (12.4-14.3) 24.2 (23.1-25.1) 38.4 (36.8-39.6) 1478 
Males 
Total, 1 year and older 24.7 (23.9-25.6) 14.0 (13.3-14.5) 25.8 (24.8-26.5) 41.8 (40.2-43.8) 3858
 1–5 years 17.4 (16.5-18.3) 8.30 (6.80-9.80) 18.3 (16.6-19.8) 32.4 (29.0-34.6) 383
 6–11 years 19.1 (17.7-20.7) 10.6 (8.80-11.7) 21.2 (18.9-22.4) 32.2 (28.4-35.5) 460
 12–19 years 24.5 (22.9-26.2) 13.3 (11.5-14.5) 25.8 (24.3-26.9) 42.8 (36.3-50.4) 1076
 20–39 years 26.9 (26.1-27.7) 16.3 (14.7-17.4) 27.1 (25.7-28.4) 45.9 (43.7-48.8) 631
 40–59 years 26.2 (24.7-27.8) 16.0 (14.3-17.9) 26.8 (25.4-28.9) 41.6 (39.8-43.2) 567
 60 years and older 25.1 (24.0-26.3) 14.5 (13.3-15.4) 25.9 (24.7-27.3) 41.7 (39.4-43.8) 741 
Females 
Total, 1 year and older 20.1 (19.5-20.7) 10.4 (9.60-11.3) 21.3 (20.9-21.7) 35.8 (33.6-38.4) 3987
 1–5 years 17.9 (15.9-20.1) 7.70 (5.90-10.4) 20.2 (16.2-23.2) 34.1 (29.2-37.1) 314
 6–11 years 19.7 (17.8-21.7) 10.1 (8.30-12.2) 21.1 (17.9-23.8) 36.1 (32.6-38.8) 423
 12–19 years 18.8 (17.6-20.0) 9.90 (9.10-10.9) 19.8 (18.4-20.9) 32.9 (31.0-36.6) 1048
 20–39 years 20.0 (18.8-21.2) 9.00 (7.90-11.1) 21.4 (19.8-23.3) 38.4 (35.0-41.1) 837
 40–59 years 20.2 (19.3-21.1) 11.5 (9.20-13.1) 21.5 (20.5-22.5) 34.8 (32.0-37.6) 628
 60 years and older 21.7 (20.5-23.0) 12.8 (11.1-14.2) 22.3 (21.1-23.6) 35.4 (31.8-37.9) 737 
Table 3.4.b. Serum transferrin saturation: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in %) for Mexican Americans in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 21.5 (20.5-22.5) 10.5 (9.90-11.4) 22.9 (21.6-24.0) 39.3 (37.0-41.2) 2707
 1–5 years 16.6 (14.9-18.4) 7.20 (5.40-9.10) 18.3 (16.5-20.1) 32.9 (28.0-38.8) 274
 6–11 years 18.8 (17.5-20.2) 10.7 (8.70-12.2) 19.9 (18.5-21.4) 30.8 (28.9-33.1) 361
 12–19 years 21.1 (20.2-22.0) 10.6 (9.70-12.0) 22.0 (20.7-22.2) 38.6 (36.4-40.3) 938
 20–39 years 23.0 (21.2-24.9) 12.1 (9.30-13.6) 24.2 (21.9-26.9) 41.2 (38.2-48.1) 407
 40–59 years 23.4 (22.5-24.2) 12.5 (10.4-15.1) 24.7 (23.3-26.4) 41.1 (37.0-44.2) 344
 60 years and older 23.6 (21.9-25.6) 13.2 (11.9-14.9) 24.0 (20.8-27.9) 41.4 (38.0-43.1) 383 
Males 
Total, 1 year and older 24.6 (23.1-26.2) 13.2 (12.1-14.4) 25.8 (24.2-27.5) 43.7 (40.0-48.1) 1345
 1–5 years 16.2 (14.2-18.5) 6.90 (5.10-8.60) 17.0 (15.0-19.8) 32.9 (25.6-41.5) 150
 6–11 years 18.7 (16.8-20.8) 10.8 (8.60-12.9) 19.5 (18.2-21.3) 29.6 (27.4-34.2) 198
 12–19 years 24.6 (23.3-26.0) 13.3 (12.1-14.9) 25.9 (24.3-27.3) 41.0 (38.7-44.1) 480
 20–39 years 28.4 (26.0-30.9) 16.6 (14.6-19.5) 28.6 (25.0-33.0) 49.5 (41.8-56.0) 170
 40–59 years 28.6 (26.8-30.5) 18.4 (14.1-21.2) 28.4 (26.7-30.8) 44.6 (40.9-49.3) 152
 60 years and older 25.6 (23.9-27.5) 13.3 (10.4-16.3) 27.4 (23.2-30.4) 43.8 (38.5-49.0) 195 
Females 
Total, 1 year and older 18.6 (17.5-19.7) 8.90 (8.00-10.0) 20.1 (18.9-21.2) 33.2 (31.0-35.8) 1362
 1–5 years 17.1 (15.5-18.9) 6.80 (5.20-9.70) 19.8 (16.5-22.7) 33.4 (28.0-37.1) 124
 6–11 years 18.9 (17.1-20.9) 10.4 (5.80-13.2) 20.3 (18.8-21.8) 30.8 (29.3-31.7) 163
 12–19 years 18.2 (17.1-19.5) 8.70 (7.50-10.3) 19.7 (18.1-21.3) 33.4 (30.2-36.3) 458
 20–39 years 18.1 (15.9-20.7) 8.10 (6.80-10.4) 19.0 (16.7-21.9) 32.5 (29.5-38.1) 237
 40–59 years 19.3 (18.0-20.7) 8.90 (6.40-12.3) 20.6 (18.5-23.9) 34.1 (31.7-41.0) 192
 60 years and older 21.9 (19.8-24.2) 12.8 (11.8-15.1) 23.0 (19.8-24.2) 35.0 (31.9-41.4) 188 
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Table 3.4.c. Serum transferrin saturation: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in %) for non-Hispanic blacks in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 20.3 (19.5-21.2) 9.90 (9.30-10.8) 21.6 (20.5-22.7) 36.5 (34.4-39.0) 1773
 1–5 years 18.3 (16.4-20.3) 10.2 (8.20-12.5) 19.0 (16.1-21.6) 30.7 (26.6-38.1) 171
 6–11 years 19.6 (18.3-21.0) 10.8 (8.60-12.7) 21.3 (19.6-22.3) 31.0 (29.4-34.4) 257
 12–19 years 19.7 (18.2-21.3) 10.0 (8.80-11.3) 21.3 (20.0-22.7) 34.9 (32.2-38.3) 582
 20–39 years 20.8 (19.4-22.4) 8.90 (7.50-10.7) 22.1 (20.4-24.9) 38.4 (35.3-44.2) 273
 40–59 years 20.9 (19.3-22.6) 10.7 (8.50-12.9) 21.4 (19.3-23.2) 37.6 (34.3-42.1) 249
 60 years and older 20.2 (18.9-21.6) 11.4 (9.40-12.9) 21.2 (19.6-22.5) 34.9 (30.6-39.0) 241 
Males 
Total, 1 year and older 23.5 (22.4-24.8) 13.6 (12.5-14.7) 24.5 (22.5-26.1) 39.3 (36.2-41.8) 867
 1–5 years 18.7 (16.6-21.2) 10.4† (9.00-12.4) 19.0 (15.5-22.5) 30.2† (24.6-40.8) 92
 6–11 years 19.7 (17.8-21.7) 10.4 (7.90-13.7) 21.7 (18.9-24.0) 30.1 (28.0-34.3) 126
 12–19 years 22.5 (21.3-23.8) 12.2 (11.1-14.4) 24.2 (22.4-25.6) 36.5 (33.6-39.3) 299
 20–39 years 26.7 (24.8-28.8) 17.4 (14.3-19.8) 27.1 (24.9-30.1) 40.3 (35.7-45.8) 117
 40–59 years 24.2 (21.7-27.0) 13.9 (10.9-16.3) 23.9 (21.4-28.0) 42.2 (37.1-46.8) 120
 60 years and older 22.6 (20.8-24.4) 12.9 (11.4-15.8) 22.4 (20.6-24.3) 38.1 (32.1-41.6) 113 
Females 
Total, 1 year and older 17.8 (16.9-18.7) 8.60 (7.40-9.30) 19.2 (17.9-20.2) 34.3 (31.6-36.0) 906
 1–5 years 17.7 (15.2-20.6) 9.40† (5.30-12.7) 19.4 (14.7-21.8) 29.4† (26.4-38.1) 79
 6–11 years 19.5 (17.8-21.3) 11.5 (6.70-14.1) 21.0 (18.7-22.5) 32.7 (29.4-35.3) 131
 12–19 years 17.1 (14.9-19.5) 8.10 (5.50-10.8) 18.9 (15.5-21.5) 32.3 (28.2-37.0) 283
 20–39 years 16.9 (15.5-18.4) 7.30 (5.40-8.70) 18.0 (15.9-20.1) 37.4 (33.1-41.7) 156
 40–59 years 18.5 (16.3-20.9) 9.90 (6.90-12.0) 19.9 (17.1-21.8) 31.5 (27.1-35.0) 129
 60 years and older 18.6 (17.2-20.0) 9.40 (8.70-11.8) 19.9 (17.8-21.7) 31.3 (28.5-35.0) 128 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 3.4.d. Serum transferrin saturation: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in %) for non-Hispanic whites in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 22.9 (22.0-23.8) 12.6 (11.7-13.2) 24.0 (23.2-24.9) 39.6 (38.3-41.5) 2629
 1–5 years 18.7 (16.9-20.6) 9.20 (6.80-11.4) 20.8 (16.5-23.9) 34.0 (29.2-36.7) 167
 6–11 years 19.5 (17.9-21.2) 9.90 (8.50-11.6) 21.2 (17.0-23.2) 35.7 (32.0-38.8) 191
 12–19 years 22.4 (21.1-23.8) 11.6 (10.2-13.2) 23.2 (21.8-24.1) 41.4 (36.3-44.8) 418
 20–39 years 23.8 (22.3-25.5) 12.7 (10.9-14.6) 25.1 (23.5-26.3) 43.5 (40.9-45.2) 608
 40–59 years 23.4 (22.0-24.8) 14.0 (12.8-15.1) 24.1 (22.8-25.8) 38.6 (35.6-41.5) 494
 60 years and older 23.5 (22.3-24.7) 13.6 (12.4-14.7) 24.5 (23.3-25.6) 38.5 (36.8-39.4) 751 
Males 
Total, 1 year and older 25.1 (23.9-26.4) 14.4 (13.3-15.3) 25.9 (24.5-27.1) 43.0 (40.2-45.2) 1305
 1–5 years 18.5 (16.4-20.8) 9.10† (6.80-12.3) 20.1 (16.5-23.1) 33.2† (28.8-36.7) 89
 6–11 years 19.2 (17.1-21.7) 9.90† (6.10-11.7) 21.6 (17.5-23.4) 32.4† (28.7-36.4) 101
 12–19 years 25.3 (22.8-28.0) 13.4 (11.3-14.5) 26.0 (23.0-29.0) 45.2 (38.4-57.1) 213
 20–39 years 27.0 (26.2-27.9) 16.4 (14.5-18.0) 26.7 (25.2-28.8) 46.3 (44.1-48.9) 264
 40–59 years 26.2 (24.0-28.6) 16.1 (14.1-18.5) 26.2 (24.6-29.2) 40.5 (38.6-43.8) 253
 60 years and older 25.3 (24.0-26.7) 14.2 (13.0-15.9) 26.1 (25.0-27.8) 41.9 (39.2-45.4) 385 
Females 
Total, 1 year and older 20.9 (20.1-21.7) 11.5 (10.4-12.4) 22.0 (21.1-22.9) 36.6 (34.0-39.2) 1324
 1–5 years 19.0 (16.4-21.9) 9.20† (5.10-11.9) 21.1 (15.4-24.5) 34.2† (29.7-41.2) 78
 6–11 years 19.8 (16.8-23.4) 10.2† (6.60-12.8) 21.1 (15.3-26.2) 38.4† (34.7-40.6) 90
 12–19 years 19.6 (17.4-22.0) 10.1 (9.00-13.6) 19.9 (18.1-22.6) 33.0 (30.7-38.7) 205
 20–39 years 21.1 (18.9-23.5) 10.9 (7.80-13.0) 23.0 (19.4-26.3) 39.2 (35.0-42.6) 344
 40–59 years 20.8 (19.9-21.7) 12.4 (10.9-13.8) 21.9 (20.4-22.9) 35.6 (31.5-41.0) 241
 60 years and older 22.1 (20.8-23.5) 13.1 (11.4-14.8) 22.8 (21.3-24.4) 36.1 (31.8-38.4) 366 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 3.5.a. Erythrocyte protoporphyrin: Total population 
Geometric mean and selected percentiles of red blood cell concentrations (in µg/dL) for the total U.S. population aged 1 year 
and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 47.6 (46.7-48.6) 33.0 (32.0-33.0) 46.0 (44.0-47.0) 72.0 (70.0-73.0) 7985
 1–5 years 47.8 (45.9-49.9) 32.0 (31.0-34.0) 45.0 (42.0-48.0) 69.0 (67.0-72.0) 728
 6–11 years 45.2 (42.7-47.8) 31.0 (29.0-34.0) 45.0 (42.0-48.0) 65.0 (60.0-72.0) 905
 12–19 years 46.0 (44.5-47.5) 33.0 (31.0-34.0) 45.0 (43.0-46.0) 70.0 (67.0-73.0) 2139
 20–39 years 46.7 (45.5-47.9) 31.0 (30.0-32.0) 44.0 (42.0-44.0) 72.0 (69.0-76.0) 1477
 40–59 years 48.3 (47.3-49.3) 34.0 (32.0-35.0) 45.0 (44.0-47.0) 71.0 (67.0-75.0) 1217
 60 years and older 51.1 (50.1-52.1) 33.0 (32.0-34.0) 48.0 (48.0-50.0) 76.0 (73.0-80.0) 1519 
Males 
Total, 1 year and older 42.9 (41.9-44.0) 30.0 (30.0-32.0) 41.0 (40.0-43.0) 59.0 (58.0-61.0) 3926
 1–5 years 47.2 (45.0-49.5) 31.0 (30.0-34.0) 46.0 (43.0-49.0) 68.0 (64.0-73.0) 401
 6–11 years 44.1 (41.4-47.0) 31.0 (28.0-33.0) 43.0 (41.0-47.0) 61.0 (54.0-72.0) 473
 12–19 years 41.6 (40.0-43.2) 30.0 (29.0-32.0) 41.0 (39.0-42.0) 56.0 (53.0-59.0) 1082
 20–39 years 40.5 (38.8-42.2) 30.0 (28.0-31.0) 39.0 (37.0-40.0) 58.0 (54.0-61.0) 634
 40–59 years 43.1 (42.2-44.2) 32.0 (30.0-33.0) 41.0 (40.0-42.0) 57.0 (55.0-61.0) 578
 60 years and older 47.2 (46.3-48.1) 32.0 (32.0-34.0) 45.0 (43.0-46.0) 71.0 (66.0-76.0) 758 
Females 
Total, 1 year and older 52.7 (51.5-53.9) 35.0 (34.0-37.0) 49.0 (48.0-51.0) 79.0 (77.0-82.0) 4059
 1–5 years 48.6 (45.3-52.2) 34.0 (31.0-36.0) 45.0 (42.0-50.0) 71.0 (66.0-77.0) 327
 6–11 years 46.4 (43.5-49.4) 32.0 (30.0-35.0) 46.0 (42.0-48.0) 68.0 (62.0-75.0) 432
 12–19 years 51.1 (49.2-53.0) 34.0 (32.0-37.0) 49.0 (47.0-51.0) 76.0 (71.0-81.0) 1057
 20–39 years 53.8 (52.5-55.0) 36.0 (36.0-37.0) 49.0 (49.0-51.0) 83.0 (78.0-89.0) 843
 40–59 years 53.6 (51.3-56.0) 36.0 (34.0-37.0) 51.0 (48.0-52.0) 83.0 (74.0-93.0) 639
 60 years and older 54.4 (52.5-56.5) 37.0 (34.0-38.0) 52.0 (49.0-55.0) 80.0 (75.0-85.0) 761 
Table 3.5.b. Erythrocyte protoporphyrin: Mexican Americans 
Geometric mean and selected percentiles of red blood cell concentrations (in µg/dL) for Mexican Americans in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 52.3 (50.8-53.9) 35.0 (33.0-36.0) 49.0 (48.0-51.0) 84.0 (80.0-88.0) 2741
 1–5 years 53.6 (50.5-56.9) 38.0 (35.0-40.0) 50.0 (48.0-52.0) 79.0 (71.0-94.0) 283
 6–11 years 51.8 (49.6-54.1) 34.0 (33.0-38.0) 49.0 (47.0-53.0) 81.0 (73.0-87.0) 368
 12–19 years 53.9 (50.6-57.5) 35.0 (34.0-37.0) 50.0 (48.0-52.0) 89.0 (73.0-116) 942
 20–39 years 50.6 (47.7-53.7) 32.0 (32.0-36.0) 47.0 (45.0-51.0) 80.0 (71.0-93.0) 410
 40–59 years 53.8 (52.0-55.8) 34.0 (33.0-36.0) 52.0 (48.0-55.0) 88.0 (79.0-94.0) 345
 60 years and older 53.1 (50.8-55.4) 34.0 (33.0-37.0) 51.0 (47.0-54.0) 82.0 (77.0-86.0) 393 
Males 
Total, 1 year and older 46.6 (45.1-48.1) 31.0 (29.0-33.0) 45.0 (43.0-46.0) 69.0 (66.0-71.0) 1361
 1–5 years 55.4 (51.6-59.5) 39.0 (34.0-40.0) 52.0 (47.0-53.0) 84.0 (72.0-120) 156
 6–11 years 50.6 (47.6-53.8) 37.0 (33.0-40.0) 48.0 (46.0-53.0) 73.0 (62.0-90.0) 200
 12–19 years 47.5 (46.1-48.9) 33.0 (31.0-36.0) 45.0 (43.0-46.0) 70.0 (66.0-74.0) 482
 20–39 years 42.7 (40.6-44.8) 31.0 (27.0-34.0) 41.0 (40.0-43.0) 61.0 (54.0-66.0) 172
 40–59 years 45.9 (43.8-48.2) 32.0 (29.0-35.0) 44.0 (41.0-47.0) 66.0 (61.0-78.0) 153
 60 years and older 47.7 (45.4-50.2) 33.0 (29.0-35.0) 46.0 (41.0-49.0) 73.0 (67.0-86.0) 198 
Females 
Total, 1 year and older 59.2 (57.0-61.5) 38.0 (37.0-40.0) 56.0 (54.0-58.0) 96.0 (88.0-108) 1380
 1–5 years 51.4 (47.8-55.3) 37.0 (31.0-41.0) 48.0 (45.0-53.0) 71.0 (64.0-88.0) 127
 6–11 years 53.2 (50.8-55.7) 34.0 (33.0-38.0) 51.0 (48.0-54.0) 86.0 (73.0-89.0) 168
 12–19 years 60.8 (55.0-67.1) 40.0 (38.0-42.0) 57.0 (53.0-61.0) 110 (69.0-127) 460
 20–39 years 61.3 (56.1-67.0) 39.0 (36.0-42.0) 58.0 (52.0-63.0) 101 (81.0-138) 238
 40–59 years 62.5 (60.3-64.8) 37.0 (34.0-41.0) 60.0 (56.0-64.0) 100 (90.0-119) 192
 60 years and older 58.5 (55.6-61.5) 39.0 (36.0-41.0) 56.0 (53.0-59.0) 85.0 (80.0-97.0) 195 
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Table 3.5.c. Erythrocyte protoporphyrin: Non-Hispanic blacks 
Geometric mean and selected percentiles of red blood cell concentrations (in µg/dL) for non-Hispanic blacks in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 47.4 (45.8-49.1) 31.0 (30.0-33.0) 44.0 (43.0-47.0) 72.0 (69.0-75.0) 1817
 1–5 years 45.4 (43.1-47.8) 31.0 (28.0-33.0) 45.0 (42.0-48.0) 61.0 (57.0-68.0) 180
 6–11 years 44.9 (42.7-47.2) 30.0 (29.0-31.0) 44.0 (42.0-46.0) 63.0 (58.0-71.0) 270
 12–19 years 45.2 (43.0-47.5) 31.0 (28.0-32.0) 42.0 (40.0-44.0) 67.0 (63.0-75.0) 587
 20–39 years 48.0 (44.9-51.3) 32.0 (29.0-34.0) 45.0 (40.0-49.0) 76.0 (67.0-84.0) 277
 40–59 years 48.3 (46.0-50.7) 32.0 (31.0-34.0) 46.0 (43.0-48.0) 71.0 (62.0-93.0) 255
 60 years and older 51.0 (48.2-54.0) 34.0 (32.0-38.0) 48.0 (45.0-51.0) 78.0 (70.0-86.0) 248 
Males 
Total, 1 year and older 41.9 (40.1-43.9) 29.0 (28.0-32.0) 41.0 (39.0-43.0) 58.0 (56.0-62.0) 890
 1–5 years 45.4 (42.7-48.3) 31.0† (28.0-36.0) 46.0 (39.0-49.0) 61.0† (53.0-68.0) 98
 6–11 years 43.4 (41.6-45.3) 30.0 (27.0-32.0) 43.0 (40.0-45.0) 60.0 (56.0-70.0) 134
 12–19 years 40.5 (39.0-42.1) 29.0 (28.0-31.0) 39.0 (37.0-40.0) 57.0 (51.0-63.0) 301
 20–39 years 39.3 (36.2-42.7) 29.0 (26.0-32.0) 38.0 (34.0-40.0) 54.0 (45.0-67.0) 117
 40–59 years 42.7 (40.7-44.8) 30.0 (27.0-32.0) 42.0 (38.0-43.0) 57.0 (52.0-63.0) 123
 60 years and older 47.5 (43.9-51.4) 32.0 (26.0-36.0) 46.0 (41.0-50.0) 71.0 (62.0-80.0) 117 
Females 
Total, 1 year and older 53.0 (51.1-54.8) 34.0 (33.0-37.0) 50.0 (48.0-53.0) 82.0 (77.0-88.0) 927
 1–5 years 45.4 (42.0-49.0) 31.0† (28.0-33.0) 43.0 (39.0-49.0) 68.0† (58.0-79.0) 82
 6–11 years 46.5 (42.6-50.8) 30.0 (29.0-33.0) 45.0 (41.0-49.0) 72.0 (62.0-76.0) 136
 12–19 years 50.7 (46.2-55.6) 35.0 (32.0-37.0) 46.0 (44.0-50.0) 79.0 (65.0-94.0) 286
 20–39 years 56.6 (52.7-60.7) 37.0 (33.0-39.0) 54.0 (51.0-58.0) 82.0 (71.0-104) 160
 40–59 years 53.6 (49.4-58.3) 34.0 (31.0-37.0) 53.0 (48.0-56.0) 84.0 (70.0-99.0) 132
 60 years and older 53.8 (50.5-57.3) 36.0 (34.0-39.0) 51.0 (46.0-52.0) 82.0 (70.0-105) 131 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 3.5.d. Erythrocyte protoporphyrin: Non-Hispanic whites 
Geometric mean and selected percentiles of red blood cell concentrations (in µg/dL) for non-Hispanic whites in the U.S. 
population aged 1 year and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 1 year and older 46.3 (45.4-47.3) 31.0 (30.0-32.0) 43.0 (43.0-45.0) 68.0 (66.0-70.0) 2674
 1–5 years 45.8 (43.0-48.8) 31.0 (30.0-34.0) 44.0 (40.0-47.0) 67.0 (60.0-72.0) 177
 6–11 years 43.3 (39.7-47.2) 31.0 (27.0-34.0) 43.0 (40.0-46.0) 61.0 (53.0-73.0) 192
 12–19 years 44.2 (42.1-46.3) 32.0 (29.0-33.0) 44.0 (41.0-45.0) 62.0 (58.0-72.0) 423
 20–39 years 45.1 (43.5-46.8) 32.0 (30.0-32.0) 44.0 (42.0-44.0) 69.0 (61.0-73.0) 610
 40–59 years 46.7 (45.8-47.6) 34.0 (32.0-35.0) 45.0 (43.0-46.0) 66.0 (63.0-71.0) 502
 60 years and older 50.3 (49.5-51.0) 34.0 (32.0-34.0) 48.0 (47.0-50.0) 75.0 (72.0-78.0) 770 
Males 
Total, 1 year and older 42.0 (40.8-43.2) 30.0 (30.0-32.0) 41.0 (40.0-42.0) 58.0 (56.0-60.0) 1330
 1–5 years 44.1 (41.3-47.0) 31.0† (28.0-33.0) 44.0 (40.0-47.0) 64.0† (55.0-67.0) 95
 6–11 years 41.9 (37.8-46.5) 29.0† (26.0-33.0) 41.0 (39.0-45.0) 61.0† (49.0-72.0) 103
 12–19 years 40.7 (38.1-43.5) 28.0 (26.0-32.0) 41.0 (37.0-43.0) 54.0 (49.0-59.0) 215
 20–39 years 39.1 (37.5-40.9) 29.0 (25.0-30.0) 37.0 (35.0-39.0) 53.0 (49.0-59.0) 265
 40–59 years 42.7 (41.3-44.2) 32.0 (28.0-34.0) 41.0 (40.0-43.0) 56.0 (52.0-60.0) 258
 60 years and older 46.4 (45.3-47.4) 33.0 (32.0-34.0) 43.0 (42.0-45.0) 67.0 (64.0-74.0) 394 
Females 
Total, 1 year and older 51.0 (49.7-52.3) 35.0 (34.0-37.0) 47.0 (46.0-49.0) 75.0 (73.0-80.0) 1344
 1–5 years 47.9 (42.0-54.7) 34.0† (31.0-36.0) 42.0 (38.0-49.0) 69.0† (60.0-93.0) 82
 6–11 years 45.0 (40.8-49.5) 32.0† (29.0-35.0) 44.0 (39.0-50.0) 60.0† (55.0-77.0) 89
 12–19 years 48.4 (46.0-50.9) 33.0 (32.0-37.0) 47.0 (45.0-50.0) 73.0 (67.0-77.0) 208
 20–39 years 51.9 (49.2-54.8) 36.0 (34.0-39.0) 48.0 (47.0-49.0) 81.0 (72.0-99.0) 345
 40–59 years 51.0 (48.8-53.3) 36.0 (34.0-37.0) 49.0 (45.0-52.0) 74.0 (68.0-83.0) 244
 60 years and older 53.7 (51.8-55.7) 36.0 (34.0-39.0) 52.0 (49.0-56.0) 79.0 (73.0-84.0) 376 
† Estimate is subject to greater uncertainty due to small cell size. 
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Trace Elements: 
Iodine 
Iodine, a trace element found in soil, is an essential component of the 
thyroid hormones involved in regulating the body’s metabolic processes. 
Iodized salt and seafood are the major dietary sources of iodine. In the 
United States, salt is iodized with potassium iodide at 100 parts per million 
(76 milligram [mg] of iodine per kilogram [kg] of salt). Iodized salt is 
chosen by about 50–60 percent of the U.S. population (Institute of Medicine 
2001). Still, most ingested salt comes from processed food (approximately 
70 percent), which is typically not iodized in either the United States or in 
Canada (The Public Health Committee of the American Thyroid Association 2006). 
For the thyroid to synthesize thyroid hormones, iodine is essential. Iodine 
deficiency disorders include mental retardation, hypothyroidism, goiter, 
cretinism, and varying degrees of other growth and developmental 
abnormalities. Iodine deficiency is the most preventable cause of mental 
retardation in the world (World Health Organization 2007). Thyroid enlargement 
(goiter) is usually the earliest clinical feature of iodine deficiency. Thyroid 
hormone is particularly important in the development of the central 
nervous system during the fetal and early postnatal periods. In areas 
where iodized salt is common, iodine deficiency is rare. 
The median intake of iodine from food in the United States is 
approximately 240 to 300 micrograms (µg) per day for men and 190 to 
210 µg/day for women, largely owing to the iodization of salt (Institute of 
Medicine 2001). Iodine deficiency develops when iodide intake is less than 
20 μg/day (Beers 2006). Most dietary iodine absorbed in the body eventually 
appears in the urine; thus, urinary iodine excretion is recommended for 
assessing recent dietary iodine intake worldwide (World Health Organization 
2007). 
Excess iodine intake may also result in goiter, as well as in hyper- or 
hypothyroidism. High iodine intake has also been associated with 
increased risk for thyroid papillary cancer (Institute of Medicine 2001). For most 
people, iodine intake from usual foods and supplements is unlikely to 
exceed the tolerable upper intake level (1,100 μg/day). 
The Institute of Medicine recommends iodine intake at 150 µg per day for 
nonpregnant adults, 220 µg per day for pregnant women and 290 µg per 
day during lactation (Institute of Medicine 2001). 
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World Health Organization (WHO) categories for median urinary iodine 
concentrations in school-age children and adults (excluding pregnant and lactating 
women) are widely used to define iodine intake and nutrition status for populations 
(World Health Organization 2007) (Table 4.a). An additional adequacy criterion is that not 
more than 20 percent of samples from children and non-pregnant women are below 
50 nanograms per milliliter (ng/mL) of iodine. 
Table 4.a  Epidemiological criteria for assessing iodine nutrition based on median urinary iodine 
concentrations of school-age children (≥ 6 years)* 
Median Urinary 
Iodine (ng/mL) 
Iodine Intake Iodine Status 
< 20 Insufficient Severe iodine deficiency 
20–49 Insufficient Moderate iodine deficiency 
50–99 Insufficient Mild iodine deficiency 
100–199 Adequate Adequate iodine nutrition 
200–299 Above 
requirements 
Likely to provide adequate intake for 
pregnant/lactating women but may pose a 
slight risk of more than adequate intake in 
the overall population 
> 300 Excessive Risk for adverse health consequences 
(e.g., iodine-induced hyperthyroidism, 
autoimmune thyroid diseases) 
*Applies to adults but not to pregnant and lactating women 
Note that these categories are useful for classifying population risk but are not 
categories to define individual risk for adverse health outcomes. The large day-to-day 
variations in urine iodine excretion, even among individuals with stable iodine intake, 
tend to offset one another when the sample includes an adequately large number 
(50–100 people per site) of representative individuals (Borak 2005). 
For pregnant women, median urinary iodine concentrations of 150–249 ng/mL 
represent adequate iodine intake (World Health Organization 2007). 
The Public Health Committee of the American Thyroid Association (2006) has 
recommended that until additional physiologic data are available to determine the 
appropriate requirements during pregnancy and lactation, iodine supplementation 
(150 μg/day) is appropriate for these two life stages in the United States and in 
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Canada. This decision was based on data for pregnant women from NHANES III 
and NHANES 2001–2002: median urinary iodine concentrations were lower than 
recommended during NHANES III (141 ng/mL) and within the recommended range 
during NHANES 2001–2002 (173 ng/mL), but 95 percent confidence intervals ranged 
from 75 to 229 ng/mL (Caldwell 2005). 
For more information about iodine, 
see the Institute of Medicine’s Dietary 
Reference Intake report (Institute of 
Medicine 2001) as well as information 
from the American Society for Nutrition 
(http://jn.nutrition.org/nutinfo/). 
Since 1971, NHANES has measured 
urinary iodine. The NHANES III 
survey (1988–1994) showed a 
sizable decrease in urinary iodine 
concentrations compared with 
concentrations measured during 
NHANES I (1971–1974) (Hollowell 1998). 
This decline may have been due to 
the dairy industry’s effort in the mid­
1980s to reduce the iodine residue 
in milk from feed supplements and 
iodophor sanitizing agents (Pennington 
1996). Decreased concentrations of 
iodine in fruit-flavored breakfast 
cereals—the industry’s response 
to a ban on erythrosine (an iodine-
containing food dye)—could also have 
contributed to the decline in urinary 
iodine concentrations (Pennington 1996). Since 2000, urinary iodine has been measured 
in the continuous NHANES survey. CDC uses a new method, involving inductively 
coupled plasma mass spectrometry (ICP-MS), to make these measurements (Caldwell 
2003). This method has been compared with the established Sandell-Kolthoff 
spectrophotometric method used in NHANES III (Pino 1998). The two methods strongly 
correlate (r2 = 0.98), and the average difference between them is not statistically 
significant (Caldwell 2003). When CDC laboratory scientists used this new method to 
measure urinary iodine concentrations in NHANES 2000 (U.S. Centers for Disease Control 
and Prevention 2000) and NHANES 2001–2002 (Caldwell 2005), they found that the U.S. 
median urinary iodine concentration had stabilized since the initial drop that had 
occurred from NHANES I to NHANES III. This finding confirms the stability of the U.S. 
iodine intake and continued adequate iodine nutrition for the country generally. 
Chemist performs maintenance on instrumentation used to measure urinary 
iodine. 
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Selected Observations and Highlights 
The following example observations and figures are taken from the uncorrected 
tables of 2001–2002 data contained in this report. Statements about categorical 
differences between demographic groups noted below are based on non-
overlapping confidence limits from univariate analysis without adjusting for 
demographic variables (i.e., age, sex, race/ethnicity) or other determinants of these 
urine concentrations (i.e., dietary intake, supplement usage, smoking, BMI). A 
multivariate analysis may alter the size and statistical significance of these categorical 
differences. Furthermore, additional significant differences of smaller magnitude may 
be present despite their lack of mention here (e.g., if confidence limits slightly overlap 
or if differences are not statistically significant before covariate adjustment has 
occurred). For a selection of citations of descriptive NHANES papers related to these 
biochemical indicators of diet and nutrition, see Appendix E. 
General Observations 
•	 Children (aged 6–11 years) have higher urinary iodine concentrations than 
people in any other age group. 
•	 Females have lower urinary iodine concentrations than males. 
Highlights 
After a sharp decline that occurred from 1971–1988, from 1988–2002 median 
concentrations of urinary iodine appear to have stabilized in various population 
subgroups (Fig 4.a). This finding has been shown previously (Caldwell 2005). 
Figure 4.a 
Median concentrations (95 percent confidence intervals) of urinary iodine in the U.S. population, 
aged 6 years and older, and in population subgroups, National Health and Nutrition Examination 
Survey, 1971–2002. Data shown for NHANES 1971–1974 and 1988–1994 are not part of the tables 
displayed in this report but were analyzed separately to generate this figure. 
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On the basis of median urinary iodine concentrations, the iodine intake of women 
of childbearing age appears adequate (Fig 4.b). Appropriate consideration should be 
given, however, to the higher intake recommendation for pregnant women (World 
Health Organization 2007). 
Figure 4.b 
Median concentrations (95 percent confidence intervals) of urinary iodine among women of 
childbearing age, National Health and Nutrition Examination Survey, 2001–2002. 
Table 4.1.a. Urinary iodine: Total population 
Geometric mean and selected percentiles of urine concentrations (in ng/mL) for the total U.S. population aged 
6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 162 (152-172) 44.0 (41.0-49.0) 167 (158-176) 503 (466-543) 2837 
6–11 years 235 (208-266) 78.0 (61.0-89.0) 249 (221-289) 682 (571-737) 374 
12–19 years 192 (178-207) 58.0 (42.0-68.0) 206 (189-214) 594 (511-693) 831 
20–39 years 148 (132-166) 49.0 (34.0-58.0) 153 (136-175) 429 (356-482) 627 
40–59 years 140 (121-162) 37.0 (25.0-45.0) 142 (118-169) 478 (403-577) 496 
60 years and older 177 (156-200) 57.0 (49.0-65.0) 173 (152-199) 524 (440-633) 509 
Males 
Total, 6 years and older 192 (178-208) 64.0 (54.0-73.0) 197 (179-209) 542 (478-619) 1333 
6–11 years 250 (213-294) 86.0 (55.0-126) 266 (223-316) 682 (498-864) 185 
12–19 years 238 (214-265) 75.0 (67.0-104) 234 (210-271) 639 (545-896) 386 
20–39 years 176 (155-200) 63.0 (48.0-89.0) 178 (143-213) 425 (345-479) 271 
40–59 years 169 (147-194) 44.0 (35.0-71.0) 172 (149-207) 496 (391-596) 255 
60 years and older 211 (172-258) 75.0 (40.0-102) 202 (163-249) 615 (417-904) 236 
Females 
Total, 6 years and older 137 (127-148) 37.0 (31.0-43.0) 140 (127-157) 458 (421-516) 1504 
6–11 years 220 (182-267) 64.0 (44.0-88.0) 239 (185-293) 638 (524-738) 189 
12–19 years 154 (137-173) 40.0 (28.0-62.0) 174 (148-193) 454 (368-587) 445 
20–39 years 127 (105-153) 34.0 (23.0-53.0) 133 (108-162) 425 (314-507) 356 
40–59 years 115 (93.2-141) 28.0 (22.0-36.0) 111 (78.0-146) 456 (292-695) 241 
60 years and older 155 (135-177) 51.0 (44.0-62.0) 156 (117-189) 440 (349-550) 273 
Table 4.1.b. Urinary iodine: Mexican Americans 
Geometric mean and selected percentiles of urine concentrations (in ng/mL) for Mexican Americans in the U.S. population, age 
6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 176 (163-189) 56.0 (45.0-60.0) 186 (167-205) 487 (442-518) 720 
6–11 years 241 (210-277) 95.0 (62.0-150) 231 (193-297) 621 (487-699) 112 
12–19 years 179 (161-198) 56.0 (40.0-72.0) 190 (160-213) 524 (392-583) 266 
20–39 years 168 (142-198) 50.0 (40.0-66.0) 173 (141-218) 442 (375-534) 166 
40–59 years 156 (124-197) 31.0† (14.0-74.0) 169 (146-215) 472† (380-700) 90 
60 years and older 152 (131-176) 56.0† (36.0-75.0) 156 (115-203) 427† (303-477) 86 
Males 
Total, 6 years and older 201 (173-233) 60.0 (43.0-79.0) 203 (172-236) 524 (442-792) 325 
6–11 years 246 (190-318) 76.0† (42.0-138) 246 (174-374) 677† (469-926) 53 
12–19 years 190 (163-221) 58.0 (33.0-100) 198 (153-226) 511 (344-583) 113 
20–39 years 195 (146-261) 58.0† (28.0-79.0) 197 (137-255) 495† (374-1170) 75 
40–59 years 191 (134-274) 37.0† (15.0-146) 193 (154-311) 453† (346-713) 48 
60 years and older 209 (165-265) 82.0† (13.0-161) 203 (154-345) 455† (324-1210) 36 
Females 
Total, 6 years and older 151 (136-168) 45.0 (31.0-60.0) 169 (137-202) 441 (370-480) 395 
6–11 years 237 (193-290) 107† (79.0-150) 218 (179-297) 510† (370-656) 59 
12–19 years 167 (143-194) 46.0 (32.0-62.0) 189 (146-213) 506 (351-676) 153 
20–39 years 140 (109-179) 40.0† (22.0-69.0) 167 (97.0-247) 331† (294-480) 91 
40–59 years 123 (85.4-178) 22.0† (7.00-58.0) 125 (86.0-178) 433† (186-532) 42 
60 years and older 120 (94.1-154) 51.0† (28.0-61.0) 111 (82.0-158) 299† (158-521) 50 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 4.1.c. Urinary iodine: Non-Hispanic blacks 
Geometric mean and selected percentiles of urine concentrations (in ng/mL) for non-Hispanic blacks in the U.S. population, age 
6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 156 (137-178) 54.0 (45.0-65.0) 143 (124-173) 478 (402-608) 670 
6–11 years 247 (201-302) 97.0 (67.0-138) 257 (175-311) 600 (467-954) 121 
12–19 years 183 (151-221) 62.0 (43.0-78.0) 172 (156-200) 555 (384-695) 248 
20–39 years 145 (117-181) 58.0 (31.0-95.0) 134 (106-169) 398 (306-478) 121 
40–59 years 136 (99.7-185) 44.0† (31.0-57.0) 120 (82.0-197) 627† (275-923) 106 
60 years and older 127 (91.6-176) 40.0† (18.0-64.0) 112 (94.0-129) 268† (213-525) 74 
Males 
Total, 6 years and older 161 (143-181) 55.0 (39.0-68.0) 156 (134-173) 540 (414-681) 325 
6–11 years 259 (201-334) 90.0† (53.0-149) 240 (175-318) 932† (496-1100) 61 
12–19 years 201 (162-249) 65.0 (50.0-101) 186 (161-214) 624 (381-873) 120 
20–39 years 161 (127-204) 69.0† (23.0-126) 149 (127-183) 459† (242-745) 57 
40–59 years 120 (83.6-171) 31.0† (11.0-65.0) 113 (76.0-180) 594† (180-1010) 55 
60 years and older 120 (79.4-183) 45.0† (25.0-99.0) 119 (56.0-232) 320† (156-525) 32 
Females 
Total, 6 years and older 153 (128-182) 53.0 (41.0-60.0) 135 (108-174) 449 (352-608) 345 
6–11 years 234 (177-309) 97.0† (73.0-138) 257 (143-334) 531† (424-744) 60 
12–19 years 167 (134-207) 38.0 (32.0-68.0) 168 (146-186) 487 (366-670) 128 
20–39 years 135 (103-176) 53.0† (47.0-86.0) 121 (92.0-176) 340† (201-471) 64 
40–59 years 152 (104-223) 50.0† (36.0-65.0) 124 (65.0-352) 702† (350-994) 51 
60 years and older 132 (69.1-252) 30.0† (16.0-73.0) 104 (66.0-200) 255† (208-1780) 42 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 4.1.d. Urinary iodine: Non-Hispanic whites 
Geometric mean and selected percentiles of urine concentrations (in ng/mL) for non-Hispanic whites in the U.S. population, age 
6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 163 (150-176) 44.0 (40.0-49.0) 169 (158-179) 511 (468-569) 1222 
6–11 years 229 (195-270) 61.0† (44.0-92.0) 266 (206-327) 682† (516-738) 111 
12–19 years 205 (182-231) 59.0 (41.0-81.0) 214 (192-240) 619 (537-769) 248 
20–39 years 148 (125-176) 47.0 (27.0-63.0) 157 (133-185) 421 (324-507) 280 
40–59 years 139 (115-168) 35.0 (23.0-45.0) 138 (107-169) 480 (387-659) 258 
60 years and older 185 (161-211) 56.0 (48.0-68.0) 186 (163-200) 552 (435-670) 325 
Males 
Total, 6 years and older 199 (180-221) 64.0 (51.0-78.0) 204 (187-219) 548 (470-653) 575 
6–11 years 247 (192-319) 92.0† (37.0-139) 271 (206-320) 682† (389-864) 57 
12–19 years 279 (246-316) 97.0 (67.0-150) 280 (223-344) 696 (586-1020) 116 
20–39 years 179 (149-215) 63.0 (44.0-95.0) 181 (136-247) 407 (323-468) 112 
40–59 years 174 (146-206) 43.0 (35.0-75.0) 172 (141-212) 477 (389-659) 132 
60 years and older 224 (178-282) 80.0 (40.0-107) 212 (168-271) 633 (417-1040) 158 
Females 
Total, 6 years and older 135 (122-149) 35.0 (28.0-43.0) 140 (122-157) 473 (419-569) 647 
6–11 years 211 (153-291) 58.0† (24.0-124) 225 (129-399) 689† (451-895) 54 
12–19 years 153 (126-185) 40.0 (21.0-62.0) 175 (127-194) 454 (323-740) 132 
20–39 years 126 (95.4-166) 28.0 (20.0-53.0) 133 (96.0-169) 425 (303-576) 168 
40–59 years 110 (83.1-144) 28.0 (22.0-36.0) 96.0 (67.0-152) 480 (265-873) 126 
60 years and older 159 (140-181) 52.0 (43.0-65.0) 158 (121-194) 444 (365-634) 167 
† Estimate is subject to greater uncertainty due to small cell size.
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Table 4.1.e. Urinary iodine: Total population (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in μg/g creatinine) for the total U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 163 (153-173) 64.5 (59.5-68.3) 151 (141-165) 437 (406-470) 2835 
6–11 years 273 (246-304) 116 (101-131) 257 (219-321) 699 (608-817) 374 
12–19 years 149 (137-161) 66.7 (59.9-70.2) 138 (129-146) 364 (297-479) 830 
20–39 years 135 (127-143) 56.7 (51.2-63.7) 128 (116-136) 346 (307-431) 627 
40–59 years 151 (130-175) 59.5 (52.5-66.3) 141 (119-176) 407 (300-478) 496 
60 years and older 216 (192-244) 87.2 (75.8-97.2) 200 (176-230) 518 (452-629) 508 
Males 
Total, 6 years and older 156 (143-171) 59.6 (53.1-69.1) 145 (136-161) 415 (368-501) 1333 
6–11 years 292 (263-325) 123 (92.0-148) 321 (260-359) 774 (533-963) 185 
12–19 years 162 (144-182) 63.8 (58.1-72.5) 151 (136-181) 412 (303-578) 386 
20–39 years 131 (122-141) 57.9 (49.7-65.6) 119 (107-136) 341 (273-470) 271 
40–59 years 133 (112-158) 52.5 (43.9-60.2) 134 (103-162) 315 (269-423) 255 
60 years and older 200 (168-238) 74.8 (57.6-94.9) 190 (145-238) 474 (362-704) 236 
Females 
Total, 6 years and older 170 (161-179) 67.6 (63.1-70.5) 158 (146-169) 449 (426-508) 1502 
6–11 years 254 (213-303) 109 (95.1-119) 220 (195-298) 631 (481-978) 189 
12–19 years 136 (124-149) 66.8 (59.7-71.2) 128 (111-137) 337 (265-434) 444 
20–39 years 139 (127-153) 56.1 (48.6-68.2) 133 (116-144) 359 (299-449) 356 
40–59 years 171 (148-198) 65.4 (56.0-78.4) 155 (133-186) 436 (392-576) 241 
60 years and older 230 (199-265) 96.9 (81.8-113) 207 (179-251) 571 (446-667) 272 
Table 4.1.f. Urinary iodine: Mexican Americans (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in μg/g creatinine) for Mexican Americans 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 164 (152-176) 65.4 (61.8-74.5) 154 (140-178) 424 (344-467) 720 
6–11 years 298 (253-350) 135 (104-162) 304 (239-344) 726 (469-939) 112 
12–19 years 144 (132-157) 65.2 (53.5-82.7) 132 (119-149) 314 (255-445) 266 
20–39 years 146 (127-168) 63.0 (54.9-70.8) 143 (109-175) 328 (248-492) 166 
40–59 years 142 (124-164) 62.0† (40.1-83.0) 140 (117-186) 325† (241-479) 90 
60 years and older 200 (170-234) 74.3† (61.9-112) 195 (156-245) 452† (391-765) 86 
Males 
Total, 6 years and older 157 (137-181) 62.2 (53.8-74.4) 150 (125-182) 428 (308-522) 325 
6–11 years 300 (227-395) 141† (93.0-193) 304 (209-375) 766† (459-1090) 53 
12–19 years 133 (116-151) 61.1 (49.3-81.4) 123 (108-146) 282 (182-493) 113 
20–39 years 144 (115-181) 57.3† (49.4-69.3) 143 (102-182) 328† (202-613) 75 
40–59 years 130 (98.3-172) 58.9† (9.93-108) 129 (103-214) 294† (241-405) 48 
60 years and older 193 (130-287) 84.0† (60.9-117) 180 (110-342) 452† (245-765) 36 
Females 
Total, 6 years and older 172 (154-192) 74.1 (63.2-83.7) 159 (139-184) 428 (339-534) 395 
6–11 years 296 (233-375) 130† (90.6-163) 304 (198-373) 726† (428-1070) 59 
12–19 years 157 (136-182) 73.9 (60.8-82.9) 141 (119-168) 364 (255-778) 153 
20–39 years 147 (123-176) 65.4† (42.9-89.7) 145 (108-190) 316† (210-466) 91 
40–59 years 159 (115-218) 70.0† (40.1-119) 143 (95.1-233) 408† (230-705) 42 
60 years and older 204 (158-265) 66.3† (58.5-122) 195 (143-257) 437† (331-1110) 50 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 4.1.g. Urinary iodine: Non-Hispanic blacks (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in μg/g creatinine) for non-Hispanic blacks 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 113 (103-124) 45.7 (41.3-51.0) 103 (92.5-115) 321 (257-381) 669 
6–11 years 209 (161-273) 89.7 (75.5-110) 206 (121-293) 510 (393-775) 121 
12–19 years 110 (93.7-128) 45.9 (36.8-58.8) 95.5 (87.7-114) 303 (208-406) 247 
20–39 years 94.6 (86.0-104) 42.8 (37.1-55.4) 88.3 (82.4-104) 190 (172-247) 121 
40–59 years 101 (82.3-124) 37.9† (23.6-55.9) 98.7 (69.1-130) 339† (218-441) 106 
60 years and older 122 (93.7-160) 51.3† (38.8-59.3) 102 (93.5-117) 339† (175-394) 74 
Males 
Total, 6 years and older 102 (87.9-119) 37.9 (29.0-48.1) 95.6 (79.1-118) 305 (260-356) 325 
6–11 years 208 (148-292) 84.0† (75.0-107) 204 (109-321) 510† (356-802) 61 
12–19 years 111 (89.6-138) 44.9 (33.7-60.7) 99.1 (80.0-119) 332 (201-479) 120 
20–39 years 90.0 (78.5-103) 37.6† (27.9-53.9) 83.8 (63.3-109) 300† (153-362) 57 
40–59 years 74.7 (54.5-102) 26.9† (7.53-54.1) 73.6 (41.3-148) 188† (116-280) 55 
60 years and older 105 (85.8-129) 50.6† (35.5-67.1) 97.1 (69.5-134) 211† (126-359) 32 
Females 
Total, 6 years and older 123 (111-135) 51.9 (46.3-57.8) 108 (98.7-117) 329 (239-414) 344 
6–11 years 211 (152-293) 101† (33.7-124) 214 (120-328) 478† (297-915) 60 
12–19 years 108 (94.4-124) 45.9 (36.4-62.9) 94.3 (87.7-106) 257 (189-468) 127 
20–39 years 98.2 (82.4-117) 48.6† (37.1-67.5) 90.4 (75.0-115) 184† (157-235) 64 
40–59 years 133 (99.2-178) 48.3† (44.6-65.4) 117 (79.3-162) 441† (303-699) 51 
60 years and older 136 (83.5-222) 51.3† (38.8-71.8) 107 (94.7-115) 270† (120-9060) 42 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 4.1.h. Urinary iodine: Non-Hispanic whites (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in μg/g creatinine) for non-Hispanic whites 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 175 (163-188) 69.2 (64.5-72.4) 164 (151-177) 452 (420-517) 1221 
6–11 years 290 (256-328) 121† (98.2-148) 298 (214-366) 738† (570-857) 111 
12–19 years 159 (145-175) 70.2 (62.5-75.3) 143 (129-175) 353 (297-578) 248 
20–39 years 145 (133-157) 64.5 (52.9-69.7) 133 (121-144) 386 (322-451) 280 
40–59 years 159 (133-191) 62.0 (55.9-69.8) 147 (123-191) 416 (315-562) 258 
60 years and older 232 (203-265) 102 (84.3-116) 211 (188-249) 567 (455-667) 324 
Males 
Total, 6 years and older 167 (149-187) 66.5 (55.6-76.5) 156 (142-175) 432 (371-532) 575 
6–11 years 320 (268-383) 134† (98.2-157) 359 (237-379) 785† (404-1200) 57 
12–19 years 182 (160-206) 67.4 (57.8-89.1) 180 (143-229) 559 (297-710) 116 
20–39 years 139 (122-158) 66.9 (49.7-78.7) 126 (107-145) 352 (228-514) 112 
40–59 years 140 (115-171) 54.7 (43.9-64.8) 137 (99.2-179) 369 (276-439) 132 
60 years and older 215 (175-264) 81.1 (54.1-116) 197 (159-263) 514 (366-830) 158 
Females 
Total, 6 years and older 182 (172-193) 69.6 (65.3-74.3) 169 (158-183) 468 (431-569) 646 
6–11 years 260 (201-336) 106† (85.9-132) 215 (167-368) 631† (449-978) 54 
12–19 years 140 (121-162) 69.2 (59.7-73.5) 131 (103-148) 328 (264-434) 132 
20–39 years 150 (130-172) 62.7 (47.2-69.7) 138 (122-161) 397 (322-451) 168 
40–59 years 182 (150-221) 69.6 (60.7-84.5) 177 (122-231) 437 (387-730) 126 
60 years and older 246 (209-289) 109 (89.4-132) 212 (192-278) 571 (446-700) 166 
† Estimate is subject to greater uncertainty due to small cell size.
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Selenium is a trace mineral essential to good health. The major dietary 
source of selenium is plant foods. Selenium concentrations in plants 
generally reflect the concentration of selenium in soils, but some meats 
and seafood can also contribute dietary selenium; in the United States, 
meats and bread are common sources. Depending on foodstuff origin, 
variation in its selenium content can be between 11- and 72-fold; thus, 
predicting dietary intake by relying on estimates from nutrient databases 
is difficult (Keck 2006). 
Selenium functions through selenoproteins, several of which are 
oxidant-defense enzymes. For example, the selenium-dependent 
glutathione peroxidase defends the body against oxidative stress. Other 
selenium-associated proteins regulate the action of thyroid hormones 
and the oxidation-reduction status of vitamin C and other molecules 
(Institute of Medicine 2000). Most selenium in animal tissues is present as 
selenomethionine or selenocysteine. 
Selenium deficiency in the United States is rare, but it is seen in other 
countries, most notably in China, where the concentration of selenium 
in soil is low. In the United States, most cases of selenium depletion or 
deficiency are associated with severe gastrointestinal problems, such as 
Crohn’s disease, or with the surgical removal of part of the stomach, and 
are therefore a result of impaired selenium absorption (Kuroki 2003; Rannem 
1992; Bjerre 1989). 
By itself, selenium deficiency does not usually cause illness. Rather, it can 
make the body more susceptible to illnesses caused by other nutritional, 
biochemical, or infectious stresses (Beck 2003). Three specific diseases have 
been associated with selenium deficiency. Keshan disease occurs only in 
selenium-deficient children and is associated with an enlarged heart and 
poor heart function. Kashin-Beck disease is a disorder of the bones and 
joints of the hands and fingers, elbows, knees, and ankles of children and 
adolescents. Lastly, myxedematous endemic cretinism, a condition that 
results in mental retardation, occurs in infants born to mothers deficient in 
both selenium and iodine (Institute of Medicine 2000). 
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Chemists review selenium data. 
Evidence is limited as to whether intakes of selenium 
greater than the amount needed to allow full expression 
of selenoproteins may have chemopreventive effects 
against cancer. Controlled intervention studies are 
needed to adequately evaluate selenium as a cancer 
chemopreventive agent (Institute of Medicine 2000). 
Blood concentrations of selenium greater than 1,000 
nanograms per milliliter (ng/mL) (12.7 micromoles per liter 
[μmol/L]) can result in a condition known as selenosis (Koller 
1986). Manifestations of selenosis include gastrointestinal 
upset, hair loss, white blotchy nails, garlic-breath odor, 
fatigue, irritability, and mild nerve damage (Goldhaber 2003). 
The National Academy of Sciences has established an 
estimated average requirement (EAR) for selenium that 
is based on the amount needed to maximize plasma 
glutathione peroxidase activity and prevent Keshan 
disease. The EAR is the average daily nutrient intake level 
estimated to meet the requirement of half of the healthy 
individuals in a particular life stage and sex group. The EAR 
for selenium for boys and girls 9–13 years old or 14–18 
years old is 35 and 45 micrograms (μg) daily, respectively. 
For healthy children aged 1–3 years or 4–8 years, the 
currently recommended EAR for selenium is 17 and 23 
μg daily, respectively. These values are extrapolated from 
adult values (Institute of Medicine 2000). 
A diagnosis of selenium deficiency is confirmed by measuring concentrations of 
selenium in serum or plasma. Values less than 70 ng/mL or 0.8 μmol/L suggest 
synthesis of selenium-associated proteins has not yet reached a plateau and that 
selenium supplies are limited (Institute of Medicine 2000). 
For more information about selenium, see the Institute of Medicine’s Dietary 
Reference Intake report (Institute of Medicine 2000), the selenium fact sheet from the 
National Institutes of Health, Office of Dietary Supplements (http://ods.od.nih.gov/ 
factsheets/selenium.asp), as well as information from the American Society for Nutrition 
(http://jn.nutrition.org/nutinfo/). 
Using serum selenium concentrations measured in the U.S. population in NHANES 
III (1988–1994), it appears that the diets of most U.S. residents provide the 
recommended amounts of selenium (Niskar 2003). The mean and median serum 
selenium concentrations were 1.58 μmol/L and 1.56 μmol/L, respectively. Serum 
selenium concentrations differed by age, sex, race, ethnicity, poverty-income 
ratio, and geographic region. In NHANES 2001–2002, less than 3 percent of survey 
participants had a dietary intake of selenium below the EAR (Moshfegh 2005). 
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Selected Observations and Highlights 
The following example observations are taken from the tables of 1999-2000 data 
contained in this report. Only data for children were available for the NHANES survey 
period covered in this report. Statements about categorical differences between 
demographic groups noted below are based on non-overlapping confidence limits 
from univariate analysis without adjusting for demographic variables (i.e., age, sex, 
race/ethnicity) or other determinants of these blood concentrations (i.e., dietary 
intake, supplement usage, smoking, BMI). A multivariate analysis may alter the size 
and statistical significance of these categorical differences. Furthermore, additional 
significant differences of smaller magnitude may be present despite their lack of 
mention here (e.g., if confidence limits slightly overlap or if differences are not 
statistically significant before covariate adjustment has occurred). For a selection of 
citations of descriptive NHANES papers related to these biochemical indicators of 
diet and nutrition, see Appendix E. 
General Observations 
•	 Younger children (aged 3–5 years) have lower serum selenium concentrations 
than do older children (aged 6–11 years). 





The majority of U.S. children (> 90 percent) have adequate serum concentrations of 
selenium (≥ 70 ng/mL). No evidence has surfaced of excessive exposure to selenium 
(> 1,000 ng/mL) in U.S. children. 
4 Trace Elements 103
104
Table 4.2.a. Serum selenium: Total population 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for the total U.S. population aged 
3 years and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total,3-11 years 112 (110-114) 93.0 (91.0-96.0) 113 (111-114) 130 (127-133) 1186
 3–5 years 107 (104-110) 90.0 (83.0-94.0) 110 (105-112) 128 (124-131) 343
 6–11 years 114 (111-116) 95.0 (93.0-102) 113 (111-116) 130 (128-134) 843 
Males 
Total,3-11 years 113 (110-116) 94.0 (91.0-98.0) 114 (111-116) 134 (129-137) 626
 3–5 years 108 (103-112) 87.0 (64.0-95.0) 108 (104-112) 129 (123-136) 188
 6–11 years 115 (111-119) 96.0 (91.0-104) 114 (110-121) 134 (129-137) 438 
Females 
Total,3-11 years 111 (108-113) 93.0 (90.0-96.0) 112 (110-116) 128 (126-131) 560
 3–5 years 107 (102-111) 89.0 (72.0-96.0) 110 (105-115) 126 (119-131) 155
 6–11 years 112 (109-115) 93.0 (89.0-98.0) 113 (109-117) 128 (126-131) 405 
Table 4.2.b. Serum selenium: Mexican Americans 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for Mexican Americans in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total,3-11 years 110 (107-113) 93.0 (87.0-96.0) 109 (106-113) 126 (123-131) 477
 3–5 years 108 (104-112) 90.0 (83.0-98.0) 107 (103-113) 124 (120-129) 131
 6–11 years 111 (108-114) 95.0 (91.0-100) 111 (107-114) 128 (123-133) 346 
Males 
Total,3-11 years 111 (108-115) 93.0 (85.0-98.0) 111 (108-114) 129 (125-135) 262
 3–5 years 109 (105-113) 87.0† (83.0-99.0) 108 (104-114) 125† (120-135) 71
 6–11 years 112 (109-116) 93.0 (87.0-100) 111 (107-115) 133 (126-135) 191 
Females 
Total,3-11 years 108 (105-112) 95.0 (89.0-98.0) 108 (105-114) 123 (118-126) 215
 3–5 years 106 (100-112) 89.0† (76.0-98.0) 105 (100-112) 123† (116-130) 60
 6–11 years 109 (106-112) 96.0 (87.0-99.0) 111 (105-114) 123 (118-132) 155 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 4.2.c. Serum selenium: Non-Hispanic blacks 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for non-Hispanic blacks in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total,3-11 years 107 (104-110) 91.0 (87.0-94.0) 107 (104-111) 124 (120-126) 341
 3–5 years 104 (101-107) 91.0† (84.0-94.0) 104 (102-109) 121† (116-125) 98
 6–11 years 108 (105-112) 92.0 (87.0-94.0) 108 (105-112) 124 (121-130) 243 
Males 
Total,3-11 years 108 (105-112) 91.0 (86.0-94.0) 109 (104-113) 124 (118-130) 173
 3–5 years 104 (99.4-109) 83.0† (50.0-91.0) 105 (103-112) 118† (113-131) 56
 6–11 years 110 (106-115) 92.0 (86.0-101) 110 (105-115) 126 (119-133) 117 
Females 
Total,3-11 years 106 (104-108) 91.0 (87.0-95.0) 107 (103-109) 122 (118-124) 168
 3–5 years 105 (101-109) 93.0† (84.0-96.0) 103 (98.0-112) 120† (112-127) 42
 6–11 years 106 (104-109) 92.0 (87.0-96.0) 106 (103-110) 121 (118-124) 126 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 4.2.d. Serum selenium: Non-Hispanic whites 
Geometric mean and selected percentiles of serum concentrations (in ng/mL) for non-Hispanic whites in the U.S. 
population aged 3 years and older, National Health and Nutrition Examination Survey, 1999–2000. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total,3-11 years 113 (110-116) 94.0 (90.0-102) 116 (112-118) 130 (127-135) 265
 3–5 years 107 (102-113) 87.0† (57.0-103) 114 (105-118) 130† (123-133) 81
 6–11 years 115 (111-119) 94.0 (90.0-104) 116 (111-120) 131 (127-136) 184 
Males 
Total,3-11 years 113 (109-118) 93.0 (91.0-102) 114 (109-121) 134 (128-137) 140
 3–5 years 106 (98.9-114) 87.0† (57.0-99.0) 105 (99.0-122) 125† (123-135) 41
 6–11 years 116 (110-122) 102† (84.0-110) 115 (110-123) 134† (129-139) 99 
Females 
Total,3-11 years 112 (108-117) 94.0 (80.0-102) 116 (111-119) 130 (126-132) 125
 3–5 years 108 (101-117) 80.0† (33.0-107) 114 (107-118) 130† (120-133) 40
 6–11 years 114 (109-119) 93.0† (79.0-105) 118 (110-120) 130† (126-135) 85 
† Estimate is subject to greater uncertainty due to small cell size.
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Phytoestrogens are naturally occurring polycyclic phenols found in certain 
plants that may, when ingested and metabolized, have weak estrogenic 
effects. Two important groups of phytoestrogens are isoflavones and 
lignans. The isoflavones considered in this report are daidzein, genistein, 
O-desmethylangolensin (ODMA), and equol. The lignans considered in 
this report are enterodiol and enterolactone. 
Plant sources of isoflavones include legumes, with the largest contribution 
coming from soy-based foods. Since soy flour and soy protein isolates 
may be added to processed meats, meat substitutes, breads, and protein-
food bars, these items can be a major source of isoflavones (Grace 2004; 
Lampe 1999). However, the isoflavone content of soy protein preparations 
can vary widely and is affected by production techniques (Erdman 2004). 
Daidzein and genistein are the main soy isoflavones. Kudzu root, used 
in some dietary supplements, also contains appreciable amounts of 
daidzein. Naringenin, a precursor to genistein, is found in some citrus 
fruits. Formononetin and biochanin A are methylated isoflavones found 
in clovers, which may be used in red clover dietary supplements, and 
they are metabolized in the body to daidzein and genistein, respectively. 
Ingested daidzein is further metabolized to ODMA and to equol by 
intestinal bacteria. Equol, but not ODMA, has estrogenic activity. About 
30 percent of adults produce equol and have higher serum equol 
concentrations after they consume daidzein (Setchell 2003a; Cassidy 2006). 
This ability to produce equol may be related to an individual’s intestinal 
microflora and influenced by dietary habits (Rowland 2000; Setchell 2006). It is 
unclear whether the ability to produce equol results in any health-related 
effects (Vafeiadou 2006). 
Lignans include matairesinol and secoisolariciresinol, which are 
transformed by intestinal bacteria into the estrogenic compounds, 
enterolactone, and enterodiol, respectively (Cornwell 2004; Rowland 2003). 
Enterodiol may also convert into enterolactone and vice versa. Lignans are 
found in flax seeds, whole wheat flour, tea, some fruits, and other cereal 
grains. 
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Diet is the source of human exposure to phytoestrogens. The absorption and 
metabolism of phytoestrogens varies considerably among individuals, which may 
relate to differences in absorption, enterohepatic circulation, and metabolism by 
intestinal bacteria. Phytoestrogens are ingested in their naturally occurring beta-
glycosidic forms. The beta-glycosidic forms are hydrolyzed to their aglycones in the 
intestine, absorbed, and then linked in the intestinal wall and liver with glucuronic 
acid to make them more water-soluble, a process known as glucuronidation (Doerge 
2000; Rowland 2003). The glucuronidated metabolites of isoflavones predominate in 
blood and urine (Setchell 2001). 
Isoflavones are excreted from the body within about 24 hours after ingestion, 
mainly in urine and, to a lesser extent, in feces (Setchell 2001). Urinary concentrations 
of daidzein and genistein may not correlate well with the ingested doses, perhaps 
because of the limited absorption of these isoflavones at higher doses (Setchell 2003b). 
In contrast, lignan concentrations in plasma and urine concentrations after flax seed 
consumption increases in a dose-dependent manner (Nesbitt 1999). Equol excretion 
may depend on diet, the type of intestinal bacteria present, and individual genetic 
factors (Rowland 2000; Setchell 2002; Setchell 1999). 
Generally, phytoestrogens are much less potent than endogenously produced 
estrogens, but phytoestrogens can be present in much greater quantities 
(100 to 1000 times the concentration of endogenous estrogens). Additionally, 
phytoestrogens bind less tightly to steroid-hormone serum-transport proteins than 
do endogenous estrogens (Nagel 1998). Equol has more potent estrogen activity than 
its precursor daidzein and has been proposed to be most important in explaining the 
mechanism of action of isoflavones in disease prevention (Setchell 2002). 
In comparison with Western diets, Asian diets typically provide higher intakes of 
soy-based foods. Some have suggested that the higher isoflavone intake in Asian 
diets may account for the lower incidence among Asians of menopause-related 
symptoms and for other associated beneficial health outcomes, such as reduced 
risk for breast, prostate, and colon cancer; cardiovascular health; and modulation of 
osteoporosis. A recent evidence report from the Agency for Healthcare Research and 
Quality (Balk 2005) about the effects of soy on health outcomes reported that there is 
no conclusive evidence of a dose-response effect of either soy protein or isoflavone 
on cardiovascular diseases, menopausal symptoms, endocrine function, cancer, 
bone health, reproductive health, kidney diseases, cognitive function, or glucose 
metabolism. For reducing low-density lipoprotein concentrations, however, soy 
protein could possibly have a dose-response effect. 
Adverse effects on fertility have been observed in animals that graze on red clover. 
Results of chronic feeding studies in pregnant animals suggest that high doses of 
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phytoestrogens alter the fetal hormonal environment (Cornwell 2004). Infants who 
consume soy-based formula can have plasma concentrations of isoflavones that ar
13,000–22,000 times higher than concentrations of endogenous estrogen in infants
(Setchell 1997). Yet, studies of children who had been fed soy-based formula as infants
and who were followed through adolescence (Klein 1998) and young adulthood (Stro
2001) found no adverse reproductive or endocrine effects. In vitro and animal studie
also suggest that soy isoflavones may have immunologic and thyroid effects (Doerge
2002). The Center for the Evaluation of Risks to Human Reproduction of the National 
Toxicology Program reviewed the developmental and reproductive toxicity of both 
soy formula and genistein and concluded that available data were inadequate to 
determine the effects of soy formula on developmental or reproductive toxicity 
(Rozman 2006a). The expert review panel expressed negligible concern for adverse 
effects in the general population of consuming dietary sources of genistein: under 
current exposure conditions, adults would be unlikely to consume sufficient daily 
levels of genistein to cause adverse reproductive and/or developmental effects 
(Rozman 2006b). 
For more information about soy isoflavones, see the fact sheet from the National 








Phytoestrogens have been measured in NHANES since 1999. In NHANES 1999–2000, 
CDC scientists detected enterolactone in the highest concentration, and daidzein 
was detected with the highest 
frequency among the six measured 
phytoestrogens (Valentin-Blasini 2005). 
CDC’s Third National Report on Human 
Exposure to Environmental Chemicals 
has presented geometric means 
and selected percentiles (50th, 75th, 
90th, and 95th) for concentrations of 
phytoestrogens by age, sex, and race/ 
ethnicity for participants in NHANES 
1999–2000 and 2001–2002 (U.S. Centers 
for Disease Control and Prevention 2005). 
Chemist verifies sample for phytoestrogen analysis. 
Selected Observations and Highlights 
The following example observations are taken from the uncorrected tables of 
1999–2002 data contained in this report. Statements about categorical differences 
between demographic groups noted below are based on non-overlapping 
confidence limits from univariate analysis without adjusting for demographic 
variables (i.e., age, sex, race/ethnicity) or other determinants of these urine 
concentrations (i.e., dietary intake, supplement usage, smoking, BMI). A multivariate 
analysis may alter the size and statistical significance of these categorical differences. 
Furthermore, additional significant differences of smaller magnitude may be present 
despite their lack of mention here (e.g., if confidence limits slightly overlap or if 
differences are not statistically significant before covariate adjustment has occurred). 
For a selection of citations of descriptive NHANES papers related to these biochemical 
indicators of diet and nutrition, see Appendix E. 
General Observations 
•	 Urinary isoflavone (genistein, daidzein, equol, and ODMA) concentrations are 
generally lower in adults than they are in children and adolescents, whereas 
urinary lignan concentrations either do not differ by age (enterodiol) or show 
a U-shaped age pattern (enterolactone). 
•	 Males and females have similar phytoestrogen concentrations. 
•	 Non-Hispanic whites have higher equol concentrations than non-Hispanic 
blacks and Mexican Americans. Mexican Americans have lower ODMA 
concentrations than non-Hispanic blacks and non-Hispanic whites. 
Highlights 
Urinary isoflavone and lignan concentrations show only small variations by 
demographic variables such as age, sex, or race/ethnicity. 
National Report on Biochemical Indicators of Diet and Nutrition in the U.S. Population 1999-2002 112 
National Report on Biochemical Indicators of Diet and Nutrition in the U.S. Population 1999-2002 1135   Isoflavones & Lignans 
Table 5.1.a. Urinary genistein: Total population 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for the total U.S. population aged 
6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 28.5 (25.5-31.8) 3.27 (2.70-4.17) 28.4 (25.7-30.7) 293 (253-330) 5351 
6–11 years 33.8 (29.3-39.1) 5.80 (4.20-7.05) 31.8 (25.2-37.3) 248 (197-328) 727 
12–19 years 38.0 (32.2-44.7) 5.60 (4.00-8.20) 34.8 (29.0-41.4) 314 (249-365) 1498 
20–39 years 31.3 (26.5-37.0) 3.10 (2.40-4.80) 29.0 (25.8-34.3) 349 (269-437) 1140 
40–59 years 23.7 (19.1-29.3) 2.22 (.900-3.40) 24.4 (21.3-29.4) 298 (202-402) 951 
60 years and older 24.1 (20.8-28.0) 2.90 (2.20-3.95) 24.2 (20.3-29.8) 227 (155-308) 1035 
Males 
Total, 6 years and older 31.1 (26.8-36.2) 3.86 (3.10-5.20) 30.3 (27.6-34.0) 298 (235-341) 2597 
6–11 years 34.6 (27.6-43.3) 5.36 (3.30-7.04) 35.2 (24.3-51.0) 218 (146-348) 368 
12–19 years 36.3 (28.1-46.8) 6.21 (2.62-10.6) 31.0 (25.6-41.4) 299 (204-363) 736 
20–39 years 33.5 (26.5-42.3) 3.16 (2.30-5.39) 30.7 (26.8-35.9) 385 (245-522) 500 
40–59 years 26.5 (19.7-35.6) 3.35 (1.32-5.60) 28.4 (20.1-35.7) 281 (195-383) 480 
60 years and older 29.8 (24.4-36.6) 4.17 (3.10-5.73) 31.1 (23.7-36.6) 233 (141-335) 513 
Females 
Total, 6 years and older 26.1 (23.7-28.8) 2.85 (2.22-3.83) 25.6 (23.5-28.4) 285 (242-353) 2754 
6–11 years 33.1 (26.2-41.9) 5.50 (3.75-7.84) 27.0 (21.8-36.1) 272 (197-426) 359 
12–19 years 39.8 (34.0-46.7) 5.52 (4.00-8.40) 36.8 (31.3-46.3) 321 (247-445) 762 
20–39 years 29.3 (24.0-35.8) 2.99 (1.95-4.86) 27.6 (22.5-36.3) 312 (217-461) 640 
40–59 years 21.2 (17.3-26.1) 1.60 (<LOD-3.00) 22.8 (18.7-26.0) 327 (194-495) 471 
60 years and older 20.5 (17.3-24.3) 2.50 (1.26-3.51) 20.3 (16.4-25.3) 190 (129-290) 522 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
Table 5.1.b. Urinary genistein: Mexican Americans 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for Mexican Americans in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 29.7 (25.4-34.8) 4.07 (3.40-4.60) 27.4 (23.5-32.5) 294 (216-328) 1498 
6–11 years 37.5 (26.3-53.4) 3.78 (1.64-6.00) 42.6 (22.7-63.5) 432 (220-671) 226 
12–19 years 32.4 (26.6-39.4) 3.80 (2.50-5.40) 34.2 (27.7-41.1) 314 (216-367) 543 
20–39 years 30.7 (22.8-41.3) 4.50 (3.40-5.70) 25.8 (18.5-37.5) 302 (201-427) 301 
40–59 years 24.8 (19.7-31.1) 3.60 (2.08-5.62) 25.7 (18.5-34.4) 168 (106-286) 221 
60 years and older 20.3 (16.5-25.0) 2.48 (1.06-4.07) 19.0 (13.7-31.1) 190 (113-489) 207 
Males 
Total, 6 years and older 33.6 (26.0-43.4) 4.28 (3.10-5.40) 31.6 (24.1-45.0) 324 (294-432) 724 
6–11 years 37.7 (23.6-60.3) 3.30 (1.40-7.80) 42.8 (22.4-63.5) 341 (172-830) 117 
12–19 years 34.0 (26.5-43.7) 3.67 (2.09-5.70) 39.7 (26.4-54.2) 324 (216-373) 276 
20–39 years 37.3 (23.9-58.2) 4.50 (2.70-7.05) 32.3 (19.1-72.9) 406 (244-514) 127 
40–59 years 28.7 (20.9-39.4) 4.40† (2.80-8.30) 29.0 (19.5-38.9) 205† (97.3-540) 105 
60 years and older 19.1 (12.5-29.4) 2.48† (<LOD-6.30) 16.9 (11.2-31.1) 125† (57.0-614) 99 
Females 
Total, 6 years and older 26.0 (23.0-29.4) 3.80 (3.18-4.38) 24.4 (20.7-26.9) 220 (193-309) 774 
6–11 years 37.2 (23.9-57.8) 4.60† (<LOD-7.20) 27.4 (19.3-84.7) 523† (220-813) 109 
12–19 years 30.6 (23.4-40.1) 3.94 (2.00-6.11) 30.2 (25.0-38.1) 267 (166-492) 267 
20–39 years 24.3 (19.0-31.2) 4.32 (3.18-6.30) 20.0 (14.6-26.9) 215 (125-349) 174 
40–59 years 21.3 (15.8-28.6) 2.95 (<LOD-5.62) 24.2 (17.0-34.4) 146 (87.3-286) 116 
60 years and older 21.4 (14.9-30.6) 1.90† (<LOD-3.80) 23.5 (10.9-38.9) 213† (128-489) 108 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.1.c. Urinary genistein: Non-Hispanic blacks 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic blacks in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 31.5 (25.2-39.3) 3.73 (2.40-5.00) 33.2 (26.8-41.5) 328 (237-393) 1289 
6–11 years 42.3 (32.8-54.4) 4.70 (3.50-6.90) 43.7 (32.4-58.0) 417 (272-600) 249 
12–19 years 46.7 (37.7-57.9) 7.20 (5.84-10.0) 39.5 (34.4-48.0) 378 (306-467) 451 
20–39 years 31.7 (22.9-43.8) 3.70 (1.60-6.30) 34.9 (25.4-49.1) 301 (164-474) 197 
40–59 years 24.3 (16.3-36.4) 1.90 (<LOD-5.20) 27.9 (18.5-39.7) 246 (114-402) 210 
60 years and older 24.6 (16.8-36.0) 2.79 (1.20-5.40) 23.7 (15.4-34.7) 228 (137-641) 182 
Males 
Total, 6 years and older 33.5 (24.7-45.6) 4.60 (2.30-7.21) 36.9 (28.8-49.1) 257 (178-388) 628 
6–11 years 45.0 (31.5-64.5) 4.96 (3.33-7.05) 49.6 (34.6-73.9) 387 (205-687) 127 
12–19 years 45.8 (36.6-57.4) 7.00 (4.72-10.2) 43.0 (34.6-56.7) 334 (227-445) 212 
20–39 years 30.2 (18.1-50.6) 3.80† (<LOD-8.30) 41.5 (24.0-57.2) 252† (104-513) 91 
40–59 years 26.7 (16.3-44.0) 3.70† (<LOD-10.0) 30.1 (16.6-50.4) 178† (87.4-367) 109 
60 years and older 33.2 (18.3-60.1) 4.70† (<LOD-7.96) 30.3 (15.9-58.6) 276† (108-1120) 89 
Females 
Total, 6 years and older 29.8 (24.0-37.1) 3.00 (2.10-4.40) 30.3 (23.3-38.2) 363 (245-472) 661 
6–11 years 39.4 (29.0-53.6) 4.74 (1.70-9.70) 34.5 (24.7-50.8) 432 (203-600) 122 
12–19 years 47.7 (35.9-63.4) 7.54 (5.90-11.2) 37.4 (29.6-47.6) 394 (233-717) 239 
20–39 years 32.8 (22.5-47.8) 2.99† (<LOD-8.40) 34.4 (21.0-50.7) 346† (161-577) 106 
40–59 years 22.4 (14.0-35.9) 1.50† (<LOD-4.40) 23.3 (17.1-38.6) 285† (106-495) 101 
60 years and older 20.2 (13.1-31.1) 2.30† (<LOD-5.42) 17.4 (10.6-33.3) 228† (105-641) 93 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 5.1.d. Urinary genistein: Non-Hispanic whites 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic whites in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 27.1 (24.2-30.4) 2.96 (2.40-3.91) 26.5 (23.9-29.5) 281 (238-330) 2112 
6–11 years 31.3 (25.2-38.9) 6.40 (4.20-8.15) 28.4 (22.4-37.3) 217 (155-272) 196 
12–19 years 36.4 (29.3-45.3) 5.10 (3.30-9.70) 33.3 (27.9-41.0) 257 (209-331) 375 
20–39 years 30.5 (24.0-38.7) 2.80 (1.92-4.86) 27.9 (23.7-34.0) 387 (254-537) 529 
40–59 years 23.9 (18.6-30.6) 2.14 (<LOD-3.40) 24.3 (19.7-29.5) 335 (214-466) 434 
60 years and older 22.2 (19.0-26.0) 2.74 (1.71-3.98) 22.5 (18.7-27.9) 182 (129-282) 578 
Males 
Total, 6 years and older 30.6 (26.1-35.9) 3.90 (2.80-5.60) 29.5 (26.5-33.1) 293 (226-371) 1038 
6–11 years 31.0 (22.9-42.0) 6.20† (3.10-8.15) 32.9 (20.6-48.3) 190† (104-257) 101 
12–19 years 33.2 (22.9-48.1) 5.09 (2.20-11.5) 28.3 (22.8-38.8) 238 (141-371) 190 
20–39 years 32.2 (23.7-43.8) 2.90 (1.90-5.91) 27.9 (23.7-34.3) 413 (229-734) 231 
40–59 years 29.1 (21.7-39.1) 3.42 (1.32-5.85) 28.7 (21.7-38.7) 298 (195-447) 225 
60 years and older 28.9 (23.0-36.4) 4.17 (3.10-6.00) 29.8 (21.9-36.7) 229 (129-335) 291 
Females 
Total, 6 years and older 24.1 (21.6-27.0) 2.59 (1.50-3.20) 23.7 (20.9-26.1) 268 (226-353) 1074 
6–11 years 31.7 (21.7-46.3) 6.89† (3.51-10.2) 26.7 (17.3-37.9) 256† (131-500) 95 
12–19 years 40.4 (33.6-48.6) 5.10 (3.51-9.13) 37.8 (29.0-53.2) 305 (212-446) 185 
20–39 years 28.9 (21.6-38.8) 2.59 (1.40-4.90) 27.0 (18.7-39.0) 330 (206-626) 298 
40–59 years 19.6 (14.5-26.6) .960 (<LOD-2.87) 18.7 (14.3-24.9) 355 (174-627) 209 
60 years and older 18.1 (14.8-22.1) 2.20 (1.00-3.75) 18.4 (14.1-24.3) 136 (118-202) 287 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.1.e. Urinary genistein: Total population (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for the total U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 26.6 (23.7-29.8) 3.78 (3.08-4.46) 24.8 (22.5-27.6) 242 (209-274) 5351 
6–11 years 36.7 (31.1-43.4) 6.94 (5.22-8.13) 34.9 (27.6-41.3) 243 (186-292) 727 
12–19 years 27.5 (23.3-32.4) 4.36 (3.68-5.09) 24.4 (20.9-30.8) 192 (153-258) 1498 
20–39 years 25.1 (21.5-29.2) 3.77 (2.96-4.59) 22.8 (19.1-26.3) 244 (202-318) 1140 
40–59 years 23.8 (19.3-29.3) 2.48 (1.17-4.08) 22.3 (18.5-28.7) 270 (196-335) 951 
60 years and older 28.9 (25.4-33.0) 4.48 (3.17-5.31) 26.6 (22.4-32.3) 222 (175-285) 1035 
Males 
Total, 6 years and older 25.0 (21.4-29.3) 4.02 (3.25-4.74) 23.0 (19.8-26.8) 203 (177-265) 2597 
6–11 years 36.5 (28.4-46.8) 6.65 (4.52-8.13) 35.4 (27.1-50.3) 200 (154-286) 368 
12–19 years 25.8 (20.4-32.5) 4.23 (3.54-5.09) 22.2 (18.6-31.7) 164 (115-264) 736 
20–39 years 23.3 (18.4-29.4) 4.01 (1.99-5.04) 19.0 (15.6-24.7) 227 (170-330) 500 
40–59 years 22.0 (16.1-30.0) 3.21 (1.36-4.87) 21.0 (16.1-30.9) 222 (167-334) 480 
60 years and older 28.0 (23.6-33.2) 4.74 (3.44-6.19) 27.1 (22.2-33.1) 177 (143-324) 513 
Females 
Total, 6 years and older 28.1 (25.3-31.3) 3.50 (2.95-4.23) 26.6 (23.8-29.7) 265 (230-308) 2754 
6–11 years 37.0 (28.2-48.6) 7.69 (4.92-9.64) 30.9 (21.9-47.9) 255 (182-488) 359 
12–19 years 29.3 (24.9-34.6) 4.65 (3.09-6.00) 28.2 (23.2-33.2) 216 (162-304) 762 
20–39 years 27.0 (22.4-32.5) 3.32 (3.01-4.41) 25.8 (21.1-30.3) 265 (192-349) 640 
40–59 years 25.6 (21.2-30.8) 2.23 (<LOD-3.81) 24.7 (17.6-36.0) 287 (230-381) 471 
60 years and older 29.7 (24.8-35.5) 4.27 (2.52-5.68) 26.6 (21.6-35.0) 252 (191-319) 522 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
Table 5.1.f. Urinary genistein: Mexican Americans (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for Mexican Americans 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 27.6 (24.1-31.6) 3.85 (3.35-4.65) 24.5 (19.7-30.0) 243 (208-279) 1498 
6–11 years 48.0 (37.4-61.6) 5.98 (3.95-8.12) 42.4 (31.7-62.9) 601 (317-717) 226 
12–19 years 25.5 (21.4-30.4) 3.42 (2.96-4.23) 24.6 (19.7-31.7) 188 (165-254) 543 
20–39 years 25.3 (19.5-32.9) 3.79 (3.16-5.11) 19.1 (14.8-32.6) 215 (181-257) 301 
40–59 years 24.8 (19.9-31.0) 4.01 (2.88-5.44) 25.6 (18.6-32.8) 176 (124-279) 221 
60 years and older 23.4 (18.4-29.6) 3.49 (1.13-5.08) 22.1 (15.8-35.0) 216 (142-329) 207 
Males 
Total, 6 years and older 27.7 (22.5-34.1) 4.01 (3.10-5.17) 25.7 (18.7-34.9) 228 (190-285) 724 
6–11 years 45.3 (30.6-66.9) 4.29 (2.85-9.69) 40.7 (29.1-66.8) 627 (206-776) 117 
12–19 years 25.6 (20.3-32.3) 3.62 (2.22-4.66) 24.7 (18.3-40.4) 185 (165-270) 276 
20–39 years 27.5 (18.7-40.3) 3.99 (2.72-5.71) 19.8 (13.5-41.2) 226 (180-323) 127 
40–59 years 24.1 (17.7-32.8) 4.91† (3.21-6.44) 25.6 (14.8-34.3) 159† (96.9-335) 105 
60 years and older 18.0 (12.2-26.6) 3.05† (<LOD-5.74) 18.5 (10.8-32.4) 135† (50.5-292) 99 
Females 
Total, 6 years and older 27.5 (24.0-31.4) 3.72 (3.27-4.42) 23.8 (19.2-26.2) 253 (195-324) 774 
6–11 years 51.0 (37.5-69.4) 7.40† (<LOD-9.57) 44.0 (25.1-94.3) 537† (253-926) 109 
12–19 years 25.5 (19.4-33.4) 3.42 (2.71-4.65) 24.5 (16.1-36.3) 195 (131-313) 267 
20–39 years 23.0 (18.2-29.1) 3.60 (3.20-4.61) 16.8 (13.8-25.5) 205 (119-325) 174 
40–59 years 25.6 (19.8-33.2) 3.17 (<LOD-5.96) 24.4 (17.5-33.6) 219 (121-324) 116 
60 years and older 29.0 (19.9-42.2) 3.50† (<LOD-11.2) 27.9 (14.7-59.2) 237† (142-408) 108 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.1.g. Urinary genistein: Non-Hispanic blacks (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic blacks 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 21.2 (17.0-26.4) 3.24 (2.52-4.26) 21.1 (17.2-26.1) 192 (154-239) 1289 
6–11 years 39.5 (31.0-50.4) 5.59 (3.92-9.81) 38.5 (28.9-51.2) 279 (203-409) 249 
12–19 years 26.2 (21.4-32.1) 4.25 (3.54-5.18) 24.9 (20.0-30.8) 224 (138-351) 451 
20–39 years 18.0 (12.8-25.3) 2.82 (.344-4.26) 19.0 (13.4-25.6) 186 (95.1-281) 197 
40–59 years 16.4 (11.4-23.7) 2.56 (<LOD-4.68) 16.4 (11.5-23.7) 152 (101-217) 210 
60 years and older 23.1 (17.0-31.5) 4.13 (2.22-5.31) 20.9 (14.9-30.9) 178 (106-384) 182 
Males 
Total, 6 years and older 20.3 (15.1-27.3) 3.24 (1.99-4.68) 20.7 (16.4-28.5) 162 (109-222) 628 
6–11 years 41.8 (29.2-59.7) 5.47 (3.10-12.9) 41.3 (28.5-71.2) 274 (165-450) 127 
12–19 years 25.0 (20.1-31.0) 3.12 (1.84-5.01) 26.1 (20.0-34.8) 176 (114-260) 212 
20–39 years 14.7 (8.72-24.7) 2.82† (<LOD-5.12) 17.2 (10.1-25.6) 103† (53.9-191) 91 
40–59 years 16.3 (10.0-26.5) 2.56† (<LOD-5.14) 18.7 (10.4-30.4) 112† (49.6-236) 109 
60 years and older 24.7 (14.3-42.4) 4.86† (<LOD-7.14) 20.4 (14.7-32.8) 322† (74.5-783) 89 
Females 
Total, 6 years and older 22.1 (17.9-27.1) 3.33 (2.58-4.15) 21.6 (16.5-26.9) 224 (159-317) 661 
6–11 years 37.3 (28.2-49.4) 5.59 (2.77-9.59) 31.6 (21.3-54.0) 344 (185-462) 122 
12–19 years 27.6 (21.0-36.2) 5.14 (4.13-6.43) 22.9 (16.6-32.3) 261 (130-460) 239 
20–39 years 21.2 (14.5-31.1) 3.01† (<LOD-5.56) 23.3 (13.5-30.3) 247† (140-415) 106 
40–59 years 16.5 (10.9-25.0) 2.22† (<LOD-4.89) 14.3 (10.6-25.0) 154† (109-247) 101 
60 years and older 22.1 (15.5-31.6) 3.95† (<LOD-5.45) 20.0 (13.1-33.8) 178† (90.2-446) 93 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 5.1.h. Urinary genistein: Non-Hispanic whites (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic whites 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 27.0 (24.1-30.2) 3.80 (2.98-4.66) 25.6 (22.7-28.8) 242 (207-284) 2112 
6–11 years 34.0 (26.7-43.3) 7.20 (4.92-10.4) 31.7 (23.3-40.8) 186 (145-279) 196 
12–19 years 27.6 (22.0-34.7) 4.76 (2.77-6.72) 24.1 (20.6-33.0) 166 (130-232) 375 
20–39 years 26.6 (21.7-32.5) 3.89 (2.96-4.86) 24.4 (17.5-31.5) 268 (208-348) 529 
40–59 years 25.0 (19.6-31.9) 2.47 (<LOD-4.07) 24.2 (18.1-33.2) 287 (204-367) 434 
60 years and older 27.7 (24.4-31.4) 4.63 (2.98-6.09) 26.0 (21.9-32.0) 185 (150-274) 578 
Males 
Total, 6 years and older 25.9 (22.1-30.4) 4.35 (3.66-5.13) 24.6 (20.6-29.3) 196 (169-284) 1038 
6–11 years 34.1 (24.7-47.1) 6.08† (2.28-11.9) 35.3 (18.9-60.1) 168† (115-279) 101 
12–19 years 25.2 (17.9-35.5) 4.35 (2.76-6.73) 21.0 (17.0-29.6) 124 (95.4-264) 190 
20–39 years 24.5 (18.3-32.7) 4.48 (1.42-5.71) 19.5 (14.8-28.4) 246 (170-365) 231 
40–59 years 24.5 (17.9-33.5) 3.32 (1.55-5.13) 22.0 (16.3-35.8) 271 (167-379) 225 
60 years and older 27.6 (23.4-32.7) 4.85 (3.73-6.59) 26.8 (20.5-34.3) 170 (111-285) 291 
Females 
Total, 6 years and older 28.1 (25.0-31.6) 3.16 (2.45-4.27) 26.6 (22.5-31.3) 274 (230-323) 1074 
6–11 years 33.9 (22.4-51.4) 7.69† (4.25-11.6) 27.6 (17.4-41.1) 200† (140-571) 95 
12–19 years 30.5 (24.3-38.4) 4.74 (2.59-7.08) 29.8 (21.7-40.1) 203 (141-304) 185 
20–39 years 28.8 (22.6-36.7) 3.20 (2.63-4.86) 27.0 (19.6-37.3) 283 (206-357) 298 
40–59 years 25.5 (19.2-34.0) 1.62 (<LOD-4.07) 24.2 (15.6-40.4) 323 (220-480) 209 
60 years and older 27.8 (22.5-34.2) 4.27 (2.00-6.44) 25.9 (19.9-35.0) 222 (155-319) 287 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.2.a. Urinary daidzein: Total population 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for the total U.S. population aged 
6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 61.0 (55.2-67.3) 6.75 (5.68-8.00) 59.2 (54.0-66.6) 545 (491-642) 5347 
6–11 years 88.1 (78.0-99.4) 15.6 (13.0-19.7) 80.2 (68.2-108) 544 (446-726) 726 
12–19 years 89.7 (73.2-110) 10.9 (7.50-16.5) 87.5 (74.3-103) 786 (569-1090) 1497 
20–39 years 63.7 (55.6-73.1) 6.59 (5.20-8.10) 57.3 (49.9-70.6) 590 (494-781) 1138 
40–59 years 52.3 (43.4-63.1) 5.62 (2.90-7.81) 53.9 (44.2-63.0) 505 (397-725) 951 
60 years and older 44.8 (38.9-51.6) 4.80 (2.00-6.70) 44.6 (38.7-54.2) 394 (300-519) 1035 
Males 
Total, 6 years and older 64.8 (57.2-73.4) 7.29 (5.62-9.40) 63.0 (57.2-70.9) 542 (470-694) 2595 
6–11 years 95.6 (77.5-118) 19.1 (14.4-20.3) 83.6 (56.3-139) 544 (443-745) 368 
12–19 years 87.4 (65.2-117) 12.0 (6.72-18.7) 87.5 (71.0-118) 660 (445-1100) 735 
20–39 years 64.4 (53.6-77.3) 6.50 (4.00-11.4) 57.0 (48.2-69.8) 663 (494-935) 499 
40–59 years 54.8 (43.2-69.4) 5.70 (3.50-7.81) 58.1 (49.5-68.4) 467 (332-774) 480 
60 years and older 54.2 (44.6-65.9) 4.89 (2.60-8.70) 57.9 (43.3-78.7) 414 (300-576) 513 
Females 
Total, 6 years and older 57.5 (51.9-63.7) 6.41 (5.00-8.00) 56.0 (49.3-62.0) 553 (459-702) 2752 
6–11 years 80.7 (66.0-98.8) 13.7 (11.3-19.7) 76.6 (62.3-106) 524 (390-989) 358 
12–19 years 92.1 (75.4-112) 10.4 (6.10-16.5) 89.7 (70.2-115) 922 (642-1330) 762 
20–39 years 63.1 (51.3-77.7) 7.18 (4.70-8.40) 58.1 (48.2-79.2) 517 (411-987) 639 
40–59 years 50.2 (40.5-62.1) 4.40 (1.86-8.22) 46.1 (37.8-61.0) 591 (364-1220) 471 
60 years and older 38.7 (32.8-45.7) 4.40 (1.80-6.97) 37.4 (32.0-43.6) 356 (280-461) 522 
Table 5.2.b. Urinary daidzein: Mexican Americans 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for Mexican Americans in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 55.9 (45.6-68.6) 5.10 (2.41-6.76) 52.5 (43.8-67.4) 618 (513-824) 1495 
6–11 years 81.7 (56.7-118) 10.2 (4.39-14.0) 74.5 (43.4-123) 866 (534-1240) 225 
12–19 years 71.6 (61.0-84.1) 8.50 (6.30-11.4) 74.6 (56.5-98.5) 595 (475-915) 543 
20–39 years 51.9 (36.3-74.2) 3.50 (<LOD-6.82) 47.1 (29.7-68.6) 585 (406-931) 299 
40–59 years 46.8 (35.3-62.2) 3.20 (<LOD-6.90) 53.9 (35.8-71.4) 584 (297-980) 221 
60 years and older 35.1 (24.7-49.8) 1.96 (<LOD-7.99) 36.3 (27.1-47.3) 366 (182-635) 207 
Males 
Total, 6 years and older 62.7 (45.6-86.2) 5.20 (1.80-8.41) 62.9 (45.8-85.0) 745 (515-994) 723 
6–11 years 91.4 (61.1-137) 12.7 (4.37-26.6) 84.3 (50.0-123) 896 (505-1240) 117 
12–19 years 74.9 (57.6-97.4) 7.50 (4.33-11.7) 81.0 (55.8-117) 664 (498-1100) 276 
20–39 years 61.9 (37.0-104) 2.40 (<LOD-9.60) 57.6 (30.1-108) 706 (446-1070) 126 
40–59 years 52.5 (33.6-82.1) 5.03† (<LOD-11.2) 56.0 (33.5-92.5) 872† (331-1090) 105 
60 years and older 29.1 (16.5-51.3) < LOD† 31.6 (18.2-47.3) 284† (106-659) 99 
Females 
Total, 6 years and older 49.4 (41.1-59.4) 5.40 (1.70-7.52) 45.9 (35.7-54.0) 522 (388-682) 772 
6–11 years 72.8 (43.9-121) 6.59† (<LOD-12.5) 60.6 (29.5-195) 824† (514-1420) 108 
12–19 years 68.1 (57.5-80.8) 9.70 (6.30-11.8) 69.0 (48.5-93.2) 541 (299-1440) 267 
20–39 years 42.2 (28.9-61.6) 4.30 (<LOD-10.7) 35.4 (26.3-51.4) 450 (324-669) 173 
40–59 years 41.5 (28.4-60.6) < LOD 50.1 (26.2-71.4) 302 (213-800) 116 
60 years and older 41.0 (25.7-65.5) 2.70† (<LOD-11.2) 37.4 (22.8-76.8) 370† (170-804) 108 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.2.c. Urinary daidzein: Non-Hispanic blacks 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic blacks in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 76.1 (62.0-93.4) 8.10 (5.45-11.1) 88.4 (68.8-106) 628 (491-906) 1288 
6–11 years 120 (95.7-151) 12.5 (8.61-17.9) 135 (99.1-172) 1130 (628-1850) 249 
12–19 years 119 (98.9-144) 15.1 (10.6-20.4) 118 (98.1-148) 950 (660-1370) 450 
20–39 years 77.7 (56.4-107) 9.50 (3.00-12.2) 91.3 (58.1-149) 578 (363-1330) 197 
40–59 years 58.7 (40.0-86.2) 6.05 (<LOD-12.1) 66.1 (41.5-96.3) 529 (393-816) 210 
60 years and older 45.2 (29.3-69.9) 1.90 (<LOD-6.60) 44.7 (26.5-70.9) 556 (377-1140) 182 
Males 
Total, 6 years and older 78.3 (56.9-108) 8.98 (<LOD-14.2) 90.4 (65.6-122) 632 (489-1040) 627 
6–11 years 142 (104-194) 16.4 (11.3-24.2) 161 (94.9-244) 1360 (597-1850) 127 
12–19 years 123 (101-150) 14.9 (10.5-21.1) 142 (104-183) 1030 (650-1320) 211 
20–39 years 74.4 (45.4-122) 8.45† (<LOD-15.0) 86.4 (42.6-198) 582† (305-1340) 91 
40–59 years 52.3 (29.5-92.9) 5.80† (<LOD-16.4) 65.5 (31.2-117) 358† (233-594) 109 
60 years and older 55.7 (28.3-110) < LOD† 58.1 (31.0-104) 519† (377-1960) 89 
Females 
Total, 6 years and older 74.2 (61.5-89.6) 7.70 (3.61-11.3) 85.9 (66.6-103) 611 (473-856) 661 
6–11 years 100 (70.3-144) 10.0 (<LOD-26.2) 107 (79.6-152) 1130 (467-2300) 122 
12–19 years 115 (88.3-151) 15.2 (6.80-24.8) 106 (85.2-129) 805 (545-1840) 239 
20–39 years 80.4 (57.7-112) 9.50† (2.80-14.3) 98.0 (58.7-155) 465† (331-1400) 106 
40–59 years 64.8 (44.8-93.5) 5.70† (<LOD-13.6) 68.8 (37.7-101) 541† (393-1170) 101 
60 years and older 39.4 (23.9-64.8) 2.30† (<LOD-5.45) 33.9 (21.6-61.6) 560† (267-1140) 93 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 5.2.d. Urinary daidzein: Non-Hispanic whites 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic whites in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 58.4 (53.0-64.3) 6.60 (5.33-8.10) 56.2 (51.5-61.0) 505 (439-636) 2112 
6–11 years 83.8 (69.3-101) 16.5 (13.0-20.3) 76.6 (58.9-112) 443 (385-694) 196 
12–19 years 84.2 (62.7-113) 9.60 (4.93-16.9) 85.3 (68.3-119) 755 (493-1310) 375 
20–39 years 62.0 (52.1-73.8) 6.59 (4.00-9.20) 52.1 (44.3-65.5) 601 (437-987) 529 
40–59 years 54.7 (44.4-67.5) 5.70 (3.16-8.00) 54.8 (44.8-62.3) 508 (393-852) 434 
60 years and older 41.5 (35.3-48.9) 5.00 (2.00-7.70) 41.7 (36.9-50.6) 337 (235-416) 578 
Males 
Total, 6 years and older 63.4 (55.9-71.9) 7.77 (5.80-10.1) 59.0 (53.2-69.8) 505 (418-667) 1038 
6–11 years 86.4 (62.7-119) 20.2† (13.0-26.6) 77.7 (43.8-155) 470† (317-694) 101 
12–19 years 79.2 (50.9-123) 11.1 (3.70-19.2) 76.9 (53.0-121) 586 (354-1300) 190 
20–39 years 59.7 (48.0-74.3) 5.30 (2.00-12.0) 48.9 (37.3-66.9) 663 (362-1410) 231 
40–59 years 62.4 (50.6-76.9) 6.30 (5.20-10.1) 58.4 (49.8-71.1) 501 (322-838) 225 
60 years and older 53.1 (42.5-66.3) 5.20 (2.90-10.0) 57.2 (42.3-78.2) 377 (273-570) 291 
Females 
Total, 6 years and older 54.0 (48.2-60.4) 6.20 (3.63-7.77) 52.0 (44.8-59.2) 505 (432-705) 1074 
6–11 years 81.0 (59.0-111) 13.7† (11.6-22.0) 76.6 (58.9-121) 466† (284-1130) 95 
12–19 years 90.3 (67.4-121) 9.30 (3.80-18.9) 90.5 (68.3-140) 922 (566-1410) 185 
20–39 years 64.3 (49.0-84.4) 6.70 (3.63-9.30) 56.2 (43.1-79.2) 530 (369-1300) 298 
40–59 years 48.1 (35.4-65.4) 3.16 (<LOD-10.1) 45.0 (35.4-64.2) 638 (220-1370) 209 
60 years and older 34.3 (27.8-42.3) 3.60 (<LOD-7.08) 34.6 (28.5-41.1) 262 (190-398) 287 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.2.e. Urinary daidzein: Total population (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for the total U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 56.9 (51.4-63.0) 6.67 (5.54-8.00) 56.3 (50.0-64.0) 536 (460-600) 5347 
6–11 years 95.6 (83.2-110) 18.4 (14.3-21.2) 88.9 (73.4-112) 635 (494-733) 726 
12–19 years 64.8 (52.3-80.3) 8.03 (5.73-10.4) 63.4 (50.0-86.2) 600 (402-797) 1497 
20–39 years 51.1 (44.8-58.3) 5.91 (4.85-7.32) 48.8 (41.2-57.7) 523 (390-624) 1138 
40–59 years 52.6 (43.7-63.2) 5.54 (3.58-7.49) 51.0 (43.3-65.4) 535 (391-689) 951 
60 years and older 53.7 (46.4-62.1) 6.01 (3.90-8.62) 55.5 (43.5-71.3) 389 (308-555) 1035 
Males 
Total, 6 years and older 52.1 (45.8-59.3) 5.96 (5.05-7.39) 51.0 (45.2-59.7) 497 (373-601) 2595 
6–11 years 101 (80.4-127) 22.7 (14.5-30.1) 88.8 (58.6-143) 553 (447-733) 368 
12–19 years 62.0 (47.2-81.5) 9.03 (6.10-10.4) 61.6 (48.6-85.6) 547 (301-921) 735 
20–39 years 44.8 (36.8-54.7) 5.36 (3.66-7.20) 41.2 (33.1-47.9) 497 (268-847) 499 
40–59 years 45.5 (35.9-57.6) 5.05 (3.28-7.38) 45.2 (32.0-65.0) 478 (263-693) 480 
60 years and older 50.9 (41.8-62.0) 4.52 (3.09-7.91) 61.8 (44.2-81.0) 363 (255-659) 513 
Females 
Total, 6 years and older 61.9 (55.4-69.1) 7.18 (5.91-9.10) 61.0 (53.3-70.4) 564 (468-628) 2752 
6–11 years 90.3 (72.6-112) 14.9 (11.9-19.0) 86.3 (70.8-112) 668 (414-838) 358 
12–19 years 67.9 (54.6-84.3) 6.80 (5.25-9.92) 65.1 (48.1-91.9) 628 (478-742) 762 
20–39 years 58.1 (47.6-70.9) 6.74 (3.67-9.55) 56.2 (45.0-78.2) 571 (370-783) 639 
40–59 years 60.3 (48.0-75.8) 6.58 (3.42-9.23) 62.4 (43.2-75.6) 564 (387-950) 471 
60 years and older 56.0 (47.2-66.3) 6.52 (4.52-11.4) 50.9 (39.3-64.8) 451 (312-560) 522 
Table 5.2.f. Urinary daidzein: Mexican Americans (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for Mexican Americans 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 52.0 (43.7-61.9) 4.81 (3.32-7.03) 48.7 (38.2-65.0) 546 (460-645) 1495 
6–11 years 105 (81.0-136) 11.9 (8.98-17.4) 91.1 (65.5-149) 957 (715-1660) 225 
12–19 years 56.5 (47.8-66.8) 7.20 (5.28-9.29) 58.1 (45.6-71.6) 511 (358-684) 543 
20–39 years 43.0 (31.3-59.0) 3.88 (<LOD-6.82) 35.3 (23.2-57.9) 486 (307-608) 299 
40–59 years 46.9 (35.3-62.4) 3.22 (<LOD-6.50) 47.5 (36.0-67.3) 483 (303-708) 221 
60 years and older 40.3 (28.2-57.8) 3.97 (<LOD-8.56) 41.0 (27.1-73.4) 343 (223-638) 207 
Males 
Total, 6 years and older 51.8 (39.5-68.0) 4.77 (2.90-7.95) 51.0 (38.2-72.0) 585 (471-708) 723 
6–11 years 110 (79.0-152) 14.8 (10.2-24.5) 91.1 (57.4-149) 957 (596-1140) 117 
12–19 years 56.4 (43.0-73.9) 5.65 (3.59-9.03) 64.9 (39.8-90.0) 614 (358-837) 276 
20–39 years 45.8 (28.9-72.6) 3.90 (<LOD-7.95) 40.6 (21.8-91.4) 495 (307-641) 126 
40–59 years 44.2 (27.9-69.9) 3.31† (<LOD-9.43) 45.9 (32.2-68.7) 542† (198-1020) 105 
60 years and older 27.4 (15.6-48.1) < LOD† 35.5 (15.0-63.9) 201† (141-458) 99 
Females 
Total, 6 years and older 52.2 (44.0-62.0) 4.81 (3.00-8.02) 43.5 (34.1-65.5) 495 (384-600) 772 
6–11 years 100 (70.6-142) 8.61† (<LOD-15.7) 103 (55.2-201) 1080† (649-2300) 108 
12–19 years 56.6 (47.1-68.0) 8.23 (5.38-9.99) 51.2 (36.9-65.0) 399 (266-684) 267 
20–39 years 39.9 (27.9-57.0) 3.50 (<LOD-10.4) 30.6 (22.1-66.4) 384 (271-517) 173 
40–59 years 50.1 (36.0-69.6) < LOD 49.8 (27.9-102) 474 (245-708) 116 
60 years and older 55.6 (35.9-86.1) 8.02† (<LOD-12.3) 54.0 (28.9-89.9) 479† (258-984) 108 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.2.g. Urinary daidzein: Non-Hispanic blacks (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic blacks 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 51.3 (42.1-62.4) 5.54 (3.95-7.05) 57.1 (46.5-70.5) 447 (306-599) 1288 
6–11 years 113 (91.3-139) 15.4 (10.2-21.8) 109 (83.6-145) 955 (683-1280) 249 
12–19 years 67.0 (56.1-80.1) 9.23 (6.59-10.9) 75.7 (54.8-93.7) 561 (317-975) 450 
20–39 years 44.2 (32.2-60.8) 5.07 (2.92-7.58) 52.1 (38.4-71.7) 348 (207-541) 197 
40–59 years 39.6 (28.3-55.4) 3.95 (<LOD-7.27) 46.5 (26.5-64.1) 272 (215-446) 210 
60 years and older 42.5 (29.7-60.7) 2.34 (<LOD-8.65) 40.4 (27.2-79.3) 488 (249-721) 182 
Males 
Total, 6 years and older 47.3 (34.8-64.3) 5.07 (<LOD-8.50) 54.1 (40.2-70.2) 472 (297-600) 627 
6–11 years 132 (96.4-180) 17.7 (9.66-30.8) 151 (80.0-229) 1050 (661-1300) 127 
12–19 years 67.3 (55.8-81.2) 9.03 (4.93-11.3) 80.8 (61.6-106) 499 (370-650) 211 
20–39 years 36.1 (22.5-57.7) 5.17† (<LOD-8.50) 41.2 (24.5-70.2) 249† (162-541) 91 
40–59 years 31.9 (18.4-55.2) 1.76† (<LOD-10.2) 38.4 (20.4-64.8) 258† (117-696) 109 
60 years and older 41.4 (22.1-77.7) < LOD† 36.0 (23.1-92.3) 562† (214-1370) 89 
Females 
Total, 6 years and older 54.9 (46.3-65.0) 6.20 (3.75-8.65) 62.2 (48.7-77.1) 430 (302-639) 661 
6–11 years 95.0 (71.7-126) 11.9 (<LOD-20.6) 86.3 (69.7-129) 773 (381-1640) 122 
12–19 years 66.7 (51.9-85.8) 9.35 (5.68-12.5) 72.7 (42.1-91.2) 622 (251-1160) 239 
20–39 years 51.9 (37.2-72.6) 4.86† (2.92-7.58) 64.6 (47.0-92.1) 372† (207-639) 106 
40–59 years 47.6 (35.3-64.2) 6.58† (<LOD-11.1) 48.4 (29.1-70.8) 302† (215-802) 101 
60 years and older 43.2 (28.0-66.6) 2.31† (<LOD-10.0) 44.0 (24.3-85.9) 463† (248-828) 93 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 5.2.h. Urinary daidzein: Non-Hispanic whites (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic whites 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 58.1 (52.9-64.0) 6.90 (5.66-9.03) 57.8 (51.0-64.2) 506 (413-601) 2112 
6–11 years 90.9 (75.0-110) 19.0 (14.3-25.4) 88.3 (70.8-112) 494 (324-710) 196 
12–19 years 63.8 (46.5-87.6) 7.18 (4.27-12.2) 63.6 (44.8-96.2) 601 (386-987) 375 
20–39 years 54.0 (47.0-62.1) 6.52 (4.85-8.83) 49.8 (39.7-60.4) 579 (384-847) 529 
40–59 years 57.4 (47.5-69.3) 6.54 (4.23-9.94) 59.0 (44.1-70.2) 548 (377-807) 434 
60 years and older 51.8 (44.0-61.0) 6.01 (3.86-8.87) 53.4 (41.3-69.6) 318 (260-475) 578 
Males 
Total, 6 years and older 53.7 (47.4-60.7) 6.62 (5.39-8.80) 54.1 (45.5-63.3) 464 (336-586) 1038 
6–11 years 95.0 (70.0-129) 24.9† (14.1-31.9) 88.3 (56.2-152) 425† (302-710) 101 
12–19 years 60.2 (39.6-91.4) 9.03 (4.43-12.7) 58.5 (41.9-92.6) 463 (217-1030) 190 
20–39 years 45.4 (36.2-56.9) 5.50 (2.82-8.07) 40.4 (29.1-54.6) 497 (248-850) 231 
40–59 years 52.5 (43.0-64.0) 6.03 (4.60-9.94) 47.0 (34.5-71.5) 502 (276-723) 225 
60 years and older 50.7 (40.7-63.3) 5.14 (3.40-8.87) 61.7 (45.4-80.0) 313 (215-555) 291 
Females 
Total, 6 years and older 62.8 (55.9-70.5) 7.48 (5.49-10.5) 60.8 (52.8-70.4) 564 (423-655) 1074 
6–11 years 86.6 (62.6-120) 16.5† (11.1-21.2) 86.6 (55.2-113) 655† (275-938) 95 
12–19 years 68.2 (48.9-95.0) 6.56 (4.27-9.12) 73.4 (45.1-113) 628 (442-990) 185 
20–39 years 64.0 (51.1-80.2) 8.28 (2.74-14.0) 58.0 (44.1-88.7) 607 (384-852) 298 
40–59 years 62.7 (46.3-84.9) 6.79 (<LOD-12.6) 65.4 (41.0-79.9) 564 (356-1220) 209 
60 years and older 52.6 (42.5-65.1) 6.27 (<LOD-11.3) 49.2 (35.1-66.1) 316 (250-555) 287 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.3.a. Urinary equol: Total population 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for the total U.S. population aged 
6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 8.77 (7.84-9.81) < LOD 8.28 (7.21-9.50) 38.5 (33.1-45.2) 4976 
6–11 years 11.5 (9.82-13.5) < LOD 13.4 (10.1-16.1) 45.9 (32.3-59.6) 668 
12–19 years 10.4 (9.08-11.9) < LOD 10.5 (8.70-12.1) 43.1 (35.6-53.1) 1401 
20–39 years 8.54 (7.40-9.86) < LOD 8.16 (6.78-9.80) 37.6 (29.5-47.4) 1043 
40–59 years 8.39 (7.24-9.73) < LOD 7.80 (6.20-9.20) 37.1 (28.7-48.7) 909 
60 years and older 7.52 (6.59-8.58) < LOD 6.68 (5.13-8.20) 34.5 (27.9-41.7) 955 
Males 
Total, 6 years and older 9.26 (8.17-10.5) < LOD 8.70 (7.63-10.3) 39.6 (32.7-48.7) 2417 
6–11 years 12.7 (10.1-16.0) < LOD 13.7 (8.95-17.2) 56.0 (38.3-78.9) 347 
12–19 years 10.5 (8.82-12.5) < LOD 10.4 (8.49-12.9) 43.1 (35.2-56.1) 690 
20–39 years 8.68 (7.39-10.2) < LOD 7.90 (6.40-9.40) 38.2 (29.5-48.9) 454 
40–59 years 8.90 (7.47-10.6) < LOD 9.20 (7.10-10.5) 34.4 (27.4-45.2) 454 
60 years and older 8.19 (6.75-9.94) < LOD 6.83 (5.30-9.68) 35.6 (29.8-46.7) 472 
Females 
Total, 6 years and older 8.33 (7.39-9.39) < LOD 7.89 (6.80-9.17) 37.6 (32.2-42.7) 2559 
6–11 years 10.3 (8.60-12.3) < LOD 12.6 (9.40-15.5) 33.5 (28.0-51.0) 321 
12–19 years 10.3 (8.87-11.9) < LOD 10.5 (8.70-12.1) 42.9 (32.1-58.7) 711 
20–39 years 8.40 (6.97-10.1) < LOD 8.60 (6.50-10.9) 37.5 (25.3-50.9) 589 
40–59 years 7.94 (6.53-9.66) < LOD 6.27 (4.70-8.04) 40.3 (28.5-56.6) 455 
60 years and older 7.04 (6.28-7.89) < LOD 6.56 (4.60-8.13) 30.5 (23.5-43.2) 483 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
Table 5.3.b. Urinary equol: Mexican Americans 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for Mexican Americans in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 6.16 (5.59-6.79) < LOD 5.20 (4.44-6.05) 25.0 (19.9-31.0) 1405 
6–11 years 7.70 (6.18-9.60) < LOD 6.51 (5.11-9.20) 29.0 (20.7-48.7) 216 
12–19 years 7.72 (6.95-8.58) < LOD 6.90 (5.70-8.10) 33.0 (25.9-44.4) 507 
20–39 years * < LOD 4.40 (<LOD-5.50) 21.1 (13.7-32.2) 276 
40–59 years 6.06 (5.00-7.34) < LOD 5.10 (4.00-6.44) 21.3 (13.4-39.9) 213 
60 years and older * < LOD 4.07 (<LOD-5.05) 16.9 (12.9-22.8) 193 
Males 
Total, 6 years and older 6.25 (5.48-7.14) < LOD 5.18 (4.20-6.50) 26.2 (19.1-32.9) 676 
6–11 years 8.16 (6.20-10.8) < LOD 8.53 (4.83-12.8) 29.5 (20.3-48.7) 112 
12–19 years 7.31 (6.40-8.35) < LOD 6.50 (5.50-7.67) 31.0 (19.7-48.6) 256 
20–39 years * < LOD 4.20 (<LOD-5.49) 20.5 (13.7-32.1) 117 
40–59 years 6.91 (5.13-9.30) < LOD† 6.50 (3.86-9.48) 22.1† (14.0-42.4) 98 
60 years and older * < LOD† 4.14 (<LOD-5.51) 14.8† (9.20-22.8) 93 
Females 
Total, 6 years and older 6.07 (5.49-6.71) < LOD 5.36 (4.30-6.00) 22.3 (19.1-29.0) 729 
6–11 years 7.25 (5.56-9.44) < LOD† 6.30 (4.96-8.20) 28.6† (18.8-76.3) 104 
12–19 years 8.20 (7.23-9.30) < LOD 7.56 (5.84-8.90) 37.2 (21.3-56.4) 251 
20–39 years 5.51 (4.44-6.85) < LOD 4.99 (3.30-6.60) 16.9 (12.3-35.4) 159 
40–59 years 5.32 (4.29-6.59) < LOD 4.50 (3.50-5.42) 17.3 (10.1-32.7) 115 
60 years and older * < LOD† 3.88 (<LOD-6.08) 19.0† (8.30-160) 100 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
* Not calculated. Proportion of results below limit of detection was too high to provide a valid result. 
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Table 5.3.c. Urinary equol: Non-Hispanic blacks 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic blacks in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 6.89 (6.04-7.86) < LOD 6.09 (4.86-7.50) 28.8 (23.3-34.4) 1196 
6–11 years 8.83 (7.19-10.8) < LOD 9.90 (5.70-13.6) 31.0 (23.5-44.0) 223 
12–19 years 9.45 (8.03-11.1) < LOD 9.90 (7.77-12.0) 40.4 (29.9-51.0) 424 
20–39 years 6.93 (5.62-8.55) < LOD 5.90 (4.40-7.80) 29.6 (21.4-41.4) 178 
40–59 years 6.12 (5.16-7.26) < LOD 5.00 (3.60-7.43) 24.4 (19.4-30.2) 199 
60 years and older * < LOD < LOD 18.9 (11.6-27.6) 172 
Males 
Total, 6 years and older 7.68 (6.62-8.92) < LOD 6.90 (5.10-8.50) 31.4 (26.1-39.8) 588 
6–11 years 9.56 (7.44-12.3) < LOD 9.90 (5.49-13.6) 34.4 (30.2-79.5) 120 
12–19 years 9.68 (7.99-11.7) < LOD 10.6 (6.90-13.6) 40.8 (28.4-51.6) 201 
20–39 years 7.64 (5.88-9.92) < LOD† 5.47 (4.20-9.71) 35.6† (21.5-89.9) 80 
40–59 years 7.30 (6.02-8.84) < LOD† 7.40 (5.05-9.00) 26.0† (19.8-35.3) 104 
60 years and older * < LOD† < LOD 18.9† (7.60-32.0) 83 
Females 
Total, 6 years and older 6.28 (5.36-7.36) < LOD 5.44 (3.70-7.13) 26.2 (18.9-35.4) 608 
6–11 years 8.00 (6.05-10.6) < LOD† 9.48 (4.10-14.7) 26.2† (19.8-31.8) 103 
12–19 years 9.22 (7.50-11.3) < LOD 9.60 (7.20-11.6) 40.8 (29.9-73.4) 223 
20–39 years 6.44 (4.84-8.57) < LOD† 6.17 (3.50-8.30) 22.9† (14.3-43.4) 98 
40–59 years * < LOD† 3.80 (<LOD-6.99) 21.2† (13.4-34.1) 95 
60 years and older * < LOD† < LOD 20.7† (10.5-43.8) 89 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
* Not calculated. Proportion of results below limit of detection was too high to provide a valid result. 
Table 5.3.d. Urinary equol: Non-Hispanic whites 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic whites in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 9.62 (8.32-11.1) < LOD 9.49 (7.73-11.2) 41.3 (35.0-48.9) 1955 
6–11 years 13.7 (10.7-17.6) < LOD 15.2 (11.1-19.4) 53.3 (38.5-68.1) 179 
12–19 years 11.3 (9.28-13.7) < LOD 11.7 (9.74-13.6) 45.5 (36.9-58.8) 350 
20–39 years 9.66 (7.87-11.9) < LOD 9.80 (7.63-12.4) 39.0 (29.2-55.1) 486 
40–59 years 9.34 (7.68-11.4) < LOD 9.00 (6.50-10.8) 41.7 (31.7-60.7) 415 
60 years and older 7.92 (6.81-9.21) < LOD 7.30 (5.58-9.40) 34.5 (27.9-41.7) 525 
Males 
Total, 6 years and older 10.1 (8.58-11.8) < LOD 9.86 (8.00-12.2) 44.0 (35.1-53.8) 965 
6–11 years 14.6 (10.1-21.2) < LOD† 15.2 (8.00-26.3) 59.0† (45.9-85.4) 95 
12–19 years 11.1 (8.64-14.4) < LOD 10.9 (7.90-15.2) 48.1 (36.9-81.5) 179 
20–39 years 9.81 (7.97-12.1) < LOD 9.18 (7.60-12.3) 38.6 (29.5-57.5) 214 
40–59 years 9.51 (7.58-11.9) < LOD 9.82 (6.70-12.5) 39.7 (27.4-53.8) 213 
60 years and older 8.91 (7.00-11.3) < LOD 7.51 (5.52-12.4) 36.8 (30.1-46.7) 264 
Females 
Total, 6 years and older 9.22 (7.83-10.8) < LOD 9.00 (7.40-11.1) 39.7 (34.1-45.8) 990 
6–11 years 12.7 (9.69-16.7) < LOD† 15.1 (11.7-19.4) 36.3† (28.6-53.3) 84 
12–19 years 11.4 (9.19-14.1) < LOD 12.1 (9.90-14.1) 39.4 (25.1-61.5) 171 
20–39 years 9.51 (7.30-12.4) < LOD 10.0 (7.11-13.3) 39.0 (26.2-55.1) 272 
40–59 years 9.18 (6.95-12.1) < LOD 7.80 (5.04-9.80) 42.1 (33.3-93.9) 202 
60 years and older 7.21 (6.46-8.06) < LOD 7.26 (4.97-8.67) 28.5 (22.1-38.4) 261 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.3.e. Urinary equol: Total population (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for the total U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 8.22 (7.38-9.17) < LOD 7.98 (7.07-9.04) 35.1 (30.3-39.5) 4976 
6–11 years 12.4 (10.5-14.7) < LOD 12.5 (10.3-16.0) 45.6 (33.6-62.8) 668 
12–19 years 7.68 (6.80-8.67) < LOD 7.82 (6.91-8.70) 30.3 (24.3-39.1) 1401 
20–39 years 6.90 (6.03-7.89) < LOD 6.68 (5.68-7.53) 30.3 (25.0-36.3) 1043 
40–59 years 8.40 (7.25-9.73) < LOD 7.88 (6.66-9.16) 37.3 (29.6-46.3) 909 
60 years and older 9.02 (7.98-10.2) < LOD 8.94 (7.32-10.2) 37.8 (27.8-42.4) 955 
Males 
Total, 6 years and older 7.39 (6.53-8.36) < LOD 7.38 (6.30-8.42) 31.1 (27.0-37.8) 2417 
6–11 years 13.3 (10.4-16.9) < LOD 12.7 (8.51-17.5) 48.1 (33.8-93.3) 347 
12–19 years 7.55 (6.50-8.77) < LOD 7.63 (6.45-8.89) 32.2 (25.9-45.3) 690 
20–39 years 5.95 (5.04-7.03) < LOD 5.59 (4.93-6.42) 25.0 (19.7-32.9) 454 
40–59 years 7.30 (6.20-8.59) < LOD 7.53 (6.06-8.81) 27.7 (22.4-39.5) 454 
60 years and older 7.69 (6.43-9.20) < LOD 7.36 (5.50-9.92) 27.9 (22.3-42.4) 472 
Females 
Total, 6 years and older 9.10 (8.09-10.2) < LOD 8.71 (7.60-9.84) 37.8 (32.9-42.5) 2559 
6–11 years 11.5 (9.40-14.0) < LOD 12.3 (10.3-16.3) 37.5 (29.0-50.0) 321 
12–19 years 7.82 (6.72-9.10) < LOD 8.02 (6.97-9.00) 27.0 (23.3-31.7) 711 
20–39 years 7.97 (6.78-9.36) < LOD 7.61 (6.23-9.54) 32.9 (25.6-41.3) 589 
40–59 years 9.57 (7.81-11.7) < LOD 8.63 (6.66-10.0) 46.3 (36.4-67.7) 455 
60 years and older 10.2 (9.23-11.3) < LOD 9.64 (8.27-10.6) 38.8 (27.8-44.8) 483 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
Table 5.3.f. Urinary equol: Mexican Americans (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for Mexican Americans 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 5.77 (5.28-6.31) < LOD 5.68 (4.95-6.39) 26.3 (22.3-28.8) 1405 
6–11 years 9.84 (8.15-11.9) < LOD 9.32 (7.52-11.9) 37.1 (27.6-47.8) 216 
12–19 years 6.19 (5.75-6.65) < LOD 6.02 (5.42-6.85) 23.4 (19.2-30.2) 507 
20–39 years * < LOD 4.46 (<LOD-5.96) 18.9 (15.2-23.6) 276 
40–59 years 6.12 (5.11-7.34) < LOD 5.68 (4.55-7.16) 27.6 (18.7-32.6) 213 
60 years and older * < LOD 5.16 (<LOD-7.14) 21.8 (16.2-33.3) 193 
Males 
Total, 6 years and older 5.24 (4.74-5.79) < LOD 5.05 (4.19-6.31) 21.2 (17.9-24.6) 676 
6–11 years 9.88 (7.79-12.5) < LOD 10.0 (7.61-13.4) 31.4 (22.3-46.6) 112 
12–19 years 5.60 (4.95-6.34) < LOD 5.92 (4.60-6.66) 22.8 (16.2-28.6) 256 
20–39 years * < LOD 3.66 (<LOD-5.72) 15.2 (10.7-19.9) 117 
40–59 years 5.84 (4.35-7.84) < LOD† 5.46 (3.86-7.32) 27.6† (14.9-36.3) 98 
60 years and older * < LOD† 3.76 (<LOD-5.42) 14.7† (7.75-34.2) 93 
Females 
Total, 6 years and older 6.40 (5.66-7.24) < LOD 5.99 (5.19-6.97) 29.2 (25.3-35.3) 729 
6–11 years 9.80 (7.76-12.4) < LOD† 9.00 (6.55-11.4) 43.1† (27.9-106) 104 
12–19 years 6.89 (6.07-7.82) < LOD 6.06 (5.10-7.73) 25.2 (19.1-39.0) 251 
20–39 years 5.13 (4.19-6.30) < LOD 5.17 (3.54-6.64) 24.0 (15.7-39.6) 159 
40–59 years 6.42 (4.80-8.60) < LOD 5.68 (4.55-8.65) 27.9 (18.7-41.1) 115 
60 years and older * < LOD† 6.77 (<LOD-8.26) 25.9† (16.9-51.7) 100 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
* Not calculated. Proportion of results below limit of detection was too high to provide a valid result. 
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Table 5.3.g. Urinary equol: Non-Hispanic blacks (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic blacks 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 4.68 (4.10-5.34) < LOD 4.48 (3.70-5.41) 19.1 (16.5-23.3) 1196 
6–11 years 8.21 (6.66-10.1) < LOD 8.40 (6.92-10.6) 33.6 (20.5-45.4) 223 
12–19 years 5.35 (4.55-6.28) < LOD 5.46 (4.72-6.49) 21.0 (17.2-28.1) 424 
20–39 years 4.02 (3.23-4.99) < LOD 3.56 (2.85-4.96) 15.8 (13.0-23.1) 178 
40–59 years 4.09 (3.31-5.05) < LOD 3.64 (2.99-5.00) 17.1 (11.9-22.7) 199 
60 years and older * < LOD < LOD 18.8 (12.3-25.7) 172 
Males 
Total, 6 years and older 4.66 (3.95-5.50) < LOD 4.48 (3.48-5.49) 19.5 (16.9-25.2) 588 
6–11 years 8.62 (6.68-11.1) < LOD 8.38 (6.11-12.2) 38.3 (25.6-48.1) 120 
12–19 years 5.27 (4.27-6.52) < LOD 5.49 (4.76-7.37) 20.2 (14.0-33.9) 201 
20–39 years 3.82 (2.78-5.23) < LOD† 3.47 (1.97-4.57) 15.8† (10.5-35.3) 80 
40–59 years 4.32 (3.51-5.30) < LOD† 4.07 (3.28-5.42) 17.3† (11.6-27.0) 104 
60 years and older * < LOD† < LOD 12.3† (9.13-22.5) 83 
Females 
Total, 6 years and older 4.69 (4.05-5.45) < LOD 4.48 (3.56-5.75) 18.6 (15.0-24.5) 608 
6–11 years 7.74 (5.98-10.0) < LOD† 8.63 (6.25-10.9) 26.2† (17.1-43.8) 103 
12–19 years 5.42 (4.46-6.59) < LOD 5.44 (4.15-6.94) 24.2 (17.0-32.1) 223 
20–39 years 4.18 (3.16-5.53) < LOD† 3.76 (2.72-5.93) 15.0† (12.3-23.1) 98 
40–59 years * < LOD† 3.05 (<LOD-5.74) 17.1† (9.11-38.0) 95 
60 years and older * < LOD† < LOD 21.2† (12.5-31.3) 89 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
* Not calculated. Proportion of results below limit of detection was too high to provide a valid result. 
Table 5.3.h. Urinary equol: Non-Hispanic whites (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic whites 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 9.61 (8.36-11.0) < LOD 9.30 (7.93-10.6) 38.7 (32.7-46.3) 1955 
6–11 years 14.6 (11.3-18.8) < LOD 15.1 (11.4-21.4) 51.5 (33.8-99.8) 179 
12–19 years 8.77 (7.38-10.4) < LOD 8.89 (7.38-10.2) 31.9 (25.8-47.4) 350 
20–39 years 8.46 (7.10-10.1) < LOD 8.57 (6.85-10.3) 32.9 (28.0-41.4) 486 
40–59 years 9.78 (8.16-11.7) < LOD 8.78 (7.22-10.4) 44.5 (32.3-55.9) 415 
60 years and older 9.85 (8.61-11.3) < LOD 10.0 (8.48-11.6) 38.0 (27.8-42.8) 525 
Males 
Total, 6 years and older 8.44 (7.22-9.86) < LOD 8.48 (7.07-9.94) 35.8 (28.8-43.3) 965 
6–11 years 15.9 (11.1-22.8) < LOD† 15.8 (8.10-27.0) 64.3† (37.4-120) 95 
12–19 years 8.63 (6.94-10.7) < LOD 8.51 (7.06-10.2) 37.3 (26.8-64.3) 179 
20–39 years 7.22 (5.89-8.86) < LOD 7.02 (5.59-9.20) 28.8 (20.5-37.8) 214 
40–59 years 7.97 (6.53-9.72) < LOD 7.97 (6.66-9.70) 30.2 (22.7-42.3) 213 
60 years and older 8.49 (6.91-10.4) < LOD 8.71 (5.85-12.3) 28.9 (22.3-42.8) 264 
Females 
Total, 6 years and older 10.9 (9.38-12.7) < LOD 10.2 (8.63-12.3) 41.8 (36.4-50.0) 990 
6–11 years 13.2 (9.56-18.1) < LOD† 14.7 (11.6-20.7) 43.3† (28.8-60.7) 84 
12–19 years 8.94 (7.23-11.1) < LOD 9.00 (7.33-11.5) 26.0 (21.5-41.7) 171 
20–39 years 9.92 (8.12-12.1) < LOD 9.54 (7.50-12.7) 36.4 (28.0-55.9) 272 
40–59 years 11.9 (9.14-15.5) < LOD 9.71 (7.33-12.5) 65.3 (37.7-94.0) 202 
60 years and older 11.1 (9.88-12.4) < LOD 10.3 (9.38-12.0) 41.0 (27.8-53.2) 261 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.4.a. Urinary O-desmethylangolensin: Total population 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for the total U.S. population aged 
6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 4.18 (3.65-4.78) < LOD 4.00 (3.40-4.74) 98.7 (75.9-122) 5065 
6–11 years 5.97 (4.69-7.59) < LOD 6.50 (4.63-9.68) 105 (59.6-176) 683 
12–19 years 5.87 (4.59-7.50) < LOD 6.47 (4.47-8.60) 122 (99.0-152) 1411 
20–39 years 3.59 (2.91-4.43) < LOD 3.03 (2.50-4.10) 121 (70.1-189) 1085 
40–59 years 4.67 (3.64-5.98) < LOD 4.30 (3.20-5.50) 111 (66.1-160) 896 
60 years and older 2.94 (2.39-3.62) < LOD 3.01 (1.90-4.12) 63.9 (40.3-73.7) 990 
Males 
Total, 6 years and older 4.24 (3.58-5.01) < LOD 4.22 (3.50-5.29) 102 (74.2-137) 2462 
6–11 years 6.61 (4.59-9.51) < LOD 8.40 (3.96-11.3) 121 (52.7-235) 345 
12–19 years 6.19 (4.51-8.50) < LOD 7.00 (4.22-10.6) 105 (74.1-148) 690 
20–39 years 3.44 (2.53-4.66) < LOD 3.00 (2.00-4.47) 135 (53.9-259) 474 
40–59 years 4.49 (3.45-5.86) < LOD 4.50 (2.80-6.30) 108 (57.3-160) 455 
60 years and older 3.18 (2.56-3.95) < LOD 3.60 (2.43-5.57) 58.4 (36.3-85.2) 498 
Females 
Total, 6 years and older 4.12 (3.55-4.79) < LOD 3.90 (3.00-4.56) 93.3 (70.9-128) 2603 
6–11 years 5.38 (4.06-7.12) < LOD 5.10 (3.43-8.80) 88.5 (59.2-161) 338 
12–19 years 5.56 (4.09-7.55) < LOD 5.69 (3.63-7.80) 137 (85.6-195) 721 
20–39 years 3.75 (2.85-4.95) < LOD 3.11 (2.40-4.90) 94.8 (57.2-228) 611 
40–59 years 4.84 (3.43-6.82) < LOD 4.10 (2.83-5.51) 125 (64.9-233) 441 
60 years and older 2.77 (2.05-3.73) < LOD 2.40 (1.50-4.00) 68.0 (33.8-81.6) 492 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
Table 5.4.b. Urinary O-desmethylangolensin: Mexican Americans 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for Mexican Americans in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 2.43 (1.78-3.34) < LOD 1.80 (1.00-2.84) 86.0 (59.7-105) 1400 
6–11 years 3.17 (2.23-4.49) < LOD 2.84 (1.70-4.04) 61.5 (36.8-129) 212 
12–19 years 3.07 (2.35-4.01) < LOD 2.49 (1.83-3.50) 98.0 (65.2-137) 508 
20–39 years * < LOD 1.40 (<LOD-3.40) 87.8 (44.2-129) 282 
40–59 years * < LOD 1.30 (.700-3.60) 95.2 (36.5-191) 209 
60 years and older * < LOD .420 (<LOD-2.40) 25.2 (16.0-37.9) 189 
Males 
Total, 6 years and older 2.70 (1.77-4.13) < LOD 2.10 (.800-4.70) 90.9 (66.4-129) 686 
6–11 years 3.72 (2.29-6.02) < LOD† 3.75 (1.60-8.50) 60.2† (29.3-140) 111 
12–19 years 3.32 (2.53-4.36) < LOD 3.20 (2.00-5.02) 86.5 (61.0-144) 262 
20–39 years * < LOD 1.31 (<LOD-6.54) 97.6 (59.7-189) 122 
40–59 years 2.49 (1.48-4.19) < LOD† 1.30 (.500-4.70) 122† (28.3-237) 100 
60 years and older * < LOD† .420 (<LOD-3.30) 17.0† (8.73-34.6) 91 
Females 
Total, 6 years and older 2.16 (1.63-2.87) < LOD 1.62 (.880-2.50) 70.9 (40.6-90.1) 714 
6–11 years 2.67 (1.88-3.81) < LOD† 2.28 (1.44-3.30) 55.0† (20.3-129) 101 
12–19 years 2.80 (1.86-4.23) < LOD 2.40 (1.25-3.60) 98.0 (48.2-152) 246 
20–39 years * < LOD 1.39 (<LOD-2.83) 57.4 (25.2-88.3) 160 
40–59 years * < LOD† 1.00 (<LOD-5.20) 86.0† (18.6-191) 109 
60 years and older * < LOD† < LOD 33.2† (18.4-150) 98 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
* Not calculated. Proportion of results below limit of detection was too high to provide a valid result. 
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Table 5.4.c. Urinary O-desmethylangolensin: Non-Hispanic blacks 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic blacks in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 5.54 (4.63-6.64) < LOD 6.40 (5.10-7.98) 116 (95.5-155) 1219 
6–11 years 10.6 (7.78-14.5) < LOD 13.4 (9.40-22.5) 226 (157-303) 235 
12–19 years 10.5 (7.71-14.3) < LOD 13.2 (8.40-17.8) 165 (131-238) 424 
20–39 years 4.69 (2.93-7.51) < LOD 5.55 (2.66-9.30) 103 (52.4-161) 187 
40–59 years 4.42 (2.98-6.55) < LOD 4.67 (2.40-8.71) 87.6 (58.0-114) 199 
60 years and older 3.33 (1.97-5.64) < LOD 3.04 (1.20-5.70) 99.1 (33.4-357) 174 
Males 
Total, 6 years and older 6.36 (4.70-8.59) < LOD 7.20 (4.80-10.2) 143 (105-177) 590 
6–11 years 13.2 (8.14-21.3) < LOD 22.5 (10.1-39.1) 250 (158-355) 121 
12–19 years 12.2 (8.73-17.0) < LOD 14.5 (7.90-20.7) 171 (136-394) 194 
20–39 years 5.91 (3.47-10.1) < LOD† 5.93 (2.60-14.3) 128† (52.4-308) 85 
40–59 years 3.78 (2.07-6.90) < LOD† 3.50 (1.10-9.30) 99.4† (31.4-120) 103 
60 years and older 4.09 (2.10-7.93) < LOD† 5.30 (1.18-7.60) 77.4† (33.7-255) 87 
Females 
Total, 6 years and older 4.94 (4.05-6.02) < LOD 5.69 (4.50-7.90) 100 (73.8-128) 629 
6–11 years 8.38 (5.30-13.2) < LOD 10.4 (5.53-13.6) 147 (64.2-281) 114 
12–19 years 9.07 (5.81-14.2) < LOD 11.8 (6.64-20.1) 141 (95.1-201) 230 
20–39 years 3.92 (2.22-6.93) < LOD† 4.98 (1.40-9.40) 79.7† (26.6-191) 102 
40–59 years 5.04 (2.88-8.81) < LOD† 5.30 (2.10-13.3) 81.6† (40.2-313) 96 
60 years and older 2.89 (1.62-5.16) < LOD† 2.70 (.700-5.31) 99.1† (21.0-502) 87 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 5.4.d. Urinary O-desmethylangolensin: Non-Hispanic whites 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic whites in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 4.25 (3.59-5.04) < LOD 3.98 (3.30-4.80) 98.7 (72.8-135) 2021 
6–11 years 5.98 (4.20-8.50) < LOD 6.97 (3.43-11.5) 88.0 (45.0-191) 181 
12–19 years 6.26 (4.47-8.77) < LOD 6.50 (4.00-10.0) 122 (76.9-172) 360 
20–39 years 3.47 (2.58-4.66) < LOD 2.80 (2.03-4.40) 129 (61.0-228) 511 
40–59 years 5.40 (4.03-7.23) < LOD 4.56 (3.31-6.40) 137 (76.4-202) 405 
60 years and older 2.88 (2.23-3.71) < LOD 2.83 (1.71-4.20) 58.4 (30.2-78.0) 564 
Males 
Total, 6 years and older 4.22 (3.44-5.18) < LOD 4.12 (3.31-5.40) 96.8 (65.7-137) 995 
6–11 years 6.33 (3.52-11.4) < LOD† 7.20 (3.30-15.7) 88.0† (43.4-311) 90 
12–19 years 6.27 (4.21-9.32) < LOD 6.50 (3.60-13.5) 103 (61.6-148) 181 
20–39 years 2.95 (1.95-4.48) < LOD 2.51 (1.20-4.47) 96.0 (25.2-260) 223 
40–59 years 5.35 (4.05-7.06) < LOD 5.28 (3.31-8.00) 111 (58.4-178) 213 
60 years and older 3.27 (2.60-4.12) < LOD 3.60 (1.90-6.00) 58.4 (29.9-98.9) 288 
Females 
Total, 6 years and older 4.29 (3.50-5.25) < LOD 3.98 (2.79-4.98) 106 (70.6-154) 1026 
6–11 years 5.63 (3.55-8.95) < LOD† 5.90 (2.70-14.3) 72.2† (30.5-176) 91 
12–19 years 6.26 (3.92-10.0) < LOD 6.40 (3.50-11.7) 166 (58.3-367) 179 
20–39 years 4.05 (2.76-5.94) < LOD 3.80 (2.05-5.71) 135 (51.2-250) 288 
40–59 years 5.46 (3.47-8.59) < LOD 4.30 (2.36-6.40) 154 (64.9-322) 192 
60 years and older 2.59 (1.81-3.72) < LOD 2.10 (1.21-4.05) 59.9 (17.7-85.1) 276 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.4.e. Urinary O-desmethylangolensin: Total population 
(creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for the total U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 3.91 (3.38-4.52) < LOD 3.74 (3.09-4.50) 87.6 (69.8-108) 5065 
6–11 years 6.62 (5.15-8.52) < LOD 6.64 (4.63-10.6) 93.7 (65.0-144) 683 
12–19 years 4.28 (3.25-5.65) < LOD 4.45 (3.22-6.51) 76.5 (61.6-102) 1411 
20–39 years 2.89 (2.33-3.59) < LOD 2.63 (1.96-3.66) 87.8 (50.8-126) 1085 
40–59 years 4.67 (3.70-5.90) < LOD 3.87 (2.73-5.68) 112 (71.8-155) 896 
60 years and older 3.51 (2.81-4.37) < LOD 3.19 (2.12-4.95) 64.7 (50.8-76.0) 990 
Males 
Total, 6 years and older 3.43 (2.85-4.12) < LOD 3.51 (2.56-4.45) 75.2 (58.5-96.5) 2462 
6–11 years 7.12 (4.73-10.7) < LOD 6.80 (3.59-17.0) 97.8 (56.2-233) 345 
12–19 years 4.45 (3.20-6.19) < LOD 4.71 (3.41-8.02) 70.2 (48.8-115) 690 
20–39 years 2.40 (1.73-3.33) < LOD 2.05 (1.38-3.06) 88.9 (34.3-151) 474 
40–59 years 3.76 (2.88-4.92) < LOD 3.66 (2.46-5.76) 80.3 (53.1-118) 455 
60 years and older 2.96 (2.35-3.73) < LOD 2.92 (1.84-4.68) 51.7 (35.4-64.2) 498 
Females 
Total, 6 years and older 4.43 (3.76-5.21) < LOD 3.92 (3.15-5.00) 98.3 (70.3-140) 2603 
6–11 years 6.14 (4.67-8.09) < LOD 6.61 (4.42-10.5) 88.0 (52.7-158) 338 
12–19 years 4.12 (2.97-5.71) < LOD 3.87 (2.50-5.90) 89.5 (61.4-111) 721 
20–39 years 3.45 (2.58-4.61) < LOD 3.62 (2.28-4.64) 86.0 (43.2-155) 611 
40–59 years 5.76 (4.18-7.94) < LOD 3.90 (2.69-7.27) 147 (85.2-280) 441 
60 years and older 4.00 (2.93-5.47) < LOD 3.40 (1.92-6.17) 69.8 (56.9-109) 492 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
Table 5.4.f. Urinary O-desmethylangolensin: Mexican Americans 
(creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for Mexican Americans 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 2.26 (1.70-3.00) < LOD 1.69 (1.12-2.67) 58.8 (48.6-87.8) 1400 
6–11 years 4.11 (3.09-5.47) < LOD 3.69 (2.16-7.00) 79.8 (53.6-114) 212 
12–19 years 2.43 (1.85-3.19) < LOD 2.13 (1.55-3.17) 61.5 (47.4-86.3) 508 
20–39 years * < LOD 1.17 (<LOD-2.67) 56.4 (29.9-103) 282 
40–59 years * < LOD 1.56 (.805-3.55) 58.8 (27.8-145) 209 
60 years and older * < LOD 1.03 (<LOD-2.70) 30.4 (21.4-55.3) 189 
Males 
Total, 6 years and older 2.23 (1.52-3.27) < LOD 1.64 (.932-3.90) 61.4 (48.6-93.0) 686 
6–11 years 4.52 (2.88-7.09) < LOD† 4.87 (1.72-8.95) 93.0† (50.2-145) 111 
12–19 years 2.50 (1.87-3.35) < LOD 2.82 (1.54-4.31) 56.1 (37.2-71.2) 262 
20–39 years * < LOD 1.45 (<LOD-4.56) 60.0 (25.8-113) 122 
40–59 years 2.04 (1.26-3.32) < LOD† 1.42 (.661-4.23) 57.2† (19.6-218) 100 
60 years and older * < LOD† .698 (<LOD-3.02) 23.6† (11.1-33.2) 91 
Females 
Total, 6 years and older 2.30 (1.77-2.99) < LOD 1.69 (1.17-2.08) 57.7 (41.7-87.6) 714 
6–11 years 3.73 (2.62-5.29) < LOD† 2.44 (1.68-7.00) 78.3† (27.1-108) 101 
12–19 years 2.35 (1.57-3.52) < LOD 1.78 (1.10-2.78) 68.3 (45.6-115) 246 
20–39 years * < LOD 1.03 (<LOD-2.15) 41.7 (15.5-87.6) 160 
40–59 years * < LOD† 1.77 (<LOD-3.90) 76.8† (29.1-145) 109 
60 years and older * < LOD† < LOD 55.3† (20.9-970) 98 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
* Not calculated. Proportion of results below limit of detection was too high to provide a valid result. 
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Table 5.4.g. Urinary O-desmethylangolensin: Non-Hispanic blacks 
(creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic blacks 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 3.73 (3.08-4.51) < LOD 4.12 (3.20-5.48) 71.9 (54.7-100) 1219 
6–11 years 9.94 (7.43-13.3) < LOD 10.6 (8.27-18.2) 217 (118-305) 235 
12–19 years 5.88 (4.34-7.98) < LOD 7.25 (4.64-10.2) 95.0 (57.0-142) 424 
20–39 years 2.68 (1.70-4.23) < LOD 3.66 (1.67-5.69) 45.4 (26.8-100) 187 
40–59 years 2.95 (2.07-4.19) < LOD 2.93 (1.61-5.48) 60.4 (36.7-81.9) 199 
60 years and older 3.11 (1.99-4.85) < LOD 2.91 (1.64-4.83) 75.6 (47.2-167) 174 
Males 
Total, 6 years and older 3.84 (2.85-5.19) < LOD 4.45 (2.64-7.30) 79.7 (55.2-118) 590 
6–11 years 12.3 (7.52-20.0) < LOD 18.0 (9.43-32.4) 233 (119-363) 121 
12–19 years 6.63 (4.79-9.18) < LOD 7.65 (4.69-11.1) 109 (59.1-198) 194 
20–39 years 2.87 (1.70-4.84) < LOD† 2.95 (1.28-8.61) 42.9† (23.4-100) 85 
40–59 years 2.27 (1.24-4.17) < LOD† 2.18 (.996-5.61) 67.8† (23.2-84.4) 103 
60 years and older 3.05 (1.64-5.69) < LOD† 2.79 (1.12-5.83) 79.7† (26.3-151) 87 
Females 
Total, 6 years and older 3.63 (2.96-4.46) < LOD 4.05 (3.26-5.22) 64.4 (47.0-90.4) 629 
6–11 years 7.89 (5.57-11.2) < LOD 8.27 (4.80-10.9) 104 (62.9-305) 114 
12–19 years 5.24 (3.35-8.21) < LOD 5.83 (3.15-11.1) 71.9 (47.5-142) 230 
20–39 years 2.54 (1.45-4.46) < LOD† 3.36 (1.42-5.69) 42.1† (22.1-185) 102 
40–59 years 3.67 (2.23-6.04) < LOD† 3.61 (1.61-7.58) 54.4† (34.1-147) 96 
60 years and older 3.14 (1.90-5.19) < LOD† 2.91 (1.31-6.30) 75.6† (23.8-359) 87 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 5.4.h. Urinary O-desmethylangolensin: Non-Hispanic whites 
(creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic whites 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 4.24 (3.55-5.07) < LOD 3.78 (3.05-4.95) 97.4 (71.8-125) 2021 
6–11 years 6.69 (4.67-9.58) < LOD 6.80 (3.78-13.6) 85.2 (47.9-190) 181 
12–19 years 4.79 (3.27-7.03) < LOD 4.70 (3.14-8.91) 83.6 (60.3-125) 360 
20–39 years 3.01 (2.28-3.98) < LOD 2.72 (1.89-3.77) 97.4 (50.8-151) 511 
40–59 years 5.67 (4.36-7.37) < LOD 5.32 (2.96-7.96) 136 (71.8-210) 405 
60 years and older 3.56 (2.74-4.64) < LOD 3.17 (1.83-5.45) 64.5 (45.6-83.0) 564 
Males 
Total, 6 years and older 3.60 (2.89-4.49) < LOD 3.51 (2.54-4.68) 76.4 (54.1-102) 995 
6–11 years 7.20 (3.84-13.5) < LOD† 6.80 (2.85-21.3) 90.2† (39.0-407) 90 
12–19 years 4.85 (3.15-7.46) < LOD 4.71 (3.05-13.5) 62.2 (45.9-125) 181 
20–39 years 2.24 (1.48-3.39) < LOD 1.96 (1.27-3.06) 88.2 (23.5-151) 223 
40–59 years 4.56 (3.50-5.94) < LOD 4.91 (2.73-7.08) 96.5 (43.2-161) 213 
60 years and older 3.12 (2.43-4.01) < LOD 3.17 (1.83-5.10) 49.3 (31.6-76.0) 288 
Females 
Total, 6 years and older 4.97 (4.04-6.10) < LOD 4.15 (3.15-6.03) 120 (72.2-153) 1026 
6–11 years 6.19 (4.04-9.49) < LOD† 6.86 (3.85-13.6) 84.7† (37.9-179) 91 
12–19 years 4.74 (2.93-7.67) < LOD 4.64 (2.43-8.27) 98.9 (61.4-292) 179 
20–39 years 4.01 (2.77-5.79) < LOD 4.01 (2.52-5.73) 97.4 (45.6-165) 288 
40–59 years 7.07 (4.69-10.7) < LOD 5.35 (2.45-10.1) 159 (97.6-421) 192 
60 years and older 3.96 (2.70-5.81) < LOD 2.86 (1.64-6.60) 71.5 (49.1-114) 276 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.5.a. Urinary enterodiol: Total population 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for the total U.S. population aged 
6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 31.1 (28.2-34.3) 4.35 (3.35-5.50) 36.7 (34.2-39.4) 173 (155-189) 5321 
6–11 years 30.2 (25.1-36.5) 5.70 (3.50-7.90) 33.4 (28.3-39.4) 154 (113-219) 723 
12–19 years 32.5 (28.8-36.8) 5.50 (4.40-6.96) 36.8 (31.8-40.7) 165 (134-188) 1488 
20–39 years 31.2 (27.1-35.8) 4.15 (2.50-5.70) 37.6 (34.4-44.2) 170 (140-197) 1139 
40–59 years 31.9 (27.1-37.5) 3.80 (1.72-6.20) 37.7 (33.9-42.6) 191 (167-231) 945 
60 years and older 29.1 (25.5-33.1) 4.20 (2.80-5.50) 33.1 (29.3-37.6) 163 (142-190) 1026 
Males 
Total, 6 years and older 30.3 (26.8-34.2) 3.79 (2.70-5.05) 36.7 (33.2-40.4) 168 (146-187) 2581 
6–11 years 30.1 (24.1-37.6) 5.70 (2.74-9.10) 34.6 (27.0-44.1) 132 (109-162) 366 
12–19 years 28.6 (24.2-33.7) 4.30 (2.70-6.94) 32.7 (27.9-38.0) 140 (111-186) 729 
20–39 years 30.6 (25.9-36.0) 3.60 (2.40-5.13) 37.3 (32.0-46.5) 152 (131-190) 500 
40–59 years 32.7 (26.5-40.4) 3.50 (<LOD-6.66) 40.2 (33.8-48.4) 207 (163-269) 478 
60 years and older 27.0 (22.4-32.7) 3.35 (2.00-4.47) 33.1 (26.5-39.1) 155 (118-197) 508 
Females 
Total, 6 years and older 31.8 (28.9-35.1) 5.01 (3.50-6.40) 37.0 (34.7-39.8) 175 (160-197) 2740 
6–11 years 30.3 (23.2-39.7) 5.85 (2.40-8.53) 33.4 (25.6-40.2) 174 (98.1-279) 357 
12–19 years 37.3 (31.6-44.0) 6.70 (5.01-8.57) 41.7 (34.7-49.8) 171 (148-215) 759 
20–39 years 31.8 (27.3-37.0) 5.30 (1.80-7.40) 38.5 (32.8-45.7) 180 (139-220) 639 
40–59 years 31.1 (25.5-37.9) 3.88 (<LOD-8.50) 36.0 (30.9-41.4) 183 (148-231) 467 
60 years and older 30.7 (26.1-36.2) 5.00 (2.84-7.17) 32.8 (29.3-37.7) 163 (139-209) 518 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
Table 5.5.b. Urinary enterodiol: Mexican Americans 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for Mexican Americans in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 25.8 (23.1-28.8) 2.76 (1.68-4.00) 30.9 (27.5-35.2) 146 (128-169) 1470 
6–11 years 19.4 (16.0-23.6) < LOD 22.3 (18.6-30.2) 120 (92.6-156) 222 
12–19 years 27.2 (22.6-32.8) 3.80 (1.68-5.50) 29.5 (25.4-37.8) 159 (134-213) 533 
20–39 years 28.6 (23.3-35.0) 3.60 (1.60-6.50) 34.3 (26.9-42.4) 143 (110-202) 300 
40–59 years 26.5 (21.5-32.6) 2.38 (<LOD-6.60) 32.4 (26.0-38.7) 173 (141-256) 216 
60 years and older 19.6 (15.3-25.2) 2.13 (<LOD-5.40) 23.8 (20.4-34.6) 92.1 (74.0-143) 199 
Males 
Total, 6 years and older 23.5 (20.0-27.6) 2.04 (<LOD-3.80) 29.5 (23.7-35.0) 137 (105-169) 710 
6–11 years 18.4 (15.3-22.1) < LOD 21.3 (15.1-32.8) 99.2 (79.2-158) 115 
12–19 years 20.9 (16.8-26.0) 1.68 (<LOD-4.53) 24.9 (20.4-29.0) 121 (99.9-159) 269 
20–39 years 26.7 (19.8-36.0) 1.84 (<LOD-6.30) 30.9 (21.3-43.3) 144 (92.5-216) 127 
40–59 years 25.0 (18.6-33.6) 2.36† (<LOD-7.70) 33.0 (19.2-43.3) 115† (75.9-244) 104 
60 years and older 18.4 (12.8-26.4) < LOD† 22.0 (15.7-31.9) 73.1† (43.8-134) 95 
Females 
Total, 6 years and older 28.5 (25.3-32.2) 3.80 (2.21-5.74) 33.4 (28.3-39.0) 168 (141-192) 760 
6–11 years 20.6 (14.6-29.0) 2.01† (<LOD-5.30) 24.2 (16.5-35.3) 120† (92.6-219) 107 
12–19 years 36.2 (29.2-45.0) 5.20 (3.90-9.21) 38.5 (29.3-51.0) 197 (152-282) 264 
20–39 years 31.0 (24.7-38.9) 5.83 (<LOD-9.20) 36.0 (26.9-48.1) 132 (97.3-187) 173 
40–59 years 28.2 (20.9-38.0) 2.21 (<LOD-7.20) 31.3 (20.0-47.2) 197 (159-279) 112 
60 years and older 20.7 (15.1-28.5) 2.21† (<LOD-5.48) 25.5 (16.8-37.9) 101† (63.9-199) 104 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.5.c. Urinary enterodiol: Non-Hispanic blacks 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic blacks in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 30.4 (26.5-34.9) 4.87 (3.30-6.21) 35.4 (31.4-38.4) 168 (140-181) 1289 
6–11 years 30.7 (26.3-35.9) 6.64 (4.46-8.75) 33.7 (27.5-38.7) 132 (112-167) 249 
12–19 years 34.9 (30.9-39.3) 6.11 (3.56-8.33) 41.6 (36.8-47.6) 162 (132-213) 451 
20–39 years 28.8 (22.0-37.7) 5.80 (<LOD-8.67) 35.3 (26.6-41.7) 167 (115-210) 197 
40–59 years 32.3 (25.6-40.9) 4.54 (2.30-10.3) 33.2 (25.7-44.9) 207 (123-278) 210 
60 years and older 25.7 (19.0-34.9) 2.72 (<LOD-4.33) 32.9 (24.4-40.4) 147 (107-219) 182 
Males 
Total, 6 years and older 25.2 (21.6-29.3) 4.00 (1.80-5.97) 29.9 (25.0-34.3) 124 (104-163) 628 
6–11 years 29.5 (23.2-37.5) 5.80 (3.30-8.75) 35.5 (26.2-44.5) 129 (80.3-167) 127 
12–19 years 30.3 (25.8-35.4) 5.70 (3.01-8.57) 34.6 (25.9-42.1) 140 (119-218) 212 
20–39 years 22.8 (16.3-32.0) < LOD† 27.9 (16.6-35.3) 107† (72.4-214) 91 
40–59 years 25.2 (17.8-35.5) 3.50† (<LOD-10.5) 26.0 (20.0-34.9) 123† (75.8-227) 109 
60 years and older 20.3 (14.8-28.0) < LOD† 29.1 (19.3-38.0) 96.3† (65.0-143) 89 
Females 
Total, 6 years and older 35.8 (29.9-42.9) 5.50 (3.30-8.70) 41.7 (35.4-47.0) 180 (154-237) 661 
6–11 years 32.1 (25.6-40.2) 7.34 (4.00-11.4) 33.7 (27.2-38.8) 137 (92.6-230) 122 
12–19 years 40.2 (33.4-48.4) 6.13 (3.20-12.0) 47.0 (38.7-59.2) 171 (125-247) 239 
20–39 years 34.7 (24.7-48.8) 7.80† (<LOD-10.6) 41.7 (32.5-50.4) 176† (115-237) 106 
40–59 years 40.0 (28.9-55.4) 5.50† (2.30-13.1) 37.8 (25.9-63.7) 250† (144-340) 101 
60 years and older 30.1 (18.5-48.8) 2.80† (<LOD-6.25) 36.3 (22.5-49.2) 172† (123-396) 93 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 5.5.d. Urinary enterodiol: Non-Hispanic whites 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic whites in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 32.4 (29.3-35.8) 4.68 (3.50-5.90) 38.5 (36.0-41.7) 173 (152-195) 2110 
6–11 years 32.5 (24.6-42.8) 5.90 (2.40-10.5) 35.7 (28.1-44.8) 152 (106-253) 196 
12–19 years 32.7 (27.6-38.7) 6.10 (3.97-7.80) 35.4 (29.7-43.8) 162 (127-185) 375 
20–39 years 33.4 (28.3-39.5) 4.70 (2.70-6.10) 43.1 (37.4-47.1) 174 (138-214) 529 
40–59 years 33.2 (27.3-40.4) 3.80 (<LOD-7.40) 40.5 (35.8-46.7) 207 (158-254) 433 
60 years and older 29.6 (25.7-34.1) 4.35 (2.74-6.10) 33.4 (29.7-38.7) 160 (139-190) 577 
Males 
Total, 6 years and older 32.7 (28.6-37.4) 4.20 (2.92-5.56) 40.0 (35.4-44.1) 174 (146-198) 1036 
6–11 years 33.7 (24.0-47.3) 7.55† (<LOD-14.6) 37.8 (25.7-50.9) 135† (103-215) 101 
12–19 years 28.6 (22.9-35.7) 4.30 (2.38-7.80) 32.5 (24.3-40.7) 131 (99.1-174) 190 
20–39 years 33.9 (27.3-42.2) 3.79 (<LOD-5.95) 44.2 (34.9-55.1) 174 (132-226) 231 
40–59 years 35.9 (28.1-46.0) 3.65 (<LOD-7.40) 46.7 (37.8-53.2) 213 (167-263) 224 
60 years and older 28.1 (22.8-34.7) 3.35 (2.00-5.30) 33.2 (26.5-40.0) 163 (120-205) 290 
Females 
Total, 6 years and older 32.1 (29.0-35.6) 5.35 (3.53-6.70) 37.6 (35.0-41.1) 171 (148-209) 1074 
6–11 years 31.2 (20.5-47.7) 5.85† (<LOD-12.2) 34.1 (22.3-50.8) 174† (87.0-327) 95 
12–19 years 38.0 (29.5-48.9) 6.87 (3.97-11.2) 43.5 (29.3-58.0) 170 (144-245) 185 
20–39 years 33.0 (26.9-40.4) 5.70 (1.80-7.60) 41.1 (30.1-47.8) 166 (130-220) 298 
40–59 years 30.8 (24.1-39.4) 4.09 (<LOD-10.4) 36.2 (27.8-42.5) 195 (127-259) 209 
60 years and older 30.8 (25.6-37.2) 5.18 (2.74-7.50) 32.9 (29.2-39.8) 160 (127-209) 287 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.5.e. Urinary enterodiol: Total population (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for the total U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 29.0 (26.5-31.7) 4.17 (3.19-5.13) 33.6 (31.1-36.8) 150 (136-163) 5321 
6–11 years 32.8 (27.6-39.0) 5.61 (3.48-7.95) 36.2 (30.8-42.7) 188 (140-244) 723 
12–19 years 23.5 (21.1-26.3) 4.27 (2.64-5.42) 26.6 (24.1-30.4) 102 (93.2-117) 1488 
20–39 years 25.0 (21.6-28.9) 3.52 (2.52-5.12) 28.2 (25.3-32.7) 124 (108-156) 1139 
40–59 years 32.0 (27.7-36.9) 3.50 (2.54-5.86) 39.1 (33.2-44.8) 162 (140-197) 945 
60 years and older 34.9 (31.1-39.2) 5.13 (4.30-7.13) 41.3 (35.6-46.2) 174 (157-194) 1026 
Males 
Total, 6 years and older 24.3 (21.7-27.4) 3.17 (2.52-4.34) 28.8 (25.2-31.7) 129 (111-152) 2581 
6–11 years 31.8 (25.1-40.2) 4.62 (2.80-8.38) 34.8 (28.3-43.7) 172 (112-244) 366 
12–19 years 20.3 (17.2-23.9) 3.27 (1.98-4.96) 23.9 (20.5-28.1) 94.1 (81.5-111) 729 
20–39 years 21.3 (18.3-24.8) 2.84 (2.15-4.03) 24.6 (21.2-28.1) 111 (96.4-130) 500 
40–59 years 27.2 (22.4-33.0) 3.19 (<LOD-5.80) 31.7 (28.3-41.9) 160 (121-201) 478 
60 years and older 25.5 (20.5-31.7) 2.96 (2.04-4.74) 30.2 (23.8-35.4) 138 (105-179) 508 
Females 
Total, 6 years and older 34.2 (31.2-37.5) 5.26 (4.20-7.08) 39.9 (36.6-43.8) 162 (148-178) 2740 
6–11 years 33.9 (26.8-42.8) 6.64 (3.93-8.55) 37.3 (28.6-50.1) 193 (108-304) 357 
12–19 years 27.5 (24.0-31.5) 5.26 (3.66-7.26) 30.0 (26.2-34.9) 115 (100-132) 759 
20–39 years 29.2 (24.7-34.6) 4.73 (2.54-7.41) 33.5 (28.1-40.6) 141 (108-182) 639 
40–59 years 37.3 (31.0-44.9) 4.11 (<LOD-9.07) 44.6 (39.0-53.0) 165 (140-217) 467 
60 years and older 44.4 (38.2-51.7) 7.53 (5.23-12.3) 51.4 (44.8-58.8) 188 (164-222) 518 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
Table 5.5.f. Urinary enterodiol: Mexican Americans (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for Mexican Americans 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 23.8 (21.5-26.3) 3.21 (2.34-4.32) 27.6 (25.2-30.2) 134 (116-158) 1470 
6–11 years 24.8 (20.1-30.6) < LOD 32.4 (23.9-40.2) 140 (105-182) 222 
12–19 years 21.7 (18.2-25.7) 3.35 (1.53-5.17) 23.9 (19.0-30.4) 115 (99.3-134) 533 
20–39 years 23.6 (19.5-28.6) 2.78 (1.62-5.36) 27.1 (22.4-30.1) 127 (91.4-181) 300 
40–59 years 26.0 (21.3-31.6) 4.20 (<LOD-6.80) 30.6 (21.5-42.2) 157 (126-192) 216 
60 years and older 22.7 (17.8-28.9) 2.26 (<LOD-7.79) 31.3 (25.7-38.1) 110 (80.0-149) 199 
Males 
Total, 6 years and older 19.4 (16.9-22.2) 2.48 (<LOD-4.32) 21.9 (18.9-26.1) 117 (87.5-141) 710 
6–11 years 21.9 (17.5-27.5) < LOD 26.9 (19.9-39.3) 129 (83.7-188) 115 
12–19 years 15.9 (12.6-20.2) 1.99 (<LOD-3.66) 18.3 (15.2-22.5) 85.9 (73.8-115) 269 
20–39 years 19.6 (14.9-25.9) 2.34 (<LOD-5.83) 20.0 (15.7-27.8) 117 (82.1-179) 127 
40–59 years 20.9 (15.9-27.5) 4.92† (<LOD-6.91) 23.5 (13.6-36.6) 120† (59.6-192) 104 
60 years and older 17.5 (12.0-25.7) < LOD† 22.7 (17.0-36.2) 74.3† (49.3-179) 95 
Females 
Total, 6 years and older 29.8 (26.5-33.6) 4.68 (2.71-7.01) 34.4 (29.6-38.8) 154 (127-193) 760 
6–11 years 28.1 (20.5-38.7) 2.82† (<LOD-6.25) 37.3 (25.1-48.1) 144† (98.7-279) 107 
12–19 years 30.3 (25.3-36.3) 6.40 (3.13-9.44) 31.6 (24.0-43.4) 156 (112-195) 264 
20–39 years 29.3 (23.8-36.0) 5.23 (<LOD-9.41) 31.0 (27.1-38.8) 133 (93.6-193) 173 
40–59 years 32.7 (24.9-43.0) 4.56 (<LOD-10.1) 44.8 (27.0-59.4) 183 (141-235) 112 
60 years and older 28.2 (20.3-39.3) 3.80† (<LOD-8.93) 34.5 (28.6-42.2) 130† (78.9-213) 104 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.5.g. Urinary enterodiol: Non-Hispanic blacks (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic blacks 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 20.5 (17.5-24.0) 3.30 (2.47-4.03) 23.3 (19.7-26.6) 118 (97.4-138) 1289 
6–11 years 28.7 (24.0-34.4) 5.03 (4.02-7.59) 31.1 (26.1-38.8) 126 (95.2-168) 249 
12–19 years 19.6 (17.2-22.3) 3.48 (2.11-4.47) 23.5 (19.7-27.2) 86.8 (72.7-116) 451 
20–39 years 16.4 (12.2-22.0) 2.15 (<LOD-4.41) 19.3 (14.1-23.8) 96.0 (68.6-128) 197 
40–59 years 21.8 (16.9-28.2) 3.57 (2.35-5.11) 23.3 (16.2-31.4) 145 (94.5-187) 210 
60 years and older 24.2 (17.8-32.8) 2.94 (<LOD-5.25) 27.0 (22.7-38.6) 146 (88.0-241) 182 
Males 
Total, 6 years and older 15.2 (12.9-18.0) 2.40 (1.44-3.12) 18.0 (14.6-21.0) 84.6 (65.9-108) 628 
6–11 years 27.3 (20.5-36.4) 4.14 (2.52-9.49) 30.8 (25.6-42.5) 106 (77.7-168) 127 
12–19 years 16.5 (14.0-19.5) 2.23 (1.22-4.05) 20.0 (15.1-24.3) 82.9 (61.4-103) 212 
20–39 years 11.1 (7.62-16.1) < LOD† 12.9 (10.3-18.0) 70.4† (30.6-154) 91 
40–59 years 15.3 (11.1-21.3) 2.65† (<LOD-5.24) 15.9 (12.8-21.0) 72.6† (41.9-155) 109 
60 years and older 15.1 (11.2-20.4) < LOD† 24.0 (13.9-30.2) 66.1† (45.5-97.2) 89 
Females 
Total, 6 years and older 26.5 (21.6-32.5) 4.41 (3.40-5.50) 30.1 (23.5-37.7) 138 (112-180) 661 
6–11 years 30.3 (24.4-37.7) 6.64 (4.20-8.88) 33.8 (23.2-41.8) 134 (93.9-209) 122 
12–19 years 23.2 (19.3-28.0) 3.96 (2.30-6.55) 26.2 (22.6-30.0) 106 (71.7-145) 239 
20–39 years 22.4 (15.8-31.8) 4.87† (<LOD-7.83) 26.6 (18.2-41.9) 99.4† (68.6-138) 106 
40–59 years 29.4 (20.0-43.3) 4.32† (2.35-8.07) 34.8 (22.6-48.1) 158† (118-321) 101 
60 years and older 33.0 (20.2-53.7) 3.35† (<LOD-9.66) 33.3 (22.7-54.5) 229† (123-590) 93 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 5.5.h. Urinary enterodiol: Non-Hispanic whites (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic whites 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 32.3 (29.5-35.3) 5.15 (3.94-6.23) 37.4 (33.7-41.4) 158 (140-174) 2110 
6–11 years 35.3 (27.5-45.2) 6.62 (3.23-9.63) 40.3 (29.4-50.4) 188 (132-281) 196 
12–19 years 24.8 (21.2-29.0) 5.02 (2.36-7.01) 28.1 (24.3-33.6) 99.5 (91.3-121) 375 
20–39 years 29.1 (24.9-34.2) 4.84 (2.92-6.99) 31.3 (27.2-37.6) 140 (109-182) 529 
40–59 years 34.9 (29.3-41.5) 3.68 (<LOD-7.14) 43.4 (37.7-52.9) 165 (135-208) 433 
60 years and older 37.0 (32.4-42.2) 5.89 (4.17-7.67) 44.0 (36.7-50.3) 179 (155-209) 577 
Males 
Total, 6 years and older 27.7 (24.5-31.3) 3.53 (2.80-5.38) 31.9 (28.0-36.9) 138 (114-170) 1036 
6–11 years 37.0 (25.9-52.8) 6.62† (<LOD-14.2) 42.2 (21.7-60.2) 202† (105-290) 101 
12–19 years 21.7 (17.2-27.5) 4.74 (1.98-6.23) 24.7 (20.8-33.1) 94.1 (71.7-119) 190 
20–39 years 25.8 (21.2-31.4) 3.41 (<LOD-6.26) 28.0 (24.0-34.9) 121 (100-167) 231 
40–59 years 30.2 (24.4-37.5) 3.13 (<LOD-6.83) 38.0 (30.0-51.0) 160 (114-216) 224 
60 years and older 27.0 (21.1-34.5) 3.19 (2.17-5.13) 31.1 (23.8-40.0) 138 (104-189) 290 
Females 
Total, 6 years and older 37.4 (34.2-40.9) 7.08 (4.81-7.92) 43.1 (38.7-48.7) 168 (151-196) 1074 
6–11 years 33.4 (23.1-48.3) 6.28† (<LOD-10.0) 35.5 (27.5-60.6) 150† (87.0-325) 95 
12–19 years 28.7 (23.3-35.3) 6.14 (3.02-7.64) 32.1 (26.2-38.8) 112 (90.2-146) 185 
20–39 years 32.8 (27.1-39.8) 6.46 (3.12-10.7) 34.9 (27.8-47.5) 166 (107-235) 298 
40–59 years 40.1 (32.3-49.8) 6.00 (<LOD-14.4) 48.7 (39.0-58.5) 165 (129-224) 209 
60 years and older 47.2 (39.4-56.7) 8.54 (6.23-14.9) 53.0 (46.4-65.3) 189 (157-225) 287 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.6.a. Urinary enterolactone: Total population 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for the total U.S. population aged 
6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 249 (227-273) 23.6 (19.6-29.5) 330 (303-370) 1710 (1500-1960) 5342 
6–11 years 297 (251-352) 55.1 (41.1-73.7) 340 (288-412) 1420 (1250-2050) 727 
12–19 years 256 (223-294) 31.5 (22.1-48.0) 317 (266-377) 1560 (1250-1900) 1490 
20–39 years 237 (203-276) 20.3 (13.0-28.0) 317 (255-380) 1850 (1420-2320) 1139 
40–59 years 231 (190-280) 15.9 (11.0-25.3) 334 (272-399) 1810 (1510-2240) 951 
60 years and older 276 (245-311) 32.9 (17.9-50.3) 362 (303-417) 1680 (1330-2170) 1035 
Males 
Total, 6 years and older 258 (234-285) 21.7 (17.5-25.3) 349 (310-389) 1890 (1600-2280) 2594 
6–11 years 322 (267-387) 55.3 (35.8-102) 363 (309-456) 1380 (1120-1810) 368 
12–19 years 246 (212-287) 29.6 (19.4-41.7) 318 (252-391) 1560 (1250-1820) 733 
20–39 years 249 (208-299) 19.2 (11.2-30.9) 337 (258-389) 2050 (1650-2540) 500 
40–59 years 246 (194-312) 16.6 (12.7-25.3) 360 (278-438) 1940 (1580-2530) 480 
60 years and older 274 (228-330) 19.9 (12.9-43.2) 361 (291-458) 1790 (1410-2470) 513 
Females 
Total, 6 years and older 241 (215-270) 25.9 (18.1-38.7) 321 (281-359) 1500 (1300-1810) 2748 
6–11 years 273 (203-368) 55.5 (24.0-83.6) 325 (236-420) 1520 (847-2280) 359 
12–19 years 267 (218-326) 37.2 (20.1-59.1) 314 (259-383) 1500 (1040-2130) 757 
20–39 years 225 (181-279) 21.4 (9.30-38.4) 312 (239-381) 1450 (991-2000) 639 
40–59 years 217 (164-288) 15.8 (7.30-44.9) 311 (227-399) 1510 (1180-1810) 471 
60 years and older 277 (231-333) 43.4 (18.9-66.5) 362 (282-419) 1490 (1190-2140) 522 
Table 5.6.b. Urinary enterolactone: Mexican Americans 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for Mexican Americans in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 236 (198-280) 32.0 (17.7-40.2) 316 (266-354) 1550 (1230-1890) 1492 
6–11 years 209 (155-282) 31.4 (17.7-50.6) 265 (192-375) 913 (796-1420) 226 
12–19 years 272 (238-312) 36.6 (29.5-61.7) 314 (253-370) 1650 (1350-1990) 538 
20–39 years 262 (203-340) 34.5 (8.76-49.8) 346 (280-424) 1840 (1280-2620) 300 
40–59 years 192 (149-249) 12.9 (8.00-35.8) 245 (200-347) 1390 (929-2060) 221 
60 years and older 197 (137-285) 23.0 (6.66-50.5) 296 (180-415) 967 (825-1490) 207 
Males 
Total, 6 years and older 253 (200-320) 32.7 (15.7-46.3) 346 (266-416) 1640 (1000-2380) 722 
6–11 years 236 (170-328) 35.1 (24.7-55.1) 316 (171-476) 972 (815-1800) 117 
12–19 years 236 (210-266) 34.3 (21.7-55.3) 293 (210-357) 1510 (950-1900) 274 
20–39 years 317 (225-446) 39.6 (6.81-79.5) 455 (280-628) 2380 (1280-3560) 127 
40–59 years 166 (104-265) 10.4† (4.10-38.8) 238 (148-389) 1030† (647-2120) 105 
60 years and older 266 (176-402) 37.2† (6.66-99.7) 374 (248-488) 967† (679-2570) 99 
Females 
Total, 6 years and older 218 (167-285) 30.2 (11.9-53.2) 279 (228-344) 1380 (980-1840) 770 
6–11 years 184 (106-319) 16.8† (<LOD-80.4) 236 (170-375) 847† (745-1550) 109 
12–19 years 319 (241-422) 56.1 (19.5-105) 352 (258-473) 1710 (1290-2530) 264 
20–39 years 209 (134-328) 17.3 (2.91-77.7) 308 (183-414) 1100 (790-2580) 173 
40–59 years 224 (159-316) 19.1 (3.44-58.0) 245 (193-392) 1480 (980-2200) 116 
60 years and older 154 (96.7-246) 11.3† (<LOD-43.0) 231 (148-322) 920† (524-1490) 108 
< LOD means less than the limit of detection, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.6.c. Urinary enterolactone: Non-Hispanic blacks 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic blacks in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 272 (230-322) 26.3 (17.6-43.6) 392 (339-441) 1500 (1270-1890) 1286 
6–11 years 369 (297-457) 75.1 (41.0-99.1) 470 (391-521) 1520 (1220-2160) 249 
12–19 years 351 (315-391) 53.9 (34.8-87.3) 428 (385-479) 1850 (1450-2340) 448 
20–39 years 239 (167-344) 12.0 (5.40-49.4) 342 (248-504) 1680 (993-2300) 197 
40–59 years 254 (202-320) 23.1 (14.5-45.9) 366 (283-479) 1350 (1050-1920) 210 
60 years and older 237 (179-312) 15.2 (7.90-44.9) 399 (296-502) 1270 (1020-1960) 182 
Males 
Total, 6 years and older 266 (215-329) 20.9 (12.0-36.5) 416 (339-497) 1630 (1250-2080) 627 
6–11 years 362 (304-430) 65.4 (21.5-107) 487 (341-524) 1370 (1070-1720) 127 
12–19 years 330 (266-409) 38.6 (26.3-77.1) 422 (363-484) 1770 (1360-2440) 211 
20–39 years 261 (163-417) 17.7† (4.49-116) 416 (260-596) 1670† (1000-2500) 91 
40–59 years 235 (160-345) 16.6† (4.20-34.6) 401 (184-559) 1350† (741-2580) 109 
60 years and older 183 (119-281) 6.00† (3.30-19.5) 267 (155-488) 1290† (1000-1980) 89 
Females 
Total, 6 years and older 278 (235-327) 39.1 (18.9-53.2) 360 (314-427) 1500 (1190-1870) 659 
6–11 years 376 (259-547) 75.8 (28.7-130) 416 (299-664) 1740 (1050-2410) 122 
12–19 years 374 (325-431) 87.3 (39.1-136) 441 (378-521) 1870 (1320-2260) 237 
20–39 years 224 (152-330) 9.10† (3.10-49.7) 314 (219-499) 1500† (854-2140) 106 
40–59 years 272 (218-340) 43.4† (15.2-71.6) 358 (246-469) 1270† (842-1540) 101 
60 years and older 281 (197-401) 32.6† (9.50-102) 438 (307-565) 1270† (900-2210) 93 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 5.6.d. Urinary enterolactone: Non-Hispanic whites 
Geometric mean and selected percentiles of urine concentrations (in µg/L) for non-Hispanic whites in the U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 259 (230-291) 23.9 (18.1-33.1) 344 (301-387) 1810 (1580-2100) 2112 
6–11 years 308 (244-388) 57.5 (35.8-103) 331 (262-412) 1600 (1290-2310) 196 
12–19 years 249 (203-306) 29.6 (17.5-58.1) 310 (242-384) 1620 (1200-2420) 375 
20–39 years 235 (196-281) 19.1 (11.1-33.1) 317 (240-383) 1780 (1300-2180) 529 
40–59 years 249 (195-319) 16.4 (9.30-34.1) 387 (278-424) 2030 (1610-2750) 434 
60 years and older 297 (256-345) 44.8 (19.9-73.6) 372 (303-424) 1730 (1340-2260) 578 
Males 
Total, 6 years and older 272 (240-308) 22.9 (17.2-33.1) 360 (310-400) 1970 (1620-2450) 1038 
6–11 years 336 (257-441) 70.2† (35.8-152) 348 (283-474) 1390† (881-2600) 101 
12–19 years 242 (192-306) 23.2 (10.6-64.4) 316 (222-445) 1560 (1150-2180) 190 
20–39 years 236 (185-300) 19.2 (11.0-32.3) 258 (209-389) 2000 (1300-2620) 231 
40–59 years 290 (218-386) 17.3 (12.7-39.6) 424 (307-555) 2400 (1710-3540) 225 
60 years and older 296 (236-372) 29.6 (12.9-62.1) 377 (292-492) 1750 (1310-2730) 291 
Females 
Total, 6 years and older 246 (212-286) 25.4 (15.8-43.7) 328 (280-383) 1490 (1290-2010) 1074 
6–11 years 279 (185-420) 47.3† (15.7-117) 325 (224-427) 1530† (719-2900) 95 
12–19 years 257 (189-349) 45.4 (17.5-62.1) 286 (222-403) 1800 (944-2950) 185 
20–39 years 234 (176-310) 17.4 (7.50-43.7) 323 (238-431) 1310 (980-1970) 298 
40–59 years 214 (148-310) 13.0 (5.28-46.1) 347 (206-418) 1660 (1010-2750) 209 
60 years and older 298 (245-363) 53.0 (19.4-78.0) 348 (265-418) 1700 (1190-2240) 287 
† Estimate is subject to greater uncertainty due to small cell size. 
5 Isoflavones & Lignans 135 
Table 5.6.e. Urinary enterolactone: Total population (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for the total U.S. 
population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 233 (213-254) 21.2 (17.4-24.5) 309 (286-335) 1500 (1380-1630) 5342 
6–11 years 323 (277-375) 69.3 (41.1-91.9) 375 (305-423) 1490 (1190-1780) 727 
12–19 years 185 (163-211) 23.4 (15.2-31.9) 231 (206-256) 1110 (908-1330) 1490 
20–39 years 190 (163-221) 14.0 (10.4-20.9) 278 (240-304) 1290 (1110-1520) 1139 
40–59 years 232 (194-277) 16.3 (11.7-24.2) 315 (267-377) 1630 (1380-1940) 951 
60 years and older 331 (286-383) 37.6 (20.3-65.1) 437 (380-492) 1860 (1540-2040) 1035 
Males 
Total, 6 years and older 208 (190-227) 17.4 (13.9-21.6) 279 (254-303) 1360 (1210-1540) 2594 
6–11 years 339 (283-408) 76.0 (49.3-101) 397 (291-480) 1580 (1130-2120) 368 
12–19 years 175 (152-201) 19.0 (12.9-29.6) 226 (200-247) 1090 (907-1310) 733 
20–39 years 174 (143-210) 15.1 (10.4-22.6) 240 (206-276) 1180 (872-1530) 500 
40–59 years 204 (165-253) 12.3 (8.16-24.2) 282 (243-350) 1420 (1150-1850) 480 
60 years and older 257 (208-318) 18.2 (11.4-35.3) 380 (282-486) 1590 (1210-1940) 513 
Females 
Total, 6 years and older 259 (232-290) 27.9 (18.6-32.9) 342 (307-379) 1590 (1440-1800) 2748 
6–11 years 306 (237-394) 55.4 (30.2-126) 343 (263-401) 1400 (1110-1610) 359 
12–19 years 197 (163-237) 25.9 (16.2-36.8) 243 (198-306) 1150 (850-1490) 757 
20–39 years 207 (165-259) 13.9 (8.20-27.9) 302 (259-360) 1370 (1120-1800) 639 
40–59 years 261 (204-335) 18.7 (9.02-39.1) 355 (267-447) 1850 (1450-2300) 471 
60 years and older 401 (339-474) 60.5 (30.9-103) 472 (404-562) 2020 (1590-2250) 522 
Table 5.6.f. Urinary enterolactone: Mexican Americans (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for Mexican Americans 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 219 (191-252) 24.2 (18.6-33.2) 283 (258-328) 1270 (1030-1490) 1492 
6–11 years 268 (200-359) 41.3 (20.8-64.7) 348 (240-437) 1190 (871-1980) 226 
12–19 years 215 (185-250) 33.0 (18.7-49.5) 257 (215-296) 1110 (955-1310) 538 
20–39 years 217 (174-270) 24.2 (9.46-37.2) 281 (242-398) 1410 (995-1730) 300 
40–59 years 193 (146-254) 18.1 (6.78-23.3) 277 (214-371) 1220 (1020-1430) 221 
60 years and older 227 (160-323) 25.3 (10.0-60.4) 334 (231-450) 1200 (985-1800) 207 
Males 
Total, 6 years and older 208 (169-257) 22.6 (14.9-36.1) 264 (227-328) 1270 (946-1730) 722 
6–11 years 284 (191-421) 41.3 (12.9-83.0) 355 (217-504) 1840 (898-2790) 117 
12–19 years 178 (152-208) 19.9 (14.6-43.8) 233 (184-281) 939 (716-1150) 274 
20–39 years 233 (171-318) 26.9 (9.46-54.1) 280 (206-444) 1570 (868-2190) 127 
40–59 years 140 (90.5-216) 8.37† (3.50-22.6) 213 (126-282) 1030† (597-1430) 105 
60 years and older 251 (161-390) 26.8† (3.62-67.2) 298 (206-503) 1390† (989-2520) 99 
Females 
Total, 6 years and older 231 (193-277) 24.2 (11.1-58.9) 308 (273-366) 1280 (1070-1440) 770 
6–11 years 252 (166-382) 28.5† (<LOD-97.1) 319 (223-455) 1010† (786-1490) 109 
12–19 years 266 (208-339) 50.2 (18.0-87.9) 282 (225-373) 1400 (1030-1630) 264 
20–39 years 199 (138-286) 13.3 (2.46-70.4) 280 (179-409) 1220 (981-1650) 173 
40–59 years 270 (189-387) 21.9 (7.00-73.6) 394 (233-611) 1480 (1170-2140) 116 
60 years and older 209 (135-324) 21.1† (<LOD-63.0) 333 (154-422) 1070† (773-1500) 108 
< LOD means less than the limit of detection for the uncorrected urine value, which may vary for some compounds by year. See Appendix D for LOD. 
† Estimate is subject to greater uncertainty due to small cell size. 
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Table 5.6.g. Urinary enterolactone: Non-Hispanic blacks (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic blacks 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 183 (153-220) 17.9 (12.0-29.9) 269 (219-309) 1090 (911-1230) 1286 
6–11 years 345 (285-417) 76.0 (48.1-108) 429 (331-495) 1170 (972-1650) 249 
12–19 years 197 (176-221) 32.3 (14.1-53.4) 244 (215-273) 931 (804-1180) 448 
20–39 years 136 (92.9-199) 7.64 (3.17-26.6) 197 (138-288) 888 (628-1590) 197 
40–59 years 172 (134-220) 15.8 (7.07-28.9) 251 (181-318) 1010 (678-1230) 210 
60 years and older 222 (167-295) 15.7 (6.74-56.4) 341 (252-439) 1390 (872-1690) 182 
Males 
Total, 6 years and older 161 (128-202) 12.0 (7.64-31.9) 236 (197-278) 1010 (850-1220) 627 
6–11 years 335 (272-413) 60.3 (38.6-112) 409 (329-507) 1100 (937-1570) 127 
12–19 years 180 (147-221) 20.1 (11.8-45.1) 217 (186-271) 931 (728-1250) 211 
20–39 years 126 (78.3-204) 7.64† (1.31-32.6) 177 (125-242) 1100† (556-1590) 91 
40–59 years 143 (97.7-209) 9.30† (2.81-28.1) 252 (152-319) 820† (615-1420) 109 
60 years and older 136 (86.0-215) 7.45† (1.61-15.7) 220 (128-344) 885† (705-1470) 89 
Females 
Total, 6 years and older 205 (172-245) 28.9 (17.0-37.7) 298 (241-340) 1090 (911-1390) 659 
6–11 years 356 (270-468) 88.1 (59.4-126) 431 (279-552) 1180 (972-1670) 122 
12–19 years 216 (187-250) 50.3 (24.3-69.9) 262 (221-298) 911 (686-1300) 237 
20–39 years 144 (96.1-217) 12.1† (2.05-37.2) 218 (142-326) 888† (622-1670) 106 
40–59 years 200 (157-256) 28.4† (7.07-51.5) 247 (184-354) 1060† (604-1440) 101 
60 years and older 308 (214-443) 41.0† (17.0-90.6) 428 (302-549) 1460† (869-2020) 93 
† Estimate is subject to greater uncertainty due to small cell size. 
Table 5.6.h. Urinary enterolactone: Non-Hispanic whites (creatinine corrected) 
Geometric mean and selected percentiles of urine concentrations (in µg/g creatinine) for non-Hispanic whites 
in the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999–2002. 
Geometric mean 
(95% conf. interval) 
Selected percentiles (95% conf. interval) Sample 
size10th 50th 90th 
Males and Females 
Total, 6 years and older 257 (229-289) 22.6 (17.1-27.9) 338 (308-377) 1630 (1460-1880) 2112 
6–11 years 334 (277-402) 76.1 (48.9-108) 378 (291-435) 1580 (1220-2020) 196 
12–19 years 189 (155-229) 22.8 (15.9-29.6) 238 (192-288) 1240 (900-1720) 375 
20–39 years 205 (172-243) 14.5 (9.83-22.6) 296 (268-323) 1370 (1160-1640) 529 
40–59 years 261 (210-326) 16.4 (10.2-29.9) 362 (282-444) 1850 (1410-2490) 434 
60 years and older 371 (310-443) 44.3 (20.3-96.7) 468 (386-570) 1920 (1570-2200) 578 
Males 
Total, 6 years and older 230 (206-257) 21.2 (14.6-25.2) 308 (276-336) 1520 (1290-1690) 1038 
6–11 years 370 (282-484) 82.0† (69.3-123) 435 (247-601) 1780† (1180-2940) 101 
12–19 years 184 (146-233) 19.7 (7.43-31.9) 238 (189-287) 1210 (900-1880) 190 
20–39 years 179 (141-227) 14.0 (9.83-24.7) 251 (201-309) 1270 (755-1630) 231 
40–59 years 244 (189-316) 16.0 (8.16-29.9) 327 (254-433) 1630 (1240-2490) 225 
60 years and older 283 (220-364) 19.6 (13.0-44.7) 424 (301-576) 1590 (1170-1980) 291 
Females 
Total, 6 years and older 287 (247-333) 27.9 (16.9-37.7) 370 (327-418) 1850 (1520-2020) 1074 
6–11 years 299 (215-416) 55.2† (25.1-142) 342 (249-401) 1400† (847-1800) 95 
12–19 years 194 (147-256) 21.7 (13.8-36.8) 241 (172-344) 1250 (783-1800) 185 
20–39 years 233 (174-311) 14.0 (6.11-30.6) 322 (280-424) 1410 (1180-2010) 298 
40–59 years 279 (204-383) 16.9 (6.44-48.4) 378 (281-532) 1930 (1450-2560) 209 
60 years and older 457 (377-553) 76.3 (30.9-151) 513 (404-681) 2040 (1620-2580) 287 
† Estimate is subject to greater uncertainty due to small cell size. 
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No. 11(243), 1998. 
Fulwood R, Johnson CL, Bryner JD, Gunter EW, McGrath CR. Hematological and nutritional 
biochemistry reference data for persons 6 months–74 years of age: United States, 1976–1980. 
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National Center for Health Statistics (NCHS) Series 2 Reports 
http://www.cdc.gov/nchs/products/pubs/pubd/series/ser.htm#sr2 
Looker AC, Gunter EW, Cook JD, Green R, Harris JW. Comparing serum ferritin values from different 
population surveys. National Center for Health Statistics. Vital Health Stat Series No. 2(111), 1991. 
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http://www.cdc.gov/nchs/about/major/nhanes/advancedatas.htm 
Advance Data No. 349. Prevalence of leading types of dietary supplements used in the Third National 
Health and Nutrition Examination Survey, 1988–94. 
Advance Data No. 341. Dietary intake of selected minerals for the United States population: 
1999–2000. 
Advance Data No. 339. Dietary intake of selected vitamins for the United States population: 
1999–2000. 
Advance Data No. 334. Dietary intake of ten key nutrients for public health, United States: 1999–2000. 
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Life Sciences Research Office (LSRO) Reports 
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Societies for Experimental Biology; 1985. 
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(MD): Federation of American Societies for Experimental Biology; 1984. 
Pilch SM, Senti FR. Assessment of iron nutritional status of the U.S. population based on data collected 
in the Second National Health and Nutrition Examination Survey, 1976–1980. Bethesda (MD): 
Federation of American Societies for Experimental Biology; 1984. 
Pilch SM, Senti FR. Assessment of zinc nutritional status of the U.S. population based on data collected 
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Federation of American Societies for Experimental Biology; 1984. 
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Appendix B: 
References for Analytical Methods for Biochemical 
Indicators 
Detailed Laboratory Procedure Manuals for Analytical Methods 
•	 NHANES 1999–2000: 
http://www.cdc.gov/nchs/about/major/nhanes/lab_methods99_00.htm 
•	 NHANES 2001–2002: 
http://www.cdc.gov/nchs/about/major/nhanes/lab_methods01_02.htm 
Additional Useful Analytical Method References 
Water-Soluble Vitamins & Related Biochemical Compounds 
Life Sciences Research Office. Assessment of folate methodology used in the Third National Health 
and Nutrition Survey (NHANES 1988–1994). Washington, D.C.: Center for Food Safety and Applied 
Nutrition, Food and Drug Administration, Department of Health and Human Services; 1994. 
Gunter EW, Bowman BA, Caudill SP, Twite DB, Adams MJ, Sampson EJ. Results of an international 
round robin for serum folate and whole-blood folate. Clin Chem. 1996;42:1689-94. 
Pfeiffer CM, Twite D, Shih J, Holets-McCormack SR, Gunter EW. Method comparison for total plasma 
homocysteine between the Abbott IMx analyzer and an HPLC assay with internal standardization. Clin 
Chem. 1999;45(1):152-3. 
Pfeiffer CM, Huff DL, Smith SJ, Miller DT, Gunter EW. Comparison of plasma total homocysteine 
measurements in 14 laboratories: an international study. Clin Chem. 1999;45(8):1261-8. 
Pfeiffer CM, Caudill SP, Gunter EW, Bowman BA, Jacques PF, Selhub J, et al. Discussion of critical issues 
related to the comparison of homocysteine values between the Third National Health and Nutrition 
Examination Survey (NHANES) and NHANES 1999+. J Nutr. 2000;130:2850-4. 
Pfeiffer CM, Smith SJ, Miller DT, Gunter EW. Comparison of serum and plasma methylmalonic acid 
measurements in 13 laboratories: an international study. Clin Chem. 1999;45:2236-42. 
Fat-Soluble Vitamins & Micronutrients 
Sowell AL, Huff DL, Yeager PR, Caudill SP, Gunter EW. Retinol, alpha-tocopherol, lutein/zeaxanthin, 
beta-cryptoxanthin, trans-lycopene, alpha-carotene, trans-beta-carotene, and four retinyl esters in 




Paschal DC, Kimberly MM. Automated direct determination of selenium in serum by electrothermal 
atomic absorption spectroscopy. At Spectrosc. 1986;7:75-8. 
Caldwell KL, Maxwell CB, Makhmudov A, Pino S, Braverman LE, Jones RL, et al. Use of inductively 
coupled plasma mass spectrometry to measure urinary iodine in NHANES 2000: comparison with 
previous method. Clin Chem. 2003;49:1019-21. 
Iron-Status Indicators 
Blanck HM, Pfeiffer CM, Caudill SP, Reyes R, Gunter EW, Imperatore G, et al. Serum iron and iron-
binding capacity: a round-robin interlaboratory comparison study. Clin Chem. 2003;49:1672-5. 
Looker AC, Gunter EW, Johnson CL. Methods to assess iron status in various NHANES surveys. Nutr 
Rev. 1995;53:246-54. 
Isoflavones & Lignans 
Valentin-Blasini L, Blount BC, Rogers HS, Needham LL. HPLC-MS/MS method for the measurement of 
seven phytoestrogens in human serum and urine. J Expo Anal Environ Epidemiol. 2000;10:799-807. 
Kuklenyik Z, Ye X, Reich JA, Needham LL, Calafat AM. Automated on-line and off-line solid 
phase extraction methods for measuring isoflavones and lignans in urine. J Chromatogr Sci. 
2004;42:495-500. 
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Appendix C: 
Confidence Interval Estimation for Percentiles 
A common practice to calculate confidence intervals from survey data is to use large-sample normal 
approximations. Ninety-five percent confidence intervals on point estimates of percentiles are often 
computed by adding and subtracting from the point estimate a quantity equal to twice its standard 
error. This normal approximation method may not be adequate, however, when estimating the 
proportion of subjects above or below a selected value (especially when the proportion is near 0.0 or 
1.0 or when the effective sample size is small). 
In addition, confidence intervals on proportions deviating from 0.5 are not theoretically expected to 
be symmetric around the point estimate. Further, adding and subtracting a multiple of the standard 
error to an estimate near 0.0 or 1.0 can lead to impossible confidence limits (i.e., proportion estimates 
below 0.0 or above 1.0). 
We used the method of Korn and Graubard (1998) to compute Clopper-Pearson 95 percent 
confidence intervals about percentile estimates. We describe the method below, using SAS Proc 
Univariate and SUDAAN. SAS code for calculating these confidence intervals can be downloaded from 
http://www.cdc.gov/exposurereport. 
Procedure to calculate confidence intervals about percentiles 
Step 1: Use SAS (SAS Institute Inc., 1999) Proc Univariate to obtain a point estimate of the percentile 
of a chemical’s results for the demographic group of interest (e.g., the 90th percentile of blood 
lead results for children aged 1–5 years). Use the Freq option to assign the correct sample 
weight for each chemical result. 
Step 2: Use SUDAAN (SUDAAN Users Manual, 2001) Proc Descript with Taylor Linearization DESIGN = 
WR (i.e., sampling with replacement) and the proper sampling weight to estimate the 
proportion (p) of subjects with results below the percentile estimate obtained in Step 1 and 
to obtain the standard error (sep) associated with this proportion estimate. Compute the 
degrees-of-freedom adjusted effective sample size 
n  =((t /t )2)p(1 - p)/(se 2) (1)df num denom p 
where t and t  are 0.975 critical values of the Student’s t distribution with degrees of num denom
freedom equal to the sample size minus 1 and the number of PSUs minus the number of 
strata, respectively. Note: the degrees of freedom for t  can vary with the demographic denom
subgroup of interest (e.g., males). 
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Step 3: After obtaining an estimate of p (i.e., the proportion obtained in Step 2), compute the 
Clopper-Pearson 95 percent confidence interval (P (x,n ), P (x,n )) as follows: L df U df 
P (x,n ) = v F  (0.025)/(v  + v F (0.025)) & P (x,n ) = v F  (0.975)/(v  + v F (0.975)) (2)L df 1 v1,v2 2 1 v1,v2 U df 3 v3,v4 4 3 v3,v4
where x is equal to p times n , v = 2x, v = 2(n  - x + 1), v = 2(x + 1), v = 2(n  - x), and F (β) df 1 2 df 3 4 df d1,d2
is the β quantile of an F distribution with d1 and d2 degrees of freedom. (Note: If ndf is greater 
than the actual sample size, or if p is equal to zero, then the actual sample size should be 
used.)  This step will produce a lower and an upper limit for the estimated proportion 
obtained in Step 2. 
Step 4: Use SAS Proc Univariate (again using the Freq option to assign weights) to determine the 
chemical values that correspond to the proportion obtained in Step 2 and the lower and 
upper limits on this proportion obtained in Step 3. 
Example: 
To estimate the 75th percentile, use SAS Proc Univariate with the Freq option to get a weighted point 
estimate of the chemical value that corresponds to the 75th percentile. Then use SUDAAN to estimate 
the weighted proportion of subjects with results below the 75th percentile (which should be very 
near 0.75). Next, obtain a confidence interval on this proportion by computing the weighted Clopper-
Pearson 95 percent confidence limits using the degrees-of-freedom adjusted effective sample size. 
Suppose these confidence limits are 0.67 and 0.81, then use SAS Proc Univariate with the Freq option to 
determine the chemical values corresponding to the weighted 67th and 81st percentiles. These point 
estimates are the lower and upper confidence limits on the 75th percentile. 
References 
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Appendix D: 
Limit of Detection Table 
The table below presents the analytical limit of detection (LOD) for each of the different indicators. 
The LOD is the level at which the measurement has a 95 percent probability of being greater than 
zero (Taylor 1987). For the same indicator, LOD values may change over time as a result of changes to 
analytical methods. This was the case for urinary phytoestrogens. We used the higher of the two LOD 
values for the analysis of the combined four-year data. 
Indicator Units 1999–2000 2001–2002 
Water-Soluble Vitamins & Related Biochemical Compounds 
Serum folate ng/mL 0.1 0.1 
Red blood cell (RBC) folate ng/mL RBC 20 20 
Serum vitamin B12 pg/mL 20 20 
Plasma homocysteine µmol/L 0.35 0.35 
Plasma methylmalonic acid µmol/L 0.05 0.05 
Fat-Soluble Vitamins & Micronutrients 
Serum vitamin A µg/dL 1.03 1.03 
Serum vitamin E µg/dL 40.7 40.7 
Serum gamma-tocopherol µg/dL 10.7 10.7 
Serum alpha-carotene µg/dL 0.7 
Serum trans-beta-carotene µg/dL 0.8 
Serum beta-cryptoxanthin µg/dL 0.9 
Serum lutein/zeaxanthin µg/dL 2.4 
Serum	trans-lycopene µg/dL 0.8 
Serum vitamin D, 25-hydroxy ng/mL 1.5 
Iron-Status Indicators 
Serum ferritin ng/mL 1.1 1.1 
Serum iron µg/dL 2 
Serum total iron-binding capacity µg/dL 6 
Serum transferrin saturation % n/a 
Erythrocyte protoporphyrin µg/dL RBC 1 
Trace Elements 
Urinary iodine ng/mL 1.0 
Serum selenium ng/mL 8 
Isoflavones & Lignans 
Urinary genistein µg/L 0.3 0.8 
Urinary daidzein µg/L 0.5 1.6 
Urinary equol µg/L 3.0 3.3 
Urinary O-desmethylangolensin µg/L 0.2 0.4 
Urinary enterodiol µg/L 0.8 1.5 
Urinary enterolactone µg/L 0.6 1.9 
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Appendix E: 
Selected References of Descriptive NHANES Papers on 
Biochemical Indicators of Diet and Nutrition 
Water-Soluble Vitamins & Related Biochemical Compounds 
Bentley TGK, Willett WC, Weinstein MC, Kuntz KM. Population-level changes in folate intake by age, 
gender, and race/ethnicity after folic acid fortification. Am J Public Health. 2006;96:2040-7. 
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Dietrich M, Brown CJP, Block G. The effect of folate fortification of cereal-grain products on blood 
folate status, dietary folate intake and dietary folate sources among adult non-supplement users in 
the United States. J Am Coll Nutr. 2005;24:266-74. 
Ganji V, Kafai MR. Trends in serum folate, RBC folate, and circulating total homocysteine 
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Ganji V, Kafai MR. Population references for plasma total homocysteine concentrations for US children 
and adolescents in the post-folic acid fortification era. J Nutr. 2005;135:2253-6. 
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